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"It seemed to me that a careful examination of the room and the lawn might possibly reveal 
some traces of this mysterious individual. You know my methods, Watson. There was not 
one of them which I did not apply to the enquiry. And it ended by my discovering traces, but 
very different ones from those which I had expected." 
    
     Sherlock Holmes in "The Crooked Man"  
     From The Memoirs of Sherlock Holmes (1893) by Sir Arthur Conan Doyle (Writer, 1859-1930) 
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Abstract of the Dissertation 
 
Extracts from the resin exudates of the frankincense tree again returned into the focus of 
pharmacological research within the last 20 years. So far, several research groups reported 
on promising anti-inflammatory, anti-microbial and even anti-tumour effects (in vitro and in 
vivo). The Boswellic acids are regarded as one of the most potent active agents thereof. 
However, the resins still contain innumerable amounts of terpenoid compounds. Their 
interactions, when administered as an extract, are not really understood hitherto. In addition, 
the information given in literature as to which molecular entity refers to which species has not 
been clearly verified in several publications. 
Thus, this work reports on qualitative and quantitative analytical methods (LC, GC, TLC, MS 
and NMR), which enable the unequivocal identification of the common incense species 
Boswellia papyrifera (Eritrea, Ethiopia), Boswellia serrata (India) and Boswellia sacra (Oman, 
Yemen), respectively, Boswellia carterii (Somalia). Based on these results, a general, though 
not yet empirically verified, hypothesis on the biosynthetic routes has been postulated. 
Besides, a partial-synthetic method for the enrichment of one compound (Incensole acetate) 
was developed. In cooperation with Prof. Werz (Jena) a few of the isolated compounds were 
tested to evaluate their pharmacological potential. The results delivered evidence on possible 
synergistic effects which were partly based on decompositions of single molecules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zusammenfassung der Dissertation 
_________________________________________________________________________________ 
 
Zusammenfassung der Dissertation 
 
Weihrauchharzbaumextrakte sind innerhalb der letzten 20 Jahre wieder verstärkt in den 
Fokus der pharmakologischen Forschung gerückt. So wurden bis dato verschiedenste in 
vitro und in vivo Arbeiten mit Hinweisen auf anti-inflammatorische, anti-mikrobielle und sogar 
zytostatischer Wirkung veröffentlicht. Als potenteste Wirkstoffklasse werden die 
Boswelliasäuren angesehen. Jedoch beinhalten diese Harze noch eine unzählbare Menge 
an terpenoiden Verbindungen, deren Zusammenspiel, wenn als Extrakt verabreicht, bisher 
noch gänzlich unbekannt ist. Hinzu kommt, dass die Angaben in der Literatur, welche 
molekulare Entität von welcher Harzsorte stammt, oft noch divergieren. 
Diese Arbeit liefert qualitative und quantitative analytische Methoden (LC, GC, DC, MS und 
NMR), die eine eindeutige Identifizierung der drei weitverbreiteten Weihrauchspezies 
Boswellia papyrifera (Eritrea, Äthiopien), Boswellia serrata (Indien) und Boswellia sacra 
(Oman, Yemen) bzw. Boswellia carterii (Somalia) ermöglichen. Auf Basis dieser Ergebnisse 
ist eine Hypothese zur Biosynthese aufgestellt worden. Außerdem wurde eine 
partialsynthetische Methode zur Anreicherung eines potentiellen Wirkstoffkandidaten 
(Incensol-Acetat) entwickelt. In Zusammenarbeit mit Prof. Werz (Jena) wurden einige der 
hier isolierten Verbindungen auf ihre pharmakologische Wirkung hin untersucht. Die 
Resultate lieferten Hinweise auf mögliche synergistische Effekte, die zum Teil auf 
Zersetzungsprodukten der Moleküle beruhten. 
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Explanatory Notes 
 
It should be noted that some “awkwardly” sounding abbreviations, such as RE for raw 
extract, NB for neutral fraction and RS for acid fraction, are based on the German terms and 
are kept as the author has become too familiar with them [e.g. RE = Rohextrakt (Ger.), 
basically the same as in English, NB = Neutralbestandteile (Ger.), RS = Rohsäure (Ger.)]. 
In this work, merely the most important molecules (biomarkers for qualitative and quantitative 
analysis by TLC, HPLC, GC, MS and NMR) were indicated by a representative number (1 to 
30). Other molecules are discussed but not explicitly addressed by an abbreviation. 
The abbreviations Ser-OH and Iso-Ser, used in this work, are representative for the 
diterpenes serratol and its isomer iso-serratol, and do not refer to the amino acids serine and 
iso-serine, respectively. 
 
 
Major Symbols and Abbreviations 
 
°C    Degrees (Celsius scale) 
µg    Micro gram 
µl    Micro litre 
µM    Micro mol 
11-OH-ß-ABA   3α-O-Acetyl-11-OH-ß-boswellic acid (7) 
11-OMe-ß-ABA   3α-O-Acetyl-11-OMe-ß-boswellic acid (8) 
1D    One-Dimensional 
2D    Two-Dimensional 
3-O-TA    3-Oxo-8,24-dien-tirucallic acid (13) 
3ß-OH-Tir   3ß-OH-Tirucallol (29) 
3α-OH-KU   3α-OH-11-keto-urs-12-en (30) 
9,11-dehydro-ß-ABA  3α-O-Acetyl-9,11-dehydro-ß-boswellic acid (10) 
9,11-dehydro-ß-BA  3α-OH-9,11-dehydro-ß-boswellic acid (9) 
AA    Arachidonic Acid 
ABAs    Acetylated Boswellic acids (including here compound 2 and 4) 
AcLA    Acetyl-lupeolic acid (12) 
ACN    Acetonitrile 
AD    Anno domini (when Christ was born) 
BAs    Boswellic acids (including here compound 1 and 3) 
BC    Before Christ 
Bcar    Boswellia carterii 
Bpap    Boswellia papyrifera 
br s     (abbrev. Broad singlet etc.)   
BSA    Bovine Serum Albumine 
Bsac    Boswellia sacra 
Bser    Boswellia serrata 
c     Concentration 
C.V.    Coefficient of Variation (S.D./Mean * 100 %) 
C.V.s    Plural of CV (Coefficient of Variation) 
CI    Chemical Ionisation 
conc.     Concentrated 
CYP    Cytochrome P 450 Oxygenase (Enzyme) 
d    Dublet 
DAD    Diode Array Detector, respectively, Detection 
DCM    Dichloromethane 
dd    dublet of dublets (ddd, dddd, etc) 
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Delta (δ)    Chemical shift (in NMR spectroscopy) 
DEPT 135   Distortionless Enhancement by Polarization Transfer 135 
DEPT 90   Distortionless Enhancement by Polarization Transfer 90 
DMEM    Dulbecco’s Modified Eagle Medium 
DXP    1-Deoxy-Pentulose-5-Phosphate Pathway 
ec    End capped (HPLC columns) 
EC    Eppendorf Cup 
EDTA    Ethylene diamine tetra acetic acid 
et al.    and co-workers 
FCS    Fetal Calf Serum 
FID (GC)   Flame Ionisation Detection 
FID (NMR)   Free Induction Decay 
FPP    Farnesyldiphosphate 
Fr.    Fraction (isolation and preparative chromatography) 
g    Gravity (term in centrifugation; synonym: rpm) 
GC-FID    Gas Chromatography with Flame Ionisation Detection 
gem.     Geminal 
GGPP    Geranylgeranyldiphosphate 
GPP    Geranyldiphosphate 
GSH    2.5 mM Glutathione and 250 mM Sucrose 
HH-COSY   Proton-Correlated Spectroscopy (2D NMR technique) 
HMBC    Heteronuclear Multiple Bond Correlation 
HMQC    Heteronuclear Multiple Quantum Correlation 
HOAc    Acetic Acid 
HPLC    High Performance Liquid Chromatography 
HRMS    High Resolution Mass Spectrometry 
HSQC    Heteronuclear Single Quantum Coherence 
I.D.    Inner Diameter 
IC50 Inhibitory Concentration, where the enzymatic activity is only 50 % of 
the activity without inhibitor 
IL-1ß    Interleukin 1ß 
Inc    Incensole (22) 
Inc-Ac    Incensole acetate (23) 
IPP    Isopentenyldiphosphate 
Iso-Ser    Iso-Serratol (20) 
IUPAC    International Union of Pure and Applied Chemistry 
J    Coupling Constant (in NMR technology) 
k    Capacity Factor (HPLC; elution volume of an analyte) 
KI    Kovats Indices (synonym: RI) 
KPi (KPI)   Potassium phosphate buffer (pH 7.4) 
LA    Lupeolic acid (11) 
Lambda (λ)   Wavelength [nm] 
LAs    Lupeolic acids (including here compound 11 and 12) 
LC    Liquid Chromatography 
m    Mass (e.g. mg) 
m/m    Mass percent (e.g. mg / mg in %) 
MeOH    Methanol 
MevA    Mevalonat-Acetate Pathway 
MHz    Megahertz 
min     Minutes (time unit) 
MK8886   Control-Inhibitor (mPGES-1) 
mol peak   Molecular Peak (important for mass spectrometry) 
MS    Mass Spectrometry 
MU    Measurement Uncertainty 
NB Neutral Fraction (After separation from the acid fraction) 
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nm     Nanometer 
NMR    Nuclear Magnetic Resonance 
NOESY   Nuclear Overhauser Enhancement Spectroscopy   
NP    Normal Phase (term in chromatography) 
P    Penicillin 
p Significance level (e.g. p = 0.99 gives a 99 % security that the 
expected value lies within this distribution). 
PgH2    Prostaglandin H2 
PI    Prediction interval 
PMNL    Polymorphonuclear Leukocytes 
PMSF    Phenylmethanesulfonylfluoride 
ppm    Part per million (chemical shift in NMR)   
prep    Preparative (HPLC-column) 
ps tr  Pseudo triplet etc., means that it is normally a multiplet or dd which 
appears as a triplet etc. 
Psi    Pounds per square inch 
R Resolution (Chromatography) 
RE    Raw Extract (Lipophilic Olibanum Extract) 
Rf    Retention Factor (Thin Layer Chromatography, TLC) 
RI Retention Indices (synonym: KI) 
RP    Reversed Phase 
rpm    Rounds per minute (in Centrifugation) 
RS Raw Acid Extract (Raw Acid after separation of the neutral 
compounds) 
RSD    Residual Standard Deviation 
Rt    Retention Time (HPLC) 
RT    Room Temperature 
s    Second (time unit)   
S    Streptomycin 
S.D.    Standard Deviation (of a random sample) 
S/N    Signal to Noise Ratio 
Ser-OH    Serratol (21) 
SIM    Selected Ion Monitoring 
SPE    Solid Phase Extraction 
ß    beta (position of an atom above the paper plane) 
ß-ABA    ß-Acetyl-boswellic acid (4) 
ß-Ac-8,24-dien-TA  3ß-O-Acetyl-8,24-dien-tirucallic acid (19) 
ß-AKBA   3α-O-Acetyl-11-keto-ß-boswellic acid (6) 
ß-BA    ß-Boswellic acid (3) 
ß-Car    ß-Caryophyllene (27) 
ß-Car-Ox   ß-Caryophyllene oxide (28) 
ß-KBA    3α-OH-11-keto-ß-boswellic acid (5) 
ß-PgE2    Prostaglandin E2 
ß-TA    3ß-OH-8,24-dien-tirucallic acid (15) 
STI    Soybean Trypsin Inhibitor 
T    Temperature 
T/E    Trypsin/EDTA 
t0    Dead retention time (chromatography)  
TAs    Tirucallic acid (including here compound 13 – 19) 
TIC    Total Ion Current 
TLC    Thin Layer Chromatography 
tr    Retention Time (chromatography) 
UHPLC    Ultra-High Performance Liquid Chromatography 
UV    Ultra Violet 
v/v    Volume percent 
Vert-4(20),7,11-triene  Verticillia-4(20),7,11-triene (24) 
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VIS    Visual Spectral Area 
VVK    Coefficient of Variation referring to the linear calibration model 
w    Peak width (peak width: peak end minus peak start) 
α    Alpha (position of an atom under the paper plane)   
α-7,24-dien-TA   3α-OH-7,24-dien-tirucallic acid (17) 
α-ABA    α-Acetyl-boswellic acid (2) 
α-Ac-7,24-dien-TA  3α-O-Acetyl-7,24-dien-tirucallic acid (18) 
α-Ac-TA   3α-O-Acetyl-8,24-dien-tirucallic acid (16) 
α-AKBA   3α-O-Acetyl-11-keto-α-boswellic acid 
α-BA    α-Boswellic acid (1) 
α-Hum    α-Humulene (26) 
α-KBA    3α-OH-11-keto-α-boswellic acid 
α-TA    3α-OH-8,24-dien-tirucallic acid (14) 
τ-Cad-OH   τ-Cadinol (25) 
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1 Introduction 
 
The first what someone may associate with the word frankincense or incense in our modern 
western civilisation is probably the word “catholic church”. There, it is burned on coal during 
the mass and emits a more or less pleasant odour, which certainly is dependent on the 
personal preference on how to define an agreeable scent. Additionally, it is described in 
several chapters of the bible, where it for example is mentioned 22 times (see also the 
Handbook of Medicinal Plants in the Bible by J. A. Duke et al. [1]).  
A very famous quotation, in connection with frankincense and even myrrh, may be thus the 
following one (Matthew 2, 10-11, English Standard Version): “When they saw the star, they 
rejoiced exceedingly with great joy. And going into the house they saw the child with Mary his 
mother, and they fell down and worshiped him. Then, opening their treasures, they offered 
him gifts, gold and frankincense and myrrh.” Another one, likely to be less known, is that a 
mixture of myrrh and wine was offered to Jesus Christ on the cross to soothe his pain (Mark 
15:23, King James Bible): “And they gave Him to drink wine mingled with myrrh; but he 
received it not.” Finally, myrrh was also used to embalm the body of Jesus Christ (John 
19:39): “And there came also Nicodemus, which at first came to Jesus by night, and brought 
a mixture of myrrh and aloes, about a hundred pound weight.” Thus, it is somehow quite 
astonishing how valuable these materials might had been during the time of Christ when His 
life began and even ended with them (e.g. at His birth to worship Him, and in His end to 
soothe His pain and lastly to embalm Him). Surely, frankincense and myrrh do not have the 
same esteem as they had ca. two thousand years before, and according to the paper of 
Thieret [2] it may be really quite interesting what the Wise Men would bring to Christ today (to 
quote Thieret: “Perhaps gold, dates and oil.”).  
However, what probably is nowadays not known among many western community citizens is 
the fact that frankincense and also myrrh had an inestimable value for many older and 
especially ancient civilisations (e. g. the Egyptian, Greek and even the Roman cultures). At 
that time, it was not only used for religious and spiritual purposes but also for 
pharmacological applications. Most probably, the property of frankincense and myrrh, used 
as scents and for embalming, was a sign of great prosperity during these ancient times. By 
trading these goods, the early South Arabian cultures of the areas called Hadramaut and 
Dhofar (today Yemen, respectively, Oman) generated a prosperous welfare, perhaps 
comparable with the current welfare of Saudi Arabia established on the production of oil [3]. 
These days, frankincense still is important for the fragrance industry since its resins contain 
innumerable amounts of volatile and odorous molecules [4].  
Additionally, since Safayhi et al. [5] have coincidentally discovered anti-inflammatory actions 
of an Indian frankincense extract in the early nineties of the last century, the pharmacological 
interest in extracts and single isolated compounds thereof, as an alternative herbal 
treatment, has been growing enormously to the present day. Even though, there is more and 
more encouraging proof that extracts of frankincense may be an effective therapy against 
several diseases (e.g. asthma, rheumatoid arthritis and Crohn’s disease etc.), the evidence 
thus far is not absolutely compelling [6]. One advantage of frankincense preparations seems 
to be the comparably low occurrence of side-effects when used as medication. However, to 
quote E. Ernst, absence of evidence is not the same as evidence of absence [6]. The hitherto 
administered medication in cases of inflammatory diseases, the so-called Non-Steroidal Anti-
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inflammatory Drugs (NSAIDs), such as acetylsalicylic acid or ibuprofen, and the 
corticosteroids, such as cortisol, are reported to have several more severe side-effects 
instead, if taken over a longer period of time.  
Furthermore, patients with an interest and a demand of medical frankincense preparations 
mainly have to trust in nutritional supplements, as they are accredited by the European Food 
Safety Authority (EFSA) for such an application, though there is nothing established about a 
certain frankincense metabolism in the human body - Do we need frankincense resins to 
survive? Like air, sugar, proteins and water? Has anybody ever heard of a human being 
suffering and/or starving because of a lack of frankincense dietary supplements? These 
supplements are offered by several distributors, most probably with an unknown and hence 
not analytically guaranteed composition of active ingredients. How these multiple compound 
containing extracts interact in the human body is so far still elusive. Whether or not it will be 
possible to understand their interactions - in a synergistic or antagonistic manner - in the 
human body in the near future may also be questioned.  
However, these are just a few points which are currently highly discussed about the benefits 
and drawbacks of herbal preparations. If extracts of frankincense will eventually achieve the 
status of a declared and by clinical studies validated herbal remedy can not be surely 
predicted to date. It will depend on an investor being courageous enough to take a risk in the 
enormously expensive conduction of a sufficiently representative clinical trial. Thus far, the 
risk seems far too big. 
In the following introducing chapters on this topic the history, the biology and botany, some 
geographical facts, the biosynthesis of terpenes, the chemistry and the pharmacology for 
resins of Boswellia, which finally will lead to the aim of the study presented here, are 
described. 
 
 
1.1 Anecdotes of the Early History of Frankincense 
 
Beside the reports on frankincense given in the bible (see chapter 1. Introduction), there are 
several other sources witnessing the trade and application of frankincense for different 
purposes. The first reliable reports about border-crossing drug trade have been concluded 
for the old Babylonians, where the caravan roads from India, Arabia and Syria crossed each 
other, and additionally for the old Egyptians. Thus, in the old-Babylonian settlement Sippar 
(ca. 2250 BC) the drug merchants already bartered with several natural products, probably 
including frankincense and myrrh [3].  
However, the greatest insight in the cultures of pre-Christian times is granted for the early 
Egyptians. For them the historians and archaeologists revealed many indications and 
evidence for the application of resins for fumigation (Olibanum; synonym of frankincense) 
and embalmment (myrrh). Very early in time (ca. 2470-2350 BC) the old Egyptians already 
sailed with huge merchant fleets to the legendary country of Punt, which exact location is 
even hitherto not definitely known by modern historians (it is assumed around the Horn of 
Africa, today: Somalia, and even on the other shore of the Red Sea and Gulf of Aden, today 
the areas of Yemen and Oman). The Greek historian Herodot (ca. 484-425 BC) mentioned 
merely Arabia, “the outermost land of the world in the far south”, as origin for these goods. 
The most famous travel to the fabulous land of Punt was the expedition of the female 
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Egyptian pharaoh Hatshepsut (ca. 1478-1457 BC). Several wall drawings found in the great 
temple of Deir el-Bahari in Egypt witness the great expeditions of hers to this secret land. On 
these drawings depictions of frankincense and myrrh trees are shown, which were 
transported in baskets back to Egypt for cultivations. However, these claims of cultivation did 
not succeed [3,7]. 
Furthermore, one of the oldest ancient trading routes is the so called Incense Road. This 
path led from Dhofar (Oman) via Yemen, the Asir Province (Saudi-Arabia) and the landscape 
of Hedjas (western Saudi-Arabia) to the Mediterranean ports of Gaza (today Palestinian 
territory) and Damaskus (today Syria), from where these goods were further transported to 
the then prosperous Mediteranean states. The booming years of the trade along the Incense 
Road were about 800 BC, when the ancient South Arabian kingdoms of Sheba, Qataban, 
Hadhramaut and the Minaeans controlled the trade with frankincense. Therefore, these 
kingdoms generated a great prosperity during that time. However, through the resumed rise 
of the sea maritime trade (ca. 100 BC) the Incense Road lost more and more its relevance 
and the South Arabian welfare, based on the trade with frankincense, declined. There may 
be still a lot to report on these quite interesting ancient times, about the rise and fall of certain 
kingdoms, and for this purpose the corresponding literature may be consulted [3].  
Another source for the pharmacological use of frankincense can be found in India, connected 
to the philosophy of Ayurveda, a kind of traditional medicine native there. Boswellia serrata 
(Abbr.: Bser; synonym: salai gugal or salai gugul), the Indian Frankincense, is described in 
Ayurvedic text books (Charaka Samhita, 1st – 2nd century AD and in Astangahrdaya Samhita, 
7th century AD) to treat a variety of diseases [8]. Furthermore, the oldest pharmacological 
note, the papyrus Ebers (received by Moritz Fritz Ebers in 1873 from an Arabian 
businessman), already mentions frankincense as a drug. The papyrus itself contains 
information for medical doctors concerning diagnosis and treatment of several diseases. The 
age of the papyrus Ebers is dated to the time of Pharaoh Amenophis I and was thus probably 
written around 1500 BC [3]. 
Interestingly, the use of frankincense has continued, even until our modern age of 
technology. Though it is today in the common sense mainly abstracted with its smell in 
catholic churches, in a pharmacological point of view it regained a strong interest over the 
last two decades [8,9]. 
 
 
1.2 Biological, Botanical and Geographical Facts 
 
Botanically, the frankincense tree belongs to the family of the Burseracea. Its genus is 
denoted as Boswellia, whereas the myrrh trees, another similar commonly known plant, also 
belonging to the Burseracea family, are denoted as Commiphora (genus). Both are historical 
important resin providing plants. The genus of Boswellia (named after Johann Boswell, who 
wrote a paper on ambergris in 1735) contains hitherto 25 species, whereby it is not clearly 
verified if some of the species are doubly counted. It is mainly distributed in the dry areas of 
the Horn of Africa (Somalia, Sudan, Ethiopia, and Eritrea), the Arabian Peninsula (Oman and 
Yemen) and in India. There are rather differing indications in literature on the specific names 
and spreading of the single species. A few representative species are given in Table 1.1 
[3,10]. 
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The term Boswellia carterii is adopted for the Somalian tree and the term Boswellia sacra for 
the South-Arabian (Oman, Yemen) plant, although both species can be regarded as the 
same, at least on a chemotaxonomic and a botanical point of view [11-13]. The Indian tree is 
called Boswellia serrata [14]. The quite common species Boswellia papyrifera is primarily 
growing in Sudan, Eritrea and Ethiopia [15,16], and is often mistaken with the species 
Boswellia carterii from Somalia (see also chapter 1.4.5 on neutral terpenic compounds). 
Interestingly, these four species seem to be the only ones thus far which definitely have been 
described to contain the boswellic acids in great quantities, the class of pentacyclic triterpene 
acids specific for the Boswellia trees (see also chapter 1.4.1 on chemistry). 
The Boswellia plants are deciduous trees and can reach a height of up to 5 m and even 
more, dependent on the species and the growing area. They have bald stems and branches 
with a peeling bark and appear bush or tree like. The branches have compound leaves and 
an odd number of leaflets. They bloom in spring, mostly in April. 
 
Tab. 1.1 A few representative Boswellia species and their geographical distribution. The trees of 
Boswellia carterii Birdw. and Boswellia sacra Flück. can be regarded as the same species, according 
to the chemotaxonomic and biological evaluations [11-13]. They are just differing because of their 
geographical origin. 
Species Geographical Distribution 
Boswellia carterii Birdw. Somalia, Nubia 
Boswellia sacra Flück. Oman, Yemen 
Boswellia frereana Birdw. Somalia 
Boswellia papyrifera Hochst. Ethiopia, Eritrea, Sudan 
Boswellia serrata Roxb. India 
Boswellia neglecta S. Moore Somalia 
Boswellia odorata Hutch. Tropical Africa 
Boswellia dalzielli Hutch. Tropical Africa 
Boswellia ameero Balf. Fils. Socotra 
Boswellia elongata Balf. Fils. Socotra 
Boswellia socotrana Balf. Fils. Socotra 
 
The term Burseracea means that these plants produce balms and resins in special tissue 
canals. A resin is generally a mixture of several organic compounds (e.g. terpenes, 
terpenoids and polysaccharides) which has an amorphous shape. When cold, these resins 
appear often as a viscous and glassy solid. When heated they start to liquefy, and when 
cooled again, they once more become an amorphous solid without any crystallisation. Resins 
are quite robust materials, staying inert towards chemical and environmental influences [17]. 
Plant resins are products of the secondary metabolism, which basically means that neither 
energy nor material for the growth of the plant is generated thereby. On the contrary, the 
primary metabolism serves for the decomposition (catabolism, delivering mostly energy) and 
composition (anabolism, for the functional cell construction) of biologically important 
molecules [18]. The biological benefit of the secondary metabolism is not completely 
understood hitherto. A sensible reason may be the protection against hazardous 
environmental influences (e.g. against microorganisms, if the bark gets injured etc.). 
Furthermore, certain volatile compounds may serve for communication interactions between 
specific plants and insects (e.g. linalool, a monoterpene, produced by flowers often attracts 
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moth pollinators during the night, while other plant species, not producing linalool, attract 
other insects like bees and butterflies during daytime [19]). 
The harvesting of the Boswellia resins begins in spring with start of the yearly hot period (end 
of March in Somalia and April in Dhofar, Oman). Therefore, the stem and the thicker 
branches are cut with a special knife. During this process the resin containing excretion 
vessels in the bark are injured. The gum resin exudates can thus emerge. Due to the air 
exposure the viscous material solidifies to a gum resin. Gum resins are resins which contain 
besides ethereal essential oils and further non-polar terpenoids a greater amount of 
polysaccharides (ca. 25-30 %). The congealed resin is then harvested during the whole 
summer period. The first cut and drying process delivers a resin of inferior quality. The 
second cut, ca. three weeks later, delivers the yellow dyed and resinous material in greater 
quality and quantity, forming teardrop like solids when congealed. These are finally scraped 
off for the first time after one or two weeks. Dependent on the age, height and condition of 
the tree, its exploitation is executed for three consecutive years. Afterwards, a several year 
taking period of rest begins. The yield of one tree is about 3 - 10 kg, depending on the health 
and growth of the tapped tree [3]. 
Another point to be discussed may be the sustainability of the frankincense production in the 
present and even its future tendencies. Many frankincense accommodating countries are 
considered as politically unstable states with low educational levels and a poorly economical 
strength (e.g. Somalia, Sudan, Eritrea and Ethiopia), not to mention randomly happening 
existential crisis such as starvation or violent conflicts. 
The situation in India may be more promising, since most of the clinical studies have been 
implemented with extracts of Boswellia serrata, the Indian frankincense tree [6]. Therefore, 
especially the Sallaki-TABLETS® (formerly known as H15 Gufic) from the GUFIC 
BIOSCIENCES LIMITED in Karnataka, India, have been evaluated. Additionally, the Indian 
frankincense is monographed as Olibanum Indicum in the European Pharmacopeia 6.0, 
respectively, 7.0 [20,21], and a comprehensive article on its clinical particularities and 
pharmacological properties is published in the ESCOP (European Scientific Cooperative on 
Phytotherapy) Monographs [22]. Hence, there may be precautions met in India to preserve 
this highly valuable plant. 
In Oman the situation may be different, since the frankincense trade does definitely not have 
the same importance as it had in its early history [3]. The reason therefore may be the 
modern economical development, especially the oil export, which binds most of the 
workforce of the country. Furthermore, the harvest of frankincense is tedious under the harsh 
conditions such as heat and dry climate [23]. In addition to that, the agricultural economy will 
also decrease more and more in the country of Oman, if frankincense is not considered as a 
highly valuable resource anymore. 
For the country of Yemen, which also accommodates the Boswellia sacra tree, the same 
problems as reported for the Oman may be recognisable. Furthermore, Yemen, one of the 
poorest Arabian countries, accommodates forces of the terror network al-Qaeda, and 
another problem may be the addiction of the farmers to the production of the drug kath 
(Catha edulis), which is strongly consumed among the locals [24]. Thus, the country has 
definitely a lot of other worries and problems to overcome. And if the value of its indigenous 
Olibanum trees is understood there, is also questionable. 
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The situation at the Horn of Africa may be even worse than for the countries mentioned 
above. Particularly Somalia, a country without any real government since 1991 and thus 
characterised as a “failed state”, suffers regularly from food crises and terrorism. Well known 
may be the regularly reported piracy in the Gulf of Aden [25]. How the situation is going to 
develop in this region can not be really predicted. Hitherto, Somalian Olibanum is still 
available on the market. 
The situation in Ethiopia, Eritrea and Djibouti may be not really much better, since several 
border conflicts are reported (e.g. violent conflict over the border region Badme between 
Ethiopia and Eritrea; between 1998 and 2002, 100.000 people died in a war there [25]). 
Thus, there may exist still great resentments between these two countries. Additionally, the 
real value of frankincense, as a possible economical resource, is probably also not realised. 
In 2006, Ogbazghi et al. published their results of a field study on the distribution of the 
frankincense tree Boswellia papyrifera in Eritrea depending on environmental influences and 
land use [16]. They concluded that the distribution of this tree has decreased during the past 
decades, mainly due to an increasing human population, resulting in the conversion of 
woodlands into agricultural fields and increasing livestock pressure hindering natural 
regeneration. 
The temporary most reliable predictions on the future of frankincense have been made for 
the species Boswellia papyrifera in Eritrea and Ethiopia by Groenendijk et al. [26], recently 
published in 2011. The authors studied twelve populations of Boswellia papyrifera in northern 
Ethiopia and compared tapped (for resin harvesting used) and untapped populations in order 
to develop a matrix based model to predict the population dynamics. The studies took place 
from 2007 to 2009. Their outcomes are quite serious. It is concluded that under “business as 
usual” conditions (e.g. exploitation of the trees for firewood, grazing material for livestock and 
other environmental influences like beetle attacks etc.) 90 % of both populations, tapped and 
untapped, are going to decline within the next 50 years. Furthermore, a 50 % decline in 
frankincense yield within the next 15 years has been stated. Model simulations for restoration 
scenarios conclude that populations and frankincense production could only be sustained 
with intensive efforts leading to full sapling recruitment and a 50-75 % reduction in adult 
mortality. This is hitherto the first large-scale study on population dynamics of a 
frankincense-producing tree. The results also suggest that a lack of regeneration and high 
adult mortality (6-7 % per year), independent from resin tapping, is causing strong declines in 
the Boswellia papyrifera population. These findings may also be projectable to the situation 
in the other frankincense producing countries of Africa and Arabia (e.g. Somalia, Yemen). 
 
 
1.3 Biosynthesis of Terpenes 
 
Though natural products, many of them derived from plants, have been used throughout the 
history of mankind for several different purposes, the scientific evaluation of their active 
ingredients became firstly possible in the 19th century when chemistry as a science had its 
major ascendency (During that time the rise of chemistry as a science may be comparable 
with the developments in biotechnology or information sciences nowadays). 
One great class of natural products are the terpenes or terpenoids (terpenes with differing 
functional groups such as hydroxyl-, aldehyde-, ketone-, carboxylate-, etc.). The term 
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“Terpenes” has been derived from Turpentine products (e.g. the first diterpene resin acid, 
abietic acid from rosin, a by-product of turpentine oil industry was isolated although in impure 
form in 1824 [27]). They universally occur in all living organisms but especially are referred to 
the class of plants where they can be found in great quantities in special extra-cellular 
compartments. One example of a great terpene and terpenoid source are the Boswellia 
species, whose resinous material, obtained by incision of the stems of the trees, consists of 
several different terpenic compounds [3]. As universal metabolites, terpenes have several 
biological functions, and for many of them the specific function is thus far not completely 
understood. They function, for example, as pheromones for many plant and insect species 
and serve hence for the interactive communication system of these beings [19]. 
Besides, they play an important role for the flavour, fragrance and pharmaceutical industries. 
Smaller volatile terpenes (e.g. citral from lemongrass oil, Cymbopogon citratus; or linalool 
from the oil of lavender, Lavandula angustifolia) are very interesting compounds for the 
fragrance industry as they reveal, dependent on their molecular structures, specific scents. 
Others are used as spices and several more are interesting candidates for drugs with 
promising applications (e.g. the boswellic acids as anti-inflammatory agents from Boswellia 
species; or Paclitaxel, known as Taxol®, firstly isolated in minimal amounts from the pacific 
yew, syn. Taxus brevifolia, which is applied as an anti-tumour agent). Thus far, up to 30.000 
terpenes are known in literature, and still, there may be every day new derivatives or 
chemical entities described. 
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Fig. 1.1 The basic hydrocarbons of the terpenes (isoprenoids). 
 
The greatest impacts on terpene chemistry were accomplished by Wallach (Nobel Prize in 
Chemistry 1910) in the 19th century and by Ruzicka (Nobel Prize in Chemistry 1939) in the 
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20th century, two chemists whose lifework consisted of the research and structural elucidation 
of many naturally occurring terpenes. Based on their experimental observations they 
developed the so-called Isoprene Rule. This is a general principle that every terpene consists 
of C5-units (2-methyl-1,3-butadiene or isoprene units) which build up the carbon skeleton of 
the class of terpenoids. Hence, they are also denoted as isoprenoids [28-30]. Predominately, 
they can be found as hydrocarbons with several functionalities in nature (e.g. as alcohols and 
their glycosides, ethers, aldehydes, ketones, carboxylic acids and esters). The basic 
structures are shown in Fig. 1.1. It is differentiated between hemi- (C5), mono- (C10), sesqui- 
(C15), di- (C20), sester- (C25), tri- (C30), tetraterpenes (C40) and polyterpenes (C5)n with n > 8 
[31]. It should be emphasised that it is rather astonishing that the basic pathways for terpene 
synthesis are universally occurring in all kind of living organisms. This means that every 
organism, more or less, uses the same tools for the production of certain metabolites, if the 
specific pathway exists. Just another impressive example of how systematically “Mother 
Nature” works. As depicted in Fig. 1.1, the isopropyl part of 2-methylbutane is defined as 
Head. The ethyl part of it is denoted as Tail. The combinations for each isoprenoid class 
differ. For mono-, sesqui-, di- and sesterterpenes the units are connected to each other from 
Head-to-Tail. The tri- and tetraterpenes are linked to each other by one Tail-to-Tail 
connection in the centre [31]. 
In the middle of the last century the theory by Wallach and Ruzicka was finally experimentally 
proved by Lynen and Bloch (Both together obtained the Nobel Prize in Physiology or 
Medicine in 1964) [32,33]. They revealed that acetyl-coenzyme A, known as activated acetic 
acid, is the biogenetic precursor of terpenes. This classical pathway is called acetate-
mevalonate pathway (MevA). There, two equivalents of acetyl-CoA are linked to acetoacetyl-
CoA, which reaction mechanism is similar to a classical Claisen condensation. Acetoacetyl-
CoA is the biological analogue of acetoacetate. Subsequently, acetoacetyl-CoA reacts with 
another equivalent of acetyl-CoA, similar to an aldol reaction, leading to ß-hydroxy-ß-
methylglutaryl-CoA. By reduction with dihydronicotinamide adenine dinucleotide (NADPH + 
H+), a universal co-factor in enzymatic redox reactions [18], (R)-mevalonic acid is obtained 
(see Fig. 1.2). Adenosine triphosphate (ATP), another universal co-factor and the universal 
biological energy source on this planet [18], donates the pyro-phosphate leading to the 
diphosphate of mevalonic acid which is transformed into isopentenylpyrophosphate (syn. 
isopentenyldiphosphate, IPP) by decarboxylation and dehydration. Isomerisation of the latter 
gives dimethylallylpyrophosphate [31]. Further reaction steps lead to monoterpenes or 
sesquiterpenes (e.g. dimethylallylpyrophosphate reacts with IPP to geranylpyrophosphate, 
GPP, and thus monoterpenes, and the subsequent reaction of geranylpyrophosphate with 
another equivalent IPP leads to farnesyldiphosphate, FPP, and hence sesquiterpenes). The 
here described reaction steps are shown in Fig. 1.2. The next higher terpenes, the 
diterpenes (C20), are synthesised by the nucleophilic head attachment of IPP (C5) to the 
electrophilic tail of FPP (C15) leading to geranylgeranylpyrophosphate (GGPP). A further 
linkage of IPP (C5) with GGPP (C20), Head- to-Tail, gives the sesterterpenes (C25). The 
combination of two molecules FPP, Tail-to-Tail, leads to the triterpene squalene (C30). In the 
same way the Tail-to-Tail connection of two equivalents of GGPP results in the tetraterpenes 
(C40) such as 16-trans-phytoene [31]. The basic reaction schemes are presented in Fig. 1.3.  
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Fig. 1.2 Reaction scheme (MevA-pathway) of the biogenesis of mono- and sesquiterpenes. For further 
details see text or the book of Breitmaier [31]. 
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been detected a few contradictory outcomes (e.g. 
the origin of carbon atoms of 
The MevA terpene pathway had been considered as the universal biosynthetic pathway until 
the end of the 1980s. Though, there had 
isotopically labelled MevA and acetate were usually not well incorporated into carotenoids 
and monoterpenes in plant systems while they were incorporated quite well into other 
isoprenoids such as steroids; from the review of Barkovich and Liao [34]). These facts have 
been also shortly discussed in the dissertation of Basar [35]. 
Experiments by Rohmer et al. [36], published in 1993, with incorporation of 13C-labelled 
glucose, acetate, pyruvate or erythrose allowed to detect 
triterpenoids of the hopane series and of the ubiquinones from several bacteria (e.g., 
Escherichia coli, Alicyclobacillus acidoterrestris etc.). They figured out, by failed 
incorporations of 13C-labeled acetate and successful incorporations of 13C-labeled glycerol 
and pyruvate in hopanes and ubiquinones, that there exists another pathway different from 
the known acetate mevalonate pathway. The finding by Rohmer et al. showed that 
isopentenyl diphosphate (IPP) originates also from activated acetaldehyde (C2, by reaction of 
pyruvate and thiamine diphosphate) and glyceraldehyde-3-phosphate (C3). Thus, the so-
called 1-deoxy-pentulose-5-phosphate is generated delivering the first unbranched C5 
precursor of IPP. This pathway, the deoxyxylulose phosphate pathway (DXP), is depicted in 
Fig. 1.4. 
 
 
 
Fig. 1.3 Basic reaction scheme for the biogenesis of di-, tri- and tetraterpenes. For further details see
xt or the book of Breitmaier [31]. 
 
te
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o far, fungi and yeast merely use the MevA-pathway. Bacteria reveal both metabolic S
pathways. In higher plants both pathways are used, whereas the products of the cytosol 
(sterols, triterpenes) are produced via MevA and products from the chloroplasts (phytol, 
caretenoides, plastochinone and other small terpenes) are synthesised via the DXP pathway. 
Between both pathways intermediates are exchangeable (IPP, GPP, FPP, GGPP). The 
specific pathway can be identified by genes, encoding specific enzymes, or by inhibitors 
blocking these enzymes (e.g. Lovastatin for MevA or Fosmidomycin for DXP [34]). Hence, 
especially the DXP pathway is an interesting target for drugs (e.g. Fosmidomycin as an 
antibiotic [37]). 
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ig. 1.4 Reaction scheme (DXP-pathway) of the alternative precursor synthesis of IPP. For further
or the biosynthesis of further cyclic and polycyclic terpenes the participation of intermediate 
cular terpenes, found in frankincense 
F  
details see text or the book of Breitmaier and the dissertation of Basar [31,35]. 
 
F
carbenium ions is assumed. However, evidence for this in vivo was given only in some 
cases. One simple example of the synthesis of limonene, a monocyclic monoterpene, is 
given in Fig. 1.5. Through an intra-molecular reaction of the allylic cation with the spatially 
near double-bond, the GPP-cation cyclises to give a cyclohexyl cation then transformed into 
(R)- or (S)-limonene by deprotonation. The biogenesis of other terpenes is obtained by 
similar reactions steps, additionally including 1,2-hydride and 1,2-alkyl shifts (Wagner-
Meerwein rearrangements) and sigmatropic reactions (Cope rearrangements), most probably 
stereosepcifically guided by enzymes. Further examples are given in the book of Breitmaier 
or in the review of Rücker on sesquiterpenes [31,38]. 
A few assumed biogenesis pathways of some parti
resins, are depicted in chapter 3.13 as a proposal. These are based on the results obtained 
by the qualitative and quantitative HPLC experiments presented in chapter 3.7 and 3.8. 
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Fig. 1.5 The biosynthesis of (R + S)-limonene via an assumed carbo-cation intermediate stage. For 
further details see text or the book of Breitmaier [31]. 
 
Another class of tetracyclic triterpenes with a gonane or sterane carbon skeleton are the 
steroids. They are derived from tetracyclic triterpenes obtained by the biosynthesis reported 
here and only differ in the amount of C-atoms, thus, not following the classical Isoprene rule 
(multiple of C5) anymore. The structure of its mostly known representative is cholesterol (C27) 
which is the precursor for several other steroids with specific biological functions of each. 
The overview scheme on the biogenetic origins of tetracyclic triterpenes and steroids is given 
in Fig. 1.6, and in Fig. 1.7 the structure of cholesterol, including the basic skeleton of 
steroids, is shown. 
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Fig. 1.6 Overview on the specific origins of tetracyclic triterpenes and steroids. For further details see 
text or the book of Breitmaier [31]. 
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Fig. 1.7 The basic structure of the gonane-type steroids and its mostly known representative 
cholesterol. For further details see text. 
 
Cholesterol is correlated with high blood pressure and cardiovascular diseases in humans. 
Furthermore, it is the predecessor of the female and male sex hormones (oestrogens with 
C18, respectively, testosterone with C19) and several other types of functional steroids. For 
the explicit clarification of the biosynthesis routes, mechanisms and functionalities the 
corresponding literature may be consulted [18]. A good short overview is additionally 
summarised in the dissertation of Basar [35]. 
 
 
1.4 Chemistry 
 
In the following chapters a few specific classes of terpenic compounds found in Boswellia 
resins are presented. Principally, the most common classes are described. Thus far, merely 
the species Boswellia papyrifera (Bpap), Boswellia serrata (Bser), Boswellia sacra (Bsac), 
respectively, Boswellia carterii (Bcar) seem to definitely contain the boswellic acids in high 
quantities. These findings have been already clarified in the dissertation of Jochen Bergmann 
(2004) [17]. He analytically compared the species B. ameero, B. frereana, B. papyrifera, B. 
sacra, B. carterii, B. serrata and B. socotrana and only detected for the species Bpap, Bser, 
Bsac/Bcar the specific boswellic acids. B. frereana for example consisted mainly of neutral 
compounds, revealing almost no quantity of acids. Furthermore, the analysis of Boswellia 
neglecta, Boswellia rivae and again Boswellia frereana in the dissertation of Basar (2005) 
revealed boswellic acids merely in traces [35]. Consequently, the species Bpap, Bser and 
Bsac/Bcar may be the most important classes of Boswellia species, if the pharmacological 
activity, based on triterpenic acids, is regarded. 
 
 
1.4.1 Boswellic Acids 
The first comprehensive and reliable investigations on resins of frankincense were realised 
by Alexander Tschirch and Oscar Halbey during the years from 1892 to 1899. Their results 
are published in several writings and publications [39-41]. Basically, they separated the 
alcoholic extract into its neutral and acidic fraction by solvent extraction with diethyl ether 
(Et2O) and an alkaline soda solution, a method still used today. After several reprecipitation 
steps they isolated a mono-basic raw product, which they denominated as “Boswellinsäure” 
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.8). 
(Note: The expression Säure means acid in German). For this raw product they suggested 
the chemical formula C32H52O4. About the chemical structure was nothing exactly known 
then (Note: The compound most probably had been a mixture of 3-O-acetyl-ß-boswellic acid 
and its α-isomer; compounds 2 and 4 in Fig. 1
During the research of Halbey and Tschirch, the terpene chemistry had become increasingly 
important by development of the so called isoprene rule. This rule was proposed by Otto 
Wallach [28] who wrote more than 100 papers on the chemistry of terpenes, and who finally 
obtained the Chemistry Nobel Prize in 1910 therefore. His oeuvre on terpenes and especially 
the isoprene rule led to a rise of the natural product and terpenoid chemistry [29,35]. 
In 1932 two other researchers on Boswellia resins, Winterstein and Stein, revealed that the 
raw product isolated by Tschirch and Halbey is a mixture of four specific boswellic acids, 
namely the α- and ß-boswellic acids (compound 1 and 3) and their acetylated derivatives 
(compound 2 and 4) as shown in Fig 1.8. They achieved to isolate the four compounds as 
pure substances and finally suggested the correct chemical formula C32H50O4 [42]. Though, 
they did not have any clue about the correct chemical structures. 
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Fig. 1.8 The structures of α-BA (1), α-ABA (2), ß-BA (3) and ß-ABA (4). Thus far, the boswellic acid 
compounds are highly specific biomarkers for the species from Boswellia. 
 
Simpson, in 1937, published his experiments about ß-boswellic acid (3) and classified it as ß-
hydroxy-acid (Note that in this case only the position of the hydroxyl group at C-3, 
neighbouring to the carboxyl group, is meant, not the configuration; compare also with Fig. 
1.10 later in the text). He deduced this fact from reactions of chrom(VI)oxid (CrO3) with the 
free acid giving a mono-ketone by decarboxylation, and with the methyl ester which instead 
delivered the stable keto-ester [43]. 
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Ruzicka and Wirz published in 1939 and 1949 their own experiments, where they finally 
correlated a relationship between the boswellic acids and the triterpenes α- and ß-amyrine 
[44,45]. This was achieved by transformation of the α- and ß-boswellic acids into their 
corresponding amyrines (see also Fig. 1.9). By this relationship many attributes of the 
amyrine-derivates could be conveniently transferred to the boswellic acids. Ruzicka has been 
also the chemist who thoroughly developed the isoprene rule from 1921-1953 [30], based on 
the proposal by Wallach. Furthermore, for his merits on the chemistry of terpenes he 
obtained together with Butenandt the Chemistry Nobel Prize in 1939. Thus, he had also a 
major impact on the structural elucidation of the boswellic acids found in incense resins.  
In the 1950s of the last century Beton et al. elucidated finally the configuration of the OH- and 
COOH-group in ß-boswellic acid. Their results were published in 1956, and as it is depicted 
in Fig. 1.10 the configuration of the OH-group is α (meaning under the ring) and the 
configuration of the COOH-group is ß (meaning above the ring) [46]. 
 
 
 
 
Fig. 1.9 The structures of α-amyrine (left, ursane-type skeleton) and ß-amyrine (right, oleanane-type 
skeleton). Confusingly, the structures of ß-BA (3) and ß-ABA (4) refer to the α-amyrine, vice versa, for 
α-BA (1) and α-ABA (3), which refer to ß-amyrine. This has unfortunately historical reasons. 
 
 
 
Fig. 1.10 The configuration of the OH- and COOH-function in ß-BA. The OH-group is α-configured 
(under the plain) and the COOH-group is ß-configured (above the plain). 
 
The elucidation of organic molecules in the following two decades became increasingly 
easier. The reason therefore was the development and establishment of more precise 
techniques such as mass spectrometry (MS) and nuclear magnetic resonance spectroscopy 
(NMR). Both are instrumental measurement tools which made the work of organic chemists 
tremendously more convenient, especially concerning questions on unknown chemical 
structures. 
Hence, in the year 1963 Budzikiewicz et al. published the first mass spectrometric data base 
on amyrine derivates [47]. These data is even nowadays used for the characterisation of the 
molecular framework of unknown triterpenes. In 1978, Pardhy and Bhattacharyya, delivered 
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first mass spectrometric and 1H-NMR data for the ß-boswellic acids (compound 3 and 4) [48]. 
Furthermore, they presented spectroscopic data for two other very specific incense resin 
compounds, 11-keto-ß-boswellic acid (5, ß-KBA) and 3-O-acetyl-11-keto-ß-boswellic acid (6, 
ß-AKBA) shown in Fig. 1.11. The structure of compound 5 was firstly described by Snatzke 
and Vertesy in 1966 [49]. In the year 2000 the working group of Ammon published the crystal 
structure of ß-AKBA (6) [50], and in 2001 Gupta et al. published the crystal structure of ß-
ABA (4) [51]. However, it took over 20 years until Culioli et al. and Belsner et al. published in 
2003 the first complete NMR data sets (1H and 13C) for α/ß-BA (1 and 3), α/ß-ABA (2 and 4), 
the ß-BA-9,11-dehydro derivatives (9 and 10) and ß-AKBA (6) [52,53]. Before, merely the 
chemical shifts of H-3 and H-12 were certainly assigned. 
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Fig. 1.11 The structures of ß-KBA (5) and ß-AKBA (6). 
 
In 1964, Corsano and Iavarone isolated from the acid fraction of Olibanum the methyl ester 
of 3-O-acetyl-11-OH-ß-boswellic acid (7, 11-OH-ß-ABA) [54]. The compound, shown in Fig. 
1.12, is known to be rather unstable. The working group of Ammon was able to figure out in 
the 1990s the reaction pathway of compound 7, leading to 3-O-acetyl-9,11-dehydro-ß-
boswellic acid (10; 9,11-dehydro-ß-ABA) via its methoxy derivate, 3-O-acetyl-11-OMe-ß-
boswellic acid (8; 11-OMe-ß-ABA) [55]. The structures are altogether presented in Fig. 1.12. 
Seitz firstly isolated compound 7 purely without any decomposition and defined the position 
of the 11-OH-group as α-configured [56]. Furthermore, 3-OH-9,11-dehydro-ß-boswellic acid 
(9; 9,11-dehydro-ß-BA) was additionally described by Büchele et al. and quantified in the 
resin matrix by a RP-DAD-HPLC method (see also Fig. 1.12) [57]. 
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Fig. 1.12 The structures of 11-OH-ß-ABA (7); 11-OMe-ß-ABA (8); 9,11-dehydro-ß-BA (9) and 9,11-
dehydro-ß-ABA (10). 
 
Büchele et al. also isolated the corresponding 9,11-dehydro derivates of the α-boswellic 
acids (1 and 3) and quantified them by the HPLC method mentioned before. Their structures 
are shown in Fig. 1.13. 
 
 
 
Fig. 1.13 The structures of 9,11-dehydro-α-BA (left) and 9,11-dehydro-α-ABA (right). 
 
In accordance, Büchele et al. synthesised the 11-keto-derivative from α-ABA (3), α-AKBA 
(see Fig. 1.14), and separated it from ß-AKBA (6) by application of a fluorinated HPLC 
stationary phase. Thus, revealing also the difficulty of separating α-AKBA from ß-AKBA (6) 
by application of conventional reversed phase stationary phases, normally, the separation 
system of choice for HPLC separations of boswellic acids [58]. Additionally, α-KBA (see also 
Fig. 1.14) and α-AKBA may occur naturally in minor amounts, but are just not easily 
resolvable. The hypothesis may be correct as shown in the HPLC publication of Paul et al. 
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[59]. There, for each peak signal (ß-KBA, 5, and ß-AKBA, 6) at 250 nm detection 
wavelength, a minor fronting inhomogeneity is visible, which might refer to α-KBA and α-
AKBA, respectively. 
 
 
 
Fig. 1.14 The structures of 11-keto-α-BA (syn. α-KBA, left) and 11-keto-α-ABA (syn. α-AKBA, right). 
Both structures have yet not been isolated from a naturally source. For further details see text. 
 
Moreover, the existence of several oleanane-type boswellic acids (e.g. α-BA/α-ABA), similar 
to already known ursane-type boswellic acids (e.g. ß-BA/ß-ABA), has been postulated by the 
working group of Simmet in Ulm, Germany [57]. Their structures are shown in Fig. 1.15. The 
molecules depicted there (11-OH-α-BA and 11-OH-α-ABA) seem to be the predecessors of 
9,11-dehydro-α-BA and 9,11-dehydro-α-ABA shown in Fig. 1.13, following basically the 
identical discussion about reaction pathways already given for Fig. 1.12. 
 
 
 
Fig. 1.15 The structures of 11-OH-α-BA (left) and 11-OH-α-ABA (right). Both structures have yet not 
been isolated from a naturally source. For further details see text. 
 
Furthermore, Seitz firstly isolated another ß-boswellic acid where the OH-function at position 
3 is ß-configured, namely 3-ß-OH-ß-boswellic acid [56]. The structure, which was found in 
the species Boswellia carterii, is depicted in Fig. 1.16. 
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Fig. 1.16 The structure of 3-ß-OH-ß-boswellic acid. 
 
Chemically, the boswellic acids refer to the class of pentacyclic triterpenic acids. There can 
be a vast amount of naturally occurring triterpenic acids found in several different plant 
species, with only a few single functional differences in their molecular framework [31]. 
Hitherto, the boswellic acids have been merely isolated from resins of the genus Boswellia. 
Therefore, they can be regarded as genus specific thus far. 
 
 
1.4.2 Lupeolic Acids 
Another class of pentacyclic triterpenic acids found in the resins of Boswellia species are the 
lupeolic acids. These triterpenic acids are not specific for the genus of Boswellia and as well 
have been isolated from other plant material sources [31]. Culioli et al. isolated in 2003 the 
lupeolic acid (11, LA) from an methanolic extract of a gum resin called “Erytrean-type” [52]. 
Shortly thereafter in 2003, the working group of Simmet published the isolation and structural 
elucidation of 3-α-O-acetyl-lupeolic acid (12, Ac-LA) from Boswellia serrata [60]. The group of 
Choudray reported in 2005 on another lupeolic acid type derivative from the bark of 
Boswellia papyrifera. It revealed instead of a methyl group at C-27 a primary alcohol function 
and was denoted as 3-α-O-acetyl-27-OH-lupeolic acid (12a) [61]. Furthermore, Seitz 
reported on the isolation of 3-α-O-acetyl-28ß-OH-lupeolic acid (12b) from Boswellia carterii 
[56]. The structures of all here discussed lupeolic acids are depicted in Fig. 1.17.  
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Fig. 1.17 The structures of compound 11 (LA), 12 (Ac-LA), 12a and 12b. For further details see text. 
 
 
1.4.3 Tirucallic Acids 
The tirucallic acids represent another class of tetracyclic triterpenic acids that have been 
isolated from Boswellia resins. They are not genus specific for the Boswellia species, since 
they were additionally found in other plants [62-64]. In 1962, Corsano and Picconi isolated 3-
Oxo-elema-8,24-dien-21-oic-acid from an incense extract [65]. A synonym for this compound 
is also 3-oxo-8,24-dien-tirucallic-acid (13, 3-Oxo-TA), as the COOH-function can be normally 
always found at position C-21 for the class of tirucallic acids (see also Fig. 1.18). 
Similar compounds have been isolated from the resin of Boswellia serrata by Pardhy and 
Bhattacharyya in 1978 [66]. Beside the isolation of compound 13, they also reported on the 
isolation of 3-α-OH-8,24-dien-tirucallic acid (14, α-TA), 3-ß-OH-8,24-dien-tirucallic acid (15, 
ß-TA) and 3-α-O-acetyl-8,24-dien-tirucallic acid (16, α-Ac-TA). Additionally, Akihisa and 
Banno et al. [67,68] reported on the isolation of 3-α-OH-7,24-dien-tirucallic acid (17, α-7,24-
dien-TA) from Boswellia carterii in 2006, though the resin identity in their work had probably 
not been definitely verified. The crystal structure of compound 17 was published by Mora et 
al. in 2001 [69]. All tirucallic acids discussed hitherto (13-17) had been also isolated by Seitz 
from the resin of Boswellia papyrifera [56]. 
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Fig. 1.18 The structures of the tirucallic acids (13-19). For further details see text. 
 
Two further tirucallic acid structures were reported by Estrada et al. in 2010, namely 3-α-O-
acetyl-7,24-dien-tirucallic acid (18, α-Ac-7,24-dien-TA) and 3-ß-O-acetyl-8,24-dien-tirucallic 
acid (19, ß-Ac-8,24-dien-TA) [70]. Their chemical structures are also presented in Fig. 1.18. 
The authors claim that they isolated 18 and 19 from Boswellia carterii. However, about the 
isolation is nothing specific mentioned in their publication. Further on, the quoted reference 
[57], which should report on the isolation of 18 and 19, does not reveal anything about these 
two tirucallic acids in detail. As it will be later on concluded in this work, it was more likely the 
species Boswellia papyrifera instead, where these compounds (18 and 19) naturally originate 
from (see especially chapter 3.7.5). 
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1.4.4 Roburic Acids 
The roburic acids represent a class of tetracyclic triterpenic acids rarely found in natural 
sources. They are not considered to be specific for Boswellia resins, as they were also 
isolated from other plant sources (e.g. roburic acid from Gentiana macrophylla by Jong et al. 
in 1994 [71]). Fattorusso et al., in 1983, have been the first research group who found a 
representative molecule of this class in the acid fraction of Boswellia carterii [72]. The 
isolated compound was 4(23)-dihydro-roburic acid and was regarded by them as a probable 
degradation product, caused by geochemical processes. Seitz had also isolated the 4(23)-
dihydro-roburic acid and additionally three more roburic acids from the acid fraction of the 
resin Boswellia socotrana (Note: Since this species did not reveal any boswellic acids, 
expectably typical for them, it may be doubtful if it really is a Boswellia resin, according to the 
comments given in the dissertation by Seitz [56]). Thus, she elucidated the structures of 
roburic acid, 11-keto-roburic acid and 4(23)-dihydro-11-keto-roburic acid. The latter two keto-
roburic acids have been firstly described by her. The structures are shown in Fig. 1.19. 
 
 
 
Fig. 1.19 The structures of the different roburic acids. For further details see text. 
 
 
1.4.5 Neutral Terpenic Compounds 
The neutral compounds from resins of frankincense have been evaluated thoroughly 
because of their significant odour intensities. Generally, these resins contain an innumerable 
amount of monoterpenes, sesquiterpenes, diterpenes and triterpenes. Many of them are 
ubiquitously occurring in nature [31]. They can not be regarded as specific biomarkers for a 
certain species in general. However, in combination with other compounds they may be 
helpful for classification in some cases. 
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A good overview on the great volatile amounts of mono-, sesqui- and diterpenes, occurring in 
these resins, is given by Hamm et al. [13], who published their results (GC-MS) in 2005. In 
the author’s opinion, this paper can be regarded as highly important and reliable, since they 
used voucher specimens of these resins in order to evaluate the specific biomarker 
differences. Another paper by Mathe et al. [73], published in 2004, gives a good overview on 
typical neutral triterpenic compounds, mainly amyrine and lupeol derivatives, occurring in 
these resins. Some exemplary terpenic compounds are shown in Fig. 1.20. 
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Fig. 1.20 A few examples of terpenes found in the essential oils of Olibanum resins. Monoterpenes: 
limonene (a), α-pinene (b), ß-pinene (c). Sesquiterpenes: γ-cadinene (h), δ-cadinene (i), cedrol (j), τ-
cadinol (25, τ-Cad-OH), α-humulene (26, α-Hum), ß-caryophyllene (27, ß-Car), ß-caryophyllene-oxide 
(28, ß-Car-Ox). Additionally, quite specific for some species are the following molecules (no real 
classical terpenic compounds): n-octanol (d) and n-octyl-acetate (e), which both are detectable in 
huge quantities in the species Boswellia papyrifera; and methyl chavicol (f) and methyl eugenol (g), 
which both seem to be specific for the species Boswellia serrata. See also the publications of Hamm 
et al. and Camarda et al. [13,74]. 
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A few specific neutral terpenes isolated from Olibanum are discussed here. In 1967 Corsano 
and Nicoletti described the structure of a new diterpene alcohol, isolated from frankincense, 
and denoted it as incensole (22, Inc) [75]. Furthermore, they described two different 
incensole derivatives, incensole-oxide (22a) and iso-incensole-oxide (22b), in the shortly 
following years (1972 and 1973) [76,77]. In Fig. 1.21 their structures are depicted. The 
authors claimed that these molecules were isolated from the species Boswellia carterii. 
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Fig. 1.21 The structures of specific diterpenes found in incense: Incensole (22), incensole-oxide (22a), 
iso-incensole-oxide (22b, R = H) and its acetate (22b, R = Ac), incensole acetate (23) and iso-
incensole (23a, R = H) and its acetate (23a, R = Ac). Iso-incensole and its acetate seem to be specific 
biomarkers for Boswellia carterii [13,78]. Furthermore the probable predecessor molecules, where 
ese compounds originate from, are shown: cembrene A and cembrene C. th
 
However, the research, concerning the oils from Olibanum, by Obermann and his co-workers 
at the DRAGOCO Company, Holzminden, Germany (now Symrise GmbH & Co. KG) in the 
end of the 1970s gave differing results compared with the ones of Nicoletti and his team. 
Oberman analysed two different Olibanum oils, one was denoted as “Aden” and the other as 
“Eritrea”, by TLC and GC-MS and published his results in 1977 [79]. His final statement had 
been that the sort “Aden” mainly contains neutral triterpenes as it was already described by 
Snatzke and Vertesy in 1966 [49]. Incensole (22), the compound described by Corsano and 
Nicoletti in 1967 for Boswellia carterii [75], was merely found in traces by GC-MS in the 
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 its complete NMR dataset in 2011, including the evaluation of 
s antiprotozoal activity [84]. 
 
“Aden”-type. On the contrary, for the sort “Eritrea” he could detect incensole (22) and 
additionally its acetate (23, Inc-Ac) in great quantities, comparable with the quantities given 
by Corsano and Nicoletti. Furthermore, Obermann realised that the commercial grades 
Somalia and Indian Frankincense were olfactorily similar to the commercial grade “Aden”, 
whereas “Eritrea” had a significantly different odour. The same conclusions have been made 
by the author of this dissertation and are proved chemotaxonomically based on voucher 
specimens and reliable literature results (see experimental part of the dissertation; e.g. 
chapter 3.4). Thus, the sample “Aden” refers to the species Boswellia carterii, respectively, 
Boswellia sacra, since both species are chemotaxonomically identical. Moreover, the 
commercial brand “Aden” usually refers to the Somalian Olibanum, most likely to be 
Boswellia carterii, as it is transported from Somalia to the port of Aden, Yemen, and then 
internationally traded as “Aden”-type [80]. The sort “Eritrea” had been the species Boswellia 
papyrifera, since the specific biomarkers were found for it. Therefore, the publications of 
Obermann, Hamm et al. and Camarda et al. may be comparably consulted for clarification 
[13,74,79]. Additionally, Gacs-Baitz et al. published in 1978 the first complete 13C-NMR 
datasets on the fourteen-membered macrocyclic diterpene class of the incensole family [81]. 
The chemical structures of all molecules discussed up to here are depicted in Fig. 1.21. In 
the same year, 1978, Klein and Obermann in Germany, and, Pardhy and Bhattacharyya in 
India, reported on another new type of diterpenic alcohol of the cembrane type [82,83]. 
Pardhy and Bhattacharyya, who isolated the compound from Boswellia serrata, denominated 
it as serratol (21, Ser-OH). Klein and Obermann isolated the compound from the species 
Boswellia carterii (“Aden”) together with incensole (22). They also deduced already that 
serratol (21) is most probably the predecessor molecule of incensole (see also chapter 3.13 
on biosynthesis, where the probable mechanism is depicted). The structure is presented in 
Fig. 1.22. In addition, Seitz isolated serratol (21) from the resin of Boswellia carterii [56], and 
Schmidt et al. firstly published
it
 
 
Fig. 1.22 The structures of serratol (20, Ser-OH; left) and verticilla-4(20),7,11-triene (24, Vert-
(20),7,11-triene; right). 
additionally clarified by the data presented in this dissertation (see results and discussion; 
4
 
In 2001, Basar et al. reported on a new verticillane diterpene from the essential oil of 
Boswellia carterii (see also Fig. 1.22) [85]. The compound was termed as verticilla-
4(20),7,11-triene (24, Vert-4(20),7,11-triene). Interestingly, this compound has been merely 
found in the essential oils from Boswellia papyrifera by the groups of Hamm and Camarda 
[13,74]. Thus, the sample of Basar was quite probably unfortunately mistaken as Boswellia 
carterii, while it had been indeed the species Boswellia papyrifera instead. This fact may be 
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e.g. chapter 3.4-3.7). Nevertheless, the species Boswellia papyrifera has been most likely in 
many publications mistaken as Boswellia carterii (e.g. [67,68,86-88]). 
Three recent papers from Japan (Yoshikawa et al. [89] and Morikawa et al. [90,91]), 
published in 2009, 2010 and 2011, report on several new minorly occurring compounds, so 
called “Olibanumols”, from the species Boswellia carterii. All these compounds are different 
terpenic alcohols (e.g. monoterpenes, tetra- and pentacyclic triterpenes with OH-functions at 
different positions). Additionally, the newly isolated compounds are only in quite minimal 
amounts present (e.g Olibanumol A = 0.037 % to Olibanumol I = 0.00074 % from [89]) and 
though they show in some cases pharmacological activity, the concentrations are far too low 
to play a significant role for the major actions of anti-inflammatory Olibanum extract 
medications. However, particularly with regard to the finding of new bio-active compounds 
the research is definitely not unnecessary. 
Hitherto, it seems that the major compounds, which may play an important role for the 
pharmacological activities of Boswellia species, have been almost completely isolated and 
structurally elucidated, at least for the species Bpap, Bser and Bsac/Bcar. 
 
 
1.5 Pharmacology 
 
About the use of frankincense resins in older and ancient times, there is of course no real 
scientific data obtainable. Merely, the Papyrus Ebers and old scripts of the Ayurvedic 
communities in India giving witness on the use as a therapy [3]. Though frankincense was 
still mentioned in older monographs of pharmacy, the knowledge about as a herbal remedy 
became obsolete within the 20th century [8]. The reason therefore had been the ascendency 
of modern science and the pharmaceutical industry. For example, the accidental discovery of 
penicillin by A. Fleming in 1928 or the industrial production of Aspirin® by the German 
company Bayer [92,93]. So far, these single dosage preparations are the classical drug 
administrations of conventional medicinal treatment [94]. However, this way does not seem 
to be the final solution for the treatment of several diseases. Antibiotics loose more and more 
its efficacy since several bacterial strains are reported to show resistances against them [95]. 
The search for new molecular entities, useful as antibiotics, is difficult. Additionally, many 
medications show severe side effects when long-term used. Acetyl salicylic acid, for 
example, can cause ulceras since several homeostatic mediators are inhibited, and 
corticoids can lead to osteoporosis [94]. Therefore, the research on alternative treatments, 
showing fewer side effects, is still ongoing. 
 
 
1.5.1 Inflammatory Processes in General 
Invasive foreign matters and/or pathogens which infiltrate the organism have to be swiftly 
eliminated and repelled to avoid serious damages. Normally, the defence is responded by a 
locally delimited inflammation reaction of the organism. This inflammatory response is 
initiated by pathogens, physical and chemical noxins or the overreaction of the immune 
system (e.g. allergens). Symptomatically, these reactions are usually characterised by 
swellings and reddening of the tissue, including pain and local heating. The defence reaction 
is initiated by different immune cells releasing several classes of biological messenger 
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substances, the so called inflammatory mediators, coordinating and enhancing the 
immunological response. Two important mediator classes represent the prostaglandins and 
the leukotrienes, both members of the eicosanoid family, which originate from the so called 
arachidonic acid cascade [56,94,96]. The first step of this cascade is depicted in Fig. 1.23. 
Currently, acute inflammations are treated with substances inhibiting the synthesis of 
prostaglandins. Theses molecular entities are denoted as non-steroidal anti-inflammatory 
drugs (NSAIDs), such as acetyl salicylic acid or ibuprofen. Their effect is based on the 
inhibition of the cyclooxygenases 1 and 2 (COX-1, COX-2) preventing the synthesis of 
prostaglandins involved in inflammatory processes. 
 
 
 
Fig. 1.23 The first step with the release of AA from the phospholipids of the cell membrane by the 
enzyme PLA2. This step can be inhibited by the class of corticoids (e.g. cortisol). For further details 
see text. 
 
In contrast to acute inflammations, in a chronic inflammatory process the immune system is 
not able anymore to maintain its defence reactions locally and timely limited. The 
inflammatory process sustains continuously, though actually no immune response is 
necessary. Chronic diseases, revealing this phenomenon, are for example asthma, 
rheumatism, chronic bronchitis, psoriasis, neurodermatitis, Crohn’s disease and ulcerative 
colitis. All these diseases are correlated with high levels of leukotrienes, especially 
leukotriene B4 [97], and prostaglandins, particularly PGE2 [98], maintaining the inflammatory 
process at a constant level. The leukotriene pathway and the synthesis of PGH2, the 
precursor molecule of PGE2, are depicted in Fig. 1.24. 
Leukotrienes originate from arachidonic acid by lipoxygenases (5-, 11-, 12- and 15-LO; the 
number refers to the position where the AA is oxidised), via hydroperoxyeicosatetraenic acid 
(5-, 11-, 12- and 15-HpETE) intermediates, which are subsequently transformed into the 
leukotrienes (LTB4, LTA4, LTC4, LTD4, and LTE4) [99]. They are preferably synthesised by 
inflammatory cells like polymorphonuclear leukocytes, macrophages and mast cells. 
Especially the 5-LO of the classes of lipoxygenases is considered to be involved in the 
maintenance of chronic diseases (e.g. asthma) by production of leukotrienes [100]. 
The prostaglandins formed by most cells in the human body are immediately and locally 
signalling mediators acting to their site of synthesis. They are synthesised de novo from 
membrane-released arachidonic acid (AA) when the immune response is activated (e.g. 
mechanical trauma, chemical stimulus etc.). The enzymes involved in this process, receiving 
their substrates from COX-1 and COX-2, are the so called prostaglandin synthases (e.g. 
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currently research on mPGES-1 inhibitive compounds not affecting COX enzymes 
04]. 
 
PGI, PGD, PGF, PGE and TXA2 etc.) depicted in Fig. 1.25. Here especially the mPGES-1 
seems to be a promising target for inhibition, as it is assumed to be involved in inflammatory 
processes [101-103]. One problem of COX-inhibitors (NSAIDs) and COX-2 specific inhibitors 
(denoted as coxibs) is that the synthesis of several other and essential mediator compounds 
is inhibited, thus, causing side-effects (e.g. thromboxanes, TXA2 and TXB2, necessary for 
platelet aggregation, or gastrointestinal injury and renal irritations, apparently due to impaired 
biosynthesis of other physiologically relevant prostanoids [98]). Additionally, COX-1 is the 
enzyme constitutively expressed to synthesise prostaglandins useful for homeostasis (syn. 
maintenance) of the organism (e.g. protection of the gastric mucosa etc.); whereas, on the 
other hand, COX-2 is most likely involved in the synthesis of prostaglandins when the 
immune system is offended by exogenous toxicants, and thus is increasingly expressed 
[101] (It should be noted that this is merely a short simplification of rather complex 
mechanisms and interactions which are hitherto not nearly completely understood). 
Therefore, it was tried to develop COX-2 selective inhibitors which show reduced 
gastrointestinal complications. However, recent clinical trails indicated a significantly 
increased cardiovascular risk, if COX-2 is inhibited [98,101]. These facts have been leading 
to the 
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Fig. 1.24 The enzymatic steps of COX-1 and COX-2 giving finally PGH2. The biosynthesis steps for 
the 5-LO, respectively, the 11-, 12- and 15-LOX giving lastly the class of leukotrienes are also 
depicted. COX-1 and COX-2 can be inhibited by NSAIDs. For 5-LO inhibition merely the redox 
inhibitor Zileuton is approved (Asthma). ß-AKBA (6), according to the results of Ammon et al. 
[105,106] is regarded as a non-redox inhibitor of 5-LOX, though the evidence in vivo is not absolutely 
compelling so far. For further details see text. 
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In the present, severe chronic diseases are conventionally treated with glucocorticoids such 
as cortisol. These inhibit the enzyme phospholipase A2 (PLA2) and consequently stop the 
production of leukotrienes and prostaglandins as it is shown in Fig 1.23. The problem with 
these treatments of chronic diseases by NSAIDs and/or glucocorticoids is the occurrence of 
partly severe side-effects, as explained before, particularly when they are used over a 
greater period of time.  
Thus, the research on alternative treatments is still ongoing. One approach is to find 
selective redox- and non-redox lipoxygenase inhibitors. However, most of them revealed 
strong side effects during clinical trials or are less efficient in vivo than in vitro [107]. 
 
O
O
COOH
OH
PGH2
OH
HO
O
COOH
PGI Synthase
PGI2
(prostacyclin)
OH
HO
HO
O
COOH
6-keto-PGF1alpha
COOH
OH
O
HO
PGD2
COOH
OH
HO
O
PGE2
COOH
OH
HO
HO
PGF2alpha
PGD
Synthase PGF Synthase
PGE
Synthase
mPGES-1
mPGES-2
COOH
OH
O
O
TXA Synthase
TXA2
COOH
OH
OHO
OH
TXB2
 
 
Fig. 1.25 The further reaction steps leading to different classes of prostaglandins and the 
thromboxanes (TXA2 and TXB2). Especially the formation of PGE2, via COX-2 and mPGES-1 
enzymes, is involved in several inflammatory activities [101]. Therefore, the selective inhibition of 
mPGES-1 is a target of major interest since fewer side effects are assumed, if only this enzyme is 
blocked. For further details see text. 
 
Currently, the selective suppression of microsomal prostaglandin E2 synthase-1 (mPGES-1) 
seems to be a promising target to achieve anti-inflammatory effects without interfering other 
enzymes (e.g. COX-1 and 2) necessary for homeostatic processes [98]. 
Finally, the aim is to find and/or develop a therapeutic agent which is similar efficient as the 
NSAIDs and/or glucocorticoids, and additionally almost free from severe side effects. This 
   35
Introduction 
_________________________________________________________________________________ 
 
n 5-LO was 
would be an improvement for many patients suffering from the temporary situation, the 
chronic disease and the side effects of conventional therapies. Therefore, extracts of 
frankincense resins may be a promising alternative [8,108]. 
 
 
1.5.2 Pharmacology of Frankincense Extracts and their Single Compounds 
Extracts from frankincense resins have been used in traditional medicine in India and African 
countries for the treatment of a variety of diseases [3]. In the Indian folk medicine Ayurveda, 
it was mainly applied to cure chronic arthritis and bronchitis [8]. Thus far, a methanolic 
extract from the Indian frankincense, Boswellia serrata (salai gugal), is distributed under the 
brand name Sallaki® (from the company GUFIC-BIOSCIENCES LIMITED, Karnataka, India). 
This medication is only authorised as treatment for chronic arthritis in the Swiss canton 
Appenzell-Außerrhoden, at least until the end of 2013 [109]. Thus far, there is no - on 
unequivocal clinical evidence based - medication available. 
In recent years the interest in preparations, based on frankincense resins as a treatment for 
several diseases, ascended again. The first scientific evidence on the anti-inflammatory 
effects of a Boswellia extract in vivo (rat- and mice model) was published by Singh et al. in 
India in 1986 [110]. Further in vivo studies (animal- and human models) revealed 
encouraging activities of these extracts in the treatment of several inflammatory diseases 
and even malignant tumours [111-119]. Though the evidence for the effectiveness of 
Boswellia serrata is hitherto encouraging but not convincing, the existing data do warrant 
further investigation of this herbal medicine, according to the review of E. Ernst in 2008 [6]. 
The first investigations on the anti-inflammatory properties of Olibanum preparations, under a 
pharmacological point of view, were conducted by the working group of Ammon in Tübingen, 
Germany, in 1991 [5,97]. They observed the specific inhibition of the leukotriene B4 (LTB4, 
see also Fig. 1.24) synthesis through an extract of Boswellia serrata. With identification of the 
boswellic acids ß-BA (3), ß-ABA (4), ß-KBA (5) and ß-AKBA (6), they elucidated the 
compounds which have been held responsible for the inhibition of the enzyme 5-
lipoxygenase (5-LO, see also Fig. 1.24). Furthermore, Ammon et al. revealed that boswellic 
acids are specific non-redox/non-competitive inhibitors of 5-LO interacting at an allosteric 
position distant from the active centre of the enzyme [105,106,120]. They also figured out the 
importance of a hydrophilic group (e.g. -COOH or –CH2-OH) at C-4 and a keto-function at C-
11 for an effective inhibition [120]. Their investigations led to the conclusion that ß-AKBA (6) 
is the most effective 5-LO inhibitor (IC50 = 1.5 µM), followed by ß-KBA (5) and ß-BA (3), each 
IC50 = 4.5 µM, and ß-ABA (4) with an IC50 = 7 µM [56,120]. It should be noted that these 
tests were implemented with collected peritoneal exudate leukocytes (PMNL) from Wistar 
rats [5]. Evaluations of other cell systems and species gave differing results. The group of 
Ammon et al. obtained an IC50-value of 16 µM for ß-AKBA (6) with purified human 5-LO 
[121]. Werz et al., who used a cytosolic fraction of human cells of purified 5-LO instead, 
determined an IC50-value of 50 µM for ß-AKBA (6) [122]. Furthermore, at a defined 
concentration range of ß-KBA (5) and ß-AKBA (6) even a stimulatory effect o
observed [123,124].  
However, the data generated and especially the findings of rather low ß-KBA (5) and ß-
AKBA (6) plasma concentration levels in human blood samples [125-127] suggested that not 
only 5-LO may be a target enzyme for the ingredients of Boswellia extracts [128]. 
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IC50-values for ß-AKBA (6) and the new enzymatic 
rgets [56,96,129] as shown in Tab 1.2. 
 
Tab. 1.2 IC50-values on 1 and COX-2. 
IC50 ß-AKBA (6)
 [µM] 
Test
Furthermore, there may be other, hitherto unknown targets, responsible for the anti-
inflammatory properties of frankincense resins. The research groups of Jauch and Werz 
carried out so called target-fishing experiments, where ß-BA (3) and ß-KBA (5) were 
immobilised on a sepharose gel [96]. There, the interaction of ß-KBA (5) with 12-
lipoxygenase (12-LO; see also Fig. 1.24) in a cell lysate from human leukocytes was 
observed. This interaction had been excluded before then, since 5 was regarded together 
with ß-AKBA (6) as a specific 5-LO inhibitor [5]. A specific interaction of the ß-KBA (5), bound 
to sepharose, with 5-LO was not detectable. Nevertheless, this may be arbitrary as the 
sepharose-ß-KBA (5) complex may be not similar to free ß-KBA (5) in the cell. Thus, 
interpretations of in vitro findings have to be extrapolated carefully to in vivo situations. For 
COX-1 and COX-2 were additionally interactions determined, whereas COX-1 was stronger 
bound [129]. These targets, COX-1 and COX-2, had been also excluded by then [130]. The 
group of Werz determined thereupon the 
ta
of ß-AKBA (6) up  12-LO, COX-
  System 
12-LO 15 cell-free 
COX-1 6 - 23 
COX-2 100 isolated enzyme
whole cells 
COX-1 28 isolated enzyme
 
A comparison of the IC50-values from ß-AKBA (6) upon 12-LO and COX-1 with the values for 
the inhibition of 5-LO revealed a certain similarity [96]. Comparative studies by Werz et al. 
with known COX-1 inhibitors such as ibuprofen and Aspirin® showed that the action of ß-
AKBA (6) in the cell-free systems is analogue ibuprofen and even better than Aspirin®. It was 
further approved that the inhibition of COX-1 is reversible and occurs in the active centre 
[96,129]. These investigations prove that several enzymes of the arachidonic acid cascade 
are influenced by ß-AKBA (6), and, besides the inhibition of leukotriene biosynthesis, the 
prostaglandin synthesis may be equally affected. Finally, Werz and Jauch concluded that ß-
AKBA (6) can not be regarded as selective 5-LO inhibitor anymore [96]. How these findings 
may be correlated with anti-inflammatory actions in vivo is thus far not clarified. The IC50-
values for inhibition of 12-LO and COX-1 have been far above the determined plasma 
thepsin G could 
play a pivotal role for the antiphlogistic action of ß-AKBA (6) in vivo [96,132]. 
concentrations of ß-AKBA (0.10 – 0.56 µM) [125-127,131]. 
In addition to the newly discovered targets of the arachidonic acid cascade, the target-fishing 
tests by Werz and Jauch identified cathepsin G as a before unknown enzyme in correlation 
with anti-inflammation of boswellic acids [96,132]. Cathepsin G belongs to the family of 
peptidases or proteases, which are included in lysosomes and after release contribute to 
phagocytosis of exogenous microorganisms. They additionally serve for the activation of 
specific receptors participating in different inflammatory processes [56,96,132]. The 
determined IC50-values for different boswellic acids lay in the range of the ascertained ß-
AKBA (6) plasma concentrations (see Tab 1.3). Based on these findings, ca
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Tab. 1.3 IC50-value s sin G. 
 
IC50 c n G
 [µM] 
Test System
 
s of boswellic acid upon cathep
athepsi
ß-AKBA (6) 0.6 cell-free 
ß-BA (3) 0.8 cell-free 
ß-ABA (4) 1.2 cell-free 
ß-KBA (5) 3.7 cell-free 
 
Furthermore, the working group of Ammon et al. evaluated the 5-LO activity of the artefacts 
11-OMe-ß-ABA (8) and 9,11-dehydro-ß-ABA (10) originating from the decomposition of 11-
OH-ß-ABA (7). Their findings concluded that 8 is an incomplete inhibitor, whereas 10 almost 
totally suppressed the 5-LO activity. They could not isolate 7 due to its fast decomposition 
[55]. In contrast, Seitz (dissertation, 2008 [56]) has been the first person reporting on the 
successful isolation of compound 7. Moreover, newly isolated compounds showed an 
interesting pharmacological behaviour. In collaboration with the group of Werz, the activity of 
3-α-O-acetyl-28ß-OH-lupeolic acid (see Fig. 1.17, compound 12b), purified from Boswellia 
carterii, for inhibition of 5-LO was comparable with ß-AKBA (6), and for inhibition of cathepsin 
G it showed similar activity as ß-ABA (4). Further examples can be found in her dissertation 
6]. 
formation, 
also 
 partially synthesised compound α-AKBA (see Fig. 1.14) has been 
 inhibition of 
 Agency designated an orphan drug 
consumption of Boswellia serrata preparations significantly increased the plasma levels of 
[5
 
Another interesting behaviour was observed for the class of tirucallic acids (see Fig. 1.18). 
Boden et al. showed in 2001 that 3-Oxo-TA (13) even stimulates the leukotriene synthesis in 
intact polymorphonuclear cells [133]. However, by exceeding a certain concentration level 
the leukotriene synthesis was suppressed again revealing a quite contradictory behaviour. In 
cell-free systems 3-Oxo-TA (13) merely decreased the 5-LO product 
demonstrating the pivotal role of an intact cell structure for its activating property. 
In context to that, the work of Estrada et al. [70], recently published in 2009, revealed 
significant anti-tumour activities for the tirucallic acids α-Ac-7,24-dien-TA (18) and ß-Ac-8,24-
dien-TA (19). Their results showed that these compounds, 18 and 19, induce apoptosis in 
prostate cancer cell lines, but not in nontumorigenic cells. Thus, the tirucallic acids may 
play a crucial role for the bioactivity of multi-compound containing frankincense extracts. 
In two further publications by Büchele et al. in 2005 and 2006, respectively, the apoptosis 
inducing property of the
demonstrated [58,134]. 
In context to anti-tumour actions, several papers have been published hitherto, revealing 
inhibition of human topoisomerases I and IIa and apoptosis in HL60- and CCRF-CEM cells 
by application of boswellic acids [135,136]. There are several more publications giving 
evidence on the anti-proliferative action upon cancer cell lines [137-139], the
implant rejection [140] and the inhibition of elastase in human leukocytes [141]. 
Furthermore, based on positive data on the treatment of peritumoral brain edema 
accompanying gliomas [142], the European Medicines
status to Boswellia serrata resin extracts in 2002 [143]. 
Metabolic studies revealed that a concomitant high-fat food intake during the orally 
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d COX-2). 
boswellic acids (1-6). The control group (fastened state) showed lower plasma concentration 
levels. Interestingly, ß-BA (3) revealed the highest plasma concentration levels [125]. 
Another in vitro and in vivo study by Krüger et al. [143], published in 2008, gives evidence 
that ß-KBA (5) but not ß-AKBA (6) undergoes extensive phase I metabolism, and that ß-
AKBA (6) is not deacetylated to ß-KBA (5). 
Recent studies, measuring the plasma concentration levels of boswellic acids, additionally 
showed that ß-BA (3) seems to be the boswellic acid with the throughout highest plasma 
concentration levels [126,144]. Thus, this compound (ß-BA, 3) could be an interesting 
candidate responsible for the major pharmacological actions in Boswellia preparations. 
Therefore, the research group of Werz tested recently boswellic acids and derivates thereof 
upon the inhibition of microsomal prostaglandin E2 synthase-1 (mPGES1; see also Fig. 
1.25), in order to evaluate a further molecular basis for the anti-inflammatory actions of 
Boswellia extracts [104]. After evaluation of defined boswellic acids in cell-free and cell-
based assays as well as carrageenan-induced mouse paw oedema and rat pleurisy models, 
their key-findings suggest that especially ß-BA (3) may contribute to the overall anti-
inflammatory activity in vivo. Thus, the decrease in PGE2-product formation may occur 
through selective mPGES1-inhibition. Furthermore, ß-BA (3) did not significantly affect the 6-
keto PGF1α-formation (see also Fig. 1.25) in the rat model, whereas indomethacin (a NSAID) 
did. Hence, revealing a benefit for ß-BA (3) in selectivity by not significantly affecting other 
arachidonic acid cascade enzymes (e.g. COX-1 an
 
Other compounds which recently gained some attention are incensole (Inc, 22; see also Fig. 
1.21) and its acetate (Inc-Ac, 23; see also Fig. 1.21). Moussaieff et al. published three 
papers on these compounds in the years 2007 and 2008 [87,145,146]. Their key-findings 
suggested that incensole (22) and especially incensole acetate (23) are two novel anti-
inflammatory compounds inhibiting the nuclear Factor-κB activation which also may 
contribute to inflammatory processes. According to them, the boswellic acids did not reveal 
any influence in this assay, though the concentrations of Inc-Ac (23) for inhibition were rather 
high (140 – 560 µM) [87]. In another paper they reported on the agonistic effect of Inc-Ac 
(23) upon the transient-receptor-potential-vanilloid-3 (TRPV3), an ion channel implicated in 
the perception of warmth in the skin. The role of TRPV3 channels remains unknown hitherto. 
They showed that Inc-Ac (23) agonised the TRPV3 channel, causing anxiolytic-like and anti-
depressive-like behavioural effects in wild-type mice [145]. Additionally, in a further mouse 
model, they investigated the potential of Inc-Ac (23) as novel neuroprotective agent. In this 
head injury model, Inc-Ac (23) reduced glial activation, inhibited the expression of interleukin-
1b and tumor necrosis factor-α-mRNAs, and induced cell death in macrophages at the area 
of trauma [146]. These results revealed another molecular entity, isolated from Boswellia 
resins, with an interesting and perhaps promising pharmacological potential. In 2012, 
Moussaieff et al. reported also on a protective effect of Inc-Ac (23) on cerebral ischemic 
injury in a mouse model [147]. 
Furthermore, anti-microbial actions of the essential oils from frankincense resins against 
Gram-positive and Gram-negative bacteria have been described [74]. 
Generally, a good overview on important publications on all medical topics concerning 
Boswellia can be gained, if in the online PubMed library the term “boswellia OR boswellic 
acid” is entered as a key-word [148]. 
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Thus far, it is still absolutely elusive how the uncountable amounts of compounds, occurring 
in frankincense resins, influence pharmacological activities in vivo. Possibly, these 
substances interact in a synergistic and/or antagonistic manner. It is also still unclear how 
these target enzymes (e.g. cathepsin G, mPGES-1, COX-1 and COX-2 or 5-LO) react with 
different combinations of these single compounds. 
The proposal of synergistic and antagonistic effects was established on a scientific basis by 
Berenbaum in 1989 [149]. Basically, the results of Berenbaum conclude that if two or more 
bioactive substances are evaluated in a biological assay, these substances can be 
enhancing each other in their bioactivity, thus, leading to a more effective inhibition of the 
target (synergism); or, they could deteriorate the bioactivity of each other, hence, giving a 
less effective inhibition of the target enzyme (antagonism). A third case is possible, which is 
the so-called zero-interaction, when neither a synergistic nor an antagonistic effect can be 
detected. Thus, the compounds do not interact in any way with each other and just the single 
activities of each are added. A review on this interesting field, especially concerning 
phytotherapeutics like frankincense resins, has been published by Wagner and Ulrich-
Merzenich in 2009 [150]. In addition to that, the multi-compound containing frankincense 
preparations may reveal a still unknown great potential, if a synergistic effect of the single 
compounds can be approved by scientific evidence. Unfortunately, convincing experiments 
with frankincense extract preparations, revealing such phenomena, are so far still lacking. 
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1.6 Aim of the Study 
 
It was shown in chapter 1 (Introduction) that extracts of resins from frankincense and isolated 
compounds thereof reveal several pharmacological activities. Beside the primarily observed 
anti-inflammatory actions, there have been also publications on the anti-tumour and anti-
microbial potential of this natural product. The main constituents, held responsible for the 
pharmacological actions, are the boswellic acids (see Fig. 1.8). However, these extracts 
contain still an innumerous amount of several different types of terpenes and hence these 
may contribute to the overall anti-inflammatory activity in a synergistic and/or antagonistic 
manner [150]. 
Especially the tirucallic acids (see Fig. 1.18) showed a concentration-dependent 
contradictory behaviour. At certain concentrations they stimulated the leukotriene 
biosynthesis in intact polymorphonuclear cells, and after exceeding a defined concentration 
the inhibition of 5-LO was again observed [133]. Thus, one aim of the study presented here 
has been the development of a HPLC-method capable of quantifying the amounts of tirucallic 
acids in frankincense extracts, since no analytical work hitherto has published any detailed 
quantitative results on the tirucallic acid content in Boswellia preparations. Therefore, 
prepared resins from Boswellia papyrifera, Boswellia serrata and Boswellia sacra, 
respectively, Boswellia carterii, were evaluated by different analytical tools (TLC, HPLC and 
GC). 
Furthermore, since the literature reported in some cases contradictory results on the 
biomarker compositions of Boswellia carterii and Boswellia papyrifera, it had been tried to 
clarify these misinterpretations by investigation of certified sample material (voucher 
specimen). As both species are considered as African frankincense, it has been most likely 
that the species Boswellia papyrifera (Eritrea, Ethiopia and Sudan) had been purchased in 
many cases as Boswellia carterii (Somalia) instead, leading to falsely reported facts 
[35,67,68,70,75,85,86,88,146]. The clarification was additionally carried out by analysis of 
the three common species Boswellia papyrifera, Boswellia serrata and Boswellia sacra, 
respectively, Boswellia carterii, with the afore mentioned tools (TLC, HPLC and GC). 
To achieve this, already known, as external standards for HPLC-quantitation, and even new 
substances had to be isolated and purified from the extracts of Boswellia papyrifera and 
Boswellia carterii by conventional extraction (liquid-liquid) and separation methods (liquid 
chromatography). Their structures had to be elucidated by a combination of mass 
spectrometric (MS) and 1D and 2D-nuclear magnetic resonance experiments (NMR). Finally, 
the combination of all techniques (TLC, HPLC and GC) should give methods which definitely 
could clarify the identity of an unknown frankincense resin species being questioned. In 
addition, the HPLC method should be feasible to quantify as much major compounds as 
possible in order to gain a better knowledge on the overall composition of these resins. 
Through quantification of certain molecules, some evidence on the biosynthesis preferences 
of each species should be elucidated. 
In cooperation with the working group of Prof. Dr. Oliver Werz (Tübingen, Germany; now 
Jena, Germany) some of the isolated compounds and multi-compound containing extracts 
had to be tested to reveal their pharmacological potential. 
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To summarise, this work should give an intellectual tool on how to distinguish the resins of 
the three mostly distributed Boswellia species (Boswellia papyrifera, Boswellia serrata and 
Boswellia sacra, respectively, Boswellia carterii) in a chemotaxonomic point of view. In 
addition, it was tried to establish a HPLC-method capable of quantifying as many compounds 
as possible in the resin matrix, but particularly the class of tirucallic acids since no analytical 
method before has been revealing something about their quantities in detail. Furthermore, 
some characteristics on the biosynthesis differences of each species may be obtained. And 
the pharmacological potential of newly isolated chemical entities, structurally defined by MS 
and NMR experiments, should be investigated. 
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2. Experimental Part 
2.1 Material and Methods 
 
2.1.1 Resin Material 
Most of the resin material used for the investigations reported here was obtained from the 
distributor Gerhard Eggebrecht Vegetabilien und Harze, Doppelreihe 1a, D-25361, Germany. 
The material was already correctly assigned as authentic frankincense resin material in the 
PhD thesis of Dr. Jochen Bergmann [17] by comparison with voucher specimens. 
Furthermore, the data basis presented in this thesis guaranteed authenticity of the material 
purchased. Resins, obtained from other distributors and analysed, are stated explicitly in the 
corresponding chapters. A table of all analysed samples is shown in chapter 3.14 (Table 
3.37). 
 
Boswellia papyrifera (Bpap) 
Distributor: Eggebrecht; Denomination: Gum olibanum (Frankincense) Eritrea 1. Choice; 
Origin: Eritrea (Manufacturer information). 
 
Boswellia serrata (Bser) 
Distributor: Eggebrecht; Denomination: Gum olibanum (Frankincense) Indian Siftings or 
Gummi Olibanum indisch No. 1; Origin: India (Manufacturer information). 
 
Boswellia carterii (Bcar) 
Distributor: Eggebrecht; Denomination: Gum olibanum (Frankincense) Aden 1. Choice and 
Somalia 1. Choice; Origin: Somalia (Manufacturer information). 
 
Boswellia sacra (Bsac) 
Distributor: Eggebrecht; Denomination: Gum olibanum (Frankincense) Oman white No. 1; 
Origin: Oman (Manufacturer information). 
 
Article numbers of each of the resins (Bpap, Bser and Bsac, respectively, Bcar) are indicated 
in the corresponding experimental chapters.  
 
Voucher Specimen 
Certified resin samples from Bpap and Bsac were obtained from the Royal Botanic Gardens, 
Kew Gardens in England, UK, donated by Mrs. J. Steele. Additional samples of Bsac and 
Bcar were received by Dr. Jochen Bergmann from Dr. M. Al-Amri (Ministry of Agriculture, 
Rumais Research Station, Muscat, Oman) during his visit to Oman in 2004-2005 and from 
Mr. Giama, Bremerhaven, Germany. Original Gufic tablets (Bser, Sallaki Tablets®) from 
India and Bser-siccum 96% ethanolic extracts were obtained from AureliaSan GmbH, 
Bisingen, Germany. 
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50-70 %).  
2.1.2 Solvents and Chemicals 
All chemicals and solvents were obtained from Sigma Aldrich (Steinheim, Germany) or VWR 
(Darmstadt, Germany) and of analytical reagent grade unless stated otherwise. Solvents for 
extraction, thin-layer and flash chromatography (e.g. DCM, Et2O, pentane, etc.) were distilled 
prior to application. HPLC solvents (ACN, MeOH and H2O) were of appropriate “HPLC 
grade” purity. NMR spectra were normally recorded in deuterated chloroform (CDCl3; 99.8 % 
D) if not stated otherwise. HPLC quantitation standards (see also chapter 3.6.3.1) were 
isolated from Bpap by flash column chromatography and purified by preparative HPLC (purity 
> 99 % by HPLC) and the identity of each molecule was verified by co-injection HPLC tests, 
MS and NMR evaluation (see also [56]). Any peculiarities and differences from the 
descriptions given here are mentioned in the corresponding experimental chapters. 
 
 
2.2 Extraction Procedures 
 
2.2.1 Preparative Extraction Scale (Soxhlet Apparatus) 
The extraction procedures generally followed the descriptions already given in the work of 
Bergmann and Seitz [17,56]. The isolation of huge amounts of resinous materials (> 100 g) is 
also described in the paper of Paul et al. [59]. A briefly general description is given here. The 
respective resin (e.g. 200 g) was cooled in a freezer (for 1-2 h) and powdered in an electrical 
mixer. The powder was filled into an extraction thimble, covered with wed and extracted with 
1.5 l DCM or Et2O in a Soxhlet apparatus overnight. The solvent was removed under 
vacuum at 40 °C and a crude yellow and fragrant solidus material was obtained (lipophilic 
raw extract = RE, yield: ca. 
 
2.2.2 Discontinuous Extraction (Separation Funnel) 
The discontinuous extraction was implemented in a separation funnel. The crude extract 
(Soxhlet Apparatus) was dissolved again in ca. 250 ml Et2O and extracted with 100 ml 5 % 
(m/m) KOH solution. The alkaline aqueous solution was then extracted with Et2O again (3 x 
30 ml). The combined organic phases were washed with brine (saturated NaCl), dried 
(MgSO4) and evaporated in vacuo. The neutral fraction was obtained (fragrant and yellow 
orange oil, neutral fraction = NB; yield: 30–40 %). The alkaline aqueous phase was acidified 
with cooling to pH 2-3 (conc. HCl) and extracted with Et2O (3 x 50 ml). After combination of 
the organic phases, it was washed with brine, dried (MgSO4) and evaporated to dryness in 
vacuo. A less fragrant yellowish solid material was obtained (acid fraction = RS; yield: ca. 
20–30 %). 
 
2.2.3 Continuous Extraction (Kutscher-Steudel Perforator) 
The continuous extraction was carried out in a Kutscher-Steudel Perforator. The crude 
extract (Soxhlet Apparatus) was dissolved in ca. 250 ml Et2O, treated with 3 – 4 litres of 5 % 
(m/m) KOH and equilibrated with Et2O overnight. The organic phase was separated, dried 
(MgSO4) and concentrated under vacuum to give fragrant and yellow oil (neutral compounds 
= NB; yield: 30–40 %). The alkaline aqueous phase was acidified with cooling to pH 2-3 
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hase, respectively. 
(conc. HCl) and extracted with Et2O in the Kutscher-Steudel apparatus overnight. After 
separation, the organic phase was dried (MgSO4) and the solvent was removed under 
reduced pressure, leading to a less fragrant yellowish light brown powder (acid fraction = RS; 
yield: 20-30 %). 
 
2.2.4 Analytical Extraction Scale (TLC, HPLC) 
Minor amounts of resins for analytical evaluations (TLC, HPLC) were extracted using the 
following standard operation procedure: The resinous material (5-10 g; great sample 
population as even within the same sample batch great differences may occur) was put in a 
freezer (- 30 °C) for ca. 1 h. Afterwards, the resin chunks were powdered using an electrical 
mixer or a mortar and pestle. Approximately 300 – 600 mg from this powder were dissolved 
in 10 ml Et2O and sonicated for 15 min (ultra-sonic bath). The colloidal solution was then 
filtered (0.2 µm; Filtropur S, Sarstedt, Nürnbrecht, Germany) and the filtrate was evaporated 
in vacuo. The amount of raw extract (RE) was determined (yield ca. 50-60 %) and an aliquot 
(ca. 10 mg) for further HPLC analysis was saved. The rest was dissolved in 4 ml Et2O and 
12 ml KOH (1 M) were added, and the RE was extracted in a separation funnel (V = 50 ml) 
with 3 x 4 ml Et2O. The organic phases were combined (ca. 10 – 12 ml) and re-extracted 
with 5 ml KOH (1 M). Afterwards, the organic phase was dried (MgSO4), filtered and 
evaporated in vacuo, leading to the neutral fraction (NB) with a yield of ca. 20-30 % referring 
to the overall weighed sample amount. The combined KOH-phases (ca. 15–17 ml) were 
acidified with HCl (1 M) until precipitation (white solid) occurred (pH ca. 1-3). Subsequently, it 
was extracted with 3 x 8 ml Et2O and the combined organic phases were dried (MgSO4), 
filtered and evaporated in vacuo, giving the acid fraction (RS) with a yield of ca. 20-30 % 
referring to the overall weighed sample amount. Note that in some cases, especially 
experienced for samples of Bsac/Bcar (expectably high contents of BAs, 1 and 3, and ABAs, 
2 and 4), the phase separation (alkaline – organic) can be difficult (formation of an emulsion). 
To avoid this disturbing phenomenon, it is helpful to increase the difference in density 
between the phases by addition of brine or organic p
 
2.2.5 Steam Distillation (For GC analysis) 
A certain amount of the oily neutral compounds from Bpap, Bser and Bcar (ca. 1 g; see 
chapter 3.5) was dissolved in a bit of acetone (ca. 3 ml) in a 250 ml flask and 100 ml of H2O 
were added (milky white emulsion). The apparatus for steam distillation is shown in Fig. 2.1 
The mixture (oil and water) was stirred under heating (oil bath) and a slight vacuum (boiling 
temperature: 55 – 60 °C). The distillate (Liebig condenser) was collected in a cooled 
receiving flask (ice bath) and the process was stopped when almost all of the water was 
distilled. The aromatically aqueous phase (a few drops of oil were visible) was extracted with 
2 x 20 ml Et2O. The combined organic phases were dried (MgSO4) and evaporated in vacuo, 
giving a colourless very aromatic essential oil (yield: 1.5 – 6.7 % of the weighed neutral 
compounds; see also chapter 3.5). The samples were stored at 4 °C and used for further 
GC-FID analysis. 
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Fig. 2.1 The apparatus for steam distillation (see also text). 
 
 
2.3 Chromatographic Techniques 
 
2.3.1 Thin-Layer Chromatography (TLC) 
TLC Silica gel 60 F254 Multiformat prescored to 5 x 10 cm glass plates (stationary phase) 
were purchased from Merck (Darmstadt, Germany). The mobile phase standardly consisted 
of a mixture of two parts of pentane and one part of Et2O plus 1 % (v/v) of HOAc (unless 
stated otherwise). TLC plate start lines were drawn (pencil) at 1.5 cm; giving an elution 
distance of maximal 8.5 cm. Spots were put on with a small capillary. UV detection (254 nm) 
was carried out by a conventional UV light source (Duo – UV – Source for Thin-layer and 
Column chromatography, Desaga, Heidelberg, Germany). Chromatograms were further 
developed by an unspecific dyeing reagent (0.5 ml anisaldehyde in 50 ml HOAc plus 1 ml 
conc. H2SO4). After development of the chromatograms, the TLC plate was completely 
immersed into a solution of this dyeing reagent and heated with a heat gun until the coloured 
spots appeared. The spots were visually detectable after colour development at room 
temperature (ca. 15 – 30 min). The standard sample preparation procedure, if not stated 
otherwise, was as follows: The different olibanum resins were cooled in a freezer to −30 °C 
(1–2 h) and powdered in an electrical mixer. The powder (1 g) was dissolved in 80 ml 
methanol or diethyl ether (MeOH and Et2O as solvents for extraction of the powdered resins 
give identical TLC chromatograms) in a 100 ml volumetric flask and sonicated for 20 min (the 
resin will not be completely dissolved). Afterwards, 20 mL MeOH (or Et2O) were added (final 
volume = 100 ml). Aliquots (1 ml) were taken from the filtered solution (0.2 μm; Filtropur S; 
Sarstedt, Nürnbrecht, Germany) for further TLC analysis. See also the paper on TLC 
analysis of Bpap, Bser, Bsac/Bcar of Paul et al. [11]. 
 
2.3.2 Flash-Column-Chromatography 
Normal phase (NP) silica gel (stationary phase) with particle size 40-60 µm was purchased 
from Merck (Darmstadt, Germany). The mobile phase standardly used was a mixture of 
pentane/Et2O plus 1 % (v/v) HOAc (Note: HOAc was only added when the acid fraction was 
separated. For the separation of neutral fraction compounds the addition of HOAc is 
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unnecessary). A step gradient, each step 500 ml, of increasing polarity for raw material 
(neutral and acid fraction) separations was applied. The chromatography itself followed 
basically the instructions of Still et al. [151]. Silica gel was suspended with the eluent, shortly 
degassed in vacuo and filled into the column. The sample was dissolved, dependent on the 
sample size, in a bit of eluent or DCM and evenly added on top of the column bed. After the 
sample was adsorbed inside the silica gel, fine sand was put on top of the column bed to 
keep the silicagel area even when additional solvent was transferred from the reservoir 
during the chromatographic separation. Separation itself was carried out by action of a 
middle strong air-pressure (1-1.3 bar) and fractions were collected using an automatic 
fraction collector (LKB-Bromma 2211 SUPERRAC; 180 fractions, 20 ml test tubes). Fractions 
were monitored by TLC and combined to overall fractions due to their chromatographic 
analogies. Different application conditions for flash chromatography, otherwise than stated 
here, are described in the appropriate chapter. 
 
2.3.3 Preparative High Performance Liquid Chromatography 
The preparative HPLC system consisted of a S 1521 Solvent Delivery System and a S 3210 
UV/VIS Diode Array Detector (all components from Sykam, Fürstenfeldbruck, Germany). For 
sample injection a 3725-038 Valve Bracket Injector (Rheodyne) with a 10 ml loop and a 1 ml 
syringe (Hamilton, Bonaduz, Switzerland) were used. Basically, isolation and separation of 
target analytes was achieved by usage of MeOH and H2O mixtures (MeOH content always 
greater than 90 %) and is stated in detail in the corresponding chapter (see chapter 3.1.1 and 
3.1.2). As separation columns a NUCLEODUR 100-5 C18 ec, 250 x 21 mm I.D. (Machery & 
Nagel, Düren, Germany) and an YMC-Pack Pro C18 RS, 250 x 20 mm I.D. S-5 µm, 8 nm 
(YMC-Europe, Dinslaken, Germany) served. Pre-runs were carried out on the analytical 
HPLC device with the corresponding analytical columns (NUCLEODUR analogue prep 
column, only with 250 x 4 mm I.D.; YMC analogue prep column, only with 250 x 4.6 mm I.D.), 
following basically the descriptions in the book of Meyer [152] for column scale up. The 
chromatographic data was recorded with Chromstar DAD software, Version 6.2 (SCPA, 
Weyhe-Leeste, Germany). Detection was done at three different wavelengths (210, 250 and 
280 nm) simultaneously and the UV spectrum was recorded from 200-400 nm. 
 
2.3.4 Analytical High Performance Liquid Chromatography (HPLC) 
The analytical HPLC device consisted of a S 7121 Reagent Organizer, a S 1122 Solvent 
Delivery System, a S 8111 Low Pressure Gradient Mixer and a S 3210 UV/VIS Diode Array 
Detector (all components from Sykam, Fürstenfeldbruck, Germany). A Jetstream 2 Series 
column oven (Techlab, Erkerode, Germany) was used for temperature control. Samples 
were injected by a S 5111 Valve Bracket Injector (Rheodyne) with a 20 µl loop (100 µl were 
injected for quantitative determinations, overfilling) and a 250 µl syringe (Hamilton, Bonaduz, 
Switzerland). Solvent reservoirs were degassed with Helium (He) and kept constantly under 
He-pressure during analysis. 
Injected sample concentrations depended on the linearity range of the target analytes of 
interest and are in detail mentioned in the corresponding chapters (see chapter 3.6.3.1). 
Usually, the sample concentration was 5 mg/ml for RS fraction samples and 1.25 mg/ml for 
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NB fraction samples (quantitation of compound 20, 21, 22 and 23). If one of the analytes 
revealed contents above the linearity range (e.g. compound 6 in Bpap, respectively, 
Bsac/Bcar, and compound 10 as an artefact, see also [55]), a minor concentration was 
injected (c = 2 mg/ml). Compound 3 (ß-BA) was evaluated to elute as inhomogeneous peak 
(co-elution with compound 18) in samples of Bpap and Bser. If further 2D analysis was 
applied (Bpap- and Bser-RS), normally a minimum concentration of 5 mg/ml had been 
necessary to generate 2D chromatograms less susceptible to integration errors (see also 
chapter 3.6.2).  
Every sample was injected twice unless stated otherwise. After each injection, the injector 
was purged with 500 µl MeOH and the injection syringe was purged twice with 250 µl MeOH. 
The chromatographic data was recorded for 1D and 2D chromatograms with Chromstar DAD 
software, Version 6.3 (SCPA, Weyhe-Leeste, Germany). Detection was simultaneously 
carried out at three different wavelengths (210, 250 and 280 nm) and the UV spectrum was 
recorded from 200-400 nm. Peak Integration was manually implemented by comparison of 
the baseline with blank runs. Minor inhomogeneities at peak edges were separated by the 
perpendicular drop function of the integration software. Further statistical calculations were 
achieved by application of Microsoft Excel® 2003 software. 
 
2.3.4.1 General Remarks concerning the Method Development 
The method development was generally based on the descriptions given in the book of 
Dolan and Snyder [153]. Accurate quantitation of frankincense species samples has been 
revealed to be highly intricate, since these resin materials contain numerous amounts of 
several terpenic compounds. It was finally achieved to develop a HPLC method for the 
separation of almost all significant triterpenic acid peak signals in the acid fraction of the 
species Bpap, Bser and Bsac/Bcar. 
The method fulfilled the requirements for an adequate operation procedure. Interestingly, the 
boswellic and lupeolic acids follow a classical so called “regular-sample-elution pattern” (log 
k, with k = capacity factor, is linear with gradient time and no isotherm-crossing occurs; 
meaning that if log k is plotted against two different gradient times or two isocratic mixtures, 
e.g. 10 min and 20 min, while keeping all other parameters constant, the regular sample 
peaks become - theoretically - better resolved, linear in the same direction. For a detailed 
explanation see [153]).  
However, the co-existence of tirucallic acids with boswellic and lupeolic acids in these 
species made the method development more complicated and a so called “irregular-sample-
elution pattern” has been obtained (log k linearities tend to cross each other by different 
gradient times or isocratic mixtures, meaning that samples do not move in parallel in the 
same direction, as for a regular sample, and thus co-elution may occur; see again [153] for 
further details). A graphical explanation of the linear solvent strength model for a simple 
problem is demonstrated in Fig. 2.2. 
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Fig. 2.2 Graphical explanation of the Linear-Solvent-Strength model. Log k (k = retention factor) 
plotted against %B (stronger elution solvent). Minimum requirement: All parameters constant 
(temperature, column-type, flow rate, etc.) and two experiments with two different isocratic runs, 
respectively, gradient times (then log k*, see also [153]). Here: Isocratic example (run 1 = 40 % and 
run 2 = 80 % B). As can be seen, the regular sample (CD) elutes parallel with increasing %B, whereas 
the irregular sample (AB) shows different sensitivities to the change in %B and thus has similar k-
values (co-elutes) at ca. 64 % B (denoted by the vertical line). It is obvious that with an increasing 
number of compounds to be separated, the model can become extremely complicated. For further 
details see text. 
 
2.3.4.2 Standard Quantitation Conditions (1D chromatography) 
All quantitation experiments for the acid and neutral fractions were carried out using the 
following standard setting: Analytical HPLC device as described as in 2.3.4; guard-column: 
GROM Saphir 110 C18, 5 µm 20 x 4 mm I.D. (GROM, Rottenburg, Germany) for column 
protection; separation-columns: 2 x YMC-Pack Pro C18 RS 250 x 4.6 mm I.D. S-5 µm, 8 nm 
(YMC-Europe, Dinslaken, Germany) in series connected; flow rate = 0.85 ml/min; T = 45 °C.  
The mobile phase consisted of MeOH (A) and H2O plus 0.1 % TFA (B); gradient profile: 
Isocratic elution with 85 % A for 2 min, then a linear gradient to 100 % A in 13 min, followed 
by an isocratic elution with 100 % A for additional 45 min and an isocratic period with 85 % A 
for 15 min to equilibrate the columns again (Total time: 75 min each run). Data recording was 
carried out as described in point 2.3.4. Note that with only one YMC column a similar 
resolution can be obtained if the flow rate is set to 0.43 ml/min and the gradient delay to 1 
min (isocratic), followed by a gradient to 100 % MeOH in 6.5 min while keeping all other 
parameters constant (see also [153]). However, the method with two columns in series 
connected has been giving slightly better resolution values (narrower peaks). For quantitation 
experiments the method of external calibration has been applied (Peak area plotted against 
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concentration in mg/ml). All external quantitation standards were isolated from Bpap (acid 
fraction standards and compounds 22 and 23) as it is already reported in the dissertation of 
Seitz [56] or the paper of Paul and Jauch [154]. Compounds 20 and 21 were isolated from 
Bcar, as it is reported in chapter 3.1.2. Routinely, each analyte (compounds 1-8 and 10-16 
for RS samples; compounds 20, 21, 22 and 23 for NB samples) was dissolved in MeOH due 
to its corresponding linearity range (see also Tab. 3.23 - 3.25 in chapter 3.6.3.1). Normally, a 
complete master mix, containing all target analytes of interest in one solution (see also [59] 
for acid fractions and [154] for neutral fractions), was prepared. Samples were dissolved in 8 
ml MeOH in a 10 ml volumetric flask and sonicated (approximately 15-30 min). At last, the 
final volume was adjusted to 10 ml with additional MeOH. From the stem solution, 5 to 6 
standards with decreasing concentrations levels of factor two were generated (10 ml 
volumetric flasks or by calibration qualified automatic pipette systems). Prior to injections 
each solution was filtered (0.2 µm syringe filter). The expected peak area was determined by 
preliminary tests. The analyte concentration range was adjusted to the expectation value in 
the pure resin sample (see also chapter 3.8). Any peculiarities and differences from the 
descriptions given here are mentioned in the corresponding experimental chapters. 
 
2.3.4.3 Fraction Collection Conditions 2D Analysis 
During the method development it was figured out that compound 18 co-elutes with 
compound 3 (significantly in Bpap RS samples and as well in Bser RS samples). Since 
resolution of these two peak signals within one chromatography dimension was not 
achievable without sacrificing resolution of other signals (Irregular elution sample; see [153]), 
a second dimension was introduced. 
Therefore, peaks of α- and ß-boswellic acid (1 and 3) and 11-OMe-ß-ABA (8) and also the 
inhomogeneities (compound 18, co-eluting with compound 3 in Bpap and Bser, and 
compound 19 in real samples) were collected due to their retention time area in a pointed 10 
ml flask, subsequently dried under a light N2- or air-stream and stored at room temperature 
for further 2D Analysis. A short graphical overview on the complete method is presented in 
Scheme 2.1. Significant co-elution of compound 18 and 3 has been only observed for the 
species Bpap and Bser. Normally, for Bsac, respectively Bcar, the second dimension is not 
necessary (see also chapter 3.7.5). 
 
2.3.4.4 Standard 2D Quantitation Conditions (α- and ß-boswellic acid) 
Quantitation results for α- and ß-boswellic acid (ß-BA, 3, inhomogeneous peak in Bpap and 
Bser; see also chapter 3.7.5) were corrected using the following standard adjustment: 
Analytical HPLC device as described;  guard-column: GROM Saphir 110 C18, 5 µm 20 x 4 
mm I.D. (GROM, Rottenburg, Germany) for column protection; separation-column: 1 x YMC-
Pack Pro C18 RS 250 x 4.6 mm I.D. S-5 µm, 8 nm (YMC-Europe, Dinslaken, Germany); flow 
rate = 1.00 ml/min; T = 45 °C. The mobile phase consisted of 100 % ACN (isocratic run). 
Each run was recorded for 20 min. Data recording conditions were as described in point 
2.3.4. The prepared sample (see chapter 2.3.4.3) was carefully dissolved in 100 µl MeOH 
(using a calibrated 250 µl Hamilton microliter injection syringe [155]), shortly sonicated and 
immediately    injected   after    sample    preparation.  The injection    volume   contented   of 
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   280 nm 
2D preparation: Peaks 1 until 3 were together collected 
in a pointed 10 ml flask, dried under a slight air or N2 
stream and dissolved in 100 µl MeOH. 
2D injection: Chrom. conditions: T = 45 °C, u = 1 
ml/min, column: 1 x YMC-Pack Pro C18 RS (250 X 4.6 
mm I.D., 5 µm, 8 nm), isocratic run (Eluent = 100 % 
acetonitrile), run time = 20 min, UV-detection: 210 nm, 
injection loop = 20 µl, injection volume = approximately 
75 µl of the MeOH dissolved sample, containing 
compound 1, 3, 18 and 19.
Column 1 Column 2 
Diode-Array- 
Detector 
Sample 
injection 
Diode-Array 
Detector 
Column 
(second dimension) 
  Real sample 2D chromatogram 
  (210 nm) 
                           
           1       3     
                                                                     
 
                                            19 18                 
 
Data evaluation first and second 
dimension. 
 
Integration results for peak 1 
(homogeneous signal; control 
standard) and 3 (inhomogeneous 
signal) based on the comparison of the 
first and second dimension. 
 
Acceptance criteria for the accuracy of 
peak 3 in the 2D method integration 
result = +/- 5 % recovery [in mg/ml] for 
peak 1 (referring to the 1st and 2nd 
dimension peak area). 
Second Dimension (2D method) 
First Dimension (1D method): Isolation of peak 1 (homogeneous signal, control standard) and 5 
(inhomogeneous signal) and sample preparation for the second dimension (2D method). 
Sch. 2.1 Graphical explanation of the offline 2D chromatography method. 
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approximately 75 µl to guarantee sample loop overfilling (sample loop volume: 20 µl). The 
corresponding peak area in the second dimension was plotted against its associated 
concentration value (in mg/ml) in the first chromatography dimension. Compound 1 
(homogeneous peak signal) served as internal control standard for the recovery of 
compound 3 (co-elution with compound 18). The graphical overview is presented in Scheme 
2.1. 
 
 
2.3.5 Validation Parameters (1D chromatography) 
Determination of Precision, Selectivity, Peak Homogeneity, Robustness and Accuracy  
For an explicit declaration of validation parameter terms, the corresponding literature may be 
consulted (e.g. [152,156-158]). All quantitation experiments for the acid and neutral fractions 
were carried out using the standard quantitation method described in chapter 2.3.4.2. A 
Gradient System Performance Test was implemented before each quantitation experiment 
as demonstrated in the book of Snyder and Dolan [153] (chapter 4, page 145). The dwell 
volume of the low pressure gradient system has been determined to be 2.8 ml. Prior to larger 
series of quantitation sets (Bpap, Bser and Bsac/Bcar) the external calibration was carried 
out with the isolated standards (see also chapter 3.6.3.1). Generation of calibration curves 
was realised by plotting the resulting peak area against the corresponding mass of analyte 
(in mg/ml) and accepted when the correlation coefficient condition (R2 > 0.999) was satisfied. 
Operating ranges for the quantified compounds are given in chapter 3.6.3.1, Tab. 3.23 and 
Tab 3.24 for the RS fractions and in Tab. 3.25 for the NB fractions. The curves itself were 
generated by three injections of each of the six standards and accepted when the coefficient 
of variation (C.V.) for peak areas was < 2 % (system repeatability conditions) for each 
standard concentration level. At the limit of quantification (LOQ) and limit of detection (LOD) 
higher C.V. values than stated (< 2 %) were observed. Every calibration curve consisted at 
least of six points. Different linear regression models were applied (unweighted and weighted 
linear regression). In dependence on the experimental result (target analyte concentration in 
the sample), the decision, which of the regression models has been used, was made 
individually (see also chapter 3.6.3). Hence, system repeatability and thus precision of the 
external standardisation method was granted, if the requirements were met (correlation 
coefficient > 0.999 and C.V. < 2 %, peak area for three injections - above the LOQ). 
Detection specifity was evaluated for compounds additionally detectable at 250 (compound 5 
and 6) and 280 nm (compound 9 and 10), since at these wavelengths the chromatograms 
appear less complex compared with chromatograms at 210 nm detection. 
Method selectivity for compounds, merely absorbing at 210 nm, has been evaluated by 
resolution values of up to R = 1.5 (definition of peak baseline separation). Peak signals with 
R < 1.5 were separated by the perpendicular drop function of the integration software and 
generally accepted when the linearity for the specific analyte was ensured. 
Peak identity was verified by exact comparison of retention times, relative resolutions of 
neighbouring peaks, comparison of UV spectra and additionally by co-injection of all isolated 
standards. Peak homogeneity was analysed by comparing first and second derivatives of 
peaks and by comparing the ratio plot (peak height and area) at two different wavelengths if 
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necessitated [157]. Minor inhomogeneities appearing in the crude sample at the target 
analytes edges were separated by the perpendicular drop function of the integration 
software. Compound 3 (co-elution with compound 18) has been determined as 
inhomogeneous peak signal in the real samples for Bpap and Bser incense species (see also 
chapter 3.7.5). 
During the method development several parameters (solvents, temperature, stationary phase 
and gradient time) were changed to find the best resolution within the system. Basically, the 
method development followed the descriptions given in the book of Dolan and Snyder 
(chapter 3, Method Development) by application of the linear solvent strength model [153]. 
Thus, the logarithmic retention factors (logk*) of each target analyte at different gradient 
times were compared and optimised to give an acceptable value for the resolution R (see 
also chapter 2.3.4.1). Compounds 14 and 15 were defined as the most critical peak pair, 
appearing as one single peak signal at the beginning of the method development under 
already known gradient elution conditions (see for example [56,133]). The system was 
optimised for their resolution. Therefore, as a most significant parameter, the stationary 
phase was ascertained. 
Robustness of the method was evaluated by changing following parameters slightly at two 
different levels and the resulting differences in retention time, relative resolution, peak-height 
and -area were compared: 
 
- Temperature:  +/- 2 °C (One run at 43 °C and one run at 47 °C) 
- Flow rate:  +/- 0.5 ml/min (One run at 0.80 ml/min and one run at 0.90 ml/min) 
- Gradient time: +/- 0.5 min (One run at 12.5 min gradient from 85 to 100 % A and one  
run at 13.5 min from 85 to 100 % A) 
 
Accuracy has been evaluated by comparison of the external quantitation results for the 
method described here with another HPLC method, comprising less sample preparation 
steps, described in the European Pharmacopoeia 6.0 [20] (analysis on specifically detectable 
compounds 5 and 6 in the crude extract without separation of acid and neutral fraction). 
Furthermore, the accuracy for the separation of NB- from RS-fractions has been controlled 
by comparison of the corresponding chromatograms (NB overview chromatogram compared 
with corresponding RS overview chromatogram), where no significant peak signals should be 
observable for a definition of quantitative extraction. 
 
A general remark is that at 210 nm detection wavelength the standard solution 
chromatograms were considered as ideal chromatograms, the “real sample” chromatograms 
were supposed to be similar to, to guarantee accurate quantitation results.  
Determination of peak areas in the real sample chromatogram with minor peak 
inhomogeneities at the edges could be verified by statistical analysis (in general, a greater 
confidence interval is given; see also [159]). Comparison of an “ideal” standard 
chromatogram with a “real” sample chromatogram at 210 nm detection wavelength is 
presented in Fig. 2.3. 
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Fig. 2.3 Comparison of a real sample RS fraction chromatogram (upper chromatogram; Bser, c = 5 
mg/ml) with a standard chromatogram (lower chromatogram) at 210 nm detection wavelength. Ideally, 
the real sample should be as similar as possible to the standard chromatogram for accurate and 
precise quantitation results. Compound 18 co-elutes under compound 3. Compound 8 has never been 
detectable in the "real sample" chromatograms. For further details see text. 
 
 
2.3.6 Validation Parameters (2D chromatography) 
Determination of Precision, Recovery and Accuracy (compared with 1D results) 
Quantitation of α- and ß-boswellic acid (ß-BA, 3, eluted as inhomogeneous peak in Bpap and 
Bser, see chapter 3.7.5) was additionally achieved by implementation of a homomodal [160] 
second chromatography dimension, using the same column type with a different eluent 
(ACN, isocratic elution). Since ß-BA (3) was proved to elute as inhomogeneous peak in the 
first chromatography dimension, the second dimension was introduced to resolve this 
probably highly important boswellic acid compound from its inhomogeneity (Note that 
according to recent findings, ß-BA, 3, shows the highest in vivo plasma levels of all 
investigated boswellic acids hitherto and thus seems to be a promising candidate responsible 
for the anti-inflammatory actions in the human body [125,144,161]). Therefore, the whole 
eluting area of compound 1 to 8 (in case of real samples compound 18 and 19 are included) 
was collected (see also chapter 2.3.4.3). α-BA (1) served as control standard for the recovery 
of ß-BA (3).  
Second dimension calibration curves for compound 1 and 3 were generated with the 
prepared solutions from the 1D chromatograms for every injection of all six standard 
   54
Experimental Part 
_________________________________________________________________________________ 
 
concentrations and accepted when the coefficient of variation did not exceed 3 % (system 
repeatability condition; note that near the limit of quantitation, LOQ, greater C.V.s of up to 10 
% are possible) for each concentration level. Obtained peak areas of the second dimension 
were plotted against the contents (in mg/ml) referring to the first dimension. The two 
calibration curves were generated by classical and weighted linear regression models [162] 
consisting of at least five points. The values for real sample chromatograms in the second 
dimension were accepted, when the value for the control standard α-BA (1, homogenous 
peak signal in the first dimension) delivered the same content in mg/ml, within a +/- 5 % 
confidence interval (quantitative control), as determined in the first dimension, and when the 
peaks of compound 18 and 19 eluted in front of α-BA (qualitative control). The quantitative 
control value of +/- 5 % had been based on empirical results and is within the theoretical 
estimated error propagation of the system (Theory: +/-1 % failure during the slight N2-drying 
of the fraction; +/- 2 % failure by resolving in 100 µl MeOH; +/- 2 % failure by injection and 
integration; see also the review of Meyer on measurement uncertainty [163]). 
 
 
2.3.7 Statistical Analysis of the Quantitative HPLC Data 
Quantitation results were obtained by external linear regression. Confidence and prediction 
intervals for the coefficient of regression were given analogous to the descriptions in the 
book of Sachs and Hedderich (page 336-347) [159]. 
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Fig. 2.4 Linear Regression Model for compound 4 (ß-ABA), obtained as described in [159] with 
Microsoft Excel® 2003. Peak Area plotted against concentration [mg/ml]. Linear Regression: Dashed 
line (- - -). Confidence Interval: Continuous inner lines (----). Prediction Interval: Blue outer lines (----). 
For further details see text. 
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In addition to the experimental data evaluation by the Chromstar DAD software 6.3 (SCPA, 
Weyhe-Leeste, Germany), the Microsoft Excel® 2003 software was used for further statistical 
calculations. For determination of the confidence and prediction intervals, the quantile of the 
Student t-distribution [159] was chosen at 99 % probability certainty (p = 0.99). An exemplary 
graphical depiction is given for compound ß-ABA (4) in Fig 2.4. 
Furthermore, the programmed excel working sheet from the book of Kromidas and Kuss 
[162] was used for comparison of the linear regression with the weighted linear regression.  
It should be noted that depending on the analyte concentration each regression model had 
its advantages and even disadvantages (see discussion in chapter 3.6.3). However, most 
important had been the knowledge of the specific error of the regression model, particularly, 
concerning the extreme values (lowest and highest concentration value of the curve of the 
analyte being questioned). On the one hand, for a sample containing only minimal amounts 
of the analyte, the weighted linear regression model expectably gave a more accurate result; 
whereas on the other hand, for a sample containing the analyte in greater quantities, the 
conventional linear regression model had been delivering a better fit in some cases. Content 
approximation models, based on the here evaluated sample population, were as follows:  
 
- For Bpap great contents of ß-AKBA (6) and TAs (13-19) were expected, whereas LAs 
(11 and 12) and BAs (1-4) occurred in lower contents in this species. 
- For Bser great contents of BAs (1-4) and TAs (13-19) were expected, whereas LAs 
(11 and 12) and ß-KBA (5), respectively, ß-AKBA (6) occured in lower contents in this 
species. 
- For Bsac/Bcar great contents of BAs (1-4) and LAs (11 and 12) were expected, 
whereas TAs (13-19) occurred in lower contents. ß-KBA (5), respectively, ß-AKBA (6) 
had not been reliably predictable (strong extreme values for high and low contents). 
 
Finally, a careful evaluation of every chromatogram and target analyte of interest has been 
hitherto unavoidable, as thus far the pattern recognition of a human mind is still sovereign 
over a simple programmed computer algorithm (personal evaluation and experience of the 
author with chromatography software in general). 
 
The residual standard deviation (RSD) and the coefficient of variation of the applied linearity 
model (VVK) deliver a descriptive value for the scattering of measured points around the 
straight regression line (see also [162]). These two values give information on the quality and 
reliability of the generated regression model. 
 
2
)]([ 2


n
xyyRSD      
 
RSD = Residual Standard Deviation (Difference between measured and calculated y-values) 
y = Measured Signal Value 
y(x) = Signal Value as function of the regression model 
n = Number of measuring points (concentration levels)  
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VVK = Coefficient of Variation of the applied regression model referred to the mean x-value (c in 
mg/ml) of the linearity range (e.g. x1 = 1, x2 = 2, x3 = 3; thus, x2 = 2 = xM). 
RSD = Residual Standard Deviation (Difference between measured and calculated y-values) 
b = Slope-Factor for the corresponding linear regression model (y = bx + a; a = Ordinate Intercept) 
xM = Mean value of the concentration range, see also VVK 
 
Furthermore, the here in this work additionally used equations for the prediction interval (PI; 
referring to the y-deviation) and the measurement uncertainty (MU; referring to the x-
deviation) have been calculated as follows (see also [162,163]): 
 
 
  
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t = Student t factor (see also [159]). Here with p = 95 % and n – 2. 
RSD = Residual Standard Deviation 
wk = individual weighting factor at the corresponding concentration level 
w = weighting factor 
xk = concentration level referring to wk 
xw = arithmetic mean value over all measured x (centre of the calibration curve). 
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t = Student t factor (see also [159]). Here with p = 99 % and n – 2. 
RSD = Residual Standard Deviation 
b = slope of the calibration curve (y = b * x + a; with a as ordinate intercept) 
wa = individual weighting factor at the corresponding concentration level 
w = weighting factor 
ya = signal response at corresponding concentration level 
yw = arithmetic mean value over all obtained signal responses y (centre of the calibration curve) 
xa = concentration level referring to wa 
 
 
2.3.8 Principal Component Analysis (PCA) 
For the qualitative evaluation of all samples analysed by HPLC and TLC the statistical 
method of principal component analysis (PCA) was used. This approach should lead to a 
graphical separation of all samples into certain clusters (e.g. expectably, clusters for Bser, 
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Bpap, Bsac and Bcar, if distinguishable among their HPLC/TLC results) on a two-
dimensional plot, corresponding to their specific HPLC and/or TLC results. 
PCA itself is a tool in multivariate data analysis to reduce the multidimensionality of complex 
data matrices and thus to better understand the variability structure of the data being 
questioned. Briefly, the aim of PCA is to reduce the variables (m, here the quantitative HPLC 
and qualitative TLC results of all analytes for each sample) of a data matrix through a lower 
number (h < m) of mutual correlating factors (so called principal components or latent 
variables) in order to keep their original information preserved. The results of PCA give a 
simple graphical tool which enables by usage of a two dimensional plot the understanding of 
complex data sets qualitatively (e.g. here, correlation of analytes with a specific frankincense 
resin). However, for a thorough understanding of PCA methodology the corresponding 
literature may be consulted [164-166]. The technique is more and more used in the 
elucidation of significant parameters in complex biological matrices [167] and even to 
understand HPLC column systems for example [168]. Here it was used to graphically show 
the differences and commonalities for the species being investigated (Bpap, Bser and 
Bsac/Bcar). 
The calculation itself was processed with the statistiXL software Add-In-tool for Microsoft 
Excel® 2003 from statistiXL, 3302 Broadway-Nedlands, Western Australia, 6009 
(http://www.statistixl.com/). The following matrix parameters were used: The columns 
(variables) consisted of the compounds 1-6, 11-16 (acid fraction compounds) and of 20-24 
(neutral terpenic compounds) and of 28 (ß-caryophyllene-oxide). Compounds 1-6, 11-16 and 
20-23 were quantified by HPLC analysis. Thus the found contents (% in g/g referring to the 
acid and neutral fraction, respectively) have been used for calculation. For compound 24 
(verticillia-4(20),7,11-triene) and 28 (ß-caryophyllene-oxide), which both were not quantified 
by HPLC, the column values were set to 0 = not detectable and 1 = detectable. This nominal 
scale has been chosen since both were only specifically found for Bpap (compound 24, by 
GC and HPLC) and for Bsac/Bcar (compound 28, by GC and TLC) in all here analysed 
samples. Though, if quantified (GC or HPLC), both also could be used metrically. However, 
the nominal scale (0 or 1) delivers, in a good approximation, the same solution for the PCA 
applied here (see table 3.37 in chapter 3.14). The matrix rows consisted of the samples Bpap 
(n = 10), Bser (n = 14), Bcar (n = 6) and Bsac (n = 4) as shown in table 3.37 in chapter 3.14. 
Descriptive Statistics, the Correlation Matrix standardized to S.D. = 1 (for strong deviating 
variances), the Scree-Plot, the Scatter Plot, the Casewise Scores and the Coefficients were 
included into the major plot. Some of the calculation data is presented in chapter 3.14. 
 
 
2.3.9 HPLC Method (EUROPEAN PHARMACOPOEIA 6.0) 
For comparison of the standard quantitation method described in chapter 2.3.4.2 the 
validated HPLC method described in the EUROPEAN PHARMACOPOEIA 6.0 for Indian 
Frankincense [20] (Olibanum Indicum, page 2128-2129) was implemented. This method 
does not require a separation of acid- and neutral fractions as ß-KBA (5) and ß-AKBA (6) are 
specifically detectable due to their good absorption at 250 nm wavelength. The method had 
been almost adapted; only TFA was used as mobile phase additive instead of phosphoric 
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acid. Importantly, it is based on a one-point calibration. Thus, there may be a rather 
significant uncertainty in the determined quantities, if the amounts of ß-KBA (5) and ß-AKBA 
(6) in the sample differ greatly from the amounts weighed in the test solution. However, the 
method has been thus far approved to be sufficient for its main purpose, at least for the 
species Bser. 
HPLC-System: As described in chapter 2.3.4. Column: 1 x YMC-Pack Pro C18 RS, 250 x 4.6 
mm I.D. S-5 µm, 8 nm (YMC-Europe, Dinslaken, Germany). Mobile phase A: H2O + 0.1 % 
TFA. Mobile phase B: ACN + 0.1 % TFA. Flow rate: 1.0 ml/min. Detection: 250 nm. Injection: 
100 µL (20 µL loop, overfilling). Gradient profile: From 84 % B to 94 % B in 12.5 min, then to 
100 % B in 1 min, isocratic run at 100 % B for another 14.5 min and finally re-equilibration of 
the column for 15 min at 84 % B. 
Test solution: To 1.0 g of the powdered sample 90 ml of MeOH were added and it was 
sonicated for 10 min. It was diluted to 100 ml with MeOH. After settling of the undissolved 
material, the colloidal solution was filtered (0.2 µm, syringe filter) and 1 ml of the clear 
solution was diluted with 10 ml of a mixture of 16 volumes of mobile phase A and 84 volumes 
of mobile phase B. Reference solution: ß-KBA (1.0 mg) and ß-AKBA (1.0 mg) were dissolved 
in 20 ml MeOH and 1 ml of this solution was given to 10 ml of mobile phase A. Every sample 
was injected twice (test and reference solution) and values were accepted when the 
coefficient of correlation was less than 1 % (repeatability condition).  
The percentage contents of ß-KBA (5), respectively, ß-AKBA (6) in the sample (test solution) 
were calculated using the following equation (one point calibration): 
 
mA
pmA
AKBAKBA 

2
111
5
)/(%  
 
A1 = area of the peak due to ß-KBA, respectively, ß-AKBA in the chromatogram obtained with the test 
solution; 
A2 = area of the peak due to ß-KBA, respectively, ß-AKBA in the chromatogram obtained with the 
reference solution; 
m = mass of the substance to be examined, in grams; 
m1 = mass of ß-KBA, respectively, ß-AKBA in the reference solution, in grams; 
p1 = percentage content of ß-KBA, respectively, ß-AKBA in the reference material of ß-KBA, 
respectively, ß-AKBA. 
 
 
2.3.10 Gas Chromatography – Flame Ionisation Detector (GC-FID) 
The gas chromatography device consisted of a GC 9000 series (9130, EL 980, VIC 900, 
FISONS Instruments) system. Detection was realised by flame ionisation technique (FID). 
Clarity Lite software (DataApex, Prague, Czech Republic; version. 2.6.04.402) was used for 
data recording and processing. The injector temperature was adjusted to 250 °C and He was 
used as carrier gas (pressure: 14 psi). An Optima capillary column (1 : 0.25 µm, 25 m x 0.25 
mm, 340-360 °C max. Temp., Machery & Nagel, Düren, Germany) was applied as stationary 
phase. Samples were injected with a 1 µl syringe (Hamilton, Bonaduz, Switzerland) by split 
and splitless injection. The following temperature gradient was used: 40 °C for 1 min, then 9 
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°C/min for 10 min to 130 °C, then 4 °C/min for 20 min to 210 °C, then 2 °C/min for 20 min to 
250 °C, then constantly at 250 °C for another 10 min (Total time: 61 min) and afterwards 
cooling to 40 °C again. Kovats retention indices (KI or RI) [169] were obtained by injection of 
corresponding C8 to C22 homologue n-alkanes. The van den Dool variant of the Kovats 
equation had been used since a temperature gradient was performed [170], as given in the 
following equation: 
 
nx
nx
x tt
ttnRI 

1
100100  
 
RIx = Retention index (or Kovats index, KI) 
n = number of C atoms (e.g. for C9, n = 9; for C10, n = 10, etc.) 
tn = retention time of n-alkane with z C atoms, eluting in front of compound x (x = unknown peak 
signal) 
tx+1 = retention time of n-alkane with z+1 C atoms, eluting after compound x (x = unknown peak signal) 
tx = retention time of unknown peak signal x 
 
 
2.4 Spectroscopy 
 
2.4.1 Mass Spectrometry (MS) 
Mass spectrometric data was recorded on a Finnigan MAT 95S spectrometer (CI mode; 
HRMS) and a ZQ 4000-ESI-Mass spectrometer (ESI; Single quadrupol) from Waters 
(Eschborn, Germany) at the Department of Organic Chemistry at the Saarland University. 
The LC-MS conditions for the detection of compound 18 and 19 in the isolated mixture (see 
chapter 3.2.3 and 3.2.4) were as follows: ZQ 4000-ESI-MS (Single quadrupol); isocratic 
elution with solvent A (MeOH + 0.1 % HCOOH); flow rate (0.3 ml/min); run time (60 min); 
column (YMC-Pack-Pro C18 RS, 250 x 4.6 mm I.D., S-5 µm, 8 nm); UV detection (210 nm); 
ESI negative mode for molecular ion detection. The chromatograms are shown in chapter 
3.2.3, respectively, 3.2.4. 
 
2.4.2 Nuclear Magnetic Resonance Spectroscopy (NMR) 
NMR experiments were carried out on 400 MHz (AV 400) and 500 MHz (AV 500) NMR 
spectrometers from Bruker (Rheinstetten, Germany). CDCl3 was purchased from Sigma 
Aldrich (Steinheim, Germany). For structural assignment of the isolated compounds 1H, 13C, 
HH-COSY, HSQC, HMBC, 2D-NOESY, DEPT 90 and DEPT 135 spectra were recorded in 
CDCl3. The data was processed with MestReC software, version 4.9.9.6 (Mestrelab 
Research S.L.). NMR spectra were calibrated against the residual solvent peak δC(CDCl3) = 
77.0 ppm and δH(CDCl3) = 7.26 ppm. 
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2.5 Pharmacological Assays 
 
The pharmacological investigations were carried out at the University of Tübingen, Germany, 
in the Department of Biopharmaceutical Analytics under supervision of Prof. Dr. Oliver Werz 
(now Professor at the University of Jena, Germany). The experiments were conducted by 
Moritz Verhoff and/or Daniela Müller. A few of the here isolated compounds were sent there 
to evaluate their actions on the microsomal prostaglandin E2 synthase-1 (mPGES-1) in a 
cell-free assay with the microsomal preparations of Interleukin 1ß (IL-1ß) stimulated A549 
cells [102]. In the corresponding discussion (chapter 3.12), the results from compound 23 
(Inc-Ac) and its decomposition products (chapter 3.11.2) and the data of the isolated peak 
mixture, including compound 18 and 19, from Fraction 9 (see chapter 3.1.1.3) are presented. 
 
2.5.1 Purification of A549 Microsomes 
A549 cells were cultured in DMEM/high glucose (4.5 g/ml) medium supplemented with heat-
inactivated fetal calf serum (10 %, v/v), penicillin (100 U/ml) and streptomycin (100 lg/ml) at 
37 °C in a 5 % CO2 incubator. 
After 20 h, the medium was changed to DMEM/high glucose (4.5 g/ml) medium 
supplemented with heat-inactivated fetal calf serum (2 %, v/v), penicillin (100 U/ml) and 
streptomycin (100 lg/ml), and cells were stimulated with 2 ng/ml IL-1ß for 72 h. After 72 h, the 
cells were detached using 1 x trypsin/EDTA. After a wash step with PBS, pH 7.4, the pellet 
was frozen in liquid N2 and re-suspended in ice-cold homogenisation buffer (0.1 M potassium 
buffer, 250 mM sacharose, 1 mM PMSF, 60 µg/ml STI, 1 µg/ml Leupeptin, 2.5 mM GSH) and 
sonicated at low density (3 x 20 s). 
The homogenate was first centrifuged at 10000 g for 10 min and then the supernatant was 
centrifuged at 174000 g for 1 h. The pellet (microsomal fraction) was then re-suspended in 1 
ml homogenisation buffer. The total protein concentration was determined by the Coomassie 
protein assay [171]. The microsomal fraction can be stored at -80 °C for several months 
[102,103,172]. 
  
2.5.2 Determination of PGE2 Synthase Activity in Microsomes of A549 Cells 
Microsomal membranes of A549 cells were diluted in 0.1 M potassium phosphate buffer, pH 
7.4, containing 2.5 mM glutathione (total volume, 100 µl), and test compounds or vehicle 
(DMSO) were added. After 15 min, PGE2 formation was initiated by addition of PGH2 (final 
concentration, 20 µM). After 1 min at 4°C, the reaction was terminated with 100 µl of stop 
solution (40 mM FeCl2, 80 mM citric acid, and 10 µM 11ß-PGE2), and PGE2 was separated 
by solid-phase extraction on reversed phase (RP)-C18 material using acetonitrile (200 µl) as 
eluent and analysed by RP-HPLC [30% aqueous acetonitrile + 0.007% trifluoroacetic acid 
(v/v); Nova-Pak C18 column, 5 x 100 mm, 4-µm particle size, flow rate 1 ml/min], with UV 
detection at 195 nm. 11ß-PGE2 was used as internal standard to quantify PGE2 product 
formation by integration of the area under the peaks [102,103,172]. 
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2.6 Stability Tests and Estimation of Decomposition Kinetics 
 
2.6.1 Decomposition Tests with Inc-Ac (room temperature and 60 °C)  
Decomposition tests were carried out with the purified compound 23 (see chapter 3.1.1). This 
was done, since it was realised that not compound 23 (Inc-Ac) had been responsible for the 
firstly observed inhibitory effects in the mPGES1-Assay; instead a great amount of 
decomposition compounds, originating from 23, have been responsible for the inhibition. The 
same discussion is basically valid for compound 22 (Inc), where a similar behaviour was 
noticed (data not shown). Thus, these compounds, even if stable for a long time in the NB 
fraction and at low temperatures (4 °C or -30 °C), are vulnerable to oxidation at higher 
temperatures (air exposure effects and thus kinetics are temperature dependent) when 
purified as single compounds. Aliquots (EC) of the isolated compounds were therefore tested 
under air-exposition for a certain time at room temperature and in a compartment drier at 60 
°C to test their stability. The following experiments were carried out with an aliquot of 
compound 23 (Note that for Test 1-4 the same sample was used): 
 
Test 1: Stability test for 7 days at room temperature. The sample of compound 23 (2.5 mg) 
was stored in an EC (with lid open for air exposure). After 7 days it was analysed by HPLC 
(Standard Quantitation Method as described in chapter 2.3.4.2). Therefore, the sample was 
dissolved in 1 ml MeOH (c = 2.5 mg/ml) and 100 µl thereof were used for injection (HPLC). 
The remaining 900 µl were dried (slight N2-stream at room temperature) and used for the 
next test (Test 2). 
Test 2: Stability test for 16 h at 60 °C in a compartment drier. The sample of compound 23 
(2.3 mg, from Test 1) was stored in an EC (with lid open for air exposure). After 16 h it was 
analysed by HPLC (Standard Quantitation Method as described in chapter 2.3.4.2). The 
sample was dissolved in 1 ml MeOH (c = 2.3 mg/ml) and 100 µl thereof were used for 
injection (HPLC). An Aliquot (400 µl) was saved and stored at 4 °C in a refrigerator. The 
remaining 500 µl were dried (slight N2-stream at room temperature) and used for the next 
test (Test 3). 
Test 3: Stability test for another 15 h at 60 °C in a compartment drier. The sample of 
compound 23 (1.2 mg, from Test 2) was stored in an EC (with lid open for air exposure). 
After 15 h it was analysed by HPLC (Standard Quantitation Method as described in chapter 
2.3.4.2). The sample was dissolved in 1 ml MeOH (c = 1.2 mg/ml) and 100 µl thereof were 
used for injection (HPLC). No Aliquot was saved. The remaining 900 µl were dried (slight N2-
stream at room temperature) and used for the next test (Test 4). 
Test 4: Stability test for another 16 h at 60 °C in a compartment drier. The sample of 
compound 23 (1.0 mg, from Test 3) was stored in an EC (with lid open for air exposition). 
After 16 h it was analysed by HPLC (Standard Quantitation Method as described in chapter 
2.3.4.2). The sample was dissolved in 1 ml MeOH (c = 1.0 mg/ml) and 100 µl thereof were 
used for injection (HPLC). The remaining 900 µl were dried (slight N2-stream at room 
temperature) and stored at 4 °C in a refrigerator. 
 
   62
Experimental Part 
_________________________________________________________________________________ 
 
Finally, the decomposed samples from Test 2, Test 4 and an intact sample of In-Ac (23, 
purity > 99 %, HPLC) were sent to the laboratory of the University of Tübingen for mPGES-1 
testing. Hence, to prove the theory that only the decomposition products of Inc-Ac (+/- Inc-Ac 
itself) are responsible for the enzyme inhibition (see also chapter 3.12). The results of the 
decomposition tests are presented in chapter 3.11.2. 
 
2.6.2 Kinetic Study of the Decomposition of Inc-Ac 
Since purified Inc (22) and Inc-Ac (23) revealed a low stability under air-exposure and room 
or higher temperatures, the quantitative HPLC results (see chapter 2.6.1) were used to give 
an estimation of the reaction kinetics underlying their decomposition. For basic explanations 
on reaction kinetics in chemistry please view the literature (e.g. [173,174]). The reaction 
order of the decomposition of Inc-Ac (23) obeys most probably a first order reaction kinetic 
(Note: Probably, the decomposition is pseudo first order due to the excess of oxygen in the 
air), leading to the following reaction rate law: 
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Integration of this expression leads to the linear and exponential function terms: 
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v(A) = reaction rate (here first order kinetics) 
c(A) = concentration of compound A 
c0(A) = concentration of compound A at the beginning of the reaction 
dc(A) = change of concentration of compound A dependent on time 
t = time 
dt = change of time 
k = reaction rate constant 
 
 
2.7 Partial- and Semi-Synthetic Procedures 
 
2.7.1 Semi Synthesis of Compound 19 from Compound 15 
3ß-OH-8,24-dien-tirucallic acid (compound 15; 21.5 mg, 0.047 mmol) was dissolved in DCM 
(5 ml). Pyridine (0.015 ml, 0.188 mmol), acetic anhydride (0.011 ml, 0.118 mmol) and DMAP 
(2.59 mg, 0.021 mmol) were successively added. The reaction mixture was refluxed for ca. 4 
h. After cooling to room temperature, the reaction was quenched with 10 ml ice-cold 1M HCl 
and the organic phase was separated. The aqueous phase was extracted with 3 x Et2O and 
the combined organic phases were dried with MgSO4, filtered and evaporated to give the 
final product (white solid; ca. 19 mg; yield: ca. 81 %). Optional: Purification by liquid column 
chromatography or preparative HPLC. The product was used as co-injection standard for the 
structure verification of compound 19 (see also chapter 3.2.4). 
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2.7.2 Isolation and Semi-Synthesis of Inc and Inc-Ac 
Acetylation of the Neutral fraction from Boswellia papyrifera: 25 g of the orange coloured 
neutral compounds were dissolved in 30 ml dichloromethane in a 500 ml three-necked flask. 
18 ml of pyridine (17.4 g, 0.22 mol), 20.4 ml of acetic anhydride (20.4 g, 0.2 mol) and 3 g 
DMAP (0.025 mol) were added successively. The temperature was raised till the reaction 
mixture started gently to reflux. It was stirred for 4 hours. After the reaction was complete, the 
mixture was quenched with 300 ml 1 N HCl. Phases were separated and the aqueous phase 
was extracted with diethyl ether (3 x ca. 100 ml). The combined organic phases were dried 
with MgSO4 and after filtration and evaporation in vacuo orange oil was obtained (yield: 28.7 
g). 
 
Isolation of Incensole acetate (flash and instrumental preparative chromatography): The 
orange oil (28.7 g) was dissolved in 30 ml DCM. Normal phase silica gel flash 
chromatography (column diameter: 10 cm) was performed by using an eluent consisting of 6 
parts petroleum ether and one part diethyl ether (6:1). 14 fractions were collected. All 
fractions were evaporated in vacuo. Each fraction contained yellow oil. Fraction 2 (3.1 g, 43 
% 23), 3 (6.9 g, 85 % 23) and 4 (2.2 g, 61 % 23) contained incensole acetate in large 
quantities. Fraction 3, as the purest fraction (85 % by HPLC control), was further purified by 
preparative HPLC. The whole amount of fraction 3 (6.9 g) was dissolved in 100 ml methanol, 
sonicated and 30 mL (2.07 g) of this solution were filtered (0.2 µm) and used for preparative 
HPLC (The remaining 70 ml, 4.83 g, were evaporated again and stored at – 30 °C). The 
following HPLC conditions were used: As preparative column a YMC-Pack Pro C18 RS (250 
x 20 mm I.D. S-5 µm, 8 nm; YMC, Dinslaken, Germany) served; flow rate = 19 ml/min; T = 
room temperature (ca. 25 °C); eluent: 100 % methanol, injection volume = 3 mL, total 
injections = 10 (30 ml, c = 69 mg/ml); three fractions were collected (see chapter 3.11.1). The 
middle fraction contained 1.28 g (yield: 62 % of total 2.07 g) referring to compound 23 with a 
purity higher 99 %. The remaining fraction 3 (4.8 g) is stable at -30 °C (at least for 12 month, 
probably even longer, not tested anymore). For further details see chapter 3.11. 
Note: Alternative preparation conditions on a NUCLEODUR 100-5 C18 ec, 250 x 21 mm I.D., 
Machery &  Nagel, Düren, Germany, preparative column: flow rate = 27.6 ml/min; T = room 
temperature, ca. 25 °C; eluent: methanol 96 % and water 4 %. These conditions gave similar 
resolution for purifying incensole acetate.  
 
Deacetylation of Incensole acetate: The isolated incensole-acetate (350 mg, 1 mmol) was 
dissolved in 10 ml 1 N KOH in iPrOH. The reaction mixture was refluxed for 3 hours. After 
cooling to room temperature, the iPrOH was mostly removed in vacuo. The remaining 
residue was acidified with 20 ml 1 N HCl and extracted with dichloromethane (3 x 10 ml). The 
combined organic extracts were dried with MgSO4. After filtration, the solvent was 
evaporated in vacuo to give colourless oil (yield: 268 mg, 0.87 mmol, ca. 90 %; purity: > 99 
%). Optional: purification by column chromatography or preparative HPLC. 
 
Acetylation of Incensole: Incensole (25.0 mg, 82 µmol) was dissolved in 5 ml DCM, 30 µL of 
pyridine (30 µg, 372 µmol), 33 µL of acetic anhydride (32 µg, 326 µmol) and 6 mg of DMAP 
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(49 µmol) were added successively. The reaction mixture was heated until it started gently to 
reflux. It was stirred for 4 hours at that temperature. After the reaction was complete, the 
mixture was cooled to room temperature and quenched with 40 ml 1 N HCl. The organic 
phase was saved and the aqueous phase was extracted with diethyl ether (3 x ca. 10 ml). 
The combined organic phases were dried with MgSO4 and after filtration and evaporation in 
vacuo colourless oil was obtained (yield: 26.6 mg, 76 µmol, ca. 93 %; purity: > 98 %). 
Optional: Purification by column chromatography or preparative HPLC. 
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3. Results and Discussion 
3.1 Isolation of Biomarker Compounds 
3.1.1 Isolation of Compounds from Boswellia papyrifera (Bpap) 
 
3.1.1.1 Isolation of Incensole (22) and Incensole Acetate (23) 
An extract of Bpap (AS-050509-E2h) from the AureliaSan GmbH, Bisingen (Germany), which 
is used for an ointment formulation, was investigated in order to find pharmacologically 
interesting ingredients. Therefore 4 g, dissolved in 3 ml DCM, of the yellow powder were 
subjected on a normal phase silica gel column (diameter: 5 cm) and fractionated using the 
standard step gradient and fraction collection method as described in chapter 2.3.2. The 
chromatography was monitored by TLC and 13 fractions were combined. All fractions were 
evaporated in vacuo. Fr. 2 (90 mg; clear oil and minor particles) and Fr. 7 (170 mg; clear oil) 
were further purified by preparative HPLC. Fr. 2 contained incensole acetate (23). The 
purifying conditions were: NUCLEODUR C18 prep column; T = 25 °C; eluent = MeOH : H2O 
(98 : 2); flow rate = 25 ml/min; c = 6.7 mg/ml in MeOH; 4 ml each injection; yield: 26.9 mg; 
purity > 99 % (HPLC). Fr. 7 contained incensole (22). The purifying conditions were: 
NUCLEODUR C18 prep column; T = 25 °C; eluent = MeOH : H2O (95 : 5); flow rate = 25 
ml/min; c = 13.8 mg/ml in MeOH; 5 ml each injection; yield: 23.0 mg; purity > 99 % (HPLC). 
The structures are presented in Fig. 3.1. 
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Fig. 3.1 Structures of incensole 22 (left) and incensole acetate 23 (right). 
 
 
3.1.1.2 Isolation of Verticillia-4(20),7,11-triene (24) 
Verticillia-4(20),7,11-triene (24) was isolated from the neutral compounds of Bpap described 
in chapter 3.11.1. Fr. 1 (500 mg) of the by column chromatography separated fractions 
contained this compound. It was further purified through following preparative HPLC 
conditions: NUCLEODUR C18 prep column; T = 25 °C; eluent = MeOH (100 %); flow rate = 
25 ml/min; c = 10 mg/ml in MeOH; 4 ml each injection; yield: 31.6 mg; purity > 98 % (HPLC). 
The structure is shown in Fig. 3.2. 
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Fig. 3.2 Structure of verticillia-4(20),7,11-triene (24). 
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3.1.1.3 Isolation of 3α-O-Acetyl-7,24-dien-tirucallic acid (18) and 3ß-O-Acetyl-8,24-dien-
tirucallic acid (19) 
The compounds 3α-Ac-7,24-dien-TA (18) and 3ß-Ac-8,24-dien-TA (19) were firstly found in 
the Bpap extract (AS-050509-E2h; AureliaSan GmbH) described in section 3.1.1.1. Fr. 9 
(429 mg) of this extract (AS-050509-E2h) contained a not verified peak signal, which 
revealed an interesting chromatographic behaviour. In Figures 3.3 and 3.4 this behaviour is 
depicted. Interestingly, the presumed homogenous peak signal was separable into three 
further signals when a column with a higher carbon load density had been used. Conditions 
for the isolation (prep HPLC) of the peak signal shown in Fig. 3.3 and 3.4: NUCLEODUR 
C18 prep column; T = 25 °C; eluent = MeOH : H2O (97 : 3); flow rate = 25 ml/min; c = 6.6 
mg/ml in MeOH; 5 ml each injection; 9 sub fractions were collected; fraction 6 contained the 
peak signal with a overall yield of 25.1 mg. 
 
 
Fig. 3.3 Qualitative standard gradient chromatogram (210 nm) of the isolated compound from Fr. 9 on 
a NUCLEODUR C18 analytical column (250 x 4 mm I.D., 100-5 ec). The peak appears as an almost 
homogenous signal (Rt = ca. 22 min). HPLC conditions: T = 25 °C; u = 0.85 ml/min; Solvent A = 
MeOH; Solvent B = H2O + 0.1 % TFA; Gradient: 0-1 min at 15 % B, 1-13 min gradient to 0 % B, 13-45 
min 0 % B (isocratic). 
 
 
Fig. 3.4 Qualitative standard gradient chromatogram (210 nm) of the isolated compound from Fr. 9 on 
a YMC-Pack Pro C18 RS analytical column (250 x 4.6 mm I.D.; S-5 µm, 8 nm). The peak resolves into 
three signals (Rt = 25.2, 25.5 and 26.3 min). Peak 2 and 3 are 3α-Ac-7,24-dien-TA (Peak 3; Rt = 26.3 
min; rel. peak area: 46 %) and 3ß-Ac-8,24-dien-TA (Peak 2; Rt = 25.5 min; rel. peak area: 32 %). 
Peak 1 is unknown (rel. peak area: 16 %). HPLC conditions as described in Fig. 3.3 above. 
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Since the yield (only 25 mg) of these three compounds isolated from Fr. 9 was too low for an 
adequate isolation of single compounds, a new extract with more resin material from Bpap 
was made. 
Therefore 19 g, dissolved in 50 ml DCM, of the Bpap acid fraction of a newly made extract 
were subjected on a normal phase silica gel column (diameter: 10 cm) and fractionated using 
the standard step gradient and fraction collection method as described in chapter 2.3.2. The 
chromatography was monitored by TLC and 12 fractions were combined. All fractions were 
evaporated in vacuo. Fr. 5 (2 g, white solid) contained the target compounds. However, only 
peak 2 and 3 were found again as shown in Fig. 3.5. The first minor peak was not detectable 
anymore in this extract (proved by co-injection of both fractions; compare also with Fig. 3.4).  
Fr. 5 was further purified by preparative HPLC. The purifying conditions were: NUCLEODUR 
C18 prep column; T = 25 °C; eluent = MeOH : H2O (98 : 2); flow rate = 25 ml/min; c = 17.9 
mg/ml in MeOH; 5 ml each injection; 4 further fractions were collected (Nr. 1 – 4); Nr. 2 was 
the target compound containing peak 2 and 3 eluting as one peak on a NUCLEODUR C18 
prep/analytical column; yield: 92.0 mg; purity > 99 % (HPLC). 
 
 
Fig. 3.5 Qualitative standard gradient chromatogram (210 nm) of the isolated compounds from Fr. 5 
on a YMC-Pack Pro C18 RS analytical column (250 x 4.6 mm I.D.; S-5 µm, 8 nm). The peak resolves 
into two signals. The minor peak eluting at front refers to 3ß-Ac-8,24-dien-TA (rel. peak area: 19 %) 
and the main peak to 3α-Ac-7,24-dien-TA (rel. peak area: 80 %). HPLC conditions as described in Fig. 
3.3. 
 
Fraction Nr. 2 was thus further purified with following conditions: YMC-Pack Pro C18 RS 
prep column; T = 25 °C; eluent = MeOH (100 %); flow rate = 19 ml/min; c = 3.7 mg/ml in 
MeOH; 3 ml each injection; 3 fractions were obtained of which the third fraction contained 
compound α-Ac-7,24-dien-TA (18); yield: 17.0 mg; purity > 95 % (HPLC). Note that the peak 
was not baseline separated and thus only the last fraction, fraction 3, could be purified 
sufficiently enough for an unequivocal NMR structure elucidation. Fraction 1 and 2 were a 
combination of compound 18 and 19 in differing percentages, whereas the material of Fr. 1 
was negligible and Fr. 2 delivered 41 mg. The structure is presented in Fig. 3.6. 
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Fig. 3.6 Structure of 3α-O-acetyl-7,24-dien-tirucallic acid (18). 
 
The separation of 3ß-Ac-8,24-dien-TA (19) from 3α-Ac-7,24-dien-TA (18) was more difficult 
and appeared to be infeasible on a conventional preparative HPLC column (20 mm I.D.). 
However, since the resolution on the preparative scale was not implementable, it was 
realised by preparative chromatography on the analytical HPLC device. Therefore the 20 µl 
injection loop was replaced by a self-made injection loop (PEEK Tubing; 0.75 mm I.D.; length 
= 32 cm) with a thus resulting injection volume of approximately 140 µl. 
Following conditions were used: 2 x YMC-Pack Pro RS C18 analytical in row; T = 30 °C; 
eluent = MeOH (100 %); flow rate = 1.0 ml/min; c = 1.3 mg/ml in MeOH (Fr. 2, 41 mg, from 
the first separation was therefore used); 100 µl per injection; yield of compound ß-Ac-8,24-
dien-TA (19) = 1.2 mg; purity > 99 % (HPLC). An example chromatogram is shown in Fig. 3.7 
and the structure is presented in Fig. 3.8. 
 
 
Fig. 3.7 Preparative chromatogram (210 nm) on the analytical HPLC device. Peak 1 (Rt = 16.9 min) = 
3ß-O-acetyl-8,24-dien-tirucallic acid and Peak 2 (Rt = 18.0 min) = Structure of 3α-O-acetyl-7,24-dien-
tirucallic acid. For further details see text. 
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Fig. 3.8 Structure of 3ß-O-acetyl-8,24-dien-tirucallic acid (19). 
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3.1.2 Isolation of Compounds from Boswellia carterii (Bcar) 
 
3.1.2.1 Isolation of ß-Caryophyllene oxide (28) and Serratol (21)  
The yellow-orange oil (5 g, neutral compounds) of Bcar was dissolved in 5 ml DCM, 
subjected on a normal phase silica gel column (diameter: 5 cm) and fractionated using the 
standard step gradient and fraction collection method as described in chapter 2.3.2. The 
chromatography was monitored by TLC and 14 fractions were combined. All fractions were 
evaporated in vacuo. Fr. 5 (325 mg) contained ß-Car-Ox (28) and Ser-OH (21) and was 
further purified by preparative HPLC. Conditions for the isolation of ß-Car-Ox (28) and Ser-
OH (21): NUCLEODUR C18 prep column; T = 25 °C; eluent = MeOH (100 %); flow rate = 25 
ml/min; c = 16.3 mg/ml in MeOH; 5 ml each injection; yield: 200 mg, containing ß-Car-Ox 
(28) and Ser-OH (21). Pure ß-Car-Ox (28) and Ser-OH (21) were obtained by following 
chromatographic conditions: YMC-Pack Pro C18 RS prep column; T = 25 °C; eluent = MeOH 
: H2O (98 : 2); flow rate = 19 ml/min; c = 13.3 mg/ml; 5 ml each injection; three fractions were 
collected: Fr. 1 = 58 mg of ß-Car-Ox (28) with a purity > 98 %; Fr. 3 = 82 mg of Ser-OH (21) 
with a purity > 99 %. The structures are shown in Fig. 3.9. 
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Fig. 3.9 Structures of ß-caryophyllene oxide 28 (left) and serratol 21 (right). 
 
 
3.1.2.2 Isolation of τ-Cadinol (25) and Iso-Serratol (20) 
Fr. 10 (417 mg) of the separated Bcar extract contained τ-cadinol (25) and iso-serratol (20). 
The purifying conditions were as follows: NUCLEODUR C18 prep column; T = 25 °C; eluent 
= MeOH (100 %); flow rate = 25 ml/min; c = 13.9 mg/ml in MeOH; 5 ml per injection; yield: 94 
mg, containing τ-cadinol (25) and iso-serratol (20). Purification was achieved by following 
conditions: YMC-Pack Pro C18 RS prep column; T = 25 °C; eluent = MeOH : H2O (98 : 2); 
flow rate = 19 ml/min; c = 6 mg/ml; 5 ml each injection; two fractions were collected: Fr. 1 = 
36 mg of τ-cadinol (25) with a purity > 97 %; Fr. 2 = 40 mg of iso-serratol (20) with a purity > 
99 %. The structures are shown in Fig. 3.10. 
 
              
10
9
11
12
13
87
65
43
2
1 14
17
18
15
20
19
16
H
HO  
 
Fig. 3.10 Structures of τ-cadinol 25 (left) and iso-serratol 20 (right). 
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3.1.2.4 Isolation of Incensole (22) and 3-ß-OH-Tirucallol (29) 
Fr. 12 (185 mg) of the separated Bcar extract contained incensole (22) already isolated from 
Bpap and 3-ß-OH-tirucallol (29). The purifying conditions were as follows: NUCLEODUR C18 
prep column; T = 25 °C; eluent = MeOH (100 %); flow rate = 25 ml/min; c = 9.3 mg/ml in 
MeOH; 5 ml per injection; two fractions were collected: Fr. 1 = 66.5 mg (containing incensole) 
and Fr. 2 = 10.5 mg (3-ß-OH-tirucallol) with a purity > 93 %. Incensole was further purified 
with following conditions: YMC-Pack Pro C18 RS prep column; T = 25 °C; eluent = MeOH : 
H2O (98 : 2); flow rate = 19 ml/min; c = 4.4 mg/ml; 5 ml each injection; yield: 11 mg with a 
purity > 98 %. The structure of 3-ß-OH-tirucallol is shown in Fig. 3.11 and the structure of 
incensole is already presented in section 3.1.1.1.  
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Fig. 3.11 Structure of 3-ß-OH-tirucallol (29). 
 
 
3.1.2.5 Isolation of 3-α-OH-11-Keto-12-ursen (30) 
3-α-OH-11-Keto-12-ursen (30) was isolated from another Bcar neutral compound extract. 
Therefore, 3 g from the neutral compounds were separated on a normal phase silica gel 
column (diameter: 2.5 cm) using the standard step gradient and fraction collection method as 
described in chapter 2.3.2. The chromatography was monitored by TLC and combined to 8 
fractions. All fractions were evaporated in vacuo. Fr. 8 (805 mg) contained 3-α-OH-11-keto-
12-ursen (30) and was further purified by preparative HPLC. The following conditions were 
implemented: NUCLEODUR C18 prep column; T = 25 °C; eluent = MeOH : H2O (98 : 2); flow 
rate = 25 ml/min; c = 16.0 mg/ml in MeOH; 5 ml each injection; two fractions were collected; 
Fr. 2 contained 3-α-OH-11-keto-12-ursen (30); yield: 42.8 mg. This fraction was further 
purified. Conditions: YMC-Pack Pro C18 RS prep column; T = 25 °C; eluent = MeOH : H2O 
(98 : 2); flow rate = 19 ml/min; c = 4.3 mg/ml; 3 ml each injection; yield: 10 mg with a purity > 
92 %. The structure of 3-α-OH-11-Keto-12-ursen is shown in Fig. 3.12. 
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Fig. 3.12 Structure of 3-α-OH-11-keto-12-ursen (30). 
 
 
3.2 Spectroscopic Data 
 
3.2.1 Incensole (22) 
Incensole was isolated as colourless viscous oil. The structure is shown in Fig. 3.13. Analysis 
by TLC (Pentane/Et2O 2:1 and 1 % HOAc) showed a strong brown spot after dyeing and 
heating with anisaldehyde reagent at Rf = 0.27. Detection by DAD-RP-HPLC was only 
possible at 210 nm and the compound eluted at a Rt value of ca. 25.9 min under standard 
HPLC conditions (2.3.4.2).  Mass spectrometric detection (CI-MS; low resolution) delivered 
the following significant fragmentation pattern: m/z (%): 306.4 [M]+ (43); 289.2 (10);  155.1 
(35); 125.1 (70); 83.9 (100); 71.0 (50). The 13C-NMR spectrum revealed 20 carbon atom 
signals as presented in Fig. 3.14. DEPT 90/135 spectra divided these 20 C-atoms into 4 
quaternary, 4 CH-, 7 CH2- and 5 methyl carbon atoms. The 1H-spectrum is shown in Fig. 
3.15 and the further structural elucidation by conventional 2D-NMR techniques (HSQC, 
COSY, NOESY, and HMBC) is basically presented in Tab. 3.1. 
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Fig. 3.13 Structure of incensole (22). 
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Fig. 3.14 13C-NMR spectrum of incensole (22). 
 
 
Fig. 3.15 1H-NMR spectrum of incensole (22). 
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Tab. 3.1 1H and 13C NMR assignments (400 MHz) for incensole (22). 
Atom Nr. 
13C  
δ [ppm] 
1H  
δ [ppm], J [Hz] 
HMBC 
(2J in Hz)
HMBC  
(3J in Hz) HH-COSY NOESY
1 88.56  2α/ß, 
14α/ß, 18
3α/ß,  
13, 19, 20 
 
2 30.66 1.84 
1.59 (ß, ddd, J = 11.6, 7.6, 4) 
3α/ß 14α/ß, 18 2 (gem.), 3α/ß 18
3 36.36 2.06 
1.74 
2α/ß 5ß, 15 2α/ß 
4 84.14  3α/ß, 5ß, 15 2α/ß  
5 75.57 3.30 (dd, J = 10, 0.8) 4, 6α/ß 3α/ß,  
7α/ß, 15 
6α/ß, 15 2ß, 3ß, 
6α/ß,  
9, 13, 14,
15
6 30.72 1.89 (α, m) 
1.32 (ß, dddd, J = 14.0, 10.0, 5.6, 1.6)
5ß, 7α/ß  7α/ß, 6(gem.) 
5ß 
15, 
(6gem.)
7 33.65 2.12 (dd, J = 14.0, 5.6) 
1.99 (m) 
6α/ß 5ß, 9, 16  
8 134.18  7α/ß, 16 6α/ß, 10α/ß  
9 125.13 5.08 (m) 10α/ß 7α/ß, 11α/ß, 
16 
10α/ß, 16 5ß
10 24.83 2.11-2.18 (m, 2H) 9, 11α/ß   
11 38.62 2.11-2.16 (m, 2H) 10α/ß 9, 13, 17  
12 134.23  11α/ß, 17 10α/ß, 14α/ß  
13 121.79 5.12 (m) 14α/ß 17 14α/ß, 17 2ß,
5ß, 14,
18, 19, 
20
14 32.35 2.04 
2.17  
13 2α/ß, 18  
15 20.64 1.07 (s) 5ß, 3α/ß  5ß 6ß
16 18.15 1.62 (m) 8 7α/ß, 9 9 
17 16.10 1.50 (m) 12 11α/ß, 13 11α/ß, 13 
18 34.85 1.90 (sep, J = 6.8 Hz) 19, 20 2α/ß, 14α/ß 19,20 2ß, 6ß
19 17.98 0.89 (d, J = 6.8 Hz) 18 1, 20 18 15
20 18.05 0.91 (d, J = 6.8 Hz) 18 1, 19 18 15
 
 
Evaluation of the spectral data and comparison with data found in the literature [81,87] 
confirmed the isolated compound as incensole. The compound itself was firstly described by 
Corsano and Nicoletti in 1966 [75]. Obermann [79] described in the year 1977 incensole as 
one of the main constituents of the neutral fraction of the Boswellia species termed as 
“Eritrea”, thus, referring to the species Boswellia papyrifera. 
Furthermore a few special spectral characteristics from the 1H-NMR spectrum of incensole 
are described. The H6ß atom shows a specific multiplet structure which is the product of a 
dddd coupling to its four neighbours (H5, H6α and H7α/ß) as it shown in Fig. 3.16. 
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1H NMR (400 MHz, CDCl3) δ in ppm 1.32 (dddd, J = 13.87, 10.25, 5.33, 1.77 Hz, 1H) 
 
Fig. 3.16 The 1H-NMR fine structure of the H6ß signal at 1.32 ppm. 
 
1H NMR (400 MHz, CDCl3) δ in ppm 3.30 (dd, J = 10.22, 0.89 Hz, 1H) 
 
Fig. 3.17 The 1H-NMR fine structure of the H5ß signal at 3.30 ppm. 
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1H NMR (400 MHz, CDCl3) δ in ppm 1.59 (ddd, J = 12, 8, 4 Hz, 1H) 
 
                                              12 Hz 
 
 
                           8 Hz                                    8 Hz 
 
              4 Hz                    4 Hz          4 Hz                  4 Hz 
 
Fig. 3.18 The 1H-NMR fine structure of the H2ß signal at 1.59 ppm. One signal is overlapped by the 
methyl signal of C16 (1.62 ppm). 
 
 
 
 
Fig. 3.19 Newman projection of the assumed spatial orientation of the H6α/ß atoms relatively to H5ß. 
 
Exact assignment of the other coupling 1H neighbour atoms (H6α and H7α/ß) was 
unfortunately not possible as these signals have not been clearly resolved and showed 
overlapping with other signals (area: 1.85-2.25 ppm).  
In Fig. 3.17 the coupling of the H5ß with the H6ß atom is presented. Additionally, there is a 
weak coupling of about 0.8 Hz (exponential apodization with MestRec software) with H6α 
which concludes, according to the Karplus rule [175] that the H6α is preferably positioned 
about 90° to the H5ß signal; whereas the H6ß signal is ca. 0° next to the H5ß signal. The 
H6ß signal shows a strong interaction with the C15 methyl group (2D-NOESY), which leads 
to this deduction (see also the Newman projection for clarification in Fig. 3.19). The signal of 
H2ß at 1.59 ppm shows also a relatively good resolved fine structure as can be seen in Fig. 
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3.18. It gives a vicinal coupling with H3α/ß and a geminal coupling with H2α (ddd, J = 12, 8 
and 4 Hz). Again, the other coupling partner signals (H2α and H3α/ß) can not be certainly 
assigned since their fine structures are covered by additional signals. 
 
 
3.2.2 Incensole Acetate (23) 
Incensole Acetate was isolated as colourless viscous oil. The structure is shown in Fig. 3.20. 
Analysis by TLC (Pentane/Et2O 2:1 and 1 % HOAc) showed a strong brown spot after dyeing 
and heating with anisaldehyde reagent at Rf = 0.68. Detection by DAD-RP-HPLC was only 
possible at 210 nm and the compound eluted at a Rt value of ca. 33.5 min under standard 
HPLC conditions (2.3.4.2). Mass spectrometric detection (CI-MS; low resolution) delivered 
the following significant fragmentation pattern: m/z (%): 348.3 [M]+ (57); 305.2 (10) [M - 
C3H7]+; 289.2 (100) [M - CH3-COO]+;  271.2 (29);  149.1 (40); 135.1 (47); 127.1 (65); 81.1 
(62). The 13C-NMR spectrum revealed 22 carbon atom signals as presented in Fig. 3.21. 
DEPT 90/135 spectra divided these 20 C-atoms into 5 quarternary, 4 CH-, 7 CH2- and 6 
methyl carbon atoms. The 1H-spectrum is shown in Fig. 3.22 and the further structural 
elucidation by conventional 2D-NMR techniques (HSQC, COSY, NOESY, and HMBC) is 
basically presented in Tab. 3.2. 
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Fig. 3.20 Structure of incensole acetate (23). 
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Fig. 3.21 13C-NMR spectrum of incensole acetate (23). 
 
 
Fig. 3.22 1H-NMR spectrum of incensole acetate (23). 
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Tab. 3.2 1H and 13C NMR assignments (400 MHz) for incensole acetate (23). 
Atom Nr. 
13C  
δ [ppm] 
1H  
δ [ppm], J [Hz] 
HMBC 
(2J in Hz)
HMBC  
(3J in Hz) HH-COSY NOESY
1 89.23  2α/ß, 
14α/ß, 18
3α/ß,  
13, 19, 20 
 
2 30.33 1.78 
1.61 
3α/ß 14α/ß, 18  
3 35.59 1.89 
1.59 
2α/ß 5ß, 15  
4 83.07  3α/ß, 5ß, 15 2α/ß  
5 76.57 4.87 (dd, J = 10, 0.8) 4, 6α/ß 3α/ß,  
7α/ß, 15, 21 
6α/ß, 15 2ß, 3ß,
6α/ß, 7α/ß,
 9, 13, 14,
15
6 27.73 1.85 (α, m) 
1.51 (ß, dddd, J = 14.0, 10.0, 5.6, 1.6)
5ß, 7α/ß   15, 
(6gem.)
7 33.37 2.02 (dd, J = 14.0, 5.6) 
1.63 (m) 
6α/ß 5ß, 9, 16 6α/ß, 
7(gem.) 
8 133.20  7α/ß, 16 6α/ß, 10α/ß  
9 125.35 5.18 (m) 10α/ß 7α/ß, 11α/ß, 
16 
10α/ß, 16 5ß
10 24.76 2.19 (m, 2H) 9, 11α/ß   
11 38.49 2.15 (m, 2H) 10α/ß 9, 13, 17  
12 135.21  11α/ß, 17 10α/ß, 14α/ß  
13 121.05 5.16 (m) 14α/ß 17 14α/ß, 17 2ß,
5ß, 14,
18, 19, 
20
14 32.01 2.17 (m, 2H) 13 2α/ß, 18  
15 22.02 1.11 (s) 5ß, 3α/ß  5ß 6ß
16 17.66 1.59 (m) 8 7α/ß, 9 9 6α
17 16.00 1.55 (m) 12 11α/ß, 13 11α/ß, 13 11α/ß
18 34.92 1.90 (sep, J = 6.8 Hz) 19, 20 2α/ß, 14α/ß 19,20 
19 18.00 0.89 (d, J = 6.8 Hz) 18 1, 20 18 2α/ß, 3α,
14, 15, 18
20 18.04 0.91 (d, J = 6.8 Hz) 18 1, 19 18 2α/ß, 3α,
14, 15, 18
21 171.17  22 5ß  
22 21.29 2.05 (s) 21   2ß, 3ß
 
Evaluation of the spectral data and comparison with data found in the literature [35,81,87] 
confirmed the isolated compound as incensole acetate. The compound itself was firstly 
described by Obermann [79]. The first one-dimensional NMR data were obtained by Gacs-
Baitz et al. [81] and the first two-dimensional NMR assignments by Basar [35]. 
In Fig. 3.23 the 1H-NMR spectral fine structure of H6ß is shown. It is principally the same fine 
structure as already described for incensole (view chapter 3.2.1), only downfield shifted (from 
1.32 to 1.51 ppm) by the appearance of the carbonyl group in its acetate derivate. A part of 
the fine structure is covered by the methyl signal of C17 (1.55 ppm). 
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1H NMR (400 MHz, CDCl3) δ in ppm 1.51 (dddd, J = 13.87, 10.25, 5.33, 1.77 Hz, 1H) 
 
Fig. 3.23 The 1H-NMR fine structure of the H6ß signal at 1.51 ppm. 
 
 
In Fig. 3.24 the coupling of the H5ß with the H6ß atom is presented. It represents the same 
fine structure pattern as already shown for incensole (chapter 3.2.1). Likewise the signal of 
H6ß, the H5ß signal is also downfield shifted (from 3.30 ppm in incensole to 4.87 ppm in 
incensole acetate) by occurrence of the carbonyl group. The relatively big acetyl substituent 
is in an equatorial position as demonstrated in Fig. 3.24 and thus leads to the same relative 
stereochemistry as already shown for incensole. The fine structure of H5ß is presented in 
Fig. 3.25. 
 
H5
OAcR
J = 10 Hz
J = 0.8 Hz
H6 1.51ppm
R
H6 1.85ppm
 
 
Fig. 3.24 Newman projection of the assumed spatial orientation of the H6α/ß atoms relatively to H5ß. 
 
 
 
 
 
   80
Results and Discussion 
_________________________________________________________________________________ 
 
1H NMR (400 MHz, CDCl3) δ in ppm 4.87 (dd, J = 10.43, 0.79 Hz, 1H) 
 
Fig. 3.25 The 1H-NMR fine structure of the H5ß signal at 4.87 ppm. 
 
 
 
3.2.3 3α-O-Acetyl-7,24-dien-tirucallic acid (18) 
The compound was isolated as a white solid. The structure is shown in Fig. 3.26. Analysis by 
TLC (Pentane/Et2O 2:1 and 1 % HOAc) showed a strong blue spot after dyeing and heating 
with anisaldehyde reagent at Rf = 0.26, eluting between incensole and the α/ß-ABAs (see 
also section 3.4). Detection by DAD-RP-HPLC was only possible at 210 nm and the Rt value 
was ca. 33.7 min under standard HPLC conditions (2.3.4.2). Thus, the compound co-eluted 
with compound 3 (ß-BA). Mass spectrometric detection (LC-ESI-MS; negative mode, low 
resolution) gave a mol peak of 497.6 g/mol ([M – H]- ; for LC-ESI-conditions see section 
2.4.1). The mass spectroscopic data is presented in Fig. 3.27. 
 
3 5
1
7
8
9
12
28
O
18
H
29
30
15
17
19
20HOOC
21
24
25
26
27
3132
O
 
 
Fig. 3.26 Structure of 3α-O-acetyl-7,24-dien-tirucallic acid (18). 
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Fig. 3.27 Mass spectroscopic data (ESI neg. mode) of compound 18 (Peak 2). Peak 1 refers to 3ß-O-
acetyl-8,24-dien-tirucallic acid (19). For further details see text. 
SIM (neg. ESI) 
 
 
 
 
 
 
HPLC-DAD (210 nm) 
 
 
 
 
 
 
TIC 
 
The 13C-NMR spectrum revealed 32 carbon signals as presented in Fig. 3.28. The DEPT 90 
and DEPT 135 spectra divided these 32 C-atoms into 8 quaternary, 7 CH-, 9 CH2- and 8 
methyl carbon atoms. At 183.0 ppm, the downfield signal referred to a carboxyl group (C-21) 
and the signal at 170.8 ppm to a carbonyl group (C-31). Four further signals between 145.6 
and 118.2 ppm correspond to two tri-substituted double bonds. One double bond (C-24 with 
123.6 ppm; C-25 with 132.3 ppm) was characterised by a vinyl proton at 5.09 ppm (H-24, t, J 
= 7 Hz) and by an isopropylidene group with two methyl groups at 1.67 ppm (H-26, s) and 
1.58 ppm (H-27, s). The second double bond (C-7 with 118.2 ppm; C-8 with 145.6 ppm) 
revealed a quaternary carbon atom (C-8) and showed a vinyl proton at 5.26 ppm (H-7, m). 
The chemical shift signal of 78.3 ppm referred to the acetyl group substituted carbon atom 
(C-3) and also showed a significant downfield proton signal at 4.67 ppm (H-3, brs). The 1H-
spectrum is shown in Fig. 3.29 and the further structural elucidation by conventional 2D-NMR 
techniques (HSQC, COSY, NOESY, and HMBC) is basically presented in Tab. 3.3. 
Pardhy and Bhattacharyya [66] described how to easily distinguish between 3-α-OH- and 3-
ß-OH-tirucallic acids, only based on 1D-1H-NMR spectra according to the Karplus theory 
[175]. Therefore, the equatorial H at C-3 gives for the 3-α-OH-tirucallic compound a broad 
singlet, respectively, for the 3-α-OAc-group in compound 18. And the axial H at C-3 gives for 
the 3-ß-OH-tirucallic molecule a duplet of duplets, respectively, for the 3-ß-OAc group in 
compound 19. Hence, even without NOESY correlations the relative configuration of H atoms 
at position C-3 can be assigned in these classes of molecules. 
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Fig. 3.28 13C-NMR of 3α-O-acetyl-7,24-dien-tirucallic acid (18). 
 
 
Fig. 3.29 1H-NMR of 3α-O-acetyl-7,24-dien-tirucallic acid (18). 
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Tab. 3.3 1H and 13C NMR assignments (500 MHz) for 3α-O-acetyl-7,24-dien-tirucallic acid (18). 
Atom Nr. 
13C  
δ [ppm] 
1H  
δ [ppm], J [Hz] 
HMBC 
(2J in Hz)
HMBC  
(3J in Hz) HH-COSY NOESY
1 32.03 1.33 
1.33 
2α/ß 3, 5, 18 2α/ß 9, 18
2 22.86 1.64 (α) 
1.83 (ß) 
1α/ß 3 1α/ß, 2(gem.) 2(gem.)
3 78.33 4.67 (br s) 2α, 4 5, 28,
29, 31,
32(4J)
2α/ß 2α/ß,
28, 29,
32
4 36.58  3, 5,
28, 29
          2α, 6ß  
5 45.55 1.75 6α/ß 1α/ß, 9, 18
28, 29
6α/ß 9, 29
6 23.76 1.91 (ß) 
2.06 (α) 
5, 7 4 5 
7 118.18 5.26 (m) 6 5, 9, 14 6α/ß, 5, 9 5, 6α/ß,
15α/ß,
18, 30
8 145.62  11α/ß, 30  
9 48.30 2.31 11 1, 5, 12, 18 11α/ß 5, 19
10 34.74  1α/ß, 5,
18
2α, 6α  
11 17.64 1.42 (α) 
1.48 (ß) 
9, 12 8, 13 9 18
12 29.92 1.48 (α) 
1.74 (ß) 
11α/ß            17,19 12(gem.), 
19(4J) 
13 43.34  12α/ß, 17,
19
11α/ß,
20, 30
 
14 51.05  15, 30 19  
15 33.43 1.48 
1.51 
16 30 30(4J) 
16 27.17 1.31 (α) 
1.97 (ß) 
15, 17 20 15α/ß, 17 
16(gem.) 
16(gem.),
20
17 49.85 2.03 16, 20 12, 15, 19 20 
18 12.84 0.74 (s) 10 1, 5, 9 1(4J), 5(4J) 1, 2ß,
9, 11, 28
19 21.56 0.94 (s) 13 12, 14, 17 12(4J) 12α, 20
20 47.48 2.29 17, 21, 
22
13, 16,
23
17, 22α/ß 16α/ß, 19,
22
21 182.96 11.83 (br s, COOH) 20 22  
22 32.23 1.54 
1.59 
21, 23α/ß 17 20 20
23 26.06 1.94 
1.98 
22 25  27
24 123.55 5.09 (tr, J = 7 Hz)* 23α/ß 26, 27 23α/ß, 26, 27 22α/ß,
23α/ß,
20, 26
25 132.25  26, 27 23α/ß  
26 25.67 1.67 (s) 25 24, 27 27 24
27 17.62 1.58 (s) 25 24, 26 26 23
28 21.39 0.96 (s) 4 3, 29 29(4J) 2ß, 6ß,
 18, 29
29 27.24 0.83 (s) 4 3, 28 28(4J) 5, 6α, 28
30 27.37 0.97 (s) 14 13, 15 15α/ß(4J) 11ß, 12ß,
16ß, 17
31 170.81  32 3  
32 21.29 2.06 (s) 31 3(4J)  
*actually the signal represents an unresolved multiplet fine structure within the triplet structure 
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Evaluation of the spectral data confirmed the isolated compound as 3α-O-acetyl-7,24-dien-
tirucallic acid. The deacetylated derivative (3α-OH-7,24-dien-tirucallic acid, 17) was isolated 
by Seitz [56] from Bpap and by Mora et al. [69] from the resin of Protium crenatum 
(Burseraceae). Additionally, Banno et al. [68] and Akihisa et al. [67] report of compound 18 
from Bcar, which they obtained by acetylation of 3α-OH-7,24-dien-tirucallic acid (17). 
However, according to the data presented here the resin was more likely to be the species 
Bpap than Bcar, as tirucallic acids are generally less expressed in Bcar (see chapter 3.8) and 
as compound 23 (Inc-Ac, thus far a specific biomarker for Bpap) had been isolated in both 
works [67,68]. Finally, Estrada et al. [70] report on the isolation of compound 18 from Bcar 
(though again it is more likely that the resin was Bpap instead) and refer to the paper of 
Büchele et al. [57] for its isolation, although it is nothing mentioned about compound 18 in 
this paper. Thus, the NMR data presented here is the first thoroughly published description of 
this molecule, including data of its isolation (see chapter 3.1.1). 
 
 
3.2.4 3ß-O-Acetyl-8,24-dien-tirucallic acid (19) 
The compound (19) was isolated as a white solid. The structure is shown in Fig. 3.30. 
Analysis by TLC (Pentane/Et2O 2:1 and 1 % HOAc) showed a strong blue spot after dyeing 
and heating with anisaldehyde reagent at Rf = 0.26, eluting between incensole and the α/ß-
ABAs (see also section 3.4) and thus co-eluting with 3α-O-acetyl-7,24-dien-tirucallic acid (18) 
and 3α-O-Acetyl-8,24-dien-tirucallic acid (16). Detection by DAD-RP-HPLC was only possible 
at 210 nm and the compound eluted at a Rt of ca. 33.4 min between compound 1 (α-BA) and 
3 (ß-BA) under standard HPLC conditions (2.3.4.2). Mass spectrometric detection (LC-ESI-
MS; negative mode, low resolution) gave a mol peak of 497.6 g/mol ([M – H]-; for LC-ESI-
conditions see section 2.4.1). The mass spectroscopic data is presented in Fig. 3.31. 
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Fig. 3.30 Structure of 3ß-O-Acetyl-8,24-dien-tirucallic acid (19). 
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Fig. 3.31 Mass spectroscopic data (ESI neg. mode; Scan-Range: ca. 320-700 m/z) of compound 19. 
The minor peak next to at m/z ca. 520 refers to the compound + Na+ (sodium). 
 
The 13C-NMR (125 Hz, micro probe head) spectrum revealed only 31 carbon atom signals as 
presented in Fig. 3.32. The DEPT 90 and DEPT 135 spectra divided these 31 C-atoms into 8 
quaternary, 5 CH-, 10 CH2- and 8 methyl carbon atoms. At 182.3 ppm, the downfield signal 
of the carboxyl group (C-21) diminishes inside the noise (probable reason: micro probe head 
and a low sample concentration). However, as demonstrated in Fig. 3.33 the HMBC 
spectrum reveals the 2J coupling of C-21 with H-20 and the 3J coupling of Hα/ß-20 (stronger 
signal). Furthermore, the correct molecule identity was validated by acetylation of 3ß-OH-
8,24-dien-tirucallic acid (15) (see chapter 2.7.1) and co-injection by the standard RP-HPLC-
DAD method (2 x YMC column in row). The signal at 171.0 ppm belongs to a carbonyl group 
(C-31). Signals between 133.9 and 123.6 ppm correspond to a tri-substituted and a tetra-
substituted double bond. One double bond (C-24 with 123.6 ppm; C-25 with 132.2 ppm) was 
characterised by a vinyl proton at 5.09 ppm (H-24, t, J = 7 Hz) and by an isopropylidene 
group with two methyl groups at 1.68 ppm (H-26, s) and 1.58 ppm (H-27, s). The second 
double bond (C-8 with 133.3 ppm; C-9 with 133.9 ppm) revealed two quaternary carbon 
atoms. The chemical shift signal of 80.9 ppm referred to the acetyl group substituted carbon 
atom (C-3) and also showed a significant downfield proton signal at 4.50 ppm (H-3, dd, J = 
11.8 and 4.5 Hz; see also Fig. 3.35). The 1H-spectrum is shown in Fig. 3.34 and the impurity 
signals (only 1.2 mg of the compound were isolated, thus even minor proton impurities gave 
significant signal levels) are tagged (frame). The structural elucidation data by conventional 
2D-NMR techniques (HSQC, COSY, NOESY, and HMBC) is basically presented in Tab. 3.4. 
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Fig. 3.32 13C-NMR (125 Hz, micro probe head) of 3ß-O-acetyl-8,24-dien-tirucallic acid (19). 
 
 
 
Fig. 3.33 HMBC of 3ß-O-acetyl-8,24-dien-tirucallic acid (19), declaring the existence of C-21 (not 
detectable in the 13C-NMR spectrum). For further details see text. 
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Fig. 3.34 1H-NMR (500 MHz, micro probe head) of 3ß-O-acetyl-8,24-dien-tirucallic acid (19). The 
impurities are marked by the grey rectangles. 
 
1H NMR (500 MHz, CDCl3) δ in ppm 4.50 (dd, J = 11.76, 4.47 Hz, 1H) 
 
Fig. 3.35 The dd at 4.5 ppm in the 1H-NMR-spectrum declaring the α-position (axial) of the proton at 
C-3. 
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Tab. 3.4 1H and 13C NMR assignments (500 MHz; Micro probe head) for 3ß-O-acetyl-8,24-dien-
tirucallic acid (19). 
Atom Nr. 
13C  
δ [ppm] 
1H  
δ [ppm], J [Hz] 
HMBC 
(2J in Hz)
HMBC 
(3J in Hz) HH-COSY NOESY
1 34.98 1.28 (α) 
1.74 (ß) 
2ß 5, 18 1(gem.), 
2α/ß 
1(gem.)
2 24.17 1.60 (ß) 
1.68 (α) 
1α/ß 1α/ß 
3 80.85 4.50 (dd, J = 11.8, 4.5) 2, 4 1ß, 5, 28,
29, 31
2α/ß 1α, 2α/ß, 5,
29, 32
4 37.87  3, 5,
28, 29
  
5 51.03 1.22 6α/ß,
10
7α, 18,
28, 29
6α/ß, 28, 29 1α, 3, 29
6 18.74 1.42 (ß) 
1.68 (α) 
5 5 
7 27.46 1.93 (ß) 
2.08 (α) 
6α/ß 5 6ß(7α) 
8 133.30  6α, 30  
9 133.90  11ß 12α, 18  
10 37.15  1α/ß, 5,
18
2ß, 6α/ß  
11 21.52 1.91 (ß) 
2.01 (α) 
12α/ß  
12 28.75 1.37 (α) 
1.66 (ß) 
19 12(gem.) 12(gem.)
13 43.88  17, 19 11ß,
12α/ß,
30
 
14 49.59  15α, 30 12α, 19  
15 29.33 1.30 (ß) 
1.55 (α) 
30  
16 26.86 1.34 (α) 
1.95 (ß) 
17 17 16(gem.)
17 46.92 2.07 20 19, 22 16α/ß, 20 17, 21α/ß,
30
18 20.09 0.94 (s) 1α/ß, 5  1ß, 2ß, 6ß, 
11ß, 28
19 15.70 0.81 (s) 12α/ß, 17  17, 12α,
21α/ß
20 47.45 2.29 17, 21 17, 22α/ß 19, 16α/ß,
21α/ß
21 182.09*  20 22  
22 32.45 1.56 
1.56 
20, 21 17 20 
23 25.94 1.93 
2.00 
24 25 23α/ß 
24 123.59 5.09 (tr, J = 7.1 Hz)* 23α/ß 26, 27 23, 26 
27 
20, 22α/ß,
23α/ß,
26
25 132.24  26, 27 23α/ß  
26 25.68 1.68 (s) 25 24, 27 23α/ß, 
24 
27
27 17.64 1.58 (s) 25 24, 26 24 16ß, 26
28 16.62 0.87 (s) 3, 5, 29 5 6ß, 18
29 27.96 0.88 (s) 3, 5, 28 5 3, 5, 32
30 24.41 0.88 (s) 15 15α 16ß
31 171.05  32 3  
32 21.32 2.05 (s) 31   29
*actually the signal represents an unresolved multiplet fine structure within the triplet structure 
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Evaluation of the spectral data confirmed the isolated compound as 3ß-O-acetyl-8,24-dien-
tirucallic acid. The deacetylated derivative (3ß-OH-8,24-dien-tirucallic acid, 15) was isolated 
by Pardhy and Bhattacharya [66] from Bser and by Seitz [56] from Bpap. Banno et al. [68] 
and Akihisa et al. [67] reported it (15) from Bcar, though the species was more likely to be a 
sample of Bpap instead (same discussion as in chapter 3.2.3). The compound itself, as 
acetylated variety, has been firstly reported by Estrada et al. [70], isolated from Bcar (see 
also chapter 3.2.3). The isolation of it is referred by Estrada et al. [70] to the paper of 
Büchele et al. [57]. However, neither the compound itself nor something about its isolation 
are mentioned in that publication [57]. Hence, the NMR data shown here delivers the first 
thoroughly published description of this molecule, concerning as well as the isolation (see 
chapter 3.1.1.3) and the analytical evaluation. 
 
 
3.2.5 Verticillia-4(20),7,11-triene (24) 
This compound was isolated as colourless viscous oil. The structure is shown in Fig. 3.37. 
Analysis by TLC (Pentane/Et2O 2:1 and 1 % HOAc) showed a violet spot after dyeing and 
heating with anisaldehyde reagent at Rf = 0.80. Detection by DAD-RP-HPLC was only 
possible at 210 nm and the compound eluted at a Rt value of ca. 53.9 min under standard 
HPLC conditions (2.3.4.2). The 13C-NMR spectrum revealed 20 carbon signals as presented 
in Fig. 3.36. DEPT 90/135 spectra divided these 20 C-atoms into 5 quarternary, 2 CH-, 9 
CH2- and 4 methyl carbon atoms. The 1H-spectrum is shown in Fig. 3.38 and the further 
structural elucidation by conventional 2D-NMR techniques (HSQC, COSY, NOESY, and 
HMBC) is basically presented in Tab. 3.5. 
 
 
Fig. 3.36 13C-NMR spectrum of verticillia-4(20),7,11-triene (24). 
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Fig. 3.37 Structure of verticillia-4(20),7,11-triene (24). 
 
 
 
Fig. 3.38 1H-NMR spectrum of verticillia-4(20),7,11-triene (24). 
 
 
Evaluation of the spectral data and comparison with data found in the literature [85] 
confirmed the isolated compound as verticillia-4(20),7,11-triene. The compound was 
described by Basar [35] for the first time. However, Basar noted that it was isolated from the 
essential oil of Bcar. Referring to the data presented here (see chapter 3.7.1), the compound 
originates from the frankincense species Bpap and thus is a significant marker for it. 
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Tab. 3.5 1H and 13C NMR assignments (400 MHz) for verticillia-4(20),7,11-triene (24). 
Atom Nr. 
13C  
δ [ppm] 
1H  
δ [ppm], J [Hz] 
HMBC 
(2J in Hz)
HMBC 
(3J in Hz) HH-COSY NOESY
1 43.70 1.47 2α/ß, 15 3(ß), 11,
13α/ß, 16, 17
2α/ß, 14α/ß 2α, 13α,
14α, 16
2 31.64 1.58 (ß) 
1.66 (α) 
1, 3(ß) 1, 3α/ß 1
3 32.60 2.01 (α) 
2.73 (ß, ddd, J = 14.6, 7.1, 2.7)  
 
20 3(gem.), 2α/ß 3(gem.), 5ß,
17, 20(H2)
4 153.70  3α/ß, 5α/ß  
5 36.14 2.01 (ß) 
2.25 (α) 
20 6α/ß 20(H1),
5(gem.)
6 29.53 2.05 (α) 
2.18 (ß) 
5α/ß, 7 
7 129.50 5.13 (dd, J = 10.6, 3.5) 6α/ß 5α/ß, 9α/ß, 19 6α/ß, 9α/ß, 19 3ß, 5ß, 6ß,
9α/ß
8 133.53  9α/ß, 19  
9 39.20 2.03 (ß) 
2.42 (α, dtr, J = 12.4, 4.3)  
8 7, 11, 19 7, 9(gem.), 
10α/ß 
9(gem.), 18
10 25.47 2.24 (ß) 
2.30 (α) 
9α/ß 9α/ß, 10(gem.) 18
11 136.44  1, 9α/ß, 13α,
16, 17, 18
 
12 127.60  13α/ß, 18  
13 30.43 1.83 (ß) 
2.12 (α) 
12 1, 18 13(gem.), 
14α/ß 
13(gem.), 18
14 25.71 1.45 (ß) 
2.13 (α) 
1, 13α/ß 1, 14(gem.), 
13α/ß 
1
15 37.31  1, 16, 17 2α/ß  
16 33.17 0.97 (s) 15 1, 11, 17  1
17 26.65 0.95 (s) 15 1, 11, 16  3ß, 5ß,
10ß, 19
18 20.91 1.67 (br s) 12 11, 13  9α, 10α/ß,
13α/ß
19 16.68 1.61 (br s) 8 9α/ß  17
20 108.25 4.66 H1 (m) 
 
4.60 H2 (m) 
3α/ß, 5α/ß 3α/ß, 5α/ß 
 
3ß, 5α/ß 
5α
3ß
 
In Fig. 3.39-3.41 the fine structures of three relatively good resolved 1H-NMR signals are 
presented. Basically, they represent the same data already published by Basar [35]. A few 
minor differences in the resolution of signals, compared with the publications of Basar [35,85] 
(in [85] C6D6 was used as deuterated solvent), may refer to magnetic field inhomogeneities 
(not optimal shimming time etc.) and different NMR device conditions in common. 
Furthermore, the compound is rather unstable showing already strong decomposition within 
a few days when purified (even when stored at 4 °C). 
One significant difference may be found, compared with Basars data: C10 and C14 seem to 
be vice versa assigned in the publications of Basar. Both signals are near to each other in 
the 13C-Spectrum. Basar declared them vice versa than reported here. However, the HH-
COSY and HMBC data obtained leads to a different conclusion (see Tab. 3.5): C10 highfield 
shifted and C14 downfield shifted. 
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1H NMR (400 MHz, CDCl3) δ in ppm 5.13 (dd, J = 10.57, 3.50 Hz, 1H) 
 
Fig. 3.39 The 1H-NMR fine structure of the H7 signal at 5.13 ppm. 
 
 
1H NMR (400 MHz, CDCl3) δ in ppm 2.74 (ddd, J = 14.64, 7.14, 2.68 Hz, 1H) 
 
Fig. 3.40 The 1H-NMR fine structure of the H3ß signal at 2.74 ppm. 
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1H NMR (400 MHz, CDCl3) δ in ppm 2.43 (dt, J = 12.40, 4.31 Hz, 1H) 
 
Fig. 3.41 The 1H-NMR fine structure of the H9α signal at 2.43 ppm. 
 
 
3.2.6 Serratol (21) 
Serratol was isolated as colourless viscous oil. The structure is shown in Fig. 3.42. Analysis 
by TLC (Pentane/Et2O 2:1 and 1 % HOAc) showed a strong green spot after dyeing and 
heating with anisaldehyde reagent at Rf = 0.46. Detection by DAD-RP-HPLC was only 
possible at 210 nm and it eluted at a Rt value of ca. 28.3 min (co-elution with compound 14 
in the RE, if not separated by prior extraction) under standard HPLC conditions (2.3.4.2). 
Mass spectrometric detection (ESI-MS; low resolution, positive ion mode) delivered the 
following significant fragmentation pattern: m/z (%): 291.50 [M + H]+ (60); 273.4 [M – OH]+ 
(100). The 13C-NMR spectrum revealed 20 carbon atom signals. DEPT 90/135 spectra 
divided these 20 C-atoms into 4 quaternary, 4 CH-, 7 CH2- and 5 methyl carbon atoms. The 
1H-spectrum is shown in Fig. 3.43 and the 13C-spectrum is shown in Fig. 3.44. Structural 
elucidation by conventional 2D-NMR techniques (HSQC, COSY, NOESY, and HMBC) is 
basically presented in Tab. 3.6. 
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Fig. 3.42 Structure of serratol (21). 
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Fig. 3.43 1H-NMR spectrum serratol (21). 
 
 
Fig. 3.44 13C-NMR spectrum serratol (21). 
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Evaluation of the spectral data and comparison with data found in the literature [56,84] 
confirmed the isolated compound as serratol. The compound itself was firstly described in 
Bser by Pardhy and Bhattacharyya [83] and in Bcar by Klein and Obermann [82] (both 
groups in 1978). Seitz [56] isolated this compound also from Bcar and delivered the first 2D 
NMR data set on serratol. Finally, Schmidt et al. published their complete structural 
assignment 2D NMR data set of serratol (isolated from Bser) and additionally report on the 
antiprotozoal acitivity of this compound [84]. The NMR data delivered here is consistent with 
the data published by Schmidt et al. [84]. The position of α- and ß-H atoms for secondary 
carbons (CH2) is not unambiguously assignable in the NOESY data set. Serratol is a 14 
carbons containing monocylic ring and thus shows a quite high flexibility concerning the 
possible different conformations of this molecule. This phenomenon can be easily 
understood if a molecule model is build.   
 
Tab. 3.6 1H and 13C NMR assignments (400 MHz) for serratol (21). 
Atom Nr. 
13C  
δ [ppm] 
1H  
δ [ppm], J [Hz] 
HMBC 
(2J in Hz)
HMBC 
(3J in Hz) HH-COSY NOESY
1 76.83  2α/ß,
14α/ß, 15
13α/ß, 19, 20  
2 34.72 2.14 
2.20 
3 14α/ß  
3 120.87 5.24 (br dd, t)a 2α/ß 5α/ß, 16 2α/ß, 
5α/ß, 16 
2α/ß, 7, 11,
14α/ß, 15
4 136.57  5α/ß, 16 2α/ß, 6α/ß  
5 39.45 2.21 
2.21 
6α/ß 3, 16  
6 24.79 2.11 
2.30 
5α/ß, 7  
7 125.91 4.88 (br dd, t)a 6α/ß 5α/ß, 9α/ß, 17 6α/ß, 17 3, 5α/ß, 6α/ß,
9α/ß, 11, 14α/ß
8 133.27  9α/ß, 17 6α/ß  
9 39.89 1.95 
2.11 
10α/ß 7 10α/ß 
10 23.73 2.09 
2.09 
9α/ß, 11 9α/ß 
11 123.15 4.99 (br dd, t)a 10α/ß 9α/ß,
13α/ß, 18
10α/ß, 
13α/ß, 18 
3, 7, 10α/ß,
13α/ß, 14α/ß
12 135.52  13α/ß, 18 10α/ß, 14α/ß  
13 33.45 1.93 
1.75 
14α/ß 11, 18 13(gem.) 
14α/ß 
14 34.90 1.65 
1.65 
13α/ß 2α/ß 13α/ß 
15 34.51 1.71 1, 19, 20 19, 20 
16 15.04 1.54 (br s) 4 3, 5 3 
17 15.16 1.56 (br s) 8 7, 9 7 
18 16.36 1.58 (br s) 12 11, 13 11 
19 16.62b 0.94 (d, J = 6.8) 15 1, 20 1 2α/ß, 14α/ß,
15
20 16.78b 0.92 (d, J = 6.8) 15 1, 19 1 2α/ß, 14α/ß,
15
a The fine structures show actually a more complex multiplet fine structure within the triplet (dd) 
b Assignment interchangeable (see also Schmidt et al. [84]) 
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3.2.7 Iso-Serratol (20) 
Iso-Serratol was isolated as colourless viscous oil. The structure is shown in Fig. 3.45. 
Analysis by TLC (Pentane/Et2O 2:1 and 1 % HOAc) showed a dark blue spot after dyeing 
and heating with anisaldehyde reagent at Rf = 0.30. Detection by DAD-RP-HPLC was only 
possible at 210 nm and the compound eluted at a Rt value of ca. 27.7 min under standard 
HPLC conditions (2.3.4.2). Mass spectrometric detection (CI-MS; low resolution) delivered 
the following significant fragmentation pattern: m/z (%): 290.24 [M]+ (3); 273.26 [M – OH]+ 
(63); 272.24 [M – H2O]+ (100). High resolution CI-MS gave as m/z (%): 290.2589 [M]+ (8), 
calculated: 290.2610; 273.2594 [M – OH]+ (100), calculated: 273.2577. Thus, a chemical 
formula of C20H34O is given. The 13C-NMR spectrum revealed 20 carbon atom signals. DEPT 
90/135 spectra divided these 20 C-atoms into 4 quaternary, 4 CH-, 7 CH2- and 5 methyl 
carbon atoms. The 1H-spectrum is shown in Fig. 3.46 and the 13C- and DEPT 90/135 spectra 
are shown in Fig. 3.47-3.49. The structural elucidation by conventional 2D-NMR techniques 
(HSQC, COSY, NOESY, and HMBC) is basically presented in Tab. 3.7. 
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Fig. 3.45 Structure of iso-serratol (20). 
 
 
Fig. 3.46 1H-NMR spectrum of iso-serratol (20). 
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Fig. 3.47 13C-NMR spectrum of iso-serratol (20). 
 
 
 
Fig. 3.48 DEPT-90 spectrum of iso-serratol (20). 
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Fig. 3.49 DEPT-135 spectrum of iso-serratol (20). 
 
 
Fig. 3.50 HMBC spectrum declaring the interaction of C-11 and C-12 with the methyl protons of C-18 
in iso-serratol (20). 
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The 1H-NMR reveals for iso-serratol, similar as for serratol, three vinyl protons downfield 
shifted which show the same fine structures as the three vinyl protons from serratol (compare 
with data from chapter 3.2.6). Chemical shifts for the vinyl protons of C-16, C-17 and C-18 
are overlaid to a huge almost unresolved peak signal at 1.55-1.57 ppm. Integration of this 
signal reveals 9 protons. At 1.20 ppm the two methyl singlets of the isopropyl alcoholic group 
showing the same chemical shifts and thus giving just one peak (Integration gives 6 protons). 
Especially the diminishing of the duplet structures at C-19 and C-20 clarifies this fact 
(compare with data from chapter 3.2.6). Additionally, the three vinyl methyl groups (C-16, 
C17 and C-18) must have the same configuration as serratol since they deliver typical 13C-
NMR chemical shifts for cembrene type molecules (see also Gacs-Baitz et al. [81], where 
(E)-methyl carbons are assigned at approximately 16-17 ppm, while (Z)-methyl signals 
appear at 22-23 ppm, which basically is the general rule for all cembrane-type molecules 
discussed here, e.g. incensole and its acetate). Correct assignment of these three methyl 
carbons (C-16, C17 and C-18), showing almost identically chemical shifts, was achievable by 
elucidation of the HMBC spectrum as shown in Fig. 3.50, specifically by unambiguous 
assignment of the 1.55 ppm proton chemical shift. The position of α- and ß-H atoms for 
secondary carbons (CH2) is not unambiguously assignable in the NOESY data set. Iso-
serratol, like serratol, is a 14 carbons containing monocylic ring and thus shows a quite high 
flexibility concerning the possible different conformations of this molecule. This phenomenon 
can be easily understood if a molecule model is build. 
Thoroughly evaluation of the spectral data confirmed the isolated compound as a derivative 
of serratol. Hence, it was denoted as iso-serratol since only the position of the hydroxyl 
function at C-1 is interchanged with the H atom of C-15. This contention can be easily figured 
out, if both tables for iso-serratol, respectively, serratol are compared at C-1, C-15, C-19 and 
C-20. The IUPAC nomenclature denotation may be thus (1-R)-3E,7E,11E-1-isopropyl-4,8,12-
trimethyl-cyclotetradeca-trien-15-ol. The relative configuration at C-1 was not assigned, but 
seems to be reasonably R positioned (see also Fig. 3.51), since it is rather likely the product 
of the proton catalysed water addition at the double bond of the 1-methylethlyen group in 
cembrene A. However, with the data delivered here, the relative configuration of iso-serratol 
at C-1, as already described by Klein and Obermann [82], may be easily ascertainable. 
Cembrene C is hence probably the pre-cursor diterpene of serratol (see Fig. 3.52). According 
to the stability of the tertiary carbon cation, the existence of iso-serratol as an analogue of 
serratol makes sense. Cembrene A and C are ubiquitous natural diterpenes and were 
reported in Olibanum essential oils before [13,35,74,78]. Thus, it is quite reasonable that 
these two cembrenes are the pre-cursors of iso-serratol and serratol, respectively. To the 
best knowledge, this is the first report on a derivative structure of serratol, namely iso-
serratol. 
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Tab. 3.7 1H and 13C NMR assignments (400 MHz) for iso-serratol (20) 
Atom Nr. 
13C  
δ [ppm] 
1H  
δ [ppm], J [Hz] 
HMBC 
(2J in Hz)
HMBC 
(3J in Hz) HH-COSY NOESY
1 48.49 1.33 2α/ß, 14α/ß 13α/ß, 19, 20 2α/ß, 14α/ß 3, 7, 11
2 28.46 1.91 
2.13 
3 14α/ß 1, 2(gem.), 3 1, 2(gem.)
3 125.95 5.11 (br dd, t)a 2α/ß 16 2α/ß, 5α/ß, 16 1, 2α/ß, 3, 
5α/ß, 11
4 133.37  5α/ß, 16 2α/ß, 6α/ß  
5 38.83 2.12 
2.12 
6α/ß 3, 16  
6 24.67 2.20 
2.15 
7, 5α/ß  
7 125.77 4.95 (br dd, t)a 6α/ß 9α/ß, 17 6α/ß, 17 3, 11
8 133.06  9α/ß, 17 10α/ß  
9 39.41 2.02 
2.07 
10α/ß 11, 17 7 
10 24.02 2.12 
2.12 
9α/ß, 11  
11 124.99 5.00 (br dd, t)a 10α/ß 9α/ß, 13α/ß, 18 10α/ß, 13α/ß, 18 3, 7
12 134.05  13α/ß, 18 14(1.66)  
13 37.73 2.03 
2.10 
14α/ß 1, 11, 18 14α/ß 
14 28.29 1.26 
1.66 
1, 13α/ß 2α/ß 1, 13α/ß, 14(gem.) 
15 73.96  1, 19, 20 2α/ß, 14α/ß  
16 15.56 1.57 4  
17 15.31 1.57 8 7  
18 15.57 1.55 12 11 11 
19 27.52 1.20 (s)b 15 1  
20 27.67 1.20 (s)b 15 1  
a The fine structures show actually a more complex multiplet fine structure within the triplet (dd) 
b Assignment interchangeable (analogous phenomenon as serratol, see also Schmidt et al. [84]) 
 
 
 
 
Fig. 3.51 The proposed reaction scheme for the biosynthesis of iso-serratol, starting from cembrene A 
via a tertiary carbon cation. 
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Fig. 3.52 The proposed reaction scheme for the biosynthesis of serratol, starting from cembrene C via 
a tertiary carbon cation. 
 
 
3.2.8 ß-Caryophyllene oxide (28) 
The compound (28) was isolated as colourless viscous oil revealing a weak odour. The 
structure is shown in Fig. 3.53. Analysis by TLC (Pentane/Et2O 2:1 and 1 % HOAc) showed 
a pink spot after dyeing with anisaldehyde reagent and heating at Rf = 0.50. The standard 
HPLC method (2.3.4.2) gave a Rt value of ca. 21.1 min. Detection by DAD-RP-HPLC was 
only possible at 210 nm. Mass spectrometric detection (ESI-MS, positive mode; low 
resolution) delivered two significant peaks with m/z (%): 203.40 [M – H2O]+ (100) and 221.09 
[M]+ (28). The negative ion mode (ESI-MS) delivered a ternary complex of three ß-
caryophyllene oxide molecules with a base peak of m/z (%): 666.04 (100), probably due to 
the high concentration being injected. 
However, the structural assignment by 1D and 2D NMR techniques was unequivocal. The 
13C-NMR spectrum revealed 15 carbon atom signals as presented in Fig. 3.54. DEPT 90/135 
spectra divided these 15 C-atoms into 3 quaternary, 3 CH-, 6 CH2- and 3 methyl carbon 
atoms. The 1H-spectrum is shown in Fig. 3.55 and the further structural elucidation by 
conventional 2D-NMR techniques (HSQC, COSY, NOESY, and HMBC) is basically 
presented in Tab. 3.8. 
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Fig. 3.53 Structure of ß-caryophyllene oxide (28). 
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Fig. 3.54 13C-NMR spectrum of ß-caryophyllene oxide (28). 
 
 
Fig. 3.55 1H-NMR spectrum of ß-caryophyllene oxide (28). 
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Tab. 3.8 1H and 13C NMR assignments for ß-caryophyllene oxide (28). 
Atom Nr. 
13C  
δ [ppm] 
1H  
δ [ppm], J [Hz] 
HMBC 
(2J in Hz)
HMBC 
(3J in Hz) HH-COSY NOESY
1 50.70 1.77 (tr, J = 9.9) 9, 2α/ß 3α/ß, 10α/ß,
12, 13
2α/ß 2α/ß, 7ß
 15H1
2 27.19 1.43 (α) 
1.64 (ß) 
1, 3α/ß 9 1, 2(gem.), 
3α/ß 
2(gem.), 9
3 39.13 0.97 (ß) 
2.10 (α) 
2α/ß 1, 5, 14 2α/ß, 3(gem.)  3(gem.),
6α
4 59.83  3α/ß, 5 2α/ß, 6α/ß  
5 63.75 2.88 (dd, J = 10.6, 4.2) 6α/ß 3α/ß,
7α/ß, 14
6α/ß 1, 6α/ß, 
7α/ß,
13, 14
6 30.20 1.32 (α) 
2.26 (ß) 
5, 7α/ß 5, 6(gem.), 
7α/ß 
3α, 15H2
7 29.75 2.11 (α) 
2.33 (ß) 
6α/ß 9 7(gem.),  
6α/ß, 15H2 
15H2
8 151.82  7α/ß, 
9, 15H1/H2
1, 6α/ß  
9 48.72 2.62 (dd, J = 9.6, 8.8) 1, 10α/ß 2α/ß, 7α/ß 1, 10α/ß, 
15H1 
7α, 12,
15H1
10 39.73 1.63 (ß) 
1.70 (α) 
9 12, 13 9 15H1
11 34.01  1, 12, 13 2α/ß  
12 21.60 1.00 (s) 1, 10α/ß, 13  
13 29.88 0.98 (s) 10α/ß, 12  15H1
14 16.98 1.20 (s) 3α/ß  2α, 3α, 5 
15H1/H2
15 112.74 4.97 (d, J = 1.3, H1) 
4.85 (d, J = 1.6, H2) 
7α/ß, 9 15(gem.) 15(gem.)
 
Evaluation of the spectral data and comparison with data found in the literature [176] 
confirmed the isolated compound as ß-caryophyllene oxide. The compound itself has been 
reported to be the primary air-oxidation product of ß-caryophyllene [177,178], which is an 
ubiquitous compound occurring in several different plant essential oils (e.g. Cannabis: 
Cannabis sativa, oregano: Origanum vulgare, black pepper: Piper nigrum, etc. [178]). ß-
cayrophyllene oxide is volatile and for example sensed by narcotic detection dogs [178]. 
In essential oils of Boswellia species it was reported by Hamm et al. [13] and Camarda et al. 
[74] to be specific for the species Bsac and Bcar. The analytical value of this compound for 
the classification of Bsac, respectively, Bcar is discussed in chapter 3.4 and 3.5. 
The 2D NMR data set here, compared with the data of Rahman et al. [176], gives a slightly 
different assignment for the carbon signals. In their paper the carbons at position 2 and 10 
are interchanged, compared with the data presented here. Furthermore, the positions of the 
methyl groups (C-12 and C-13) are again interchanged tabulated. However, the HH-COSY 
and NOESY data (see Fig. 3.56, respectively, Fig. 3.57) confirm that the structural 
assignment reported here is correct. The J-couplings of the protons at C-1, C-5, C-9 and C15 
in the 1H-NMR data set give same values as reported by Rahman et al. [176] as 
demonstrated in (Fig. 3.58-3.61). 
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Fig. 3.56 The HH-COSY spectrum declaring the correlation of H-9 with H-1 and both protons of C-10. 
See also text for further details. 
 
 
 
 
Fig. 3.57 The NOESY spectrum declaring the relative position of C-12 and C-13, proved by 
interactions of H-12 with H-9 and H-13 with H-1. 
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1H NMR (400 MHz, CDCl3) δ in ppm 2.88 (dd, J = 10.61, 4.23 Hz, 1H) 
 
Fig. 3.58 The 1H-NMR fine structure of H-5 at 2.88 ppm. 
 
1H NMR (400 MHz, CDCl3) δ in ppm 2.62 (dd, J = 9.6 Hz, 9.77 Hz, 1H) 
 
Fig. 3.59 The 1H-NMR fine structure of H9 at 2.62 ppm. 
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1H NMR (400 MHz, CDCl3) δ in ppm 1.77 (t, J = 9.90 Hz, 1H) 
 
Fig. 3.60 The 1H-NMR fine structure of H-1 at 1.77 ppm. 
 
1H NMR (400 MHz, CDCl3) δ in ppm 4.97 (d, J = 1.28 Hz, 1H), 4.86 (d, J = 1.61 Hz, 1H) 
 
Fig. 3.61 The 1H-NMR fine structure of the vinyl protons at C-15 (declared as H1, 4.97 ppm, and H2, 
4.86 ppm). 
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3.2.9 τ-Cadinol (25) 
The compound (25) was isolated as colourless viscous oil. The structure is shown in Fig. 
3.62. Analysis by TLC (Pentane/Et2O 2:1 and 1 % HOAc) showed a dark blue spot after 
dyeing and heating with anisaldehyde reagent at Rf = 0.35. Detection by DAD-RP-HPLC was 
only possible at 210 nm (Rt ca. 21.8 min under standard HPLC conditions as described in 
chapter 2.3.4.2). The 13C-NMR spectrum revealed 15 carbon atom signals as presented in 
Fig. 3.63 (minor signals refer to impurities difficult to separate from neutral compounds by 
liquid preparative chromatography in general). DEPT 90/135 spectra divided these 15 C-
atoms into 2 quaternary, 5 CH-, 4 CH2- and 4 methyl carbon atoms. The structural 
elucidation by conventional 2D-NMR techniques (HSQC, COSY, NOESY, and HMBC) is 
basically presented in Tab. 3.9. 
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Fig. 3.62 Structure of τ-cadinol (25). 
 
 
 
Fig. 3.63 13C-NMR spectrum of τ-cadinol (25). The minor signals result probably from an isomeric 
impurity (Note that purification of NB fraction compounds is quite tedious by preparative liquid 
chromatography). 
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Tab. 3.9 1H and 13C NMR assignments (400 MHz) for τ-cadinol (25). 
Atom Nr. 
13C  
δ [ppm] 
1H  
δ [ppm], J [Hz] 
HMBC 
(2J in Hz)
HMBC 
(3J in Hz) HH-COSY NOESY
1 47.95 1.10 (dd, J = 10, 2) 1, 2α/ß, 6 3, 5, 15 2α/ß 2α/ß, 9α, 7, 15
2 22.60 1.38 (ß) 
1.93 (α) 
1 3α/ß 2(gem.)
3 30.90 1.99 
1.99 
2α/ß 1, 5, 11 2α/ß, 5, 11(4J) 2ß, 11
4 134.35  2α, 11 3α/ß  
5 122.66 5.55 (br s) 6 1, 7, 11 3α/ß, 6, 11 6, 7, 11, 12, 13
6 37.74 1.97 1, 5 2α/ß, 8α/ß 5 2ß, 5, 13
7 46.67 1.00 8α/ß 5, 9α/ß,
13, 14
8α/ß, 12 1, 5, 8α/ß
8 19.82 1.36 (α) 
1.49 (ß) 
9α/ß 9α/ß 
9 40.32 1.41 (α) 
1.74 (ß) 
8α/ß 15 8α/ß, 15(4J) 
10 70.67  9α/ß, 15 8α/ß  
11 23.76 1.67 (br s) 4 3, 5 5 3α/ß, 5
12 26.17 2.18 (dsept, J = 7.0, 3.2) 13, 14 7, 13, 14 5, 13, 14
13 15.20 0.79 (d, J = 7.0) 12 14 12 5, 6, 12, 14
14 21.40 0.92 (d, J = 7.0) 12 13 12 8ß, 12, 13
15 28.46 1.22 (s) 1, 9  1, 2α/ß, 9α/ß
 
Evaluation of the spectral data and comparison with data found in the literature [179,180] 
confirmed the isolated compound as τ-cadinol (25). It is a ubiquitously occurring 
sesquiterpenoid (e.g. Satureja gilliesii, Corymbia maculate etc.). 
Interestingly, this compound is, like ß-caryophyllene oxide (28), reported as a marker for the 
Boswellia species Bcar, respectively, Bsac. Hamm et al. [13] and Camarda et al. [74] report it 
both, by GC-MS analysis, as a specific terpenoid for these species. They did not observe it in 
Bpap and Bser. The same conclusions have been deduced in this work (see chapter 3.5 on 
the GC-FID analysis). In Fig. 3.64-3.66 a few significant 1H-NMR fine structures are shown. 
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1H NMR (400 MHz, CDCl3) δ in ppm 0.79 (d, J = 7.0 Hz, 3H) 
 
Fig. 3.64 The 1H-NMR fine structure of H-13 (methyl group) at 0.79 ppm. 
 
1H NMR (400 MHz, CDCl3) δ in ppm 0.92 (d, J = 7.0 Hz, 3H) 
 
Fig. 3.65 The 1H-NMR fine structure of H-14 (methyl group) at 0.92 ppm. 
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1H NMR (400 MHz, CDCl3) δ in ppm 2.19 (dsept, J = 7.0 Hz, 3.2 Hz, 1H) 
 
Fig. 3.66 The 1H-NMR fine structure of H-12 at 2.19 ppm. 
 
 
3.2.10 3-ß-OH-Tirucallol (29) 
3-ß-OH-tirucallol was isolated as white solid. The structure is shown in Fig. 3.67. Analysis by 
TLC (Pentane/Et2O 2:1 and 1 % HOAc) showed a dark blue/violet spot after dyeing and 
heating with anisaldehyde reagent at Rf = 0.26. Detection by DAD-RP-HPLC was only 
possible at 210 nm and the compound eluted at a Rt value of ca. 57.1 min under standard 
HPLC conditions (2.3.4.2). The 13C-NMR spectrum revealed 30 carbon signals. DEPT 90/135 
spectra divided them into 7 quaternary, 5 CH-, 10 CH2- and 8 methyl carbon atoms. The 1H-
spectrum is shown in Fig. 3.68 and the 13C- and DEPT 90/135 spectra are shown in Fig. 
3.69-3.71. Structural elucidation by conventional 2D-NMR techniques (HSQC, COSY, 
NOESY, and HMBC) is basically presented in Tab. 3.10. 
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Fig. 3.67 Structure of 3-ß-OH-tirucallol (29). 
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Fig. 3.68 1H-NMR spectrum of 3-ß-OH-tirucallol (29). 
 
 
Fig. 3.69 13C-NMR spectrum of 3-ß-OH-tirucallol (29). Signals of C-16 and C-29 are superimposed 
(view highest peak between 30-25 ppm). 
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Fig. 3.70 DEPT-90 spectrum of 3-ß-OH-tirucallol (29). 
 
 
Fig. 3.71 DEPT-135 spectrum of 3-ß-OH-tirucallol (29). Signals of C-16 (CH2) and C-29 (CH3) cancel 
each other out. Thus, the negative methylene signal and positive methyl signal both disappear. 
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Evaluation of the spectral data confirmed the isolated compound as 3-ß-OH-tirucallol [(20S)-
(+)-tirucalla-8,24-dien-3ß-ol; Trivial: Tirucallol]. These class of compounds (Tirucallanes and 
Euphanes) is frequently found in plants of the genus Euphorbiaceae (e.g. Euphorbia tirucalli) 
[31]. Lanosterol [(+)-lanosta-8,24-dien-3ß-ol], one example of compounds with lanostane 
structure, which also is abundant in Euphorbiaceae [31], differs at positions C-13, C-14, C-17 
(α-H instead of ß-H at C-17) and C-20, relatively compared with tirucallol (see Fig. 3.72). 
Thus, the literature can be sometimes a bit confusing about what kind of triterpene was used 
for the experimental conditions. For example, Fernandez-Arche et al. [181] report about the 
topical anti-inflammatory effect of tirucallol isolated from Euphorbia lactea latex. However, 
the paper does not show any chemical structure, neither of tirucallol nor of lanosterol. Only in 
the experimental part tirucallol was mentioned as lanosta-8,24-dien-3-ß-ol, which is 
confusing, since it is not clearly verfied, if either tirucallol or lanosterol was used in their 
experiments. Differentiation of tirucallol and lanosterol is simply possible by NOESY 
experiments. The data presented here (see Tab. 3.10) confirms the isolated compound as ß-
tirucallol from the Boswellia species Bcar. Interestingly, it seems to be the biosynthetic pre-
cursor of ß-OH-tirucallic acid (compound 15; see also [31]). Presumably, the methyl group at 
C-21 is oxidised by CYP-oxygenase enzymes, since they are ubiquitous on our planet for CH 
bond activation [19]. The ß-configuration of the hydroxyl group at C-3 can be conveniently 
identified by the strong proton couplings explicitly shown in Fig. 3.73 (dd, Karplus rule [175]; 
see also Pardhy and Bhattacharyya [66]) and additionally by NOESY experiments. 
 
 
 
Fig. 3.72 Structures of tirucallol (on the left) and lanosterol (on the right). 
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Tab. 3.10 1H and 13C NMR assignments (400 MHz) for 3-ß-OH-tirucallol (29). 
Atom Nr. 
13C  
δ [ppm] 
1H  
δ [ppm], J [Hz] 
HMBC 
(2J in Hz)
HMBC 
(3J in Hz) HH-COSY NOESY
1 35.25 1.19 (α) 
1.77 (ß) 
2α 18 2α/ß 
2 27.94 1.59 (ß) 
1.68 (α) 
1α/ß 1α/ß, 3 
3 79.00 3.24 (dd, J = 11.6, 4.6) 2α/ß 1α/ß, 5, 28, 29 2α/ß 1α, 2α, 5,
29
4 38.94  5, 28, 29  
5 50.96 1.13 4, 6α/ß 18, 28, 29  29
6 18.94 1.41 (ß) 
1.69 (α) 
5 7α/ß 6(gem.)
7 27.66 1.92 (α) 
2.09 (ß) 
6α/ß 7(gem.), 6α/ß 7(gem.)
8 133.54  7ß 6α, 30  
9 134.07  12ß, 18  
10 37.27  1α/ß, 5, 18 6α/ß  
11 21.45 1.94 (ß) 
2.05 (α) 
 
12 29.83 1.19 (ß) 
1.52 (α) 
19 11α/ß 
13 44.10  11ß, 12α/ß, 19 15α/ß, 30  
14 49.95  15α/ß, 30 12α/ß, 16α, 19  
15 30.79 1.69 (α) 
1.69 (ß) 
14 30 16α/ß 
16 28.05a 1.32 (α) 
1.92 (ß) 
17 15α/ß,  
16(gem.) 
16(gem.), 19
17 50.11 1.48 16α 15α/ß, 22α/ß,
19, 21
 12ß, 30
18 20.14 0.95 (s) 1ß, 5 1α(4J) 1ß, 2ß, 
6ß, 11ß
19 15.43 0.76 (s)  11α, 12α, 15α,
16α, 20, 21
20 36.33 1.42 22(1.03), 17, 21 16α  19
21 18.68 0.92 (d, J = 6.4) 22(1.03)  19
22 36.40 1.03 
1.42 
17, 21 22(gem.), 
23α/ß 
22(gem.)
23 24.94 1.88 
2.03 
22(1.03) 23(gem.), 24,  
22α/ß 
24 125.20 5.10 (ps tr, J = 7.1)b 22(1.03), 26, 27 23α/ß, 26, 27 22α/ß, 23α/ß, 26
25 130.99  26, 27  
26 25.71 1.68 (s) 25 27  
27 17.62 1.60 (s) 25 26  
28 15.52 0.80 (s) 3, 5, 29 29(4J) 3ß, 6ß, 18, 29
29 28.05a 1.00 (s) 3, 5, 28 28(4J) 3α, 5, 6α, 28
30 24.36 0.87 (s)  7ß, 11ß,
12ß, 15ß, 17
a Signals of C-16 and C-29  are superimposed in the 13C-NMR spectrum (FID manipulation by 
apodization resolves the signals) 
b Actually, the triplet shows a more complex fine structure within its three peaks 
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1H NMR (400 MHz, CDCl3) δ in ppm 3.24 (dd, J = 11.62, 4.62 Hz, 1H) 
 
Fig. 3.73 1H-NMR spectral part of the α-H at C-3 (dd) is defining the relative configuration of it. 
 
 
3.2.11 3-α-OH-11-Keto-12-ursen (30) 
3-α-OH-11-keto-12-ursen (30) was isolated as white solid. The structure is shown in Fig.  
3.74. Analysis by TLC (Pentane/Et2O 2:1 and 1 % HOAc) showed a dark blue/violet spot 
after dyeing and heating with anisaldehyde reagent at Rf = 0.25. The spot is also visible by 
UV detection (250 nm). The standard HPLC method (2.3.4.2) gives a Rt of ca. 32.4 min. 
Detection by DAD-RP-HPLC was possible at 210 and 250 nm (see also Fig. 3.75). It shows 
the same absorption maximum as ß-KBA and ß-AKBA, when the UV spectra are recorded 
during HPLC elution. The 13C-NMR spectrum revealed 30 carbon signals. DEPT 90/135 
spectra divided them into 7 quaternary, 5 CH-, 10 CH2- and 8 methyl carbon atoms. The 1H-
spectrum is shown in Fig. 3.76 and the 13C- and DEPT 90/135 spectra are shown in Fig. 
3.77-3.79. Structural elucidation by conventional 2D-NMR techniques (HSQC, COSY, 
NOESY, and HMBC) is basically presented in Tab. 3.11. The HPLC chromatogram explains 
the minor impurities found within the 1H- and 13C-NMR spectra. However, the data given here 
and comparison with the data for 3-α-acetyl-11-keto-ß-boswellic acid published in the paper 
of Belsner et al. [53] confirms the structure of 3-α-OH-11-keto-12-ursen, probably the 
precursor of its acid derivative (ß-KBA). 
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Fig. 3.74 Structure of 3-α-OH-11-keto-12-ursen (30). 
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Fig. 3.75 HPLC chromatogram at 250 nm detection. The impurity at the peak front is visible. HPLC 
conditions (T = 25 °C; u = 1 ml/min; column = 1 x YMC Pack Pro RS C18 250x4.6 mm ID, 8 nm; 
isocratic = 98 % MeOH : 2 % H2O + 0.1 % TFA). 
 
Evaluation of the spectral data confirmed the isolated compound as 3-α-OH-11-keto-12-
ursen. The compound itself is probably the precursor of 3-α-OH/acetyl-11-keto-ß-boswellic 
acid (5 and 6). The impurity almost co-eluting in the HPLC chromatogram (see Fig. 3.75) 
seems to be the 3-α-OH-11-keto-12-oleanen (same discussion as for ß-AKBA and α-AKBA, 
see introduction or Büchele et al. [58,134]). Interestingly, by comparison of the NMR data 
presented here with the data of Belsner et al. [53] the structure of 30 is clarified. Differences 
are found at C-3 (highfield shift of H-3 for the deacetylated derivative, which is a common 
phenomenon; compare also C-3 discussions of, for example, ABAs/BAs and Ac-TAs/TAs 
etc. or see also Seitz [56]). In Fig. 3.80 the fine structure of the ß-H atom at C-3 is presented. 
Rather convincing similarities can be found by comparison of the 13C-NMR data (also DEPT-
90/135 spectra), where all possible chemical shifts are almost equal the data of Belsner et al. 
[53] for ß-KBA, 5, except the COOH-function at C-24, which is in compound 30 a methyl 
group instead. 
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Fig. 3.76 1H-NMR spectrum of 3-α-OH-11-keto-12-ursen (30). For declaration of impurities see Fig. 
3.75 and discussion in the text. 
 
 
Fig. 3.77 13C-NMR spectrum of 3-α-OH-11-keto-12-ursen (30). For declaration of impurities see Fig. 
3.75 and discussion in the text. 
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Fig. 3.78 DEPT-90 spectrum of 3-α-OH-11-keto-12-ursen (30). 
 
 
Fig. 3.79 DEPT-135 spectrum of 3-α-OH-11-keto-12-ursen (30). 
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Tab. 3.11 1H and 13C NMR assignments (400 MHz) for 3-α-OH-11-keto-12-ursen (30). 
Atom Nr. 
13C  
δ [ppm] 
1H  
δ [ppm], J [Hz] 
HMBC 
(2J in Hz)
HMBC  
(3J in Hz) HH-COSY NOESY
1 33.52 1.36 (α) 
2.49 (dtr, J = 13.6, 3.6; ß) 
2α/ß 
2 25.39 1.53 (α) 
2.05 (ß) 
1α/ß 
3 75.86 3.42 (tr, J = 2.7) 23, 24  2α/ß
23, 24
4 37.50  23, 24  
5 48.36 1.23 23, 24, 25  6α, 7α, 24
6 17.45a 1.43 (ß) 
1.47 (α) 
 7α/ß 
7 32.77 1.40 (ß) 
1.71 (α) 
6α/ß 
8 45.32  9, 26 27  
9 61.44 2.45 8, 10, 11 14, 25, 26  
10 37.00  9, 25  
11 200.07  9  
12 130.43 5.54 (s) 9, 14, 18 18 18, 19,
26, 29
13 164.85  18 27  
14 43.71  27 9, 26  
15 27.17 1.20 (α) 
1.89 (ß) 
16α/ß 
16 27.52 1.01 (ß) 
2.08 (α) 
18, 28 15α/ß 
17 33.92  16α, 18, 28  
18 59.01 1.53 13, 17 12, 16ß, 20,
28, 29
12 12
19 39.21 1.40 30  12
20 39.30 0.95 29 21α/ß 
21 30.91 1.29 
1.44 
20, 22α/ß 
 
 
22 40.93 1.31 (ß) 
1.48 (α) 
20, 28 21α/ß 
23 28.42 0.97 (s) 4 3, 5, 24  6α
24 22.36 0.87 (s) 4 3, 5, 23  
25 16.39 1.18 (s) 10 5, 9  1ß, 2ß
26 18.52 1.17 (s) 8 9, 14  12
27 20.69 1.31 (s) 14 8, 13  6α, 7α, 16α
28 28.83 0.81 (s) 17 16α/ß, 18, 22  15ß, 22ß
29 17.43a 0.79 (d, J = 6.5) 20 19 12
30 21.12 0.96b 19 20 
a Signals superimpose in the 13C-NMR spectrum 
b Signal shape not visible owing to complete overlapping with H-20 
 
 
 
 
 
 
 
   120
Results and Discussion 
_________________________________________________________________________________ 
 
1H NMR (400 MHz, CDCl3) δ in ppm 3.41 (t, J = 2.72, 2.72 Hz, 1H) 
 
Fig. 3.80 1H-NMR spectral part of ß-H at C-3 (dd) defining the relative configuration as ß-configured 
according to the Karplus rule [175,182]. 
 
A general difficulty of neutral compound isolation by liquid RP chromatography, especially 
the triterpenoids, eluting rather late, is that they can not be resolved sufficiently (see also 
purity of ß-OH-tirucallol, 29). It is time consuming (late elution, even if 100 % organic phase 
is used) and quite many compounds (structural isomers) co-elute with another. Thus, 
structural assignment by GC-MS methods and isolation of them by preparative GC methods 
is preferable. However, it is still possible, even if the material can not be purified to a high 
level (> 95 % or better), by comparison of the significant and reasonable signals, to give an 
unequivocally structural elucidation of the compound in question as presented here. 
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3.3 Extraction and Separation (Acid Fraction and Neutral Fraction) 
 
3.3.1 Analytical Extraction Scale (Bpap, Bser, Bsac/Bcar) 
The discussion here refers only to the analytical extraction scale method (see also chapter 
2.2.4). For a discussion of greater extracted amounts see also the paper of Paul et al. [59]. In 
Fig. 3.81 the values for Bpap and Bsac/Bcar are presented graphically (for each species 
three different resin batch samples were extracted). Each triple series was performed on the 
same day. Thus, the differences in the Loss RE [%] during the separation of NB and RS 
fractions may additionally be due to the day performance. For a better overview, the Bser 
extraction results have been separated from the Bpap and Bsac/Bcar results and are 
presented in Fig. 3.82. 
On average, Bpap gives approximately 64 % RE. The loss during the separation of the acids 
from the neutral compounds is about 10-15 % (referred to the total weighed resin sample). 
Thus, about 30 % of the whole resin refers to the acid fraction (RS) and ca. 22 % to the 
neutral fraction (NB). For Bsac/Bcar the arithmetic mean for RE = ca. 60 %, for NB = ca. 24 
%, for RS = ca. 25 % and the total loss (summation of loss during separation of NB/RS from 
RE and the not extractable parts) is ca. 50-60 %. 
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Fig. 3.81 Stacked column diagram of Bpap (from left to right, columns 1 to 3), of Bsac (columns 4 to 6) 
and of Bcar (columns 7 to 9). Not Extr. [%]: Not by Et2O extractable material (sugars and polar 
components); Loss RE [%]: Loss during separation of NB and RS; Yield NB [%]: Yield of neutral 
compounds; Yield RS [%]: Yield of acid fraction. For further discussions see text. 
 
In Fig. 3.82 the analytical extraction scale results for samples of Bser (pure resin and Gufic 
Sallaki Tablets® preparation) are presented. The pure resin samples delivered the following 
arithmetically averaged distribution: RE = ca. 63 %, NB = ca. 25 %, RS = 29 % and a total 
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loss (Sum: Not Extr. + Loss RE) of ca. 45 %. The Sallaki medicament gives a similar 
distribution: RE = ca. 55 %, NB = ca. 25 %, RS = ca. 26 % and a total loss (Sum: Not Extr. + 
Loss RE) of ca. 49 %. 
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Fig. 3.82 Stacked column diagram of Bser. The first three rows (from left to right) represent pure resin 
samples and the last three rows show the extraction samples of the Gufic Sallaki Tablets® preparation. 
Not Extr. [%]: Not by Et2O extractable material (sugars and polar components); Loss RE [%]: Loss 
during separation of NB and RS; Yield NB [%]: Yield of neutral compounds; Yield RS [%]: Yield of acid 
fraction. For further discussions see text. 
 
 
The total average, typically obtained for any resin (Bpap, Bser, Gufic Sallaki Tablets® from 
Bser and Bsac/Bcar) extracted by the analytical extraction scale method is presented in Tab. 
3.12. 
 
Tab. 3.12 Total average of all Olibanum samples (Bpap, Bser, Bsac/Bcar) extracted by the analytical 
extraction scale method. Yield RE (raw extract); Yield RS (acid fraction); Yield NB (neutral fraction); 
Loss RE (Loss during separation of the RE into RS and NB) and Total Loss (Sum: Not Extr. + Loss 
RE). Mean: Arithmetic mean; S.D.: Standard deviation; C.V.: Coefficient of variation (S.D / Mean x 100 
%). 
Yield RE [%] Yield RS [%] Yield NB [%] Loss RE [%] Total Loss [%] 
Mean: 60.9 Mean: 27.4 Mean: 24.1 Mean: 15.1 Mean: 48.5 
S.D.: 2.3 S.D.: 2.6 S.D.: 2.1 S.D.: 3.5 S.D.: 2.9 
C.V.: 4.2 C.V.: 10.9 C.V.: 8.2 C.V.: 23.1 C.V.: 6.4 
 
The table basically demonstrates that, if one of these resins is extracted, approximately 60 % 
of RE are obtained. The RE then delivers ca. 27 % RS and 24 % NB (referred to the total 
amount of weighed resin material). The loss during the separation of the RE into the acid 
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fraction (RS) and neutral fraction (NB) is ca. 15 %. Especially the poor day performance of 
the NB/RS-separation for the Bcar samples (see Fig. 3.81) led to a worse overall average 
(Loss RE) and a very strong C.V. of 23 %. This fact should be beard in mind. The value will 
become narrower when more samples are analysed. Though it could have been treated as 
an outlier it was nevertheless accepted for the calculation. A further reason for this strong 
deviation in the Bcar samples (Loss RE) could also have been the poor phase separation 
(organic/water); as the formation of an emulsion during phase separation was specially 
observed for samples of Bsac and Bcar. This seems to be most likely due to the high content 
of BAs (1 and 3) and ABAs (2 and 4; see also chapter 3.8).  
Eventually, about 50 % of the material had been lost during the extraction of the raw resinous 
product (Summation of Loss RE and Not Extr.). Extraction differences in detail are due to the 
nature of the sample itself and the day extraction performance (manual procedure with a 
separation funnel). The data presented here may give a kind of expectation value for 
extraction of Boswellia resins in general (Bpap, Bser, Bsac/Bcar) when a questionable resin 
is analysed by separation of the NB and RS fractions. 
 
 
3.4 TLC data (Bpap, Bser, Bsac/Bcar) 
 
In this chapter representative TLC chromatograms for the crude resins of the species Bpap, 
Bser and Bcar/Bsac are presented. According to the sample population analysed in this work 
and to critically evaluated data from the literature [13,74,79,82], the TLC method 
demonstrated in this work provides a simple technique for the unambiguous 
chemotaxonomic identification of theses three species qualitatively. The chromatography 
techniques are given in chapter 2.3.1. Basically, the data presented here is already published 
in Phytochemical Analysis [11]. In Fig. 3.83 two example chromatograms and a 
corresponding model chromatogram are shown. 
The TLC data ensures the data obtained by HPLC analysis (see chapter 3.7). Furthermore, 
by combination of both methods, the identity of marker compounds, only by relative methods 
(TLC: dyeing colour and Rf value, respectively, in HPLC the Rt value, when absorption is 
merely possible at 210 nm detection wavelength), even without more specific detection 
dimensions (DAD, MS-detection or isolation and NMR), is achievable. Thus, combination of 
TLC and HPLC can be considered as a multi-dimensional classification approach, when 
techniques like an additional DAD- or MS-detection dimension are lacking. 
Very specific for Bpap is the existence of a brown spot eluting at Rf = ca. 0.68, which refers 
to incensole acetate (compound 23). Thus far, Inc-Ac has been, in all samples analysed 
here, only significantly detectable in the species Bpap. This result is consistent with data 
published by Obermann, Hamm et al. and Camarda et al. [13,74,79]. Hence, publications 
reporting the isolation of Inc-Ac (23) from Bcar (e.g. Moussaieff et al. [87] and Banno and 
Akihisa et al. [67,68]) may have been reporting of the resin Bpap instead. Accordingly, 
referring to the data population analysed and even found in the literature, this fact seems to 
be very likely. Furthermore, Bpap shows, from all species analysed here, the greatest 
amount of incensole (22, Rf at ca. 0.27; see also chapter 3.8). Another specific marker 
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compound for Bpap is the strong blue 3-Oxo-TA (13) spot at Rf = ca. 0.22, which is 
completely in accordance to the obtained HPLC results (see chapters 3.7 and 3.8). 
For Bser a strong green serratol (21) spot (Rf = ca. 0.46) is very specific. Similar to Bpap, 
Bser contains a strong and sharp 3-Oxo-TA (13) spot (Rf = ca. 0.22) eluting within α/ß-BA (1 
and 3; Rf = ca. 0.19) and α/ß-ABA (2 and 4; Rf = ca. 0.25). 
 
  
 
 
 
 
 
Rf = 0.80 
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Rf = 0.50 
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Fig. 3.83 Real chromatograms of crude resin extracts (left: MeOH extract; middle: Et2O extract; after 
dyeing and ca. 20 min development at room temperature) and the model chromatogram (right) with 
the corresponding Rf values. The model presents only the significant spots useful for resin 
identification. Conditions are as described in chapter 2.3.1 (Eluent: 2 parts of pentane and one part of 
Et2O + 1 % HOAc). Rf = ca. 0.10 (ß-KBA, 5, UV active); Rf = ca. 0.16 (ß-AKBA, 6, UV active); Rf = ca. 
0.19 (1 and 3, BAs, violet); Rf = ca. 0.22 (13, blue); Rf = ca. 0.25 (2 and 4, ABAs, violet); Rf = ca. 0.26 
(not verified, blue); Rf = ca. 0.27 (22, brown); Rf = ca. 0.46 (21, green); Rf = ca. 0.50 (28, pink); Rf = 
ca. 0.68 (23, brown); Rf = ca. 0.80 (most probably terpenes without functional group, e.g. verticillia-
4(20),7,11-triene, limonene, ß-pinene, α-humulene, ß-caryophyllene etc.; dark blue/violet). Definition 
of spots in the model chromatogram: Solid spots (good visible), hollow spots (slightly visible), hollow 
and dashed spots (barely visible). For further discussions see text. With permission from John Wiley & 
Sons Ltd., taken from Phytochemical Analysis 2012, 23, page 184-189. 
 
For Bsac/Bcar (both have the same elution pattern in common) a pink spot at Rf = ca. 0.50, 
referring to ß-Car-Ox (compound 28), is very specific. Hitherto, this spot has been only 
detected in Bsac/Bcar during this work. In compliance with the results of Camarda et al. [74] 
and Hamm et al. [13], and the detection of its probable precursor ß-caryophyllene (27) 
merely in Bsac/Bcar samples (see also chapter 3.7), it may be an additionally useful 
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biomarker for species identification, when all pattern pre-conditions for a Boswellic species 
are granted (e.g. ß-KBA, ß-AKBA, BAs and ABAs). Bsac/Bcar show also the strong green 
serratol (21) spot (Rf = ca. 0.46). Good support as well is given in the dissertation of Basar 
[35], where 34 different Olibanum essential oil TLC chromatograms are presented. There, 
the pink ß-Car-Ox (28) spot has been specific for almost any Olibanum sample from Somalia 
(Bcar) and Oman (Bsac). Hence, this evidence substantiates the statements given here thus 
far. Incensole (compound 22) has been also detectable in Bser and Bsac/Bcar, but in quite 
lower concentrations than for Bpap. Interestingly, as Ser-OH (compound 21) is reported as 
biosynthetic precursor of Inc (22) by Klein and Obermann [82], it is remarkable that Bpap 
does not reveal a Ser-OH (21) spot and a quite huge amount of Inc (22), compared with Bser 
and Bsac/Bcar (see also chapter 3.7). Furthermore, the existence of high quantities of Inc-Ac 
(23) merely in Bpap, may give proof for a different secondary metabolic pathway expression 
in this species. It seems that only Bpap generates a specific enzyme capable of acetylating 
its precursor incensole (22). However, the discussion is just speculative, but reasonable, 
based on the experimental results so far. 
 
 
Fig. 3.84 UV detection of ß-AKBA (6) and ß-KBA (5) at 254 nm (from left to right; 1st column: Bpap, 
2nd column: Bser, 3rd column: Bcar, 4th column: Bsac). The two spots per column refer to the 
extraction method, Et2O and MeOH. Note that for the Bcar and Bsac samples large deviations can be 
found for the UV detection of ß-KBA and ß-AKBA (varying concentrations of ß-KBA and ß-AKBA; see 
also 3.7 and 3.8). Hence, if only UV detection is used, the species identification may be not 
unequivocal. For further discussion see text. With permission from John Wiley & Sons Ltd., taken from 
Phytochemical Analysis 2012, 23, page 184-189. 
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All species discussed here have the classical boswellic acids in common. If only the BAs (1 
and 3, Rf = ca. 0.19) and the ABAs (2 and 4, Rf = ca. 0.25) are considered, no real qualitative 
species differentiation is achievable. However, for the identification of a questionable resin 
chunk as species from Boswellia the existence of BAs (1 and 3) and ABAs (2 and 4), 
respectively, ß-KBA (5) and ß-AKBA (6), is mandatory. 
In Fig. 3.84 the UV detection of the MeOH and Et2O extracts is presented. Expectably, Bpap 
always delivers a strong UV spot for ß-AKBA (6) and a weaker one for ß-KBA (5). Bser, as 
far as experienced in this work and according to data sceptically inspected in the literature 
[17,56,57], delivers a weaker spot for ß-AKBA (6), showing continuously more or less the 
same absorption as ß-KBA (5). Normally, samples from Bsac/Bcar reveal UV absorptions for 
ß-AKBA (6) similar the concentration levels of ß-AKBA in Bser samples. ß-KBA (5), at this 
concentration level (c = ca. 5-10 mg/ml in TLC analysis; max. 10 µl added), can only be 
guessed by UV detection. However, samples were analysed revealing in- or decreased ß-
KBA (5) and ß-AKBA (6) levels for Bsac, respectively, Bcar. Thus, if only the UV detection for 
TLC analysis is applied, the identification of the species investigated might be ambiguous. 
The results of the discussions made in this chapter are summarised in Tab. 3.13. Basically, 
there are all important points demonstrated concerning the TLC analysis of the sample 
extracts. 
 
Tab. 3.13 Marker compound properties referring to the resin species. Full name of marker compound, 
number (Nr.) and abbreviation (Abbr.), the corresponding Rf value, the colour after dyeing, UV 
detection properties and the species (Bpap, Bser, Bsac/Bcar) representative for the characteristic 
compound (Expressions in parentheses declare, if the spot is strong or faint and thus significant for a 
certain species). For further discussions see text. 
a Note that the ß-KBA and ß-AKBA UV-detection properties for Bsac/Bcar can show strong deviations 
from the conclusion given here (varying amounts of ß-KBA and ß-AKBA have been found; see also 
3.7 and 3.8).  
Compound Nr. and Abbr. 
Rf 
value
Colour (after 
dyeing) 
UV detection 
(254 nm) Species 
Incensole 22  (Inc) 0.27 brown - 
Bpap (strong), Bser, 
Bsac/Bcar 
Incensole acetate 23  (Inc-Ac) 0.68 brown - Bpap 
3-Oxo-8,24-dien-tirucallic 
acid 
13  
(3-O-TA) 0.22 blue - 
Bpap, Bser (both strong), 
Bsac/Bcar 
Serratol 21  (Ser-OH) 0.46 green - 
Bser, Bsac/Bcar  
(both strong) 
ß-Caryophyllene oxide 28  (ß-Car-Ox) 0.50 pink - Bsac/Bcar 
α- and ß-Boswellic acid 1 and 3 (a/ß-BA) 0.19 violet - Bpap, Bser, Bsac/Bcar 
α-Acetyl and ß-Acetyl 
boswellic acid 
2 and 4  
(a/ß-ABA) 0.25 violet - Bpap, Bser, Bsac/Bcar 
11-Keto-ß-boswellic acid 5  (KBA) 0.10 
yellow golden  
(if pure spot) visible Bpap, Bser, Bsac/Bcar
a 
3-O-Acetyl-11-keto-ß-
boswellic acid 
6  
(AKBA) 0.16 
yellow golden  
(if pure spot) visible 
Bpap (strong), Bser, 
Bsac/Bcara 
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3.5 GC data (Qualitative Analysis of Essential Oils from Bpap, Bser and Bcar) 
 
In this chapter the GC data of three analysed essential oils (Bpap, Bser and Bcar; Bsac, as 
showing similar properties as Bcar by TLC and HPLC was not steam distilled) is presented. 
The oils were won by steam distillation as described in chapter 2.2.5. The here reported 
results for Bpap, Bser and Bcar were compared with the GC-MS results from Basar, 
Camarda et al. and Hamm et al. [13,35,74] to verify the conclusions already given by TLC 
and HPLC analysis. Furthermore, since MS-detection lacked, the Kovats indices (KI) [169], 
using the van den Dool variant for temperature gradient programs [170], were applied for 
peak identification of unknown compounds. Therefore, the KI values published by Camarda 
et al. [74], Hamm et al. [13], the online published terpenoids library list by Dr. Hochmuth 
Scientific Consulting [183] and the GC chromatograms published by Basar [35] were used 
(Note that for verification of Bpap results, the GC chromatogram of Bcar in the dissertation of 
Basar, which is unfortunately falsely denoted as Bcar, has been used). For some compounds 
reference standards were available, which verified the specific indices in question at least by 
co-injection (limonene, ß-pinene, ß-caryophyllene, α-humulene, τ-cadinol, methylchavicol, 
methyleugenol, verticillia-4(20),7,11-triene, incensole, incensole acetate, iso-serratol, serratol 
and ß-caryophyllene oxide). However, the data presented here is solely based on 
comparison of these Kovats indices. Not verified peak signals were not assigned or a 
question mark was added in parentheses (correct peak identity strongly evidenced by data 
from literature). 
 
For Bpap, by steam distillation, ca. 15 mg from 1 g of the NB were extracted (yield: 1.5 %). In 
Tab. 3.14 the peaks presented in Fig. 3.85 are summarised for the species Bpap. 
 
Tab. 3.14 Presentation of the GC-data (Bpap) from the chromatogram in Fig. 3.85. The KIs of the 
significant marker compounds are denoted. For further discussions see text. 
Reten. Time [min] Area [mV.s] Height [mV] Area [%] KI Compound 
2,413 136,23 27,344 8,8   
2,817 3,908 13,571 0,3   
9,413 13,175 21,963 0,9 1033 Limonene 
10,2 338,794 27,351 21,9 1074 n-Octanol 
10,645 63,852 27,347 4,1 1098  
11,093 62,464 27,342 4 1122  
12,622 275,943 27,359 17,9 1202 n-Octyl acetate 
14,322 54,627 27,339 3,5 1283  
31,66 91,069 27,346 5,9 1968 Cembrene A (?) 
33,005 117,023 27,345 7,6 2021 Verticillia-4(20),7,11-triene 
36,595 177,831 27,347 11,5 2154 Inc-OH 
37,452 210,062 27,349 13,6 2186 Inc-Ac 
Total 1544,98 309,002 100   
 
As it is already reported by Camarda et al. [74], Hamm et al. [13] and Basar [35] (Note: Bcar 
results from Basar refer obviously to Bpap), typical for Bpap essential oils is the existence of 
strong n-octanol and n-octyl acetate peak signals. Furthermore, as additionally shown by 
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TLC and HPLC analysis, the existence of verticillia-4(20),7,11-triene (24), incensole (22) and 
incensole acetate (23) (Peak signals verified by co-injection) is specifically confirming the 
essential oil as Bpap. The monoterpenes limonene and the diterpene cembrene A seem to 
be universally occurring molecules in the essential oils of all three species (Bpap, Bser, 
Bsac/Bcar) [13,35,74,78]. Thus, for the unambiguous identification of the species Bpap the 
existence of compound 22, 23 and 24 and huge peak signals of n-octanol and n-octyl acetate 
may be necessary. 
 
 
Fig. 3.85 The GC-FID chromatogram of Bpap. Conditions: 100 µL essential oil in 100 µL DCM; 0.5 µL 
injection (Split open: ½ turn; Purge open: ¼); gas chromatographic conditions as described in chapter 
2.3.10. Peak signals are in detail denoted in Tab. 3.14. 
 
In Tab. 3.15 the GC results for Bser are presented. In Fig. 3.86 the corresponding 
chromatogram is shown. For Bser, ca. 23 mg from 1 g (NB) were extracted by steam 
distillation (yield: 2.3 %). In addition to the results reported by Basar [35], Camarda et al. [74] 
and Hamm et al. [13], typical volatile biomarkers for this species are methylchavicol, methyl 
eugenol and serratol (peak signals verified by co-injection). Limonene and cembrene A are 
universally occurring terpenes in Olibanum species, at least thus far reported for the species 
Bpap, Bser, Bsac/Bcar. Hence, Ser-OH (21), methylchavicol and methyleugenol seem to be 
specific biomarkers in the essential oils from the species Bser. Furthermore, Iso-Ser (20), 
which has been described for the first time in this work, is probably co-eluting with Ser-OH 
(21) under these GC-conditions. However, by the HPLC method described here, they (20 
and 21) are separable (see also chapters 3.7.2 - 3.7.4 for example). 
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Tab. 3.15 Presentation of the GC-data (Bser) from the chromatogram in Fig. 3.86. The KIs of the 
significant marker compounds are denoted. For further discussions see text. 
Reten. Time [min] Area [mV.s] Height [mV] Area [%] KI Compound 
2,483 190,76 190,76 27,37   
9,433 61,429 61,429 27,363 1013  
9,802 46,652 46,652 27,358 1033 Limonene 
10,723 61,294 61,294 27,359 1081  
11,003 73,269 73,269 27,36 1096  
11,145 52,523 52,523 27,358 1103  
11,512 85,853 85,853 27,36 1123  
11,62 83,288 83,288 27,361 1128  
12,027 140,44 140,44 27,36 1150  
12,51 117,865 117,865 27,359 1175 Methyl-Chavicol 
13,74 39,615 39,615 27,353 1236  
16,745 93,631 93,631 27,361 1372 Methyl-Eugenol 
17,153 87,613 87,613 27,352 1390  
20,613 36,025 36,025 27,347 1527  
31,865 13,06 13,06 14,11 1960 Cembrene A (?) 
37,045 164,276 164,276 27,356 2156 Ser-OH 
Total 1347,594 424,485 100   
 
 
Fig. 3.86 The GC-FID chromatogram of Bser. Conditions: 100 µL essential oil in 100 µL DCM; 0.5 µL 
injection (Split: ½ open; Purge: ¼ open); gas chromatographic conditions as described in chapter 
2.3.10. Peaks are explicitly denoted in Tab. 3.15. 
 
The data for Bcar is represented in Tab. 3.16 and in Fig. 3.87 the corresponding 
chromatogram is demonstrated. For Bcar, by steam distillation, ca. 67 mg from 1g (NB) were 
   130
Results and Discussion 
_________________________________________________________________________________ 
 
extracted (yield: 6.7 %). Compared to the chromatograms of Bpap and Bser, a more complex 
pattern is obtained. The reason therefore is a splitless injection to generally show how 
complex the composition of essential oils still is (Note: Additionally, splitless injection for 
Bpap and Bser would deliver more complex chromatograms; vice versa, split injection of 
Bcar delivers a less complex chromatogram compared with the one in Fig. 3.87. Hence, only 
the major compounds would be detectable. However, to show the differences between split 
and splitless injection, the splitless injection chromatogram for Bcar is demonstrated). Typical 
biomarkers in the essential oil of Bcar are ß-caryophyllene (27) and its oxidised derivative ß-
caryophyllene-oxide (28), τ-cadinol (25) and serratol (21) (verified by co-injection). Probably, 
iso-serratol (20) co-elutes with serratol (21) under these GC conditions. 
Furthermore, γ-cadinene, δ-cadinene and cedrol seem to be typical biomarkers for Bcar, 
respectively, Bsac. The question mark for γ-cadinene, δ-cadinene and cedrol in parentheses 
denotes that only the KI values were used for biomarker identification. 
 
Fig. 3.87 The GC-FID chromatogram of Bcar. Conditions: 100 µL essential oil in 100 µL DCM; 0.5 µL 
injection (Split closed; Purge: ¼ open); gas chromatographic conditions as described in chapter 
2.3.10. Peaks are explicitly denoted in Tab. 3.16. The closed split delivers are more complex 
chromatogram. 
 
However, according to the data of Camarda et al. [74] and Hamm et al. [13] these molecules 
seem to be quite specific for Bcar and hence Bsac samples. Thus, the species Bsac/Bcar 
seems to biogenetically produce more sesquiterpenes of the cadinane skeleton type (γ-
cadinene, δ-cadinene and τ-cadinol) and even of the cedrane type (cedrol). The work (GC-
MS study of Bsac essential oils) of Al Harrasi et al. [184] gives further evidence for the 
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conclusions deduced from here. Nevertheless, again this is just an assumption, but, 
according to the literature and the data generated here, this proposal seems to be quite 
likely. 
 
Tab. 3.16 Presentation of the GC-data (Bcar) from the chromatogram in Fig. 3.87. The KIs of the 
significant marker compounds are denoted. Question marks in parentheses declare that only the KI 
compared with literature results was used for marker identification. For further discussions see text. 
Reten. Time [min] Area [mV.s] Height [mV] Area [%] KI Compound 
2,367 167,445 27,381 4,4   
2,772 28,499 27,353 0,7   
7,617 77,187 27,369 2 939 α-Pinene (?) 
8,28 48,071 27,368 1,3 973 ß-Pinene 
8,582 67,396 27,368 1,8 989 ß-Myrcene (?) 
9,187 112,541 27,372 2,9 1021  
9,403 155,898 27,375 4,1 1032 Limonene 
9,95 4,281 10,538 0,1 1061  
10,243 39,014 27,362 1 1077  
10,52 62,752 27,368 1,6 1091  
10,683 60,57 27,368 1,6 1100  
10,905 45,344 27,364 1,2 1113  
11,333 126,271 27,37 3,3 1136  
11,455 189,749 27,372 5 1143  
12,02 91,9 27,367 2,4 1172  
12,183 46,259 27,363 1,2 1180  
12,248 50,703 27,365 1,3 1183  
12,457 151,113 27,37 4 1193  
12,757 100,1 27,316 2,6 1209  
12,958 13,399 19,277 0,4 1219  
13,097 70,032 27,367 1,8 1226  
14,197 65,187 27,368 1,7 1278  
16,622 74,341 27,368 1,9 1385  
16,89 92,972 27,369 2,4 1395  
17,712 176,964 27,369 4,6 1428 ß-Caryophyllene
18,475 106,48 27,37 2,8 1460 α-Humulene 
18,925 53,317 27,366 1,4 1478  
19,243 61,714 27,367 1,6 1490  
19,382 83,823 27,37 2,2 1495  
19,487 61,601 27,367 1,6 1499  
19,96 248,43 27,368 6,5 1517 γ-Cadinene (?) 
20,062 94,952 27,369 2,5 1521 δ-Cadinene (?) 
21,64 401,345 27,375 10,5 1581 ß-Car-Oxid 
21,87 111,425 27,373 2,9 1591  
22,208 150,407 27,37 3,9 1603 Cedrol (?) 
22,993 150,795 27,371 3,9 1633 τ-Cardinol 
36,468 180,846 27,37 4,7 2149 Ser-OH 
Total 3823,123 987,664 100   
 
 
In Tab. 3.17 the KI values for all volatile biomarker compounds discussed here are 
presented. Since mass spectrometric detection was not available, the retention indices (RI or 
KI) were used for biomarker ascertainment, when corresponding standards were not 
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available. Even though, the comparison of all KI values presented in Tab. 3.17 may verify the 
general correctness of the typical volatile biomarkers for Bpap, Bser and Bsac/Bcar, there is 
no absolute guarantee - like obtainable by an unambiguous mass spectrum - for the 
conclusions made here. However, the retention index C.V.s of ca. maximal 1 % deviation 
substantiate the general correctness thus far. 
 
Tab. 3.17 Comparison of all KI values given by Hamm et al., Camarda et al., the Terpenoids Library 
List and the data generated here (Data Diss. Paul). Mean = Arithmetic Mean (n = 4); S.D. = Standard 
Deviation (random sample); C.V. = Coefficient of Variation (S.D. / Mean * 100 %). 
Compound Hamm KI [13] 
Camarda KI 
[74] 
Terpenoid KI 
[183] 
Data Diss.  
Paul KI Mean S.D. C.V.
Methylchavicol 1200 1196 1175 1175 1187 13 1.13
Methyleugenol 1394 1400 1369 1372 1384 16 1.12
n-Octanol 1063 1072 1063 1074 1068 6 0.55
n-Octyl acetate 1220 1213 1188 1202 1206 14 1.16
Verticillia-4(20),7,11- 
Triene 2004 1999 2040 2021 2016 19 0.92
Incensole 2150 2139 2193 2154 2159 24 1.09
Incensole acetate 2189 2162 2220 2186 2189 24 1.09
Cembrene A 1959 1948 1962 1964 1958 7 0.36
γ-Cadinene 1509 1512 1507 1517 1511 4 0.29
δ-Cadinene 1524 1518 1520 1521 1521 3 0.16
ß-Caryophyllene 1426 1414 1421 1428 1422 6 0.44
α-Humulene 1454 1451 1455 1460 1455 4 0.26
ß-Caryophyllene 
oxide 1582 1577 1578 1581 1580 2 0.15
Limonene 1020 1027 1025 1033 1026 5 0.52
ß-Pinene 966 973 978 973 973 5 0.51
τ-Cadinol 1634 1638 1633 1633 1635 2 0.15
Serratol 2141a  - 2131 2153 2142 16 0.73
Cedrol 1605b 1599 1603 1603 1603 3 0.16
 
a denoted as unidentified diterpene (according to the KI, it could be Ser-OH, but not verified) 
b denoted as oxygenated sesquiterpene (according to the KI and mass data, it could be Cedrol, but not 
verified) 
 
Conclusively, even only by GC experiments the identity of the essential oils from the resins 
described here is possible. Besides the in plant species universally occurring terpenes (e.g. 
limonene, ß-caryophyllene, ß-carypophyllene oxide, etc.), it is mandatory that typical 
   133
Results and Discussion 
_________________________________________________________________________________ 
 
Olibanum markers are present (e.g. incensole and its acetate or serratol) for an 
unambiguous species assignment. Quantitative experiments were not carried out. 
Iso-incensole and iso-incensole acetate (see Fig. 1.21 in chapter 1.4.5), as reported by 
Hamm et al. [13], have never been detected in Bcar, respectively, Bsac. Though, these two 
diterpenes seem to be specific marker compounds for them (Bsac/Bcar). Probably, they may 
have an almost same KI-value as serratol (21) and/or incensole (22) and thus co-elute under 
this peak in the GC chromatograms (see also Hamm et al. [13]). However, even by screening 
of the neutral fraction of Bcar these compounds (iso-incensole and its acetate) were not 
detected during the practical part of the work presented here. 
 
 
3.6 Validation Results (1D and 2D HPLC) 
3.6.1 Validation Parameters (1D chromatography) 
Determination of Precision, Selectivity, Peak Homogeneity, Robustness and Accuracy  
 
Linearity, Precision and Inter-day Precision: The method was proved to be linear and 
thus precise for all here quantified analytes (R2 > 0.999 for all analytes in the first dimension). 
Inter-day precision was evaluated by generating for each greater quantitation series (Bpap, 
Bser and Bsac/Bcar) the comprehensive external calibration procedure (see chapter 2.3.4.2). 
Thus, the complete procedure was carried out three times for each species analysed 
quantitatively. The detailed discussion is given in chapter 3.6.3.1, where also the 
arithmetically averaged means of the linear regression functions, including their 
measurement uncertainty, are given. 
Specifity: For the determination of compounds detectable at 250 and 280 nm the method is 
highly specific. Hence, compounds 5 and 6 (at 250 nm) and compounds 9 and 10 (at 280 
nm) and even additional signals can be quantified easily. Besides the good resolution of 
these signals at these detection wavelengths, no significant interfering signals elute in the 
corresponding retention areas (see chromatograms of RS in chapter 3.7). 
Selectivity: Selectivity for compounds, merely absorbing at 210 nm, was achieved by 
generation of resolution values up to R = 1.5 (definition of baseline separation). The smallest 
resolution was obtained for compound 10 (R = 1.1 at 210 nm). However, as 10 was 
specifically quantified at 280 nm and showed only low absorption at 210 nm, the adjacent 
higher peak (compound 2) was easily resolved, giving negligible integration errors. All other 
signals gave resolution values from R = 1.2 - 7.8. A depictive chromatogram and the referring 
data therefore are presented in Fig. 3.88 and Tab. 3.18. 
Robustness: Robustness of the method has been granted since resolution and peak areas 
of target analytes did not vary significantly by changing other parameters slightly 
(Temperature: +/- 2 °C; flow rate: +/-0.5 ml/min; gradient time: +/- 0.5 min). The elution area 
of compound 11, 16, 9, 1, 19, 3, 18 and 8 (Rt ca. 30-35 min) has been most sensitive to 
these minor changes (data not shown here). However, as for quantitation of compound 1 and 
3 (co-elution with compound 18) in Bser and Bpap a second chromatography dimension was 
established, this problem had not been of greater concern. Furthermore, for Bsac/Bcar 
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samples, where compounds 18 and 19 are only in minimal contents present, the 2D 
chromatography is, as experienced hitherto, unnecessary (see also chapter 3.7.5). 
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Fig. 3.88 Depiction of a standard chromatogram at 210 nm detection wavelength, calculated on 
experimental values, plot of logk* results against gradient time [153], with Microsoft Excel® 2003 
software as described in [162]. Note: Real sample chromatograms contain more minor peak signals. In 
this “idealised” example the peak heights and areas are fitted to the expectation RS chromatogram (c 
= 5 mg/ml) for Bpap (see also [59]). Furthermore, compound 17 has not been quantified, and 
compounds 8 and 10 may not be detectable when no decomposition of compound 7 occurs [55]. In 
this simulation the peaks of compound 9, 18 and 19 have not been considered for the calculation. The 
retention times and resolution values referring to the chromatogram are presented in Tab. 3.18. For 
details see text. 
 
Tab. 3.18 Retention times (Rt) and resolution values [(calculated on baseline peak width; R = 2 x (tr2 – 
tr1) / (w1 + w2)] for each compound as depicted in Fig. 3.88. The worst resolution is given for 
compounds 17 and 11 (R = 1.2) and peak pair 10 and 2 (R = 1.1). Compound 17 has not been 
quantified. Note that R values depend on the concentrations of target analytes (here c = 5 mg/ml for 
the RS fraction of Bpap). For details see text. 
Compound Abbr. Nr. Rt [min] R 
ß-KBA 5 23.43 7.8 
ß-AKBA 6 26.38 1.5 
11-OH-ß-ABA 7 26.91 1.8 
ß-OH-TA 15 27.65 1.4 
α-OH-TA 14 28.26 1.9 
3-O-TA 13 29.06 1.6 
Dien-TA 17 30.00 1.2 
LA 11 30.51 2.0 
α-Ac-TA 16 31.33 2.2 
α-BA 1 32.40 2.5 
ß-BA 3 33.58 1.3 
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Compound Abbr. Nr. Rt [min] R 
11-OMe-ß-ABA 8 34.19 6.8 
Ac-LA 12 37.94 2.6 
9,11-Dehydro-ß-ABA 10 39.44 1.1 
α-ABA 2 40.09 3.3 
ß-ABA 4 42.17  
 
Accuracy: Accuracy was determined by comparison of the method developed here with the 
HPLC determination method for compound 5 and 6 described in the European 
Pharmacopoeia 6.0 [20]. The determination of contents for compound 5 and 6 gave similar 
values for both methods; the pharmacopoeias and the here reported one. Conclusively, the 
target compounds were almost quantitatively extracted and separated from the neutral 
fraction compounds (a minor uncertainty can never be excluded). The diterpenes 20, 21 and 
22 have been still detectable in the RS fraction extract. Thus, for them the liquid-liquid 
extraction procedure has not been optimised. Compound 22 did not co-elute with any target 
analyte of the RS fraction, whilst compound 20 and 21 did co-elute with compound 14 and 15 
in the samples of Bser and Bsac/Bcar and therefore falsifying their integration results (see 
also chapter 3.7 and 3.8). Nevertheless, most of the neutral terpenoids were separated 
quantitatively as can be noticed by qualitative evaluation (see RS/NB-chromatograms in 3.7). 
 
Tab. 3.19 Comparison of the two HPLC methods: European Pharmacopeia 6.0 (without separation of 
acid- and neutral fraction) and the method developed here (with separation of acid- and neutral 
fraction). Both determinations are recalculated to the overall amount of processed resin. Injection 
concentrations for Bpap were 2.5 mg/ml and for Bser samples 5 mg/ml for the standard HPLC method 
(1D HPLC). The Eur. Pharm. 6.0 conditions were as described in chapter 2.3.9. Recovery value is 
obtained by division of the contents (1D HPLC / Eur. Pharm. 6.0) and given in percent. Bias is 
obtained by subtraction of the Recovery value from 100 %. For further discussion see text. 
Bpap Eur. Pharm. 6.0 
1D 
HPLC   
Eur. Pharm. 
6.0 
1D 
HPLC   
 ß-KBA [g/g in %] 
ß-KBA 
[g/g in %] 
Recovery 
[%] 
Bias 
[%] 
ß-AKBA 
[g/g in %] 
ß-AKBA 
[g/g in %] 
Recovery 
[%] 
Bias 
[%] 
22-1300 1.22 0.36 29.51 -70.49 4.86 4.94 101.65 1.65 
22-1400 0.45 0.30 66.67 -33.33 4.22 4.81 113.98 13.98 
22-1400-
2010 0.65 0.36 55.38 -44.62 4.26 4.67 109.62 9.62 
Mean 0.77 0.34 43.97 -56.03 4.45 4.81 108.10 8.10 
         
Bser Eur. Pharm. 6.0 
1D 
HPLC   
Eur. Pharm. 
6.0 
1D 
HPLC   
 ß-KBA [g/g in %] 
ß-KBA 
[g/g in %] 
Recovery 
[%] 
Bias 
[%] 
ß-AKBA 
[g/g in %] 
ß-AKBA 
[g/g in %] 
Recovery 
[%] 
Bias 
[%] 
22-1560 0.59 0.53 89.83 -10.17 1.01 0.89 88.12 -11.88 
Granen 1.04 0.78 75.00 -25.00 1.23 1.18 95.93 -4.07 
22-127 0.90 0.86 95.56 -4.44 1.19 0.87 73.11 -26.89 
Mean 0.84 0.72 85.77 -14.23 1.14 0.98 85.71 -14.29 
 
For both methods, three samples of each of the two species Bpap (1. Wahl-Nr. 22-1300, Nr. 
22-1400 and Nr. 22-1400-2010) and Bser (1. Wahl-Nr. 22-1560, B.Granen and Nr. 22-127) 
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were compared (all samples were different batches from Gerhard Eggebrecht GmbH, 
Süderau, Germany). The amount of crude resinous material for each sample preparation 
was about 2 g (different small resins chunks, randomly picked from the batch, were 
processed). It should be noted that even within one resin batch, the individual chunks may 
show a quite strong variation regarding the composition of terpenic acids, even stronger for 
volatile mono- and diterpens (In general: The greater the sample population of the whole 
batch, the better the reliability of the determined result). The preparation was implemented as 
reported in the appropriate chapters (2.2.4 and 2.3.9). The comparison of results from both 
methods is given in Tab. 3.19. 
Approximately, both methods give similar measurement results. The results for the Bser 
samples show a better fit (Note: The European Pharmacopeia 6.0 method is developed for 
Indian frankincense, not for any other species). Furthermore, it is striking that the values for 
ß-KBA (5) in Bpap, by the standard HPLC method, are, on average, ca. 50 % below the 
values of the pharmacopoeias method. This could be arbitrary, since for both sample 
preparations different resin chunks from each batch had been taken. Another point could be 
that the pharmacopeia method is just a simple one-point calibration, whereas the method 
reported here is based on a calibration curve with six points. Thus, especially for the ß-KBA 
(5) contents in Bpap, which were proved to exceed the one-point calibration peak area by 
factor 1.5 for sample 22-1400-2010 and by factor 2.3 for sample 22-1300, the values are 
probably estimated too high. Interestingly, for the ß-AKBA (6) contents in Bpap both values fit 
quite well, though the ß-AKBA (6) peak area is ca. by factor 8.3 bigger as the one-point 
calibration peak area. Hence, both regression functions cover coincidentally the same range 
in the case for ß-AKBA (6) and may differ systematically for ß-KBA (5) in Bpap. 
However, the reason for these results in Bpap was not further evaluated. Probably, if the 
complete resin population is prepared from one homogenised (electrical mixer or mortar and 
pestle) sample batch, which then is divided into two sub samples (one for method A and one 
for method B), expectably the same values may be obtained. Nonetheless, in order to get an 
overview on the accuracy of results from independent sample populations within the same 
batch population, this was not done. 
Additionally, as it is shown that for Bser and for the ß-AKBA (6) content of Bpap, comparable 
results are delivered (Bias < 15 %), both methods may be valid to lead to results almost near 
the true target analyte concentration. Interestingly, by summation of the ß-KBA- and ß-
AKBA-contents (5 and 6) of each sample, the bias is almost within a classical batch to batch 
measurement uncertainty [Sum of ß-KBA and ß-AKBA contents for Bpap: 5.15 % (1D HPLC) 
compared with 5.22 % (Eur. Pharm. 6.0), Bias: -1.34 %; and for Bser: 1.70 % (1D HPLC) 
with 1.98 % (Eur. Pharm. 6.0), Bias: -14.14 %]. The minor bias difference for the Bpap 
samples is explainable by the high ß-AKBA (6) content in this species. Hence, the overall 
result for Bpap, compared with Bser, is more robust (e.g. fewer errors through integration 
errors for greater peak areas, etc.), although the ß-KBA (5) bias is comparably rather strong. 
Nonetheless, the HPLC method developed in this work could also deliver systematically 
lower values at low concentration ranges since the concentration values for both, 5 in Bpap 
and 5 and 6 in Bser, are differing at a content of ca. 1 % (in g/g) about -15 to -50 % from the 
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results obtained by the Pharmacopeia 6.0 method (see Tab. 3.19). This could be also due to 
the sample preparation steps (separation of RS and NB, see chapter 2.2.4 and 3.3.1). 
 
 
3.6.2 Validation Parameters (2D chromatography) 
Determination of Precision, Recovery and Accuracy (compared with 1D results) 
 
Linearity, Precision and Inter-day Precision: The second dimension method was proved 
to be linear. Though the coefficient of correlation was not for all calibration curves greater 
than the demanded 0.999, it was normally accepted as it included additional sample 
preparation steps, leading to a greater uncertainty (see also chapter 2.3.4.4). On average, 
the coefficient of variation, referred to the peak area, for each concentration level was less 
than 3 %. Inter-day Precision was evaluated by generating for each greater quantitation 
series (Bpap, Bser and Bsac/Bcar) the comprehensive external calibration procedure with 
the fractions collected in the first chromatography dimension (see also chapter 2.3.4.3). 
Additionally, one RS sample batch was prepared on three different days to test the 
intermediate-precision. The values therefore are presented in Tab. 3.20. As can been seen 
there, a quite good laboratory reproducibility is possible (error < 3% for intra-day precision 
and even better when only the mean values of each day, A-C, are compared; error in this 
case < 2 %). However, it must be noticed that especially for the Bpap RS samples at least a 
concentration of 5 mg/ml should be injected in the first chromatography dimension to obtain a 
sufficient signal to noise ratio (S/N) and thus a minor integration error in the second 
dimension. As evaluated, the species Bpap contains the lowest contents of BAs (1 and 3) 
compared with Bser and Bsac/Bcar (see also chapter 3.8). Thus, based on the approximate 
equation [C.V. ≈ 50/(S/N)] from [153], the uncertainty can be predicted (e.g. peak height for 
compound 1, S ≈ 70 mV divided by N ≈ 3 mV gives a C.V. of ca. 2.14 %; peak height for 
compound 3, S ≈ 80 mV divided by N ≈ 3 mV gives a C.V. of ca. 1.88 %; both estimated 
C.V.s lay within the experimental obtained C.V. as demonstrated in Tab. 3.20). 
 
Tab. 3.20 Inter-day precision for the determination of compound 1 (first row) and 3 (second row) by 
the 2D chromatography method, obtained by three injections for each day (c = 5 mg/ml, sample Bpap 
RS fraction). Mean (referring to the Peak Area); Standard Deviation (S.D.) and the Coefficient of 
Variation (C.V. in %; S.D. divided through Mean and multiplied with 100 %). Overall represents the 
arithmetic mean and referring S.D. of all three measurements (Inter-Day precision of the means A, B 
and C). 
A:Intra-Day 2D  B:Intra-Day 2D  C:Intra-Day 2D  Overall: Inter-Day 
Mean 
[PeakArea] S.D 
C.V. 
[%] 
Mean 
[PeakArea] S.D 
C.V. 
[%] 
Mean 
[PeakArea] S.D 
C.V. 
[%] 
Mean 
[PeakArea] S.D 
C.V. 
[%] 
193277 (1) 2844 1.47 195683 (1) 5235 2.68 197567 (1) 2843 1.44 195509 (1) 2151 1.10 
403638 (3) 6788 1.68 395430 (3) 5564 1.41 399794 (3) 5020 1.26 399620 (3) 4107 1.03 
 
Therefore, the peak height should be as high as possible. Otherwise the results lose a lot of 
precision and a different approach may be needed for method validation (e.g. peak heights 
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or plausibility consideration via relative percentages of peak areas obtained in the second 
dimension for compounds 1, 3 and 18). 
 
Tab. 3.21 Retention times (Rt) and resolution values [calculated on baseline peak width; R = 2*(tr2 – 
tr1) / (w1 + w2)] for each compound as depicted in Fig. 3.89. All target compounds are well resolved. 
Note that R values depend on the concentrations of target analytes (here c = 5 mg/ml for the prepared 
RS fraction of Bpap). For details see text. 
Compound Abbr. Nr. Rt [min] R 
ß-Ac-8,24-dien-TA 19 9.692 0.6 
α-Ac-7,24-dien-TA 18 9.967 1.8 
α-BA 1 10.967 2.0 
ß-BA 3 12.083 2.0 
11-OMe-ß-ABA 8 13.05  
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Fig. 3.89 Depiction of a 2D chromatogram at 210 nm detection wavelength (calculated on 
experimental values with Microsoft Excel® 2003 software as described in [162]). The chromatogram is 
based on a typical expectation value for Bpap samples, prepared from an injection concentration of 5 
mg/ml RS fraction (minimum required RS concentration for a quite reliable integration result). Note: 
Peak 8 is mostly not observable in real sample chromatograms (see also [59]). For further details see 
text. 
 
Selectivity: Selectivity is granted as resolution values greater than 1.5 were generated for 
compound 1, 3 and 8. The co-eluting compounds 18 and 19 in the first dimension are well 
resolved from the target analytes. A typical expectation chromatogram of a prepared Bpap 
RS sample (c = 5 mg/ml) is presented in Fig. 3.89 and in Tab. 3.21 the corresponding data is 
shown. 
Recovery: The quantitative control value of +/- 5 % had been evaluated on empirical results 
and normally lay within the theoretically estimated error propagation of the system (Theory: 
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+/-1 % error during the slight N2/Air-drying of the fraction; +/- 2 % error by resolving in 100 µl 
MeOH; +/- 2 % error by injection and integration; see also the review of Meyer on 
measurement uncertainty [163]). Generally, the recovery values are better the greater the 
concentrations of compound 1 and 3 in the sample are. Furthermore, the error of +/-5 % 
according to the second dimension became more precise, the more samples had been 
analysed. Normally, in this work, an error less than 3 % was obtained. For each analyte, 
dependent on the concentration level, the regression model was chosen which showed a 
better fit to the real experimental data (see also discussions in chapter 3.6.3). The calibration 
data is show in Tab. 3.23 and 3.24 in chapter 3.6.3.1. 
 
3.6.2.1 General Remarks on the 2D Method Sample Preparation 
The crucial steps to obtain reproducible results are reported here. Firstly, it is important to 
use a very slight N2-stream to definitely concentrate the sample at the bottom of the pointed 
10 ml flask. If this is not done appropriately, the white sample film will be covered over a 
great surface within the flask, which makes dissolution in 100 µl MeOH inaccurate (danger of 
evaporation!) and can lead to an insufficient sample recovery. Additionally, using a 250 µl 
Hamilton injection syringe for sample resolving with 100 µl MeOH delivers better results than 
with an automatic 100 µl pipette (empirical experience made in this work and also plausible 
as the sample gets better dissolved by a better variable solvent distribution, possible through 
the more flexible Hamilton syringes). The calibration of the 250 µl syringe is shown in Tab. 
3.22 and proves that a good precision is granted. Finally, after the sample is dissolved again, 
it must be immediately injected (evaporation danger!). If all these steps are carried out 
carefully, it is possible to obtain quite precise results for the 2D chromatography. However, 
the greater the sample amount collected in the 1D chromatography, the more accurate and 
precise will be the result in the second dimension. The minimum concentration, as already 
discussed, should be 5 mg/ml to obtain precisely reproducible results. This is especially 
important for samples of the species Bpap since the RS fractions show expectably the lowest 
contents for compound 1 and 3. 
 
Tab. 3.22 Hamilton Syringe calibration for the 2D chromatography sample preparation, according to 
[155] (MeOH was used instead of water). Mean: Arithmetic mean of 10 immediately repeated steps 
(10 x 100 µl with a 250 µl syringe); S.D.: Standard Deviation and the C.V.: Coefficient of Variation in 
percent. 
100 µL MeOH Nr. Weight [mg] Nr. Weight [mg] 
  1 0.07790 6 0.07780 
  2 0.07733 7 0.07727 
  3 0.07797 8 0.07732 
  4 0.07790 9 0.07780 
  5 0.07731 10 0.07771 
Mean:  0.07763 
S.D.:  0.00027 
C.V. [%]  0.35 
 
For Bser and Bsac/Bcar, which contain normally higher amounts of BAs, the C.V.s can be 
even better at this concentration level (c = 5 mg/ml). Anyway, the second dimension is not 
necessary for samples of Bsac/Bcar, since compounds 18 and 19 are only minimally 
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expressed (see chapter 3.7.5). Hence, the integration inaccuracy in the first chromatography 
dimension lay within the error of repeatability. For samples of Bser, which contain the 
greatest amounts of BAs (1 and 3), the integration error is smaller in the first dimension 
compared with samples of Bpap. Furthermore, if it is known that compound 18 co-elutes 
within a certain expectation interval with compound 3, the second dimension may be 
unnecessary when the confidence interval is widened or the value for compound 3 is 
corrected (on average by an factor which represents the differences in the estimated 
integration). Thus, someone may of course doubt if the huge effort for the second dimension 
is justified, when after a great analysed sample population a trustfully corrected value may be 
predictable. 
 
 
3.6.3 General Discussion and Statistical Evaluation of the HPLC Calibration 
3.6.3.1 HPLC Calibration Data 
In this chapter the data generated by external calibration is discussed thoroughly. It should 
be beard in mind that the whole method development was firstly evaluated for the species 
Bpap [59]. For the species Bser and Bsac, respectively, Bcar, there occur a few other 
characteristics, based on the here analysed sample population. Generally, prior to each 
quantitation series (Bpap quantiation, Bser quantitation and Bsac/Bcar quantitation) the 
corresponding calibration (6 standard concentrations with three injections each) was carried 
out. The same was done for the second chromatography dimension for the determination of 
compound 1 and 3. According to the evaluated differences between these species, the 
corresponding linearity range was extended for Bser and Bsac/Bcar, when a RS fraction 
concentration of 5 mg/ml was kept constant. Hence, for evaluation of Bser and Bsac/Bcar 
samples the linearity range for the compounds 1, 2, 3, 4 (BAs and ABAs) and for compounds 
11 and 12 (LAs) was expanded. The preliminary tests revealed for these species expectably 
greater amounts concerning the mentioned boswellic and lupeolic acids (e.g. for Bsac/Bcar 
great quantities of BAs, ABAs and LAs can be found, and for Bser the BAs showed a 
significant higher content level compared with Bpap). Certainly, another solution would have 
been to inject RS fraction concentrations lower than 5 mg/ml to bring the analytes in the 
expected concentration range. However, especially for accurate integration results in the 2D 
chromatography a sample concentration of at least 5 mg/ml RS fraction had been normally 
necessary. Thus, for the samples of Bser and Bsac/Bcar the linearity range was adjusted. 
The summarised calibration data is shown in Tab. 3.23. The data set represents the 
arithmetically averaged calibration curves obtained by three independent determinations. 
Besides the standard deviation, the overall measurement uncertainty is given [162]. For BAs, 
ABAs and LAs the linearity ranges were extended as mentioned above, which is indicated by 
superscripts. The extended operating ranges are demonstrated in Tab. 3.24. All 1D 
chromatography calibrations led to an acceptable precision (R2 > 0.999). Furthermore, the 
ordinate intercept has been negligible, since it is basically just a product of coincidence, and 
even the straight line through the origin gave for all references an adequate precision. The 
2D chromatography expectably revealed, as it is a product of further sample preparation 
steps, a weaker linearity (especially for compound 1). The very good linearity value for 
   141
Results and Discussion 
_________________________________________________________________________________ 
 
compound 3 may be just a matter of coincidence in this case. However, the main purpose for 
the second dimension was to resolve compound 3 from compound 18 and 19 in order to 
generate more accurate quantitation results for it. The method gave significant differences in 
the integration results when these compounds (18 and 19) co-eluted with 3 in the first 
dimension, while compound 1 (in all samples eluting as homogenous peak in the first 
dimension) delivered integration results within the predicted interval for a certain 
concentration. The strong MU value for compound 11 is explained by the great operating 
range and is similar to the values presented in Tab. 3.24 (compound 11 was analogue 
prepared as compound 12 in order to cover their greater contents in Bsac/Bcar). If the 
linearity range for this compound is minimised (e.g. 8-250 µg/ml, as for compound 12), the 
MU will be expectably decreased. 
 
Tab. 3.23 RS-fraction calibration data for the 15 quantified compounds. Linear regression (y = unit of 
peak area; x = weighed sample in mg/ml; plus/minus the ordinate intercept); the arithmetically 
averaged Measurement Uncertainty (MU; calculated according to [162]) given in % (Note that for each 
standard concentration the MU varies; high values for low concentration levels and lower values for 
higher concentration levels); Correlation Coefficient (Corr. Coeff., R2); Limit of Quantitation (LOQ) and 
the Operating Range. The Limit of Detection, LOD = LOQ / 3.33; LOD was determined by 
multiplication of the noise-standard deviation by factor 3; LOQ was determined by multiplication of the 
noise-standard-deviation by factor 10 and accepted when integration errors were negligible at this 
stage. For further details see text. 
a Operating Range extended for Bser (for RS-c = 5 mg/ml), see also Tab. 3.24. 
b Operating Range extended for Bsac/Bcar (for RS-c = 5 mg/ml), see also Tab. 3.24. 
c Great Operating Range for LA leads to a rather high MU at low concentrations (see also discussions 
about Ac-LA in chapter 3.6.3.2). The high uncertainty for low concentrations was taken into account. 
Compound Detection at 
Weighted Linear 
Regression 
(+/- stand. dev.) 
  
Averaged 
MU [%] 
Ordinate 
Intercept 
(+/- stand. dev.) 
  
Corr. 
Coeff. R2 
LOQ 
[µg/ml] 
Operating 
Range 
[µg/ml] 
  
1a, b 210 nm 7.92E+06 (+/- 7.07E+04) 6 
7.43E+03 
(+/-1.59E+04) 0.99982 15 15 – 480 
1(2D)a, b 210 nm 1.32E+06 (+/- 1.53E+04) 5 
7.50E+03 
(+/- 4.35E+03) 0.99880 60 60 – 480 
2b 210 nm 8.15E+06 (+/- 6.25E+04) 7 
-1.05E+04 
(+/- 3.03E+04) 0.99979 13 13 – 514 
3a,b 210 nm 7.50E+07 (+/- 4.72E+04) 6 
-1.49E+04 
(+/- 1.09E+04) 0.99991 15 15 – 490 
3(2D)a,b 210 nm 1.31E+07 (+/- 1.35E+04) 4 
6.09E+03 
(+/- 6.37E+03) 0.99975 60 60 - 490 
4b 210 nm 6.26E+06 (+/- 6.96E+04) 9 
-2.59E+03 
(+/- 3.75E+04) 0.99977 15 15 – 575 
5 250 nm 5.20E+07 (+/- 5.49E+05) 5 
-1.30E+04 
(+/- 2.83E+05) 0.99973 0.5 0.5 - 275 
6 250 nm 4.98E+07 (+/- 4.64E+05) 11 
5.75E+04 
(+/- 2.27E+05) 0.99984 0.7 0.7 - 260 
7 210 nm 1.23E+07 (+/- 1.40E+05) 10 
2.84E+04 
(+/- 3.51E+04) 0.99969 9 9 - 540 
8 210 nm 1.93E+07 (+/- 3.40E+05) 12 
-3.97E+02 
(+/- 2.27E+04) 0.99968 8 8 - 150 
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Compound Detection at 
Weighted Linear 
Regression 
(+/- stand. dev.) 
  
Averaged 
MU [%] 
Ordinate 
Intercept 
(+/- stand. dev.) 
  
Corr. 
Coeff. R2 
LOQ 
[µg/ml] 
Operating 
Range 
[µg/ml] 
  
10 280 nm 3.70E+07   (+/- 6.34E+05) 9 
-5.10E+04 
(+/- 3.59E+04) 0.99966 2 2 - 120 
11c 210 nm 8.48E+06 (+/- 8.81E+04) 20 
1.42E+05 
(+/- 2.14E+05) 0.99922 8 8 – 1530 
12b 210 nm 7.34E+06 (+/- 7.47E+04) 7 
-5.00E+02 
(+/- 8.64E+03) 0.99971 8 8 – 250 
13 210 nm 1.47E+06 (+/- 3.69E+05) 9 
4.21E+03 
(+/- 1.14E+05) 0.99915 8 8 – 650 
14 210 nm 1.85E+07 (+/- 1.39E+05) 4 
4.06E+04 
(+/- 3.41E+04) 0.99989 6 6 - 520 
15 210 nm 1.42E+07 (+/- 1.12E+05) 4 
2.57E+04 
(+/- 5.26E+04) 0.99965 7 7 – 680 
16 210 nm 1.77E+07 (+/- 1.30E+05) 6 
3.88E+04 
(+/- 3.32E+04) 0.99987 7 8 - 540 
 
 
Tab. 3.24 Extended Operating Range. Definitions and Abbreviations are the same as in Tab. 3.23. 
Since higher concentrations of BAs in Bser and BAs, ABAs, LA and Ac-LA in Bsac/Bcar are found, 
when RS-samples with c = 5 mg/ml are measured, the working range was extended. For further 
discussions see text. 
Compound Detection at 
Weighted Linear 
Regression 
(+/- stand. dev.) 
  
Averaged 
MU [%] 
Ordinate 
Intercept 
(+/- stand. 
dev.) 
  
Corr. 
Coeff. R2 
LOQ 
[µg/ml] 
Operating 
Range 
[µg/ml] 
  
1 210 nm 8.66E+06 (+/- 1.96E+05) 15 
-1.05E+04 
(+/-1.12E+05) 0.99929 15 15 – 1300 
1(2D) 210 nm 1.60E+06 (+/- 3.04E+04) 12 
-4.65E+03 
(+/- 1.26E+04) 0.99909 60 60 – 900 
2 210 nm 1.01E+07 (+/- 4.34E+05) 26 
-1.01E+05 
(+/- 3.69E+05) 0.99900 13 13 – 1500 
3 210 nm 8.06E+06 (+/- 1.69E+05) 12 
-2.81E+04 
(+/- 1.12E+05) 0.99932 15 15 – 1500 
3(2D) 210 nm 1.39E+06 (+/- 2.68E+04) 12 
4.19E+03 
(+/- 1.32E+04) 0.99855 60 60 - 1010 
4 210 nm 8.70E+06 (+/- 3.70E+05) 27 
-1.31E+05 
(+/- 3.19E+05) 0.99908 15 15 – 1500 
12 210 nm 8.30E+06 (+/- 2.37E+05) 17 
-1.09E+04 
(+/- 1.35E+05) 0.99952 8 8-1450 
 
In Tab. 3.24 the extended operation ranges are presented. There, as explicitly discussed for 
compound 12 in chapter 3.6.3.2, the MU values encompass a quite great interval and thus a 
lower precision. The reason for this phenomenon can be explained by the greater scattering 
of values along the greater interval and hence an entirely weaker coefficient of correlation 
compared with the smaller operating ranges presented in Tab. 3.23. 
Since the extension of the operating range for compounds 1, 2, 3, 4 and 12 was 
implemented to cover the higher contents of these compounds in Bser, respectively, 
Bsac/Bcar, their error is not as great as someone could assume by the data presented in 
there. If only the high concentration levels are regarded, the MU value is more precise. This 
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is explicitly explained in chapter 3.6.3.2, where the two linearity ranges of compound 12 are 
discussed. The conclusion made there can be referred to all standards for which the 
operating range was extended. 
 
In Tab. 3.25 the external calibration data for the neutral compounds 20, 21, 22 and 23 is 
shown. All compounds are merely quantifiable at 210 nm detection wavelength. However, 
due to the fact that compounds 20 and 21 contain three double-bond systems, their 
absorption coefficients are higher than for 22 and 23 (only two double-bond systems). This 
led to a polynomial S-shaped calibration function over a rather minimal concentration range 
(for our system: 0 – 0.5 mg/ml); or to two different linearity ranges (linearity range No. 1: ca. 
0 – 0.18 mg/ml, and linearity range No. 2: ca. 0.18 – ca. 0.45 mg/ml). Since for a polynomial 
calibration curve (order two or three) much more calibration data points are necessary to 
verify the accuracy of the function [156], it was decided to chose the minimum linearity range 
(from 0 – 0.18 mg /ml) to quantify Ser-OH (20) and Iso-Ser (21). Although, this approach 
needed in some cases two trial injections with real samples of NB to find the adequate 
working range of the function. Calibration curves for Inc (22) and Inc-Ac (23) were linear 
within a wide range (up to 600 µg/ml). 
 
Tab. 3.25 HPLC calibration data for iso-serratol (20), serratol (21), incensole (22) and its acetate (23). 
Linear regression (y = unit of peak area; x = the weighted sample in mg/ml; plus/minus the ordinate 
intercept); correlation coefficient (R2); limit of detection (LOD) and the operating range (LOD was 
determined by multiplication of the noise-standard-deviation by factor = 3; limit of quantitation, LOQ, 
was determined by multiplication of the noise-standard-deviation by factor = 10; Operating range 
results from the maximum concentration levels, within the values were linear). The measurement 
uncertainty (MU) was calculated as described in [162]. For further details see text. 
Compound Detection at 
Weighted Linear 
Regression 
(+/- stand. dev.) 
  
Averaged 
MU [%] 
Ordinate 
Intercept 
(+/- stand. 
dev.) 
  
Corr. 
Coeff. R2 
LOQ 
[µg/ml] 
Operating 
Range 
[µg/ml] 
  
20 210 nm 5.03E+07 
(+/- 4.01E+05) 6 
-5.18E+04 
(+/- 5.83E+04) 0.99965 
5 5 - 180 
21 210 nm 5.18E+07 
(+/- 4.24E+05) 8 
- 9.06E+04 
(+/- 7.73E+04) 0.99945 
5 5 - 180 
22 210 nm 1.93E+07 (+/- 6.74E+05) 19 
-2.92E+04 
(+/-1.68E+05) 0.99966 7 7-530 
23 210 nm 1.70E+07 (+/- 3.94E+04) 15 
-1.77E+04 
(+/- 1.09E+05) 0.99929 15 15-590 
 
 
3.6.3.2 General Calibration Issue (Example of Compound 12, AcLA) 
Normally, the increase of the operating range increases the slope of the calibration curve to 
keep the summation of least squares minimal. This expectation was verified in the here given 
example of the linearity range extension for AcLA (compound 12; see Fig. 3.90). Basically, 
when great operating ranges, even with an acceptable correlation coefficient (> 0.999), are 
given, the values for low concentration levels tend to be more inaccurate. 
A good example for this problem is reported in the paper of Johnson et al. [185]. Thus, for 
high operating ranges revealing a strong variance inhomogeneity (ascertainable via the F-
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test, see also [159,162]), the weighted linear regression model is recommended. Figuratively, 
like on a classical scale, the weighing of measuring points at the one end will lead to a 
difference in coordinates on the other end of the calibration curve. This model takes into 
account the relevance of the relative deviation of measuring points, whereas a conventional 
linear regression model just minimises the sum of least squares. An easily understandable 
and exemplary explanation on weighted least squares is given in the book by R. de Levie 
[186]. 
Here, two linearity ranges, generated by both models, are compared to show how difficult 
and delusive the simple and blind trust on linear models can be, without proving analytical 
results by common sense. 
A reliable linearity range for Ac-LA (12), referring to the RS fraction of Bpap and Bser, was 
finally realised to be operable within the concentration range of 8 µg – 250 µg/ml. This 
concentration range is, as far as here experienced, sufficient for quantitative experiments 
with the species Bpap, respectively, Bser (expectation value for Bpap and Bser in the real 
sample acid fraction with c = 5 mg/ml is ca. 0.05-0.12 mg/ml). Both calibration models were 
applied, the unweighted and the weighted. Since it was realised that the Bsac/Bcar samples 
contain often LA/AcLA contents above this range, the linearity range was extended to give a 
function sufficiently for all samples (Bpap, Bser and Bsac/Bcar). Furthermore, this was 
necessary to keep the overall injection concentration for acid fractions constant (c = 5 mg/ml; 
minimum RS content for the 2D chromatography, as lower RS concentrations deliver greater 
integration errors in the second dimension, see also chapter 3.6.2). Therefore, as for 
analytical measurement systems a broad linearity range is generally desirable, it was 
extended to 1.45 mg/ml and still showed a good linearity within this great interval (> 0.999). 
However, for the greater linearity range a greater overall error is given. 
The results of both regression models (weighted and unweighted) are presented in Fig. 3.90. 
There, as expected for both concentration ranges, the VVK for the weighted regression 
model delivered a better value. Additionally, the confidence and prediction interval is wider 
for the greater operating range (measurement uncertainty: from 20 % for low concentration to 
15 % for high concentrations) and, vice versa, narrower for the smaller range (measurement 
uncertainty: from 10 % for low concentrations to 4 % for high concentrations). 
Obviously, the narrower linearity range will deliver more accurate results compared with the 
extended version. However, to “really” clarify which of the regression models suits the 
concentration range best, a more profound evaluation may be necessary, in order to obtain a 
better knowledge on the calibration model. In Tab. 3.26 this approach is demonstrated. 
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Weighted Regression model 
 
y = 7,34E+06x – 5,00E+02 
 
n = 18; VVK = 0.56 % 
 
Unweighted Regression model 
 
y = 7,45E+06x – 4,23E+03 
 
R2 = 9,9971E-01 
 
n = 18; VVK = 1.97 % 
Unweighted Regression model 
 
y = 8,45E+06x + 9,61E+03 
 
R2 = 9,9952E-01 
 
n = 27; VVK = 2.83 % 
Weighted Regression model 
 
y = 8,30E+06x – 1,09E+04 
 
n = 27; VVK = 0.35 % 
Fig. 3.90 Comparison of the two different regression ranges for compound 12. Upper diagram: 8-250 
µg/ml. Lower diagram: 8-1450 µg/ml. The weighted regression models were obtained with the excel 
working sheet reported on in [162]. Both unweighted regression models were proved to be linear (R2 = 
0.99971 and 0.99952). The VVK (Coefficient of Variation, referred to the mean value of the linearity 
range) had been for the weighted linear regression model always better. The difference in the slopes 
is about 10 % between the lower and higher linearity range. The scale differences are clarified by the 
rectangles and the arrow, which indicate the enlargement of the minor linearity range. The two outer 
straight lines represent the measurement uncertainty interval (calculated according to [162]). For 
further details see text. 
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Tab. 3.26 Comparison of the two linearity ranges (denoted as A and B) by weighted and unweighted 
linear regression. Nominal [mg/ml]: The expected analyte concentration of the weighed (balance) and 
diluted (volume) sample. Calculated [mg/ml]: Calculated value, based on the respective regression 
model. Bias [+/- %]: Deviation of the calculated from the nominal value in percent (Significant 
deviations are highlighted by red colours). Sum Bias^2: The summation of the squared single bias 
values (The percent value between refers to the percentage of the minor value relative to the major 
value). The ordinate intercept was not within calculated as the failure is random and negligible (for all 
models << 0.5 %). For further details see text. 
A: Linearity Range (8-250 µg/ml) B: Linearity Range (8-1450 µg/ml) 
 
 Weighted  Unweighted   Weighted  Unweighted  
Nominal 
[mg/ml] 
Calculated 
[mg/ml] 
Bias 
[+/-%] 
Calculated 
[mg/ml] 
Bias 
[+/-%] 
Nominal
[mg/ml] 
Calculated
[mg/ml] 
Bias 
[+/-%] 
Calculated 
[mg/ml] 
Bias 
[+/-%] 
0,0077 0,0075 -1,7 0,0075 -2,9 0,0077 0,0067 -13,1 0,0066 -14,6 
0,0077 0,0076 -1,2 0,0075 -2,3 0,0077 0,0067 -12,6 0,0066 -14,1 
0,0077 0,0077 0,9 0,0077 -0,3 0,0077 0,0069 -10,8 0,0067 -12,3 
0,0154 0,0155 1,1 0,0153 -0,1 0,0154 0,0137 -10,7 0,0135 -12,2 
0,0154 0,0153 -0,1 0,0152 -1,3 0,0154 0,0136 -11,7 0,0133 -13,2 
0,0154 0,0150 -2,2 0,0148 -3,3 0,0154 0,0133 -13,5 0,0131 -15,0 
0,0307 0,0302 -1,8 0,0298 -3,0 0,0307 0,0267 -13,2 0,0262 -14,7 
0,0307 0,0313 1,9 0,0310 0,8 0,0307 0,0277 -9,9 0,0272 -11,4 
0,0307 0,0314 2,3 0,0311 1,1 0,0307 0,0278 -9,6 0,0273 -11,1 
0,0614 0,0607 -1,2 0,0600 -2,4 0,0614 0,0536 -12,7 0,0527 -14,2 
0,0614 0,0609 -1,0 0,0601 -2,1 0,0614 0,0538 -12,4 0,0529 -13,9 
0,0614 0,0601 -2,2 0,0594 -3,3 0,0614 0,0531 -13,5 0,0522 -15,0 
0,1229 0,1200 -2,4 0,1186 -3,5 0,1450 0,1462 0,8 0,1437 -0,9 
0,1229 0,1217 -1,0 0,1203 -2,1 0,1450 0,1500 3,4 0,1474 1,7 
0,1229 0,1211 -1,4 0,1197 -2,6 0,1450 0,1556 7,3 0,1529 5,4 
0,2458 0,2505 1,9 0,2476 0,8 0,2900 0,2979 2,7 0,2928 1,0 
0,2458 0,2489 1,3 0,2461 0,1 0,2900 0,3014 3,9 0,2962 2,2 
0,2458 0,2479 0,9 0,2451 -0,3 0,2900 0,2960 2,1 0,2909 0,3 
     0,4800 0,4994 4,0 0,4908 2,3 
     0,4800 0,5032 4,8 0,4946 3,0 
     0,4800 0,4982 3,8 0,4897 2,0 
     0,6700 0,6994 4,4 0,6875 2,6 
     0,6700 0,7011 4,6 0,6891 2,9 
     0,6700 0,7005 4,5 0,6885 2,8 
     1,4500 1,4637 0,9 1,4387 -0,8 
     1,4500 1,4504 0,0 1,4256 -1,7 
     1,4500 1,4799 2,1 1,4546 0,3 
  Sum Bias^2  
Sum 
Bias^2.   
Sum 
Bias^2  
Sum 
Bias^2.
  35 (= 4.9 % of) 712   8900 (= 46.2 % of) 19284 
A(8-250µg/ml): The weighted model is 
evaluated to be superior for this linearity range. 
However, both models fit approximately well. 
 
B(8-1450µg/ml): Here, also the weighted model 
is evaluated to be superior. However, for low 
concentration levels the errors for both are 
huge, and for higher concentrations the 
unweighted model is actually better. 
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The two linearity ranges were split into two columns (A and B) comparing both regression 
models with the nominal value (value obtained by weighing the reference material on a 
balance and dilution by a pipette or a volumetric flask). The calculated values are based on 
the corresponding regression equations. As it is demonstrated, the weighted linear 
regression model gives for Range A (8-250 µg/ml), as expected, a better fit. The squared 
summation of the bias leads to only 4.9 % (35/712 * 100 %) deviation compared with the 
unweighted model. Nevertheless, the unweighted model is still quite precise and not even 
much more error-prone for some concentrations levels.  
By thorough evaluation of both linear regression models for Range B (8-1450 µg/ml), it is 
quite astonishing that both models deliver for the lower concentration range (c = 0.008-0.06 
mg/ml) strong biases from the nominal values (errors of up to 15 % below the nominal value, 
indicated by the red colours). A probable reason therefore could be a systematic pipette 
failure leading to constantly lower values. However, since all nine calibration points were 
proved to be linear (> 0.999), the calibration model was accepted. The difference in the sum 
of squared biases is not as significant as obtained for Range A, only 46.2 % (8900/19284 * 
100 %). Hence, again the weighted model is expectably delivering on average a better 
accuracy. Anyhow, for the concentration range from 0.145-1450 µg/ml the unweighted model 
delivers more accurate values (compare bias-errors from 0.145-1450 µg/ml, which gives 
lower deviations for the unweighted model), while at low concentrations both models are 
quite equally insufficient. The great deviation at lower concentrations should be taken into 
account, if values within this concentration range are obtained. 
In general, the wider working range in this case leads to a quite great uncertainty at low 
concentration levels for both regressions (0.008-0.061 mg/ml) and becomes more certain at 
higher concentrations (0.145-1450 µg/ml). 
The expectation value for AcLA (12) in Bsac/Bcar RS samples (c = 5 mg/ml) was within 0.18-
0.35 mg/ml. Thus, an operating range of up to 0.70 mg/ml would have been sufficient for 
these samples and would quite likely lead to a better overall fit of the model (theory: the 
narrower the range, the more precise the results). Nevertheless, the expectation value for 
Bsac/Bcar samples had been within the more precise concentration range of the calibration. 
At least, the most important is to know the measurement uncertainty at each concentration 
level; and, if it may be insufficient for a certain purpose, to eliminate the cause of failure (in 
this example, probably a systematic volumetric error). However, as in this work the primary 
goal was not emphasised on the HPLC method optimisation and as additionally the time 
therefore was not given, the calibration model was accepted. Furthermore, if the calibration 
will be carried out several times, the random uncertainties will cancel each other and the 
regression model will become more precise. If not, then a systematic error can be derived 
and the reason therefore must be determined; in this case a pipette volume error may be the 
plausible reason for the strong deviations at low concentrations in Range B.  
Basically, this example shall just clarify that a blind trust on criterions such as VVK values or 
coefficients of correlations fulfilling the requirement for linearity (> 0.999) may be 
encountered with caution. A profound calculation as presented in Tab. 3.26 will serve the 
analyst a more thorough assurance of his calibration model and may help making decisions 
easier on which regression model should be preferred. The evaluation of calibration models 
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for all target analytes quantified in this work (see Tab. 3.23 - 3.25 in chapter 3.6.3.1) was 
carried out in a similar way as explicitly explained in this chapter for Ac-LA (12). 
Finally, to obtain precise and accurate results, it is most important to keep the sample 
expectation value of the target analyte in the centre of the operating range and thus the 
calibration curve. The model will lead to a greater certainty as shown for Range A. 
Nonetheless, it is quite difficult for natural products, growing under not controlled conditions, 
to generally make a correct estimation for an analyte of interest. This fact became clear by 
the difficulty of estimating the value for ß-AKBA (6) in Bsac/Bcar samples (see also chapter 
3.8) where quite high deviations from the expectation value had been observable. 
 
 
3.7 HPLC Analysis (Qualitative Consideration) 
 
In the following chapters representative overview chromatograms of the raw extract (RE), the 
neutral extract (NB) and the acid fraction extract (RS) of the species Bpap, Bser and 
Bsac/Bcar are shown. Each chromatogram series (RE, NB, and RS) represents two different 
sample batches. The chromatograms show typically expected fingerprints of the species 
being discussed. The standard gradient DAD-HPLC method (two columns in series) 
described in chapter 2.3.4.2 was used. Note that only significant and structurally ascertained 
peak signals are discussed. The corresponding quantitative data is reported in chapter 3.8. 
 
3.7.1 Boswellia papyrifera (RE, NB, RS) 
In Fig. 3.91-3.93 the chromatograms of the RE-, NB- and the RS-extracts are presented (two 
different extractions samples, discontinuous extraction, Et2O, Soxhlet). It is shown that the 
RE chromatogram still reveals a quite complex elution pattern with co-elution of neutral 
terpenic compounds with acidic triterpenoids (Fig. 3.91). For example, Inc-Ac (23) elutes 
between compound 1 and 3 and thus co-elutes with compound 19. Inc (22) elutes between 
ß-KBA (5) and ß-AKBA (6). Furthermore, there are several minor peak signals eluting 
between 20 and 30 min. These belong probably to all sorts of saturated mono-terpenes (e.g. 
limonene, ß-pinene; verified by co-injection of standards; data not shown) and semi-polar 
diterpenes. Thus, co-elution of them with target analytes (e.g. TAs) within the range of ca. 
20-30 min is ascertainable. ß-KBA (5) and ß-AKBA (6) can be easily determined, even 
without separation of NB- and RS-fractions, since they are specifically detectable at 250 nm. 
By separation of NB- and RS-fractions it is possible to obtain more meaningful fingerprint 
chromatograms, especially referring to the detection wavelength of 210 nm. In Fig. 3.92 the 
NB overview chromatograms are shown. There, as most significant peak signals, compound 
22, 23 and 24 (verticillia-4(20),7,11-triene) can be ascertained. Interestingly, compound 24 
has been reported by Basar et al. [85] as isolated from the species Bcar. This fact is probably 
wrong, and the compound is a specific biomarker for the species Bpap instead. Compound 
22 and 23 have been quantified (see chapter 3.6.3.1 and 3.8) and are the main diterpenic 
molecular entities in the NB fraction of Bpap. Hence, these three diterpenic compounds 
seem to be specific biomarkers for this species as already reported on by Hamm et al. [13] 
and Camarda et al. [74]. In Fig. 3.93 the RS fraction chromatograms are presented. 
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Fig. 3.91 Two examples of RE chromatograms at three different wavelengths (Extraction: Et2O, 
Soxhlet). Injection concentration: 5 mg/ml. For further discussions see text. 
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Fig. 3.92 Two examples of NB chromatograms at three different wavelengths (Extraction: Et2O, 
Soxhlet). Injection concentration: 5 mg/ml. For further discussions see text. 
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Fig. 3.93 Two examples of RS chromatograms at three different wavelengths (Extraction: Et2O, 
Soxhlet). Injection concentration: 5 mg/ml. For further discussions see text. 
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Typically for Bpap RS extracts are normally a high amount of ß-AKBA (6) and a strong 3-O-
TA (13) peak. Furthermore, as already reported in [59], ß-BA (3) co-elutes with compound 18 
(see also chapter 3.7.5). Also, the decomposition of 11-OH-ß-ABA (7) into compound 10 can 
be noticed (Bpap RS, Sample 2) [55,59]. 
 
3.7.2 Boswellia serrata (RE, NB, RS) 
In Fig. 3.94-3.96 the chromatograms of the RE-, NB- and the RS-extracts for Bser are 
presented (two different extractions samples, discontinuous extraction, Et2O, Soxhlet). 
Additionally, as shown for Bpap, the RE chromatograms still reveal a quite complex elution 
pattern with co-elution of neutral terpenic compounds with acidic triterpenoids (Fig. 3.94). 
However, a different overview RE-chromatogram compared with Bpap-RE is obtained, which 
is, as far as experienced in this work, very specific for Bser. At 210 nm detection wavelength, 
the here called “Triplet-Peak” between 25 and 30 min is highly conspicuous. This is a result 
of co-elution from ß-TA (15) with Iso-Ser (20; first minor peak), from α-TA (14) with Ser-OH 
(21; second main peak) and from 3-O-TA (13; third peak, eluting homogenous). The pattern 
was always obtained when the RE extract of Bser was analysed and can be hence used for 
species identification. At 250 nm, the peaks of ß-KBA (5) and ß-AKBA (6) are easily 
detectable, even without further separation of NB and RS fractions, and reveal the 
approximately typical 1:1 peak height ratio (significant for Bser, compared with Bpap and 
Bsac/Bcar; see also publication of Büchele et al. [57] which gives the same conclusions). 
Separation of the RE fraction into neutral and acid fraction gives more meaningful 
chromatograms. In Fig. 3.95 the NB overview chromatograms are presented. Specific for 
Bser is the existence of Iso-Ser (20) and Ser-OH (21) at 210 nm. Inc (22) is also detectable 
at 210 nm, but to a lesser amount compared with the NB fraction from Bpap. Inc-Ac (23) is 
not significantly detectable (peak heights too low in the appropriate elution area for an 
unambiguous statement and also never has been visible in the TLC experiments, see also 
chapter 3.4). 
The RS fraction overview chromatograms are shown in Fig. 3.96. As already discussed, the 
ß-KBA (5) and ß-AKBA (6) ratio of about 1:1 is very specific for Bser. Furthermore, Bser 
contains a relatively huge amount of 3-O-TA (13, similar to Bpap) and on average the highest 
amounts of α-BA (1) and ß-BA (3), compared with Bpap and Bsac/Bcar. The quantitation of 
ß-TA (15) and α-TA (14) delivers, compared with Bpap, greater peak areas for these two 
compounds. This fact can be explained since the separation of NB and RS fractions is not 
optimised for the species Bser. Thus, the RS extract still contains the quite semi-polar 
diterpenes Iso-Ser (20) and Ser-OH (21), which both co-elute with ß-TA (15), respectively, α-
TA (14). In addition, compound 18 also co-elutes with ß-BA (3) as yet demonstrated for Bpap 
samples. However, the amount of compound 18 relative to the normally higher amount of ß-
BA (3) in Bser gives a lower integration error for Bser samples compared with Bpap samples 
(see also chapter 3.7.5). In Fig. 3.96 the chromatogram of Bser sample 2 also reveals the 
decomposition of 11-OH-ß-ABA (7) into its dehydro-derivative (10) [55,59]. 
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Fig. 3.94 Two examples of RE chromatograms at three different wavelengths (Extraction: Et2O, 
Soxhlet). Injection concentration: 5 mg/ml. For further discussions see text. 
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Fig. 3.95 Two examples of NB chromatograms at three different wavelengths (Extraction: Et2O, 
Soxhlet). Injection concentration: 5 mg/ml. For further discussions see text. 
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Fig. 3.96 Two examples of RS chromatograms at three different wavelengths (Extraction: Et2O, 
Soxhlet). Injection concentration: 5 mg/ml. For further discussions see text. 
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3.7.3 Boswellia sacra (RE, NB, RS) 
In Fig. 3.97-3.99 the chromatograms of the RE-, NB- and the RS-extracts are presented (two 
different extractions samples, discontinuous extraction, Et2O, Soxhlet). Similar to Bpap and 
Bser, the RE chromatograms still reveal a quite complex elution pattern with co-elution of 
neutral terpenic compounds with acidic triterpenoids (Fig. 3.97). The overview RE-
chromatogram is different from the RE chromatograms of Bpap and Bser, and as far as 
experienced in this work, very specific for Bsac. It reveals also the existence of Inc (22) in 
minor concentrations (see also chapter 3.4 or [11]), Iso-Ser (20) and Ser-OH (21). Further 
on, the ß-caryophyllene (27) elution peak can be detected (elutes shortly after 3). The 
retention area within 55 and 60 min reveals another here called “Triplet-Peak”, of which the 
biggest middle peak refers to 3-ß-OH-tirucallol (29). Normally, the ß-AKBA (6) signal is 
always greater than the ß-KBA (5) signal in Bsac, but compared with Bpap, the amounts of 
both, ß-KBA and ß-AKBA, deliver a lower content for this species. However, there are always 
exceptions from the general expectation, since it was found in another sample of Bsac that 
the amount of ß-AKBA can be tremendously huge or contrary low (the same is valid for ß-
KBA). This phenomenon seems due to the fact that these resins are not standardised natural 
products, and the composition of their secondary metabolites may depend on different 
environmental influences [3]. However, the species can be still identified unambiguously thus 
far, even for samples with great deviations for certain biomarkers (e.g. ß-AKBA and ß-KBA), 
if all important chemotaxonomic parameters are considered (see also chapter 3.8). In Fig. 
3.98 the NB overview chromatograms are presented. Bsac delivers a somehow similar NB 
overview chromatogram as Bser. Differences can be noticed in the elution area of 30 to 35 
min, where α-humulene (26) and ß-caryophyllene (27) are detectable in Bsac (verified by co-
injection). Additionally specific for Bsac is the existence of Iso-Ser (20) and Ser-OH (21) at 
210 nm. Inc (22) is also detectable at 210 nm, but reveals a lower content compared with the 
NB of Bpap. Inc-Ac (23) is not significantly detectable (same discussion as for Bser and 
Bcar). In Fig. 3.99 the RS overview chromatograms are presented. Typical is the ratio of ß-
KBA (5) and ß-AKBA (6) of which 5 usually gives the smallest peak area of all species 
discussed here. The ß-AKBA peak is on average always higher than the ß-KBA peak, though 
great deviations from the expectation value have been observed. Interestingly, the tirucallic 
acids occur in quite minimal amounts (relative to Bpap and Bser), which is thus far always 
specific for Bsac. The BA and the ABA peak signals are normally always higher than the 
tirucallic acid peak signals (compare with the RS chromatograms of Bpap and Bser). The ß-
BA peak (3) elutes as homogenous peak, which is clarified by the 2D chromatography (see 
chapter 3.7.5). It seems that the tirucallic acids are only minimally genetically expressed in 
the species of Bsac (compounds 18 and 19 are merely in traces detectable). On the contrary, 
Bsac reveals quite huge amounts of BAs and ABAs compared with Bser and Bpap; but also 
the largest deviations for some biomarker contents (see also chapter 3.8). Another 
interesting point is that Bsac contains the greatest amounts of LA (11) and Ac-LA (12) 
compared with Bpap and Bser. Conclusively, Bsac seems to have a biogenetically stronger 
pathway directed to boswellic acids, as lupeolic acids are reported to be probably the 
biogenetic precursors of boswellic acids (see also chapter 3.13 and [31]). 
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Fig. 3.97 Two examples of RE chromatograms at three different wavelengths (Extraction: Et2O, 
Soxhlet). Injection concentration: 5 mg/ml. For further discussions see text. 
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Fig. 3.98 Two examples of NB chromatograms at three different wavelengths (Extraction: Et2O, 
Soxhlet). Injection concentration: 5 mg/ml. For further discussions see text. 
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Fig. 3.99 Two examples of RS chromatograms at three different wavelengths (Extraction: Et2O, 
Soxhlet). Injection concentration: 5 mg/ml. For further discussions see text. 
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3.7.4 Boswellia carterii (RE, NB, RS) 
In Fig. 3.100-3.102 the chromatograms of the RE-, NB- and the RS-extracts are presented 
(two different extractions samples, discontinuous extraction, Et2O, Soxhlet). Basically, the 
Bcar chromatograms reveal the same information as already given in chapter 3.7.3 for Bsac. 
Thus, the species must be regarded as identical, at least on a biological and chemo-
taxonomic point of view (Thulin & Warfa [12], Mathe et al. [73], Hamm et al. [13] and Paul et 
al. [11]). 
The RE overview chromatogram in Fig. 3.100 also reveals Inc (22), Iso-Ser (20), Ser-OH 
(21) and the here called “Triplet-peak” eluting within 55 and 60 min of which the biggest 
middle peak refers to 3-ß-OH-tirucallol (29). The NB overview chromatograms in Fig. 3.101 
show the growing peak signals of Inc (22), Iso-Ser (20), Ser-OH (21), 3-ß-OH-tirucallol (29) 
and the α-Hum (26) and ß-Car (27) peaks. Thus, a similar elution pattern as already 
presented for Bsac is obtained. In Fig. 3.102 the RS overview chromatograms of Bcar are 
demonstrated. Again, these chromatograms lead to the same conclusions as made for Bsac. 
The smallest amount for ß-KBA (5, compared with Bpap and Bser), which, compared to ß-
AKBA (6), mostly has been the minor peak in Bcar/Bsac. However, especially for the ß-
AKBA and ß-KBA contents in the species Bsac/Bcar differing compositions have been 
detected. This is explicitly shown in Fig. 3.103 for a sample from Bsac (Bergmann [17], JB03 
Probe 55) where a differing quantitative pattern is presented. There, the ß-AKBA (6) and 11-
OH-ß-ABA (7) peak signals are quite strong and corresponding to this matter of fact the BA 
(1, 3) and ABA (2, 4) peak signals are rather low. Thus, they seem to be biosynthetically 
correlated (higher expression of ß-KBA and ß-AKBA may lead to a weaker expression of 
BAs and ABAs; see also chapter 3.13 and 3.14). In addition, the tirucallic acids are present in 
significantly less contents (compared with Bpap and Bser), and the 2D chromatography (see 
chapter 3.7.5) again verifies the elution of ß-BA (3) in the first dimension as homogenous 
peak signal. For Bsac the same deductions have been made (compounds 18 and 19 are only 
in traces detectable). Thus, if peak 19 (eluting between 1 and 3) is not detectable in the first 
chromatography dimension, the second chromatography dimension may be redundant; as in 
all samples analysed so far compounds 18 and 19 seem to be directly correlated (low 
amount of 19 = low amount of 18 and vice versa). This fact may have a biogenetic reason. 
The BA (1 and 3) and ABA (2 and 4) peak signals are always bigger than the tirucallic acid 
signals and are present in great quantities in Bcar, respectively, Bsac. Additionally, Bcar 
samples show the same high deviation within its biomarker composition as it is discussed for 
Bsac, especially concerning the BAs, ABAs and keto-boswellic acids (5 and 6). The greater 
peak heights of LA (11) and Ac-LA (12), compared with Bpap and Bser, are similar to the 
results obtained for Bsac, and again give evidence that for the species Bcar (Olibanum 
Somalia) and Bsac (Olibanum Yemen, Oman) the biological pathway for the production of 
boswellic acids may be stronger expressed (relative to Bpap and Bser). For further 
discussions clarifying these contents see chapter 3.13, 3.14 and [31]. Perceivably, the quite 
high signal for compound 29 and, on the contrary, the rather low content levels of the TAs 
(13-19) in Bcar and Bsac samples, strongly indicate that they are biosynthetically correlated 
(see also chapters 3.13 and 3.14). 
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Fig. 3.100 Two examples of RE chromatograms at three different wavelengths (Extraction: Et2O, 
Soxhlet). Injection concentration: 5 mg/ml. For further discussions see text. 
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Fig. 3.101 Two examples of NB chromatograms at three different wavelengths (Extraction: Et2O, 
Soxhlet). Injection concentration: 5 mg/ml. For further discussions see text. 
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Fig. 3.102 Two examples of RS chromatograms at three different wavelengths (Extraction: Et2O, 
Soxhlet). Injection concentration: 5 mg/ml. For further discussions see text. 
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It seems that the secondary metabolite synthesis of TAs (in Bsac and Bcar) is restricted and 
leads to an enrichment of compound 29. For the species Bpap and Bser, which both reveal 
quite high TA levels, compound 29 is depleted and thus not significantly detectable. 
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Fig. 3.103 RS chromatogram of a Bsac sample from J. Bergmann [17] (JB 03, Probe 55) with differing 
expectation values concerning the ß-KBA (5), ß-AKBA (6), BA (1 and 3) and ABA (2 and 4) contents. 
As noticeable, if the ß-AKBA (6) and 11-OH-ß-ABA (7) contents are high, the BA and ABA levels are 
rather low. According to the chromatogram, the sample could be mistaken as the species Bpap, 
especially if merely the ß-KBA and ß-AKBA levels are considered. However, the comparably great 
LA/Ac-LA (11 and 12) contents and even the other data (e.g. 2D chromatography with a lack of 
compounds 18 and 19, and NB-fraction with a lack of Inc-Ac, 23; see also TLC analysis in chapter 3.4) 
declare this sample as the species Bsac, respectively, Bcar (see also chapter 3.14). For further 
discussions see text. 
 
 
3.7.5 Qualitative Comparison 2D HPLC Data 
In this chapter representative 2D chromatograms are shown. The technical discussion is 
given in chapter 2.3.4.4. Every chromatogram presented here had been obtained from the 
corresponding collected fractions of the RS samples (c = 5 mg/ml).  
The 2D chromatograms for Bpap and Bser are given in Fig. 3.104. As can be seen there, the 
application of the second chromatography dimension delivers more correct integration results 
for compound 3 (ß-BA) for these two species as they are finally resolved. Compound 19 (3ß-
OAc-8,24-dien-TA) eluted between compound 1 (α-BA) and 3 (ß-BA), and compound 18 (3α-
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OAc-7,24-dien-TA) co-eluted with compound 3 in the first dimension. Thus, the co-elution of 
18 with 3 led to wrong peak areas for compound 3. 
However, the integration error in the first dimension has been more significant for Bpap, 
since it revealed on average the least amount of ß-BA compared with Bser and Bsac/Bcar. 
Bser had approximately the highest amount of ß-BA (especially compared with Bpap). Thus, 
the co-elution of compound 18 in the first chromatographic dimension has been giving a 
lower integration error. Hitherto, these results are specific for Bpap and Bser, as for these 
two species an expectably higher expression of tirucallic acids has been observed, relatively 
compared with Bsac/Bcar (see also chapter 3.8). 
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Fig. 3.104 2D chromatograms of prepared Bpap and Bser samples at 210 nm detection (c = 5 mg/ml). 
 
In Fig. 3.105 the comparison of 2D chromatograms from Bsac and Bcar is shown. The two 
chromatograms do not reveal significant impurity signals. The peak signals of 3ß-OAc-8,24-
dien-TA (19) and 3α-OAc-7,24-dien-TA (18) are only in traces detectable. This result is due 
to the minor expression of tirucallic acids in these two olibanum species (see chapter 3.8 and 
chromatograms of Bsac and Bcar in chapters 3.7.3, respectively, 3.7.4). Furthermore, the 
comparison of 1D and 2D integration results delivered similar results (integration errors lay 
within the defined +/- 5 % limits and even better), which expectably makes the application of 
the second chromatography dimension for Bsac and Bcar samples unnecessary, at least 
among the sample population analysed in this work (see also 3.8).  
Generally, a low occurrence of chromatographically well resolved TAs (e.g. compound 13, 
14, 15, 16 and 17) and, vice versa, relatively greater peak heights for the LAs (11 and 12) 
may already indicate that the RS sample in question is almost free from compounds 18 and 
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19, and thus may strongly indicate that the questionable resin refers to the species Bsac, 
respectively, Bcar. 
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Fig. 3.105 2D chromatograms of prepared Bsac and Bcar samples at 210 nm (c = 5 mg/ml). 
 
The quantitative data is explicitly discussed in chapter 3.6.2 and additionally in chapter 3.8. 
The depictions here shall just clarify the discussions already given. Interestingly, if the 
method was firstly developed for the species Bsac, respectively, Bcar, instead, there would 
not have been any need for the second chromatography dimension. Furthermore, in samples 
of Bser, where the α/ß-BA (1 and 3) contents are rather high, the peaks would have been 
perhaps additionally regarded as homogeneous signals, not giving any clue about any 
potentially co-eluting compound (Note that the integration error would haven been only up to 
10 % in Bser; compared with Bpap, where it had been up to 25-30 %). Thus, merely the 
choice of Bpap for the HPLC method development revealed this fairly interesting matter of 
fact (Note that this species was firstly chosen since it had been in the focus of the research 
interests of the AureliaSan GmbH, Bisingen, and the pharmacologists at the University of 
Tübingen; working group, Prof. Dr. Oliver Werz, now Professor at the University of Jena, 
Germany). 
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3.7.6 Comparison of Specific Wavelengths for Bpap, Bser and Bsac/Bcar 
In this chapter, chromatograms of the first dimension of all three species (Bpap, Bser and 
Bsac/Bcar) are directly compared to give a better qualitative view and understanding on the 
differences and commonalities of these frankincense samples.  
In Fig. 3.106 the comparison of all species chromatograms at 250 nm detection wavelength 
is shown (standard HPLC method, see chapter 2.3.4.2). As already discussed, for Bpap a 
high ß-AKBA (6) signal is significant and usually always greater than the ß-KBA (5) signal. 
Bser exhibits a similar peak height, respectively, area ratio for ß-KBA and ß-AKBA 
(approximately 1:1). Bsac, respectively, Bcar, reveal a similar ratio as reported for Bpap, but 
expectably a much lower content for the ß-AKBA peak signal. Additionally, the ß-KBA signal 
shows for these species the lowest peak signal (compared with the ß-KBA signals from Bpap 
and Bser). However, especially for Bsac/Bcar samples, greater content intervals had been 
already reported in the dissertation of Bergmann [17] and have been also found in this work. 
Thus, the ß-KBA and ß-AKBA ratio should be carefully used for species differentiation (see 
also chapter 3.7.4, Fig. 3.103). 
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Fig. 3.106 Comparison of the RS-extract chromatograms from Bpap, Bser and Bsac/Bcar at 250 nm (c 
= 5 mg/ml). 
 
In Fig. 3.107 the three species are compared at 210 nm detection wavelength. There it can 
be noticed that Bpap and Bser contain higher tirucallic acid contents (TAs, 13-19) than 
Bsac/Bcar. Especially striking is the high 3-O-TA (13) peak signal for Bpap and Bser (marked 
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by the black arrows for a better overview), which is comparable with the TLC results obtained 
(see chapter 3.4). 
For Bsac/Bcar the overall tirucallic acid (13-19) amount is rather low, when compared with 
Bpap and Bser. Furthermore, the amount of LA (11) and Ac-LA (12) has been throughout 
greater in samples of Bsac/Bcar (marked by the grey arrows for a better overview).  
This phenomenon has been significant for all thus far analysed samples: Higher amounts of 
LA and Ac-LA (11 and 12) for Bsac/Bcar compared with Bpap and Bser; and higher amounts 
of 3-O-TA (and tirucallic acids in general, 13-19) for Bpap and Bser compared with 
Bsac/Bcar. Also, on average, Bsac/Bcar reveals the greatest amounts of ABAs (2 and 4). 
The BA (1 and 3) contents are quite high for Bser and Bsac/Bcar, whereas Bpap reveals the 
lowest amounts of BAs on average (see also Tab. 3.27 in chapter 3.8 for a quantitative 
discussion). 
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Fig. 3.107 Comparison of the RS-extract chromatograms from Bpap, Bser and Bsac/Bcar at 210 nm (c 
= 5 mg/ml). 
 
The comparison of NB chromatograms from all three species at 210 nm is presented in Fig. 
3.108. The significant differences are easily perceivable. Bpap shows three major peaks, 
referring to Inc (22) and its acetate (23) and to verticillia-4(20),7,11-triene (24). Bser reveals 
significant Iso-Ser (20) and Ser-OH (21) signals (Inc, 22, is just a minor compound in the 
Bser NB extract). For Bsac/Bcar the Iso-Ser (20) and Ser-OH (21) signals are also 
significantly present. Additionally interesting is the existence of the α-humulene (26) and ß-
caryophyllene (27) peak and the triplet combination with 3ß-OH-tirucallol (29) as middle main 
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peak (Bsac/Bcar) in the elution range from 55 to 60 min. Note that for Bser occur similar 
peak signals in that elution range. Compound 29 was isolated from Bcar and thus it is 
actually not verified for Bser. However, the existence of compound 29 in Bser can not be 
excluded. On the contrary and according to the general commonalities of Boswellia species it 
may also occur in all species producing tirucallic compounds (See also chapter 3.13 on 
biosynthesis hypothesis). The signals from ß-caryophyllene oxide (28) and τ-cadinol (25) are 
minimally detectable at 210 nm for the species Bsac/Bcar (verified by co-injection). These 
are more conveniently detected by GC (chapter 3.5) or TLC methods (chapter 3.4). 
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Fig. 3.108 Comparison of the NB-extract chromatograms from Bpap, Bser and Bsac/Bcar at 210 nm (c 
= 5 mg/ml).  
 
In Fig. 3.109 the RE extract overview chromatograms for all three species are shown. The 
differentiation among the RE chromatograms is also possible. For Bser the here called 
“Triplet peak”, eluting between 25 and 30 min, is specific (co-elution of ß-TA and Iso-Ser, α-
TA and Ser-OH and the 3-O-TA peak; see also chapter 3.7.2 about Bser). Bsac/Bcar reveals 
only the Iso-Ser (20) and Ser-OH (21) peak, whereas Bpap does not show any significant 
signals within this elution area, except the minor peak areas of ß-TA (15), α-TA (14) and 3-O-
TA (13). In some cases the existence of a minor peak for Ac-LA (12) may already ascertain 
an unknown resin sample as Bsac/Bcar, since for Bpap and Bser no significant peak signal is 
detectable within this elution range. Additionally, high peak signals for α-ABA (2) and ß-ABA 
(4) may identify an unknown resin sample already as Bsac/Bcar, as they expectably occur in 
greater amounts there. Furthermore, for Bsac/Bcar the existence of the broad triplet peak 
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eluting within 55 and 60 min seems to be also remarkable. Thus, even if only the RE 
chromatograms of all three species are considered, it may be still possible to figure out the 
identity, if an unknown resin is analysed. 
However, the data generated hitherto is based on a few samples which attempt to represent 
a whole population of resin samples. The data may be correct and further analysis of more 
and more samples will quite likely deliver the same information as given here. Nevertheless, 
as experienced also in this work, there are, concerning a few biomarkers (e.g. ß-KBA and ß-
AKBA in Bsac/Bcar), always differences from the rule of thumb. 
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Fig. 3.109 Comparison of the RE-extract chromatograms from Bpap, Bser and Bsac/Bcar at 210 nm (c 
= 5 mg/ml).  
 
 
3.8 HPLC Data (Quantitative Consideration) 
 
To summarise the qualitative discussions given in the chapter before, the quantitative data is 
presented in this chapter. For details concerning the technical aspects view chapter 2.3.4. 
Tab. 3.27 presents the arithmetically averaged data of all analysed samples (total of 15 
compounds) during this work concerning the RS acid fraction (Note that the arithmetic 
average was preferred, although the number of samples would suggest a median data set 
distribution, see also [159]. However, in the author’s opinion the arithmetic average gives a 
better overview and a better feeling for expectation values. Significant standard deviations 
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are explicitly discussed). The single values of each sample are given in Tab. 3.37 in chapter 
3.14, where the matrix calculation by principal component analysis is presented. 
For some values quite great standard deviations are obtained (e.g. compound 7 and 10, due 
to the fact of a random decomposition of 7 during the extraction, see also [55,59]; 3-O-TA, 
13, for Bpap; ß-AKBA, 6, α-BA, 1, ß-BA, 3, α-ABA, 2 and ß-ABA, 4, for Bsac/Bcar). The great 
standard deviations for ß-AKBA, α-BA, ß-BA, α-ABA and ß-ABA in Bsac/Bcar are due to the 
many different samples analysed (even older samples from J. Bergmann [17] were 
evaluated) and is quite interesting, since there may be always an exception from the general 
expectation value. However, the identity of Bsac/Bcar is normally granted, since the values 
for LA (11) and Ac-LA (12) always delivered significant higher results compared with Bpap 
and Bser. Another significant fact is that Bsac/Bcar did quantitatively reveal fairly low 
contents for the tirucallic acids (13-19), whereas the amounts of boswellic and acetylated 
boswellic acids have been comparably high (1-4). Additionally, for every Bsac/Bcar sample 
the typical ß-Car-Ox (28) spot (see also chapter 3.4) was detectable. Thus, even if there was 
a differing peak pattern for Bsac/Bcar and a significantly deviating ß-KBA/ß-AKBA content 
from the given mean values in Tab. 3.27, the identity of this species has been normally 
always guaranteed (e.g. extreme values for ß-AKBA have been 0.1 % and 20 % g/g in the 
RS fraction). The strong standard deviation for 3-O-TA (13) in Bpap is a result of wide limiting 
values (e.g. 5 % and 16 %, which seems to be a normal batch to batch difference). 
 
Tab. 3.27 The arithmetically averaged measurement results for the RS acid fraction (S.D. = standard 
deviation, random sample; n = numbers of different resin batches analysed; #NV = not detectable). 
Since Bcar and Bsac can be considered the same species, their data was combined to Bsac/Bcar. 
    n = 6   n = 4  n = 10  n = 14  n = 10   
Compound Nr. Bcar S.D. Bsac S.D. Bpap S.D. Bser S.D. Bsac/Bcar S.D.
   [g/g in %]    [g/g in %]  [g/g in %]  [g/g in %]  
ß-KBA 5 0.48 0.25 0.64 0.43 1.22 0.30 3.16 0.52 0.56 0.34
ß-AKBA 6 5.38 5.09 8.03 8.88 14.33 1.98 3.28 0.43 6.70 6.98
11-OH-ß-ABA 7 3.60 1.70 6.22 6.44 4.41 3.04 2.37 0.70 4.91 4.07
ß-OH-TA 15 1.20 0.28 1.20 0.43 2.98 0.77 4.44a 0.63 1.20a 0.35
α-OH-TA 14 1.33 0.91 1.45 0.75 2.47 0.89 5.77a 1.18 1.39a 0.83
3-O-TA 13 1.73 0.51 1.64 1.05 11.66 5.31 11.64 2.23 1.68 0.78
α-Ac-TA 16 0.75 0.33 0.71 0.52 3.21 1.25 3.13 1.00 0.73 0.43
α-BA 1 7.78 2.60 6.45 3.00 3.72 0.76 8.32 0.91 7.11 2.80
α-BA (2D) 1 7.64 2.52 6.40 3.01 3.73 0.77 8.12 1.10 7.02 2.76
ß-BA 3 15.94 3.83 12.19 7.27 9.21 1.66 19.45 1.48 14.07 5.55
ß-BA(2D) 3 15.92 4.00 12.15 7.25 7.01 1.37 17.43 1.55 14.04 5.62
11-Ome-ß-ABA 8 #NV #NV #NV #NV #NV #NV #NV #NV #NV #NV
LA 11 2.78 0.75 2.51 1.33 0.68 0.26 1.41 0.18 2.64 1.04
Ac-LA 12 4.89 1.13 5.04 2.04 1.81 0.27 1.07 0.31 4.97 1.58
9,11-Dehydro-ß-ABA 10 0.02 0.02 0.35 0.52 1.57 1.96 0.21 0.77 0.18 0.27
α-ABA 2 10.25 2.49 10.60 3.32 6.73 0.88 4.21 0.25 10.43 2.91
ß-ABA 4 20.08 5.59 17.18 7.84 11.13 2.11 13.83 0.89 18.63 6.72
Sumb:  76.21  74.20  72.94  77.33  75.21  
Unknown Rest: 23.79  25.80  27.06  22.67  24.79  
 
a Values of 14 and 15 in Bser and Bsac/Bcar are actually too high (Co-elution with 21 and 20, see also 
3.7.2 – 3.7.4). 
b The 2D contents of ß-BA have been used for summation. 
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The standard deviation of 11-OH-ß-ABA (7) can be explained by the decomposition of this 
compound into its 9,11-dehydro-derivative, vice versa for 9,11-dehydro-ß-ABA (10) [55,59]. 
The averaged sum shows that approximately 75 % of the acid fraction can be determined by 
this method for all species investigated. However, it should be noted that even samples with 
a much lower or higher overall content were analysed (e.g. ca. 50-80 % for Bpap; ca. 60-95 
% for Bser and ca. 40-90 % for Bsac/Bcar). Furthermore, one very critical batch of Bsac 
revealed only 22 %. This batch was not used for the arithmetic mean as it could be 
determined as an outlier referring to the analysed sample population, though it may be 
actually part of the overall population. Furthermore, it already gave a rather low amount of 
RE extract by the extraction methods described in chapter 2.2.4 for example. A great 
negative deviation from the expectation extraction values presented in chapter 3.3.1 may 
already declare the poor quality of a resin sample. 
Hence, it is still a quite difficult undertaking to give an absolutely correct overall marker 
compound distribution for these natural resins. Interestingly, the almost similar overall 
amounts of resinous acids (ca. 70-75 %) in any species may declare that every species has 
approximately the same carbon material available, which is then transformed via the different 
biosynthetic pathways. However, this is merely a presumption and thus far not proved by real 
scientific evidence. Also the environmental influences may certainly have an enormous 
impact on the secondary metabolism of these plants [3]. An easily understandable example, 
which explains the natural product dependency on environmental influences clearly, is given 
in chapter 3 in the book of Cseke et al. [19], where the production of the secondary 
metabolite camptothecin in Camptotheca accuminata, depending on light and shading 
cycles, is reported. The experiments described there may be generally valid for any kind of 
plant species on this planet. 
The values in Tab. 3.27 are shown as graphic in Fig. 3.110. This graphic may help clarifying 
the values given in Tab. 3.27. For every species (Bpap, Bser and Bsac/Bcar) the content in 
percent (g/g) of the RS acid fraction is plotted against the corresponding marker compound. 
The given confidence interval for each compound was set to +/- 20 %, referring to the 
corresponding mean value presented in Tab. 3.27. Thus, a quite good certainty of the mean 
value is given. However, the standard deviations are for some samples still greater than 20 
%, but would be confusing for the graphical depiction. 
On average, the ß-KBA content is rather low for the species Bpap and Bsac/Bcar compared 
with the ß-AKBA content. However, Bsac/Bcar samples show a very strong deviation 
concerning the ß-KBA/ß-AKBA contents (see S.D. in Tab. 3.27). For Bser the ß-KBA/ß-
AKBA ratio is balanced (expectation value = ca. 1:1 ratio). Expectably, Bpap samples 
produce the most ß-AKBA, followed by Bsac/Bcar (strong S.D.). Compounds 11-OH-ß-ABA 
and 9,11-dehydro-ß-ABA values vary heavily for all species. The reason therefore is the 
known decomposition reaction of these compounds [55,59]. For Bser and Bpap significantly 
higher values for 3-O-TA are obtained (compared with Bsac/Bcar). Furthermore, the values 
for ß-TA and α-TA in Bpap and Bser are normally higher than in Bsac/Bcar (Note that for 
Bser the ß-TA and α-TA peaks still co-elute with Iso-Ser and Ser-OH, since these two semi-
polar diterpenes are not absolutely separable by the extraction method developed here, and 
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thus the peak areas in the RS fraction of Bser are estimated too high; see also chapter 3.7.2 
about Bser). 
Bser contains on average the greatest amounts of α-BA and ß-BA. Bsac/Bcar reveal α-BA 
and ß-BA in differing quantities, but expectably always higher than in Bpap and almost likely 
high the values of Bser (Note that depending on the single resin sample even higher values 
for Bsac/Bcar, than found in Bser, had been obtained). The LA and Ac-LA amounts have 
been in every Bsac/Bcar sample greater than in Bpap and Bser, which seems to be very 
significant for Olibanum Somalia and Oman, respectively, Yemen. Furthermore, the 
maximum α-ABA and ß-ABA contents can be found in Bsac/Bcar. For Bpap and Bser the 
ABA values are almost similar and occur in lower contents compared with Bsac/Bcar. 
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Fig. 3.110 Graphical depiction of the arithmetic mean values presented in Tab. 3.27. The confidence 
interval is set to 20 % of the mean value in Tab. 3.27. The scheme here shall clarify Tab. 3.27 and 
may be useful for species identification, since for each biomarker compound analysed here an 
expectation value is given. Throughout significant levels have been obtained for the tirucallic acids 
(TAs) and lupeolic acids (LAs). For further discussions see text. 
 
Interestingly, the 2D measurement results verify the general correctness of the peak 
homogeneities in the first, respectively, the second chromatography dimension. As reported 
in the corresponding chapters (3.6.2 and 3.7.5), the second dimension is not necessary for 
samples from Bsac/Bcar (similar values for compound 1 and 3 in both dimensions within the 
estimated +/- 5 % confidence interval). For samples of Bser, the averaged error in the first 
dimension is about 10 %, meaning that on average the content for compound 3 is ca. 10 % 
lower than actually determined (1D chromatography), because of co-elution with compound 
18. Samples of Bpap reveal a greater error for the determination of compound 3 in the first 
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dimension. The reason therefore is the quite low content of 3 in samples of Bpap. Thus, a 
greater integration error is given (up to 30 %). 
As already mentioned in chapter 3.6.2, if a great sample population will be analysed, the 
error may be within a certain confidence interval predictable and hence may make the 
application of the second chromatography dimension redundant. Furthermore, for Bsac/Bcar 
samples the second dimension is thus far not necessary, and for samples of Bser it may be 
acceptable to calculate an averaged uncertainty of +/- 10 % within the real content of ß-BA 
(3). Furthermore, the techniques nowadays provided (UHPLC and MS-detection) can 
overcome such difficulties easily (e.g. easier achievable resolution of peaks with UHPLC 
columns and systems and/or application of the additional MS detection dimension for co-
eluting compounds with differing molecular masses and/or differing fragmentation patterns, 
as far as no ion-suppression takes place; therefore, see also chapter 8 in the book of Dolan 
and Snyder [153] for the discussion of MS as detection tool in liquid chromatography, and, 
for example, the paper of Wu et al. on the advantages of ultra-high performance liquid 
chromatography, UHPLC, [187]). 
 
In Tab. 3.28 the quantitative HPLC results for the neutral fractions of Bpap, Bser and 
Bsac/Bcar are given. Only significant signals were quantified. In cases where the suspected 
peak signal was too small and/or additionally not good enough resolved the compound had 
been set not detectable (= 0).  
As noticeable, Bpap distinguishes itself from the other species by the highest amounts of 
incensole (22) and incensole acetate (23). Almost 30-40 % of the neutral fraction consist thus 
of incensole and its acetate. Interestingly, Inc-Ac (23) had been only detected in samples of 
Bpap. On the other hand, Bser and Bsac, respectively, Bcar, contain serratol (21) and its 
isomeric derivative iso-serratol (20). These two, 20 and 21, have never been significantly 
detectable in samples of Bpap. Thus, there seem to be remarkable differences in the 
biogenesis. Representative NB-chromatograms can be found in chapter 3.7. The 
corresponding single values of each analysed sample are presented in Tab. 3.37 in chapter 
3.14 where the matrix calculation by principal component analysis is presented. 
 
Tab. 3.28 The arithmetically averaged measurement results for the NB neutral fractions (S.D. = 
standard deviation, random sample; n = numbers of different resin batches analysed; 0 = not 
detectable). Since Bcar and Bsac can be considered the same species, their data was combined to 
Bsac/Bcar. 
    n = 10   n = 14   n = 10   
Compound Nr. Bpap S.D. Bser S.D. Bsac/Bcar S.D. 
   [g/g in %]  [g/g in %]  [g/g in %]  
Inc 22 20.99 3.45 1.41 1.27 3.39 3.46 
Inc-Ac 23 15.17 2.62 0 0 0 0 
Ser-OH 20 0 0 8.60 5.46 7.59 7.39 
Iso-Ser 21 0 0 1.73 0.99 1.16 0.99 
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3.9 Comparison with Literature Results (HPLC) 
 
In this chapter the quantitative HPLC data obtained here is compared with quantitative 
results from the literature. The work of Ganzera et al. [188] and of Büchele et al. [57] were 
chosen therefore. In these two papers the complex extracts of Olibanum gums were 
analysed by HPLC. In another work of Ganzera et al. [189] even quantitation by capillary 
electro chromatography (CEC) was achieved. However, since this paper just delivers similar 
quantitative conclusions as already given in [188] it was not further regarded. The 
comparison of these results with the data obtained here is demonstrated in Tab. 3.29. As can 
be noticed, on average, the overall amounts of all three methods are comparable. Especially 
the overall amount for the Indian frankincense (Bser) fits quite well. The difference for African 
frankincense is greater. Though Bsac can be classified as Bcar, this species, as originated 
from the Arabian Peninsula was not explicitly tabulated (generally the same composition as 
Bcar, see also Tab. 3.27). If the single compounds are regarded, stronger deviations are 
deducable. This may be arbitrary, but is also due to the expectable naturally occurring 
differences (e.g. highly fluctuating deviations for ß-AKBA, 6, and ß-KBA, 5, in Bcar). 
Additionally, the values in the columns Paul-Bpap, -Bcar and -Bser were arithmetically 
averaged. Nevertheless, compounds 2 (α-ABA), 4 (ß-ABA), 6 (ß-AKBA), 11 (LA) and 12 (Ac-
LA) fit quite well for Bpap with the results of Büchele et al. for African frankincense. The high 
deviation for compound 10 (9,11-dehydro-ß-ABA) can be explained by the randomly 
occurring decomposition probability of compound 7 (11-OH-ß-ABA) (see also [55,59]). The 
overall difference of 3-4 % for Bcar, respectively, Bpap lies within a certain accuracy 
compared with the results of Büchele. Particularly, when regarding the contents of compound 
5, 6, 2, 4, 11 and 12, the African frankincense species may be indeed the species Bpap. 
However, this is only based on the quantitative similarities and because of the fact that Bcar 
samples showed, in all samples analysed in this work, a significant greater content for the 
lupeolic acids (11 and 12), relatively compared with Bpap (see Tab. 3.27).  
The values for Bser give an even better overall comparability. Quite good in accordance to 
the results of Büchele et al. are the determined amounts for the BAs (compound 1 and 3). 
There, a recovery of 110 % (5.05 / 4.60 x 100 %) for compound 3 (ß-BA) and a recovery of 
even 98 % (2.41 / 2.45 x 100 %) for compound 1 (α-BA) are deducible. The recovery of the 
LAs (compound 11 and 12) is also lying within the value of expectation, as these compounds 
typically occur in lower amounts in Bser, respectively, Bpap (see also Tab. 3.27).  
The determination results by Ganzera et al. for Bser would lead to the assumption that the 
sample analysed was actually the species Bpap instead, since the corresponding quantities 
fit best with this species (quite remarkable is the high ß-AKBA-value, 6, which was never 
found as similar high in the species Bser during this work). However, it should be still beard 
in mind the possibility of stronger quantitative deviations otherwise than stated here. Thus, 
for every general expectation there might be still an exception and uncertainty.  
Hitherto, the requirements how these species generate special biomarkers under certain 
environmental conditions have not been evaluated or at least have not been published by 
other research groups. There should be further scientific evaluation conducted, especially 
concerning those questions (e.g. specific genes encoding specific enzymes and experiments 
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with whole plants under certain different conditions like light- and shading cycles, soil quality, 
humidity etc. as it is described in the book of Cseke et al. [19]). 
 
Tab. 3.29 Comparison of the quantitative HPLC results generated in this work with the results of 
Büchele et al. [57] and of Ganzera et al. [188]. All values are given in percent (g/g [%]). The values for 
Paul-Bpap, -Bser and -Bcar were adjusted to the overall resin (RS results in Tab. 3.27 divided by ca. 
factor 3) to be comparable. For compound 3 the 2D chromatography result is presented. Bpap and 
Bcar, as African frankincense (African-Fr.), were compared with the results of African frankincense 
from Büchele; and Bser (Indian-Fr.) was compared with the results of Büchele and Ganzera for Indian 
frankincense. Overall: The sum of the same compounds quantified in both columns to give a 
comparable overall amount. Overall + Rest: The sum of all compounds quantified in the work reported 
here (e.g. + TAs, 13-16, and 7 compared with Büchele; +TAs and +LAs, 11-16, and 7 and 10 
compared with Ganzera). #NV: not detectable. For further details see text. 
Compound (Nr.) Paul-Bpap Büchele African-Fr. Paul-Bcar
Büchele 
African-Fr. Paul-Bser
Büchele- 
Indian-Fr. 
Ganzera 
HPLC-Ind-Fr. 
5 0.36 1.01 0.12 1.01 0.92 2.02 1.38 
6 4.51 4.70 1.29 4.70 0.95 1.43 5.40 
7 1.61  0.86  0.69   
15 0.86  0.29  1.29   
14 0.69  0.32  1.67   
13 3.12  0.42  3.38   
16 0.95  0.18  0.91   
1 1.13 2.69 1.87 2.69 2.41 2.45 1.34 
3(2D) 2.07 3.72 3.82 3.72 5.05 4.60 1.42 
11 0.19 0.23 0.67 0.23 0.41 0.32  
12 0.52 0.78 1.17 0.78 0.31 0.35  
10 0.28 0.028 0.00 0.028 0.06 0.018  
2 2.09 2.11 2.46 2.11 1.22 0.47 2.52 
4 3.57 3.98 4.82 3.98 4.01 2.54 3.34 
Overall 14.72 19.25 16.22 19.25 15.34 14.29 15.40 
        
Overall 
+Rest 21,95
a  18.29a  23.28a,b   
a Overall + Rest (for Büchele) = + results for compounds 7 and 13-16 
b Overall + Rest (for Ganzera) = + results for compounds 7 and 10-16 
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3.10 Summary (Analytics) 
 
Here, the generated qualitative and quantitative data is summarised in Tab. 3.30. This table 
may serve as an overview checklist for the identification of an Olibanum resin in question. 
The data presented is based on the results from chapters 3.4, 3.7 and 3.8. 
 
Tab. 3.30 Systematic overview table presenting the main differences and communalities of the three 
species Bpap, Bser, Bsac/Bcar. 
a Comparable with a typical orange scent (high contents of octyl acetate, which has an orange 
fragrance); quite specific for Bpap. 
b Probably due to the high content of apolar triterpenic compounds (see also chapter 3.7.6, Fig. 109) 
c Expectation value; deviations from this rule of thumb have been observed (varying ß-KBA/ß-AKBA 
contents, see also for example chapters 3.7.4, 3.8 or 3.14). 
  Bpap Bser Bcar Bsac 
Odour Sweetisha Frankincense-like Frankincense-like Frankincense-like 
Solubility of the Et2O extract 
in MeOH Clear solution Milky blur
b Milky blurb Milky blurb 
AKBA-UV (TLC at 254 nm; c 
= 5 mg/ml) Significant Faint Faint
c Faintc 
KBA-UV (TLC at 254 nm; c = 
5 mg/mL) Faint Faint Faint
c Faintc 
In-Spot (TLC after dyeing) Strong brown Faint brown Faint brown Faint brown 
In-Ac-Spot (TLC after dyeing) Brown Not detectable Not detectable Not detectable 
ß-Car-Oxid-Spot (TLC after 
dyeing) Not detectable Not detectable Faint pink Faint pink 
Serratol-Spot (TLC after 
dyeing) Not detectable Strong green Strong green Strong green 
3-O-TA-Spot (TLC after 
dyeing) Strong blue Strong blue Faint blue Fain blue 
KBA/AKBA-Ratio (HPLC, 250 
nm) ca. 1:10 ca. 1:1 ca. 1:5
c ca. 1:5c 
AKBA-Content 
(HPLC, referred to Acid 
Fraction) 
> 10 %  
(n = 10) 
ca. 2-4% 
(n = 14) 
ca. 2-13 %  
(n = 6) 
ca. 0.1-20 %  
(n = 4) 
Sum: α-BA/ß-BA-Content 
(HPLC, referred to Acid 
Fraction) 
ca. 11 %  
(n = 10) 
ca. 20-30 %  
(n = 14) 
ca. 15-30 %  
(n = 6) 
ca. 10-30 %  
(n = 4) 
Sum: α-ABA/ß-ABA-Content 
(HPLC, referred to Acid 
Fraction) 
ca. 18 % 
(n = 10) 
ca. 15 - 18 % 
(n = 14) 
ca. 20 - 35 % 
(n = 6) 
ca. 20 - 35 % 
(n = 4) 
3-O-TA-Content (HPLC, 
referred to Acid Fraction) 
ca. 5 - 15 % 
(n = 10) 
ca. 8 - 17 % 
(n = 14) 
< 3 % 
(n = 6) 
< 3 % 
(n = 4) 
Sum: LA/Ac-LA-Content 
(HPLC, referred to Acid 
Fraction) 
ca. 2 - 3 % 
(n = 10) 
ca. 2 – 3 % 
(n = 14) 
> 5 % 
(n = 6) 
> 5 % 
(n = 4) 
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3.11 Experiments with Incensole and its Acetate 
 
3.11.1 Semisynthesis of Inc-Ac (NB-fraction of Bpap) 
In this chapter the semi synthetic approach for the production of Inc-Ac (23) in high quantities 
is reported. Besides, the here presented preparation method has been already published in 
Natural Product Communications [154]. As the chromatographic analysis (TLC and HPLC) 
only revealed for the NB fraction of Bpap the existence of Inc (22) and its acetate (23) in 
good quantities (see chapter 3.8), this resin was used. The experimental procedure is 
described in chapter 2.7.2. 
Moussaieff et al. showed that incensole (22) and its acetate (23), as novel anti-inflammatory 
diterpenes, may contribute to the overall pharmacological action of frankincense gum 
preparations by inhibition of the Nuclear Factor-κB activation [87]. It is further reported by 
Moussaieff et al. that incensole acetate elicits neuronal activity in mice by activating the 
transient receptor potential cation channel 3 (TRPV3) in the brain [145]. A recent publication 
by Moussaieff et al. additionally revealed protective effects of incensole acetate on cerebral 
ischemic injury in mice models [147]. 
Hence, great amounts of these two diterpenic compounds may be desirable for further 
investigations proving their pharmaceutical potential. 
 
 
 
Sch. 3.1 “Focussing” approach to large-scale synthesis of incensole acetate; a: Ac2O/pyridine/DMAP, 
DCM, gentle reflux, 4 h; b: flash chromatography with silica gel, pentane/diethyl ether (6:1), purity of 
incensole acetate (> 80 %); preparative RP-HPLC, isocratic: methanol (100 %), purity of incensole 
acetate (> 99 %); yield of incensole acetate = 4 g of 25 g (16 %, referring to the not acetylated neutral 
compounds). Conversion reactions of 22 and 23. c: 1 N KOH in iPrOH, gentle reflux, 3 h, yield: > 90 
%, purity > 98 %, optional: Column or instrumental chromatography for guaranteed purity; d: 
Ac2O/pyridine/DMAP, DCM, gently reflux, 4 h, yield: > 90 %, purity > 99 %, optional: Column or 
instrumental chromatography for guaranteed purity. 
 
Therefore, a simple method for the isolation of incensole and its acetate from Boswellia 
papyrifera, which contains these two diterpenes in relatively high amounts, was developed. 
Since Jauch and Bergmann developed a method for the large scale preparation of 3-O-
acetyl-11-oxo-ß-boswellic acid (ß-AKBA, 6) [190] from various frankincense resins, it was 
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presumed that using a similar strategy, it should also be possible to obtain 23 in large 
amounts by acetylating the neutral fraction. The synthesis route is shown in Scheme 3.1. The 
acetylation process can be easily followed by TLC and after 4 hours 22 is completely 
converted into 23. Fig. 3.111 shows the comparison of chromatograms before and after 
acetylation. 
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Fig. 3.111 The comparison of the chromatograms of the neutral fraction before acetylation 
(chromatogram above) and after the acetylation experiment (chromatogram below). The incensole 
signal (22) disappeared. Control chromatogram conditions: 1 x Grom (guard column) and 1 x YMC 
(250x4.6 mm I.D, S-5µm, 8nm); T = 30 °C; u = 0.85 ml/min; detection: 210 nm; Gradient profile (A: 
MeOH; B: H2O + 0.1 % TFA): Isocratic from 0-1 min 85 % A, gradient from minute 1-13 to 100 % A, 
minute 13 to 45 isocratic at 100 % A, isocratic from 45-60 min at 85 % A for equilibration. For further 
details see text. 
 
By application of conventional flash column chromatography [151] the acetylated mixture 
was fractionated and 14 fractions were obtained. Note that the column was overloaded with 
material: 29 g of the acetylated mixture were separated in a 10 cm diameter column. A better 
separation may be achieved if less material (< 20 g) is separated in this dimension. However, 
a good compromise in attainable quantity and purity of incensole acetate was attained. 
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Fraction 2, 3 and 4 contained the whole amount of 23 in differing purities. Fraction 3 had the 
greatest quantity and purity (6.9 g, 85 % by HPLC control; see also Fig. 3.112) Through 
application of preparative HPLC this fraction was purified (>99 %) and a yield of 62 % was 
obtained (1.28 g from 2.07 g of fraction 3; Note: To achieve a purity >99% some of the 
incensole acetate gets lost, since the peak signal was fractionated generously, see also Fig. 
3.113). Approximately calculated, a total yield of 3.84 g from 6.9 g (62 %, purity > 99 %) 
could be obtained, if fraction 3 would have been purified completely. Thus, leading to a total 
yield of 5 % referred to the overall weighed amount of resin. Calculations for the purification 
of incensole acetate are shown in Tab. 3.31. The detailed preparative chromatographic 
procedure is explained in the experimental section (chapter 2.7.2). 
 
 
 
                      23 
Fig. 3.112 Incensole acetate in Fraction 3 after separation (flash column chromatography) of the 
acetylated neutral fraction of Boswellia papyrifera. Same chromatographic conditions as presented in 
Fig. 3.111. The fraction was further purified by preparative HPLC. For details see text. 
 
Incensole acetate and incensole can be easily converted into their counterparts as it is 
presented in Scheme 3.1. The detailed synthesis procedures are described in the 
experimental section (chapter 2.7.2). 
 
 
210 nm                                                                                                        Fraction 2 
 
                                                                                           
 
 
 
                                                                                  Fraction 1                                           Fraction 3 
Fig. 3.113 The purification of Fraction 3 via preparative HPLC. The peak was portioned in three further 
fractions. Yield of incensole acetate > 99 % (Fraction 2). For details see text. 
   181
Results and Discussion 
_________________________________________________________________________________ 
 
Tab. 3.31 The calculated yield of the semi-synthetic production of compound 23 (Inc-Ac). The data 
presented here is based on the experimental results obtained and projected to a greater quantity for 
the prepared Bpap resin sample. For further details see text. 
a Contents for incensole and incensole acetate in the NB fraction of Bpap were determined by the 
HPLC method described in chapter 2.3.4.2. 
 
 
 
Mass [g] 
 
Percentage [%] 
Crude resin 84 100 
 Yield of neutral fraction 25 30 
Incensolea 5 6 
Incensole acetatea 4 5 
Acetylated neutral fraction 29 30 
Incensole - - 
Incensole acetate 10 12 
Column chromatography   
isolation (purity > 80 %)   
Incensole acetate 7 8 
Preparative HPLC   
isolation (purity > 99 %)   
Incensole acetate 4 5 
 
In summary, the method described here allows the semi-preparative synthesis of incensole 
acetate from the neutral fraction of the frankincense species Boswellia papyrifera in large 
quantities. This is simply achieved by acetylation of incensole in the crude neutral fraction 
and thus gives a convenient method for the isolation of these two chemical entities. By 
conventional deacetylation and acetylation reactions, both diterpenes can be converted into 
one another. 
 
 
3.11.2 Decomposition Results for Incensole Acetate 
In this chapter the decomposition results are presented. Interestingly, as it was figured out 
that the presumably expected inhibitory activity of Inc-Ac (23), respectively, Inc (22) had 
been due to a decomposition of the molecules itself, tests were performed to check if these 
decomposition effects are repeatable. The chromatograms of an intact Inc-Ac batch 
compared with the first batch, which coincidently was decomposed, are depicted in Fig. 
3.114. As can be noticed, the decomposed sample shows numerous peak signals, which 
may be in combination with Inc-Ac responsible for the inhibitory action. Several different 
batches of intact Inc-Ac, respectively, Inc were tested and no inhibitory effect could be 
observed anymore. Thus, the inhibitory effect has been due to an uncountable combination 
of decomposed “daughter molecules” from Inc-Ac, respectively, Inc. This statement was 
proved as the repetition of the decomposition experiments delivered similar results and 
similar inhibitory effects, at least in the cell free mPGES-1-assay (see chapter 3.12.1). 
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   210 nm (purified Inc-Ac sample; purity > 99 % Peak-Area)                     23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    210 nm (decomposed Inc-Ac sample; purity ≈ 20 % Peak-Area)            23 
Fig. 3.114 Comparison of an intact Inc-Ac (23) compound (upper chromatogram) with an “inhibitory 
active”, decomposed sample of Inc-Ac (lower chromatogram). Standard-Gradient (2 x YMC columns, 
see chapter 2.3.4.2). The determined amount for Inc-Ac in the decomposed sample refers to ca. 6.4 % 
(g/g); thus, the 2.5 mg of the sample batch consisted of 0.16 mg Inc-Ac. The peaks eluting in front are 
most likely to be oxidation products from In-Ac. For further details see text. 
 
In Fig. 3.114 the comparison of two chromatograms at 210 nm detection wavelength is 
presented. The upper chromatogram refers to a purified (prep. HPLC) sample of Inc-Ac. The 
lower chromatogram refers to a decomposed sample of Inc-Ac. This sample was firstly 
isolated and determined to be pure as the sample shown above. Somehow, probably during 
the transport to the lab of the University of Tübingen, the pure sample got decomposed and 
finally revealed a huge “forest” of undeterminable signals (ca. 50 peak signals were 
integrated). Interestingly, these signals all elute in front of the peak of compound 23. Most 
likely, these are oxidation products from Inc-Ac and thus are smaller molecules and/or more 
polar substances (see also TLC results in chapter 3.11.4). Furthermore, since the intact Inc 
and Inc-Ac samples did not show any inhibitory actions in the mPGES1 assay, it was finally 
realised that only decomposed Inc-Ac, respectively, Inc samples are responsible for the 
inhibition (see also chapter 3.12.1). 
The analytical HPLC chromatograms for the artificial decomposition tests at 60 °C are shown 
in the upcoming figures. The experimental basics are described in chapter 2.6.1. Test 1 
(storage for 7 days at room temperature) did not reveal any significant decomposition. 
Hence, the sample is stable within a certain time at room temperature and the air caused 
decomposition is kinetically inhibited. The chromatogram after Test 2 (storage under air 
exposure for 16 h at 60 °C) is demonstrated in Fig. 3.115. It is noticeable that first 
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decomposition reactions took place at 60 °C. Hence, the decomposition of Inc-Ac is at room 
temperature, as assumed, kinetically inhibited. 
 
 
210 nm (decomposed Inc-Ac sample; Test 2)                                  23 
Fig. 3.115 Test 2: The chromatogram of the Inc-Ac sample after 16 h at 60 °C in the compartment 
drier. The compound, which had previously a purity of > 99 %, now just revealed a purity of 55.7 %. 
Thus, the effective concentration in the sample was finally 0.92 mg from 2.3 mg (40 % g/g). For further 
details see text. 
 
In Fig. 3.116 the chromatogram obtained after further 15 h (Test 3) is presented. As 
expected, the decomposition process continuous. After a total amount of 31 h at 60 °C (15h 
+ 16 h from Test 2) only 6.7 % (g/g) of compound 23 are left in the sample. At last, after 
further 16 h at 60 °C (Test 4) none of the Inc-Ac can be detected anymore. This is depicted 
in the chromatogram in Fig. 3.117. 
 
 
210 nm (decomposed Inc-Ac sample; Test 3)                                  
 
 
      23 
Fig. 3.116 Test 3: The chromatogram of the Inc-Ac sample after in total ca. 31 h (15 h + 16 h from 
Test 2) at 60 °C in the compartment drier. The compound, which had previously a purity of 55.7 % 
(after Test 2), now just revealed a purity of 15.0 %. Thus, the effective concentration in the sample 
was finally 0.08 mg from 1.2 mg (6.7 % g/g). For further details see text. 
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210 nm    (decomposed Inc-Ac sample; Test 4)                                   
 
 
      
Fig. 3.117 Test 4: The chromatogram of the Inc-Ac sample after in total ca. 47 h (15 h + 16 h + 16 h) 
at 60 °C in the compartment drier. The compound, which had previously a purity of 6.7 % (after Test 3) 
did not reveal any In-Ac peak anymore. Hence, it was completely decomposed after Test 4 (merely a 
huge garbage peak with a few signals is visible). Note that the strong baseline noise and the randomly 
occurring spikes were due to the old age of the D2 lamp. The lamp was during this analysis only used 
for qualitative control samples, not for important quantitative evaluations anymore. Even the strong 
spike in the Inc-Ac elution area is not assignable to a peak signal. This was further verified by TLC 
analysis (see chapter 3.11.4). For further details see text. 
 
 
3.11.3 Reaction Kinetic Model for the Decomposition of Incensole Acetate 
In Fig 3.118 a diagram is given, which shows the decomposition of compound 23 (Inc-Ac) 
dependent on the time at T = 60 °C (Time dependent concentration levels were determined 
with the samples from the decomposition tests, see chapter 3.11.2). The decomposition 
follows a negative slope e-function and thus may be due to a first order reaction kinetic (see 
chapter 2.6.2 or literature, e.g. [173,174]). As rather probable, the only reaction partner may 
be oxygen (and/or perhaps Inc-Ac reactions with its own entity or derived decomposed 
entities catalysed by oxygen) due to the fact that oxygen is under normal conditions in 
excess available (ca. 20 % in the air). Hence, this assumption is reasonable. 
Since the experiment primarily served to obtain the decomposition of Inc-Ac for a further 
pharmacological testing, no “real” kinetic study was implemented. Furthermore, the data 
presented here is only based on 4 experiments (Start concentration, two time dependent 
decomposed concentrations and no concentration, according to the chromatograms in Fig. 
3.114-3.117) without any repetition and measurement in duplicate. For a more accurately 
kinetic study, the experiment should be repeated and developed more precisely. Additionally, 
the discontinuous time dependent concentration determination (HPLC-measurement and 
stop of the experiment for each measurement) is not optimal and thus may have been 
leading to some falsifications. However, since the data may be interesting for other scientists 
and research groups working in the field of chemical reaction velocities, the obtained data 
values are briefly discussed. 
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Fig. 3.118 The experimental and theoretical calculated data points for the time dependent 
decomposition of compound 23 at T = 60 °C. The rhombuses (♦) represent the measured data points 
(e-function drawn as straight line). The squares (■) represent the data points obtained by the equation 
c(A) = c0(A) x e-kt (e-function drawn as dashed line, with k = 0.1). As can be noticed, both data sets fit 
quite well. Thus, the assumption (first order kinetics) may be acceptable. For further details see text. 
 
The corresponding linear model of the e-function from Fig. 3.118 is presented in Fig. 3.119. 
As noticeable, the theoretical assumption of a first order reaction kinetic seems to be fulfilled 
as the measured and calculated data points fit almost well. The great imprecision of the 
results is due to the fact that only two calculable measuring points were generated giving 
only two experimental values for the rate constant k (c = 0.92 mg/ml at t = 16 h and c = 0.08 
mg/ml at t = 31 h, giving k = 0.09, respectively, k = 0.13). For calculations with these two 
differing values of k, they have been set to one significant digit (k ≈ 0.1). 
 
Tab. 3.32 The numeric data for the time dependent decomposition of Inc-Ac at T = 60°C according to 
the first time law described in chapter 2.6.2. The data has been obtained by the HPLC quantitation 
results given in Fig. 3.114-3.117 in chapter 3.11.2. The obtained reaction constant k is rounded to one 
significant digit (k = 0.1), since the precision of the experiment carried out has not been very exact. 
Experimental Data     
Peak Area (HPLC) 70846560 15664266 1423398 0 
c [mg/ml] ♦ 4.17 0.92 0.08 0 
t [h] 0 16 31 47 
ln c 1.43 -0.08 -2.49  
Calculated Data     
e-fkt ■ 4.17 0.84 0.19 0.04 
t [h] 0 16 31 47 
ln c (calculated with k ≈ 0.1) 1.43 -0.17 -1.67 -3,27 
k constant [1/h]  0.09 (≈ 0.1) 0.13 (≈ 0.1)  
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Fig. 3.119 The linear regression model for the decomposition experiments of compound 23 (Inc-Ac) at 
T = 60 °C. The rhombuses (♦) refer to the measured data (y = -0.1261x + 1.5923; straight line) and the 
squares (■) refer to the theoretical calculated values with k = 0.1 (y = -0.1x + 1.4269). The data points 
follow approximately (R2 = 0.98) the theoretical presumed equation model, ln c(A) = -k x t + ln c0(A). 
Though the experimental values are quite imprecise, the model fulfils within a defined precision the 
equation specification of a first order kinetic time rate. For further details see text. 
 
According to the linear regression models given in Fig. 3.119, this approximation may be 
within a reliable accuracy. Though the value of k, referring to the experimental data, is more 
probable greater than 0.1 (see equation in Fig. 3.119 with k = -0.1261, giving a better fit to 
the real data set). At last and as discussed before, the experimental data set is too small for 
an unambiguous verification of the reaction kinetic model, but is most likely, based on the 
theoretical presumption (decomposition by oxygen, which is present in excess) and the 
approximately good fit, the model of choice (“pseudo”-first order). 
 
 
3.11.4 Qualitative TLC Analysis of the Decomposition Products 
The quantitative discussion about decomposition of Inc-Ac (23) can be also made 
qualitatively by TLC analysis. For evaluation, the standard NP-TLC method has been used 
as described in chapter 2.3.1. The corresponding TLC results are declared in Fig 3.120. 
Each row there is explained and must be only compared with the corresponding 
chromatograms in Fig. 3.114-3.117 in chapter 3.11.2. As shown in the NP-TLC 
chromatograms, any decomposition product has a smaller Rf-value than Inc-Ac (23). Hence, 
every decomposition product is conclusively more polar than compound 23 and most likely 
an oxidation product originating from it. Further evidence for this assumption may be given, if 
hyphenated LC-MS and/or GC-MS experiments are conducted with these decomposed 
samples. 
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Fig. 3.120 Two different TLC chromatograms (NP). From left to right: 1 = pure Inc-Ac (strong brown 
spot > 99 % by HPLC; compare with Fig. 3.114); 2 = decomposed Inc-Ac (Inc-Ac ≈ 20 %; compare 
with Fig. 3.114); 3 = NB fraction of Bpap (for comparison of Rf-values); 4 = decomposed Inc-Ac (Inc-
Ac ≈ 15 %; compare with Fig. 3.115); 5 = completely decomposed Inc-Ac (compare with Fig. 3.117); 6 
= NB fraction of Bpap. For further details see text. 
 
 
3.12 Pharmacological Results 
 
In this chapter the pharmacological results for the mPGES1-Assay (cell-free) are presented. 
The data shown here is representative for Inc-Ac (23), respectively, its decomposition 
products which have been basically responsible for the inhibition activity. Additionally, the 
data for the three isolated compounds from Fr. 9 (see chapter 3.1.1.3) and two of their single 
compounds (18 and 19) in differing concentration combinations are shown. According to the 
theory of synergy [149,150] the results presented here may be quite interesting. 
 
3.12.1 mPGES-1-Results for Incensole Acetate and its Decomposition Products 
The data for the cell free assay from Inc-Ac (23) is explicitly discussed here. The crucial step 
for the investigation of the decomposed Inc-Ac fractions (see chapter 3.11.2) had been the 
fact that only the first evaluated batch of Inc-Ac showed an inhibitory effect on the mPGES-1 
enzyme. The following tested batches from Inc-Ac paradoxically did not reveal anymore any 
inhibitory activity. Thus, the first active batch was re-analysed by HPLC (see chapter 3.11.2) 
and NMR (1H and 13C; data not shown) and exhibited a decomposed mixture of several 
unknown compounds originating from Inc-Ac. Hence, the previously purified and intact Inc-Ac 
batch was probably decomposed during the transport. The reason for the decomposition of 
        1            2              3         4            5             6 
 
Inc-Ac-Spot 
(23) 
 
 
 
 
 
 
 
 
 
Inc-Spot 
(22)
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this first batch could not be determined anymore. Subsequently, compound 23 was artificially 
decomposed as it is described in chapter 3.11.2, and the decomposed fractions were 
compared with another intact batch from compound 23 in order to evaluate their 
pharmacological activity again. The results are presented in Tab. 3.33 and in Fig. 3.121. 
Interestingly, if the first analysed batch (compound 23) was still intact, the results with the 
decomposed mixtures probably would not have been recognised. Note that the discussion 
given here for compound 23 is also valid for compound 22 (incensole). For compound 22 a 
similar behaviour was observed (data not explicitly shown here). Only the decomposed 
batches revealed inhibitory effects. 
 
Tab. 3.33 The inhibition of mPGES-1 activity in microsomal preparations of IL-1ß-stimulated A549 
cells (see chapter 2.5) for each tested sample. EC1: First active batch, decomposed (during transport 
to Tübingen), with 6.4 % (g/g) Inc-Ac; EC2: Totally decomposed sample with 0 % (g/g) Inc-Ac; EC-
16h: Decomposed sample (after 16 h at 60 °C) with 40 % (g/g) Inc-Ac; Inc-Ac pure: intact sample of 
Inc-Ac (purity > 99 %). See also chapter 3.11.2 for the corresponding chromatograms. Concentration 
levels: 0, 1, 10 and 30 µM, respectively, µg/ml. Remaining activity is given in %. For further details see 
text. 
Nominal c 
(HPLC) 6.4 % (g/g) 0 % (g/g) 40 % (g/g) 99% (g/g) 
Concentration 
EC1 [µM] 
remaining activity 
[%] 
EC2 [µg/ml] 
remaining activity 
[%] 
EC-16h [µg/ml] 
remaining activity 
[%] 
Inc-Ac pure [µM] 
remaining activity 
[%] 
0 100.00 100.00 100.00 100.00 
1 86.62 92.60 60.39 99.03 
10 22.52 24.12 12.71 100.81 
30 9.87 11.41 8.04 103.68 
 
As noticeable, the intact Inc-Ac sample does not inhibit the enzyme at any concentration 
level. In contrast, the decomposed samples EC1 (6.4 % Inc-Ac), EC2 (40 % Inc-Ac) and 
even the total decomposed sample EC2 (0 % Inc-Ac) did show a significant inhibition in the 
mPGES-1-Assay. These findings prove that Inc-Ac has been definitely not responsible for 
the observed bioactivity. Unfortunately, it could not be determined if there is a single 
chemical entity responsible for the inhibition, since every decomposed sample revealed an 
uncountable amount of peak signals. These signals seem to literally knock out the enzyme 
activity without any specific inhibition mechanism. However, to exactly detect how the 
inhibition works under these circumstances, it would be necessary to isolate every molecular 
compound from the complex mixture. Hitherto, this seems to be an impossible task. 
Additionally, there is nothing known about the stability of the decomposition products, since 
they are generated randomly and no specific degradation product or route has been 
observed. Perhaps by HPLC-SPE-NMR hyphenation techniques and/or by additional mass 
spectrometric detection further evidence on the molecular composition may be achievable. 
However, it is questionable if this is worth the huge effort which may be necessary to clarify 
these elusive findings.  
The discussion here should at least declare that every result should be treated with great 
caution, as compound 23 was before, after testing of the first batch (EC1), held for an 
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mPGES-1 bioactive entity, and further tests with complete cell-systems etc. had been 
already carried out. The results of a few other cell-assays with the decomposed products 
from Inc-Ac are presented in Tab. 3.34. Based on these results it was finally concluded that 
Inc-Ac (23) itself does not show any inhibitory action in any of these evaluated assays. 
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Fig. 3.121 The graphic referring to Table 3.33. As discussed, the pure and intact Inc-Ac sample does 
not reveal any inhibitive activity in the cell-free mPGES-1-Assay. Only the decomposed samples affect 
the enzyme inhibitive. For further details see text. 
 
If this is further proof on synergistic effects, as reported by Berenbaum [149] or Wagner and 
Ulrich-Merzenich [150] can not be verified by the results given here. There occur definitely 
too many molecular entities in the samples to reasonably substantiate this theory. 
Nevertheless, tests applied with cellular systems (LPS-stimulated monocytes and IL-1ß-
stimulated A549 cells etc.) did show some inhibitory actions for the decomposition products 
of Inc-Ac and Inc as presented in Tab. 3.34.  
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Tab. 3.34 The results (IC50) for further other biological assays with the decomposed samples from Inc-
Ac (23) and Inc (22). The data is obtained from the working group of Oliver Werz in Tübingen, 
Germany [172] and is only valid for the decomposed Inc-Ac, respectively, Inc samples. For further 
details see text. For clarification see also chapter 1.5 on pharmacology. 
mPGES-1 activity in LPS stimulated monocytes   
Inc-Acdecomposed no effect     
Incdecomposed no effect     
      
5-Lipoxygenase cell-free (purified from E. coli)   
Inc-Acdecomposed 23 µM     
Incdecomposed 58 µM     
      
5-LO activity; PMNL; stimulated with AA [20 µM] + A23187 [2,5µM]   
Inc-Acdecomposed 24 µM     
Incdecomposed 33 µM     
      
5-LO activity; PMNL; stimulated with A23187 [2,5µM]    
Inc-Acdecomposed > 50 µM     
Incdecomposed 23 µM     
      
COX-1 in human platelets     
Inc-Acdecomposed 100 µM     
Incdecomposed > 100 µM     
      
COX-2 in A549 cells      
Inc-Acdecomposed 22 µM     
Incdecomposed no effect     
      
Phospholipase-A2 (cPLA2); cell-free      
Inc-Acdecomposed no effect     
Incdecomposed no effect     
      
whole blood (5h)      
Inc-Acdecomposed no effect 
Incdecomposed no effect 
Note: Assay is vulnerable to errors. Even the 
controls did not reveal any inhibitory effect [172]. 
 
In addition to the results of Moussaieff et al. [87,145-147], who revealed for Inc (22) and Inc-
Ac (23) a few biological activities, these may be some interesting findings. The question may 
be thus, if perhaps their results are also merely based on the decomposition of Inc (22) and 
Inc-Ac (23). In the review by Moussaieff and Mechoulam in 2009 they report on the inhibition 
of COX-2 with a significant effect at 60 µM (denoted as unpublished data in their publication) 
[108]. Additionally, in the paper of cerebral ischemic injury protection in mice by Inc-Ac (23) 
[147], it is stated that the Inc-Ac (23) plasma levels were analogously measured with LC-MS 
as reported by Gerbeth et al. [144]. However, Gerbeth et al. only measured the plasma levels 
of compounds 1-6 (ß-KBA, ß-AKBA, α/ß-BA and α/ß-ABA) in the ESI-negative mode (due to 
the COOH-function) and nothing is said about the detection of Inc-Ac (23) by LC-MS in their 
paper. In the positive mode merely ß-KBA and ß-AKBA seem to be able to catch a proton 
(unpublished data [191], or see also the LC-MS/MS paper by Reising et al. [192]). 
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Consequently, a paper on the LC-MS quantification and ionization probabilities of Inc (22) 
and Inc-Ac (23) is still lacking thus far. 
As a consequence, further tests should be carried out to evaluate the real potential of Inc 
(22) and Inc-Ac (23), since according to the findings given here merely their decomposed 
mixtures were bioactive. 
 
 
3.12.2 mPGES-1-Results for Compound 18 and 19 in Differing Compositions 
The data for the cell free mPGES-1-assay from the isolated fraction E2h 6.6 (see also 
chapter 3.1.1.3), including compound 18, 19 and a further yet not known compound (1 
isomer; 16 % HPLC), is demonstrated in Tab. 3.35 and graphically depicted in Fig. 3.122. 
Interestingly, the inhibitory efficiency decreased the purer compound 18 became (Note: 
relative peak areas in % are given in parentheses behind each compound, see Tab. 3.35). 
 
Tab. 3.35 Comparison of the inhibition of mPGES-1 in microsomal preparations of IL-1ß stimulated 
A549 cells (see chapter 2.5) for different compound combinations of the isolated peak group from 
fraction E2h 6.6. The samples were purified by prep. HPLC and hence leading to the randomly 
different rel. peak area percentages (shown in parentheses). Inhibition concentrations are given in 
µg/ml, the arithmetic mean of the remaining activity in %, the standard deviation (S.D., also in %) with 
three measurements for each concentration (n = 3) and the Standard-Error in %. For further details 
see text. 
Sample Conc. [µg/ml] Remaining activity [%] (n = 3) S.D. Standard-Error 
10 20.56 4.64 2.68 
3 31.77 4.56 2.63 
1 41.46 5.78 3.33 
0.3 64.61 7.25 4.18 
α-Ac-7,24-dien-TA 
(96 % HPLC) +  
ß-Ac-8,24-dien-TA 
(4 % HPLC) 
0.1 81.11 4.88 2.81 
     
Sample Conc. [µg/ml] Remaining activity [%] (n = 3) S.D. Standard-Error 
10 25.22 8.01 4.63 
α-Ac-7,24-dien-TA  
(76 % HPLC) 
+ß-Ac-8,24-dien-TA 
(24 % HPLC) 1 41.09 4.52 2.61 
     
Sample Conc. [µg/ml] Remaining activity [%] (n = 3) S.D. Standard-Error 
10 15.82 6.28 3.63 
3 13.73 3.18 1.84 
1 13.38 3.89 2.25 
0.3 32.11 6.20 3.58 
0.1 75.03 11.17 5.59 
E2h Fraction 6.6  
α-Ac-7,24-dien-TA (46 % HPLC) +  
ß-Ac-8,24-dien-TA (32 % HPLC) + 
 1 Isomers 
 (16 % HPLC) 
0.03 97.30 11.60 6.70 
 
The most potent results were obtained with the E2h Fraction 6.6, which consisted of a 
mixture of compound 18 and 19 and the hitherto unknown compound with a probably similar 
structure (perhaps also an acetylated tirucallic acid?). 
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Thus, these results seem to confirm the theory on synergy effects stated by Berenbaum 
[149] and highly debated by Wagner and Ulrich-Merzenich [150]. In both articles it is 
discussed how different chemical entities in combination may enhance or, vice versa, 
diminish the bioactivity of a certain compound. According to the discussions there, the 
inhibition of mPGES-1 is enhanced in the example given here, at least in the cell-free assay. 
However, the data presented just delivers results with the almost purified enzymes. In whole 
cell systems completely different results could be obtained. Several reasons therefore are 
known (Cell permeability, other target enzymes, etc.). Furthermore, in animal or human 
models the hepatic metabolism of compounds has to be taken into account and even if single 
cells get inhibited, these results can generally not be extrapolated to more complex 
organisms [94]. The pharmacological results reported in this work may just clarify the 
complexity of inhibition mechanisms, not to mention how complex an Olibanum extract may 
affect several targets in the human body when used as oral administration form. At last, the 
results reported here may encourage other research groups for further examinations of such 
phenomena. 
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Fig. 3.122 The graphical depiction of the results in Tab. 3.34 for the concentration levels of 1 and 10 
µg/ml. Very interesting is the strong inhibition activity for E2h Fraction 6.6 (α-Ac-7,24-dien-TA + ß-Ac-
8,24-dien-TA + 1 isomer) at c = 1 µg/ml (ca. 13 % remaining activity of the enzyme), while at this 
conc.-level (1 µg/ml) the other two combinations still deliver a remaining activity of ca. 40 %. At c = 10 
µg/ml the values converge again. For further details see text. 
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3.13 Biosynthetic Pathway Proposal 
 
According to the obtained HPLC quantitation data (see chapter 3.8) and qualitative TLC data 
(see chapter 3.4) a hypothesis on the different particularities of the biosynthetic pathways for 
the three species Bpap, Bser and Bsac, respectively, Bcar is given here. Generally, specific 
pentacyclic biomarkers for Olibanum species are definitely the boswellic acids, at least 
verified for Bpap, Bser and Bsac/Bcar where they are detectable in huge quantities. Besides, 
there occur the tirucallic acids in great quantities and the lupeolic acids in minor quantities 
compared with the other biomarkers (BAs and TAs). The data is qualitatively summarised in 
Tab. 3.36 to present an overview on the characteristic amounts determined in the 
corresponding species.  
Interestingly, the great quantities of BAs and ABAs found in Bsac/Bcar in combination with 
always greater amounts of LAs (LA and Ac-LA), compared with Bpap and Bser, lead to the 
conclusion for Bsac/Bcar that this biological pathway is strongly expressed. Another 
interesting fact is that simultaneously the TA contents are rather low compared with Bpap 
and Bser, which both instead revealed always quite high tirucallic acid contents. As both 
pentacyclic acids, the BAs and TAs, are probably derived from two different cyclisation 
reaction directions of 2,3-epoxysqualene [31,193], it seems that these two ways are 
differently expressed in the species Bsac/Bcar and, respectively, Bpap and Bser. Thus, the 
production of TAs is probably stronger expressed in the species Bpap and Bser, while for 
Bsac/Bcar the synthesis of LAs and hence BAs seems to be superior, holding the synthesis 
of TAs in this species on a quite low level. This fact is additionally substantiated as for 
Bsac/Bcar the second chromatography dimension is unnecessary for the quantitation of 
compound 3 (ß-BA), since the two acetylated TAs, compound 18 and 19, are only minimally 
detectable (see also chapter 3.7.5). 
 
Tab. 3.36 Comparison of the quantities (HPLC) of some specific biomarkers in the species Bpap, Bser 
and Bsac/Bcar. Boswellic acids (BAs and ABAs); Tirucallic acids (All TAs); Lupeolic Acids (LA and Ac-
LA). ß-KBA and ß-AKBA are not taken into account in the table here. For further details see text. 
+++: Great quantity; ++: Average quantity; +: detectable; - : not detectable. 
 Specific Triterpenes Specific Diterpenes Sesquiterpenes 
 Boswellic Acids Tirucallic Acids Lupeolic Acids Inc Inc-Ac Serratol α-Humulene ß-Caryophyllene
Bpap ++ ++ + +++ ++ - - - 
Bser +++ ++ + + - ++ - - 
Bsac +++ + ++ + - ++ + + 
Bcar +++ + ++ + - ++ + + 
 
The synthesis of specific diterpenes such as serratol is probably given for all species. Quite 
interesting is that Bser and Bsac/Bcar reveal relatively great quantities of serratol and to a 
lesser amount incensole, which has been additionally detectable as it is reported to be 
derived from serratol [82]. For Bpap, serratol has not been significantly detectable. Instead, 
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Bpap revealed the greatest quantities of incensole (see chapter 3.8). Furthermore, incensole 
acetate, as the product molecule of incensole, has been only detectable in the species Bpap 
during this work. The other species, Bser and Bsac/Bcar, did not reveal incensole acetate, at 
least not in easily detectable quantities (HPLC-UV or TLC). Thus, it seems that only the 
species Bpap possesses a highly active specific enzyme expression for the acetylation of 
incensole. 
The existence of α-humulene and especially ß-caryophyllene in the species Bsac/Bcar, give 
evidence on a higher regulated expression of enzymes for the biosynthesis of these 
ubiquitous sesquiterpenes in Olibanum Somalia and Oman/Yemen. These two 
sesquiterpenes are quite probably very specific for Bsac and Bcar samples as similar 
conclusions have been already reported in the literature [13,74,184]. 
 
3.13.1 Proposal of the Specific Biosynthesis Pathways 
In the following the probable biogenetic synthesis pathways of some of the specific 
biomarker molecules in Bpap, Bser and Bsac/Bcar are described. Since there is nothing 
about the isolation and structural elucidation of specific enzymes from boswellic species 
published hitherto, the pathways presented here are merely based on the determination of 
their quantities (HPLC), and thus are only hypothetical. For an unambiguous clarification of 
the hypothesis given here, experiments with the plants itself may be implemented. However, 
since only the air-dried gum exudates and not the plants itself were accessible, the theory 
given in this work may be confirmed or disproved by experiments with the plants and 
biological extracts thereof. Therefore, the parts of the plants (e.g. the bark), where those 
specific enzymes are supposed to be located, must be extracted and biological tests may be 
implemented proving the occurrence and/or existence of a specific enzyme by investigations 
with specific precursor molecules (e.g. for an acetyl-transferase, acetyl-CoA and 
unacetylated precursors may be added, such as LA, incensole or α- and ß-BA).  
A good example of this approach is given in the publication of Schmidt et al. [194] where two 
highly specific enantioselective germacren-D-synthases have been detected by adding 
specific precursor molecules to subsequently purified plant extract fractions. 
However, since there was no real frankincense plant material for further investigations 
available, the pathways presented here are based on the experimental data obtained during 
this work and a hitherto merely a presumption. 
 
3.13.1.1 Sesquiterpenes 
As depicted in Fig. 3.123, the ring closure of C-1 and C-11 of farnesane produces the 11 
membered skeleton of a class of monocyclic sesquiterpenes called humulanes. The further 
C-2 and C-10 closure leads to an additional cyclobutane ring and gives the caryophyllane 
type sekeletons [31]. This probably universal pathway seems to be highly expressed in the 
Boswellia species Bsac and Bcar, respectively. In the species Bpap and Bser they were not 
detectable in similar quantities (see also HPLC chromatograms in chapter 3.7). 
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Fig. 3.123 Biosynthesis route for α-humulene and ß-caryophyllene. ß-caryophyllene-oxide is probably 
the product of the air caused oxidation of ß-caryophyllene [177]. For further details see text. 
 
 
3.13.1.2 Diterpenes 
The 1,14-cyclisation of geranylgeranylpyrophosphate via an allylic cation intermediate state 
leads to the biosynthesis of the 14-membered skeleton of 3,7,11,15-cembratetraene, also 
known as cembrene A [31]. Cembrene A, respectively, cembrene C, are thus probably the 
precursors of iso-serratol and serratol. Serratol, as reported by Klein and Obermann [82], is 
the precursor of incensole and thus its acetate. The basic biogenesis route is shown in Fig. 
3.124. Though incensole has been also detectable in samples from Bser and Bsac/Bcar, its 
acetate was merely detectable in samples from Bpap. Furthermore, serratol and iso-serratol, 
which were easily detected in samples of Bser and Bsac/Bcar, have not been detectable in 
Bpap (see also HPLC chromatograms in chapter 3.7 and TLC chromatograms in chapter 
3.4). Quite astonishing has been the fact that samples of Bpap contain incensole and 
incensole acetate in quite high quantities. Approximately 30-40 % of the neutral fraction 
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mass refers to them (22 and 23; see also chapter 3.8). On the other hand, samples of Bser 
and Bsac/Bcar reveal rather great amounts of neutral tetra- and pentacyclic triterpenes, 
which is especially deducible if the chromatograms in chapter 3.7 are considered. There, 
neutral extract samples of Bser and Bsac/Bcar showed more lately eluting peak signals than 
samples of Bpap. This could also explain their solution properties already reported [11]. An 
Et2O-extract of Bpap was easily dissolvable in MeOH, whereas the Et2O extracts of Bser and 
Bsac/Bcar gave a white dim and colloidal solution when dissolved in MeOH again. 
 
PPO
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-H+
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-H+
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O
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Fig. 3.124 Biosynthesis route for serratol, iso-serratol, incensole and incensole acetate. For further 
details see text. 
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3.13.1.3 Tetra- and Pentacyclic Triterpenes 
The biosynthetic precursor of tetracyclic triterpenes of the gonane type is 2,3-epoxysqualene 
leading via synthesis of dammarane type molecules to the synthesis of tirucallane type 
molecules, most likely the precursors of the tirucallic acids.  
Production of pentacyclic triterpenes from the bacharane type is also based on another 
cyclisation of 2,3-epoxysqualene, which leads to the synthesis of baccharane type molcules, 
the precursor of the lupanes and thus most probably of the oleanane and the ursane type 
molecules [31,193]. Finally, these represent the lupeolic and boswellic acids in the boswellic 
species. 
Interestingly, each species, beginning from 2,3-epoxysqualene reveals different priorities for 
the synthesis of their specific biological compound composition. As mentioned, Bpap and 
Bser reveal great quantities of TAs (compounds 13-19), whereas Bsac/Bcar shows huge 
amounts of BAs (compounds 1-4) and additionally the LAs (compounds 11 and 12). The 
existence of, on average, the greatest quantities of ß-AKBA (compound 6) and 11-OH-ß-ABA 
(7) in Bpap and in the same time, the lowest amounts of BAs (1-4), may declare that ß-AKBA 
is the final product of this enzyme reaction cascade. 
Furthermore, when high levels of BAs (1-4) have been found in Bsac/Bcar, the levels of ß-
KBA and ß-AKBA (5 and 6) were comparably low (as shown in the chromatograms of the 
HPLC quantitation in chapter 3.7.4, compare Fig. 3.102 with 3.103). Contrary, when the ß-
AKBA or ß-KBA and even 11-OH-ß-ABA contents (5, 6 and 7) in Bsac/Bcar were greater as 
expected, the amounts of BAs (1-4) were rather low (see also discussion on HPLC results in 
chapter 3.7.4). Thus, probably depending on the environmental conditions, the pathways are 
differently expressed. The highest amounts of α-BA and ß-BA (1 and 3) in the species Bser 
may be explainable through the low biosynthesis levels of ß-KBA and ß-AKBA (5 and 6), as 
for this species the levels of these two most likely biosynthesis end products (5 and 6) are 
rather low. The hypothetical biosynthesis pathways are given in Fig. 3.125 for the tirucallic 
acid synthesis and in Fig. 3.126, respectively, Fig. 3.127, for the lupeolic and boswellic acid 
synthesis. 
As can be seen in Fig. 3.125 the biosynthesis of the tirucallic acids may begin with the 
protonation of an 2,3-epoxysqualene. After cyclisation of 2,3-epoxysqualene to the 
corresponding dammarane (a; 3α or 3ß), it converts probably into an apotirucallane by a 
concerted migration of the hydrid (C-17 to C20) and of the methyl group C-18 from C-14 to 
C13 (b). The methyl-shift (C-30 methyl from C-8 to C14), consequently followed by 
elimination of the proton at C-9, giving the double bond (C-8 with C-9), converts it into 
tirucallane (step c). This step may be catalysed enzymatically (base = B:, which abstracts the 
proton at C-9, giving B+-H, as depicted in Fig. 3.125). The final steps for the biosynthesis of 
3ß-OH-8,24-dien-tirucallic acid may be then the C-H activation at C-21, probably by in plants 
universally occurring Cytochrome P450 enzymes [19] and further oxidation to a COOH-
function (step d). The same reaction pathway may be valid for the biosynthesis of 3α-OH-
8,24-dien-tirucallic acid. There, only the conformation of the epoxysqualene cation is 
different, which leads to an α-configured hydroxyl function. By another oxidation the 
secondary alcohol function of both 8,24-dien-tirucallic acids at C-3 is probably converted into 
3-oxo-8,24-dien-tirucallic acid (step e). However, the pathway presented here is merely a 
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hypothetical model based on the publication of Cotterell et al. [62], the book of Breitmaier 
[31] and the review by Ikuro Abe [193]. 
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Fig. 3.125 Hypothetical biogenesis pathway for α-TA, ß-TA and 3-Oxo-TA. For further details see text. 
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The acetylated derivatives (compounds 16 and 19) and also the isomers, respectively, the 
acetylated isomers with a C7-C8 double-bond (compounds 17 and 18), may follow a similar 
way as shown in Fig. 3.125, but just with differences in the hydrogen elimination (C-7 and C-
8, instead of C-8 and C-9), leading to the different double-bond positions, and an additional 
acetylating reaction for each of the compounds (probably via Ac-CoA and corresponding 
acetyl-transferases). 
 
The starting reaction for the probable biosynthesis pathway of the LAs (11 and 12) and the 
BAs (1-7) is shown in Fig. 3.126. 
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HO
H
HO
H
18
HO
H
21
HO
H
21
3alpha-hydroxybacchar-21-ene cation
3alpha-hydroxylupane cation
a
b
c
 
 
Fig. 3.126 The probable starting reactions for the biosynthesis of the LAs (11 and 12) and BAs (1-7). 
For details see text. 
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tained (f).  
On the contrary to the synthesis of the tirucallane compounds shown in Fig. 3.125, the 
cyclisation of the 2,3-epoxysqualene leads to the six-membered ring D (a).  
The following Wagner-Meerwein rearrangement (b) leads to the intermediate cation of the 
tetracyclic triterpene 3α-OH-bachar-21-ene (furthermore, the 3ß-OH-bacchar-21-ene may be 
also built, similar to as shown in Fig. 3.125 for the α/ß-dammarane skeletons). Finally, the 
ring is closed and the pentacyclic 3α-OH-lupanium cation is built (c). This product then reacts 
into the LAs and BAs as described in Fig. 3.127. For further information see the book of 
Breitmaier [31] or the review of Ikuro Abe [193]. 
The further hypothetical reaction steps for the bisoynthesis of the LAs (compounds 11 and 
12) and the BAs (compounds 1-7) are presented in Fig. 3.127. The connection of a bond 
from C-18 to C-21 of baccharane leads to the five-membered ring E of the pentacyclic 
lupanes as already shown in Fig. 3.126. The double bond C-20-C-29 may be built by 
enzymatically catalysed elimination (B: + H-CH2-R → B+-H CH2=C-R) of the proton (methyl 
at C-29). Between the steps of d and f, the C-H activation (via Cytochrome P450 enzymes 
[19]) of C-24 may occur, giving first the alcohol and finally the COOH-function. By 
acetylation, probably via Ac-CoA and an acetyl-transferase, Ac-LA (12) is then ob
The expansion of the cyclopentane ring E in lupanes to the six-membered ring E by shifting 
carbon atom C-21 from C-19 to C-20 leads to the oleanane skeleton (ß-amyrine). This may 
be achieved by concerted hydride shifts from C-18 to C19 and C-13 to C-18 (g), respectively, 
followed by elimination (B: + H-CH-R → B+-H CH=C-R) of the proton at C-12 (h), giving the 
double bond (C-12-C13). Finally, C-H activation and oxidation at C-24 (i) leads to α-BA 
(probably by Cytochrome P450 enzymes [19]). A further acetylation reaction (j) gives thus α-
ABA (probably via Ac-CoA and an acetyl-transferase). 
Further reaction steps may lead to the 11α-hydroxy-α-BA (k) and finally the 3-α-OH-11-keto-
α-BA-derivatives (l and m), though they definitely may be only expressed in infinitesimal 
quantities (Note that these two compounds have been predicted in olibanum species, see 
also [57,59], and were already partial-synthesised by Büchele et al. [58,134]). 
For the biosynthesis of ß-BAs (compound 2, 4, 5 and 6) the oleanane skeleton formally may 
undergo methyl shifts to a variety of other pentacyclic triterpene intermediates leading to the 
ursane skeleton (step n-u). Hence, the C-29-methyl group may migrate from C-20 to C-19 
giving the positive tertiary carbo-cation at C-20 (n). The following hydride shifts from C-19, C-
18 and C-13 may concertedly build the tertiary carbo-cation at C-13 (o), which thus may give 
the α-amyrine skeleton by enzymatically catalysed (B: + H-CH-R → B+-H CH=C-R) proton 
elimination of C-12 (p). Similar to as described for the synthesis of α-BA (steps i-m), the 
COOH function at C-24 may be built (q) and further acetylation may lead to ß-ABA (r). 
Oxidation at C-11 thus may lead to 11-OH-ß-BA (not detected yet, but proposed [57]) and 
11-OH-ß-ABA (7) (step s) and finally to ß-KBA (5) and ß-AKBA (6) (steps t and u). 
In which sequence the specific reactions are operated is not known hitherto. Thus, all the 
pathways presented here are merely hypothetical presumptions and are not based on real 
experimental proof. To achieve this, further biochemical experiments, especially with real 
frankincense plants, must be conducted to elucidate the correct secondary metabolism 
routes of frankincense plants. 
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Products of steps k, l, m and step s, 11-
OH-ß-BA, the deacetylated variant of 11-
OH-ß-ABA (7), are merely proposed and 
have not been isolated and/or detected yet 
in real samples of frankincense (see also 
[57,58,59,133]). 
 
Fig. 3.127 Scheme for the biosynthesis of LAs (11 and 12) and BAs (1-7) beginning from the 3α-
hydroxylupane cation as probable precursor. For details see text. 
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3.14 Validation of Biosynthesis Hypothesis by PCA 
 
The in chapter 3.13 discussed specific biosynthesis hypothesis for each species has been 
substantiated by principal component analysis (PCA) in this chapter. In table 3.37 the PCA 
matrix is presented. The calculation details are described in chapter 2.3.8. For Bpap, 10 
different resin batch samples were analysed (three different distributor sources). Bser 
samples consisted of 14 different samples (three different distributor sources). Bcar 
consisted of 6 (three different distributor sources) and Bsac of 4 (three different distributor 
sources) samples.  
 
Table 3.37 The raw data matrix for the PCA. Note that for ß-Car-Ox, compound 28, (only TLC) and 
Vert-4(20),7,11-triene, compound 24, (not quantified) a different encoding system was used (0 = not 
detectable; 1 = detectable). The other data is based on HPLC quantitation results (chapter 3.8). For 
further details see text. 
 
Compound 5 6 15 14 13 16 1  (2D)
3 
(2D) 11 12 2 4 22 23 21 20 24 28
Bpap-Seitz           1,0 13,1 2,1 1,8 7,3 2,7 3,5 4,2 0,4 1,6 6,0 10,7 24,9 18,5 0,0 0,0 1 0
Bpap-MP-0409 2,0 13,1 3,5 2,6 8,8 3,5 3,3 5,4 0,7 1,6 6,1 10,6 23,0 16,7 0,0 0,0 1 0
Bpap-AS-070509-A2b 1,4 15,3 2,5 2,1 9,1 2,3 3,5 5,7 1,0 1,8 6,9 8,5 19,6 15,2 0,0 0,0 1 0
Bpap-AS-260309-A1c 1,0 14,8 1,8 1,1 5,5 1,3 2,3 5,2 0,4 1,2 5,5 9,1 18,8 14,0 0,0 0,0 1 0
Bpap-AS-090610-F1a 1,2 16,3 3,3 3,1 12,8 4,7 4,2 7,4 1,2 1,5 6,7 10,2 22,9 16,2 0,0 0,0 1 0
Bpap-AS-060910-F1a 1,3 11,6 3,6 3,3 22,7 4,7 4,5 8,0 0,7 1,7 7,4 11,4 23,1 18,6 0,0 0,0 1 0
Bpap-AS-220509-A1c 1,0 11,0 2,1 1,3 6,2 1,4 2,8 5,1 0,4 1,2 5,6 9,3 25,0 16,6 0,0 0,0 1 0
Bpap-Caelo-Pr 1,2 15,6 4,0 3,3 15,8 3,7 4,6 11,0 0,7 1,8 7,4 13,6 15,3 10,9 0,0 0,0 1 0
Bpap-22-1300 1,2 16,5 3,5 3,6 14,2 4,0 4,5 8,9 0,7 1,8 7,6 13,0 21,3 13,2 0,0 0,0 1 0
Bpap-22-1400 1,0 16,0 3,4 2,8 14,2 3,9 4,2 9,2 0,6 2,0 8,1 15,0 16,1 11,9 0,0 0,0 1 0
Bser-AS-240309-A3c 1,6 2,5 4,3 3,8 10,5 3,5 5,3 14,3 1,1 1,0 4,0 13,6 2,5 0,0 16,8 3,1 0 0
Bser-AS-190409-A3b          1,8 2,9 4,3 4,4 10,5 3,9 6,8 15,0 1,1 1,5 4,4 14,9 0,9 0,0 5,3 0,9 0 0
Bser-AS-110809-A3c 1,5 2,5 4,9 5,9 11,5 3,6 6,8 16,1 1,0 1,0 4,2 14,2 2,2 0,0 14,2 2,6 0 0
Bser-AS-060910-F3a 2,4 2,9 4,2 5,8 9,7 3,2 7,2 17,5 1,5 0,3 4,1 13,6 2,4 0,0 4,1 0,7 0 0
Bser-AS-060810-F3b-RS 2,2 2,9 4,3 5,5 11,7 4,1 8,4 18,3 1,3 1,0 4,5 15,1 1,6 0,0 11,2 2,2 0 0
Bser-siccum 96 % EtOH-a 2,4 2,9 4,4 5,1 11,5 3,5 8,0 17,1 1,4 1,1 4,3 14,5 2,0 0,0 3,0 0,6 0 0
Bser-siccum 96 % EtOH-b 2,4 2,9 4,3 5,1 11,7 3,3 8,1 17,1 1,3 1,2 4,5 14,7 2,2 0,0 2,0 0,8 0 0
Bser-siccum 96 % EtOH-c 3,0 3,4 3,2 2,9 7,7 0,6 8,6 18,7 1,3 1,1 4,6 15,2 2,1 0,0 2,3 1,4 0 0
Bser-Art. No. 22.127 3,0 3,0 4,0 5,4 10,8 3,0 8,5 18,8 1,5 0,9 3,9 12,4 4,0 0,0 9,1 1,7 0 0
Bser Granen 2,7 4,1 3,2 3,8 8,4 2,5 8,0 16,0 1,4 1,5 4,5 13,4 0,0 0,0 6,0 1,0 0 0
Bser-No. 22-1560 1,8 3,1 5,3 7,1 16,3 4,2 7,6 17,6 1,3 1,2 4,6 15,0 0,0 0,0 5,1 0,4 0 0
Bser-Gufic, AB0918 6,7 4,6 5,7 9,1 17,2 3,3 10,7 20,9 1,8 1,0 4,2 13,3 0,0 0,0 15,7 3,1 0 0
Bser-Gufic, AB0919 7,1 4,4 5,8 10,4 15,6 3,0 10,6 19,6 2,0 1,4 3,8 12,7 0,0 0,0 15,9 3,1 0 0
Bser-Gufic, AB0920 5,7 4,1 4,4 6,7 9,9 2,3 9,1 17,1 1,7 0,9 3,5 11,4 0,0 0,0 9,1 1,7 0 0
Bcar-RS (AK Jauch) 0,9 2,2 1,5 3,0 1,4 0,7 7,5 13,7 2,8 3,8 7,2 13,6 0,0 0,0 1,0 0,3 0 1
Bcar-AS-050910-A11c 0,2 2,3 1,1 1,7 2,1 1,2 4,6 10,4 2,2 4,0 7,9 16,7 5,2 0,0 2,6 0,7 0 1
Bcar-AS-040910-F11a 0,3 2,1 1,3 0,9 2,0 0,9 6,9 16,3 2,9 6,1 11,2 23,7 5,8 0,0 2,9 0,8 0 1
Bcar-22-1238 0,5 11,1 1,3 1,1 2,3 0,9 8,4 17,0 2,1 6,1 14,1 27,9 11,4 0,0 4,5 0,8 0 1
Bcar-Giama 0,5 12,7 0,7 0,5 0,9 0,2 12,1 22,5 4,2 3,9 11,1 15,6 5,6 0,0 3,6 0,4 0 1
Bcar-Aden, Schreibmayer 0,6 1,8 1,2 0,9 1,7 0,7 6,4 15,6 2,6 5,6 10,1 23,1 1,2 0,0 1,9 0,0 0 1
Bsac-AS-040910-A10a 0,5 2,5 1,5 1,1 2,0 1,1 7,3 14,3 2,8 6,7 11,5 23,5 2,7 0,0 10,3 1,3 0 1
Bsac-22-1232 0,1 0,1 0,5 1,5 0,2 0,1 10,8 22,6 4,4 5,6 12,8 22,8 1,9 0,0 8,8 3,0 0 1
Bsac-JB03 Pr 55 1,1 20,0 1,5 1,8 2,9 1,3 4,5 5,1 1,8 5,4 13,2 10,5 0,0 0,0 0,5 0,0 0 1
Bsac-Dr. Mohsin Pr. 6 1,1 15,0 1,2 0,4 1,0 0,3 2,8 5,4 0,8 1,5 4,9 6,9 0,0 0,0 14,0 1,6 0 1
 
   203
Results and Discussion 
_________________________________________________________________________________ 
 
As usual in PCA, the matrix was built up by the objects (samples; Bpap, Bser, Bsac and 
Bcar) row-wise and the loadings (variables; compounds 1-6, 11-16, 20-24 and 28) column-
wise. Thus, a total matrix of 34 objects with 18 variables (loadings) was built. 
For the loadings, only robust biomarkers were chosen. Unstable biomarkers were not taken 
into account (Compounds 7 and 10; see also [55,59] or chapter 3.7). The 2D HPLC 
quantitation results of the BAs (1 and 3) have been used (see also chapter 3.7.5 and 3.8) for 
the PCA described here. Furthermore, the second chromatography dimension data for 
qualitative description of compounds 18 and 19 was not considered, although the data could 
be used analogously as the TLC data for example (0 = only traces of compounds; 1 = 
detectable). The biomarker ß-Car-Ox (28), as it is not really detectable by HPLC-analysis, 
but significantly by TLC (pink spot) has been used as a nominal control in the PCA (0 = not 
detectable; 1 = detectable). The same counts for Vert-4(20),7,11-triene (24), which is 
basically quantifiable, but since we did not quantified it accurately by external calibration, this 
load, as a significant compound for Bpap, had been used the same way (0 = not detectable, 
1 = detectable). For all other compounds (1-6, 11-16 and 20-23) the HPLC quantitation 
results were used (% in g/g for the acid fraction and neutral fraction results, respectively). 
The final principal component plot, including the scores (samples of Bpap, Bser and 
Bsac/Bcar) and the loadings (variables; compounds 1-6, 11-16, 20-24 and 28) is shown in 
Figure 3.128. Note that even only the HPLC results (acid and neutral fractions), without the 
nominal data (compound 24 and 28, 0 or 1), give an unambiguous principal component plot 
for species identification (data not shown here). 
 
Principal Component Plot
Ac-LA
LA
b-BA(2D)
a-BA (2D)
a-Ac-TA
3-Oxo-TA
a-OH-TA ß-OH-TA
AKBA
KBA
ß-Car-Oxid
Verticillia
Iso-Ser
Ser-OH
Inc-Ac
Inc
b-ABA
a-ABA
-2
-1
0
1
2
-2 -1 0 1 2
PCA 1 (39,9%)
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A
 2
 (3
6,
9%
)
 
Bser 
Bpap 
Bsac/Bcar 
Fig. 3.128 Principal components plot. The first two principal components (PCA 1 and PCA 2) were 
sufficient to describe the differences between Bpap, Bser and Bsac/Bcar. The vectors (e.g. AKBA, Ac-
LA, 3-Oxo-TA, etc.) determine the position of each object (sample) in the plot. For further details see 
text. 
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Basically, sample spots near each other have similar properties, whereas samples revealing 
a greater distance are described by other attributes. In this case, for every species 
investigated, a typical expectation area can be given. This may be useful for future 
predictions on other incense resin samples, since expectably same samples give a similar 
cluster. 
Though PC1 (39.9 %) and PC2 (36.9 %) just cover approximately 77 % of the total variance 
(Kaiser-criterion = every principal component Eigenvalue greater 1 is important, see also 
[165] or Fig. 3.131), both components are already sufficient to describe these “three” resins 
unambiguously. The scores plot is depicted in Fig. 3.129 and the loadings plot is shown in 
Fig. 3.130. As shown in the mixed scores and loadings plot in Fig. 3.128, Bpap is completely 
described by the vectors of ß-AKBA (6), Inc (22), Inc-Ac (23) and Vert-4(20),7,11-triene (24). 
Furthermore, the Bpap scores are influenced by the high amounts of tirucallic acids, 
especially 3-Oxo-TA (13). 
Bser distinguishes itself from the others by the on average highest amount of ß-KBA (5) and 
by high quantities of tirucallic acids (13-16), Ser-OH (21), Iso-Ser (20), and the on average 
highest amounts of BAs (1 and 3). 
The samples of Bsac and Bcar are clustering around the same area. They are mainly 
described by the highest levels of lupeolic acids (11 and 12) and the on average highest 
quantities of ABAs (2 and 4). Furthermore, the positive qualitative detection of ß-Car-Ox (28) 
in every sample of them, gives a strong vector classifying both to be identical. However, 
some precautions must be met when Bsac and Bcar are analysed. Since, for example, two 
samples of Bsac (see Table 3.37, samples JB03-Pr.55 and Dr.MohsinPr.6) revealed rather 
high quantities of ß-AKBA (6), concluding that every single observed biomarker 
concentration must be treated with the uttermost carefulness. If merely the acid fraction, 
without any neutral fraction compounds, is processed by PCA, the two samples (JB03-Pr.55 
and Dr.MohsinPr.6) would lead to the conclusion that it could be Bpap instead, which always 
constantly showed quite high ß-AKBA (6) levels. However, since these samples could be 
additionally distinguished by the other parameters (e.g. LAs, 11 and 12, low levels of tirucallic 
acids, 13-16, the existence of ß-Car-Ox, 28, and Ser-OH, 21, and the absence of Inc-Ac, 23), 
the identification has been still unequivocal. 
Interestingly, as the correlation between the serratols (20 and 21) and incensoles (22 and 23) 
is negative (compare their positions in Fig. 3.128 or 3.130), the here performed PCA gives 
also the evidence that detection of high levels of incensoles (22 and 23) reveal very low 
levels of serratols (20 and 21), vice versa. The same almost negative correlations can be 
deduced from the BAs (1 and 3) and ß-AKBA (6), and additionally for the TAs (13-16) and 
LAs (11 and 12). Here, especially AcLA (11) and 3-O-TA (13) are striking. As already 
discussed, high levels of LAs lead to low levels of TAs. And high ß-AKBA levels always 
delivered lower BA-levels, vice versa. However, the conclusions deduced here are merely 
based on the in this work analysed sample population. Thus, every single result should be 
still regarded carefully. 
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Fig. 3.129 The scores plot of all here analysed samples. Every sample can be classified by the 
principal component analysis applied here. Samples of Bsac and Bcar show the strongest deviation in 
general. For further details see text. 
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Fig. 3.130 The loadings plot of all variables. Samples of Bser are mainly described by the vectors of 
the BAs (1 and 3, ß-BA and α-BA), Iso-Ser (20), Ser-OH (21), ß-KBA (5) and the tirucallic acids. Bpap 
samples distinguish themselves by high quantities of Inc (22) and Inc-Ac (23), ß-AKBA (6) and the 
existence of verticillia-4(20),7,11-triene (24). The samples of Bsac and Bcar are classified by the 
highest LA-levels (LA and Ac-LA, 11 and 12), high ABA-levels (2 and 4, ß-ABA and α-ABA), very low 
TA-levels and the detection of ß-Car-Ox (28). For further details see text. 
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Casewise PCA Scores     
Case PCA 1 PCA 2
Bpap-Seitz           1,401 -0,826
Bpap-MP-0409 1,410 -0,478
Bpap-AS-070509-A2b 1,255 -0,721
Bpap-AS-260309-A1c 1,151 -0,865
Bpap-AS-090610-F1a 1,440 -0,397
Bpap-AS-060910-F1a 1,566 -0,161
Bpap-AS-220509-A1c 1,308 -0,878
Bpap-Caelo-Pr 1,235 -0,277
Bpap-22-1300 1,301 -0,366
Bpap-22-1400 1,155 -0,430
Bser-AS-240309-A3c -0,163 1,001
Bser-AS-190409-A3b          -0,002 0,685
Bser-AS-110809-A3c -0,144 1,178
Bser-AS-060910-F3a -0,032 0,814
Bser-AS-060810-F3b-RS -0,235 1,134
Bser-siccum 96 % EtOH-a -0,032 0,781
Bser-siccum 96 % EtOH-b -0,051 0,757
Bser-siccum 96 % EtOH-c -0,399 0,436
Bser-Art. No. 22.127 -0,210 1,027
Bser Granen -0,230 0,562
Bser-No. 22-1560 0,074 1,067
Bser-Gufic, AB0918 -0,408 2,118
Bser-Gufic, AB0919 -0,449 2,165
Bser-Gufic, AB0920 -0,256 1,314
Bcar-RS (AK Jauch) -0,898 -0,642
Bcar-AS-050910-A11c -0,691 -0,917
Bcar-AS-040910-F11a -1,296 -1,110
Bcar-22-1238 -1,228 -1,257
Bcar-Giama -1,400 -1,004
Bcar-Aden, Schreibmayer -1,198 -1,109
Bsac-AS-040910-A10a -1,429 -0,921
Bsac-22-1232 -2,134 -0,760
Bsac-JB03 Pr 55 -0,282 -1,352
Bsac-Dr. Mohsin Pr. 6 -0,128 -0,569
Scree Plot
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Explained Variance (Eigenvalues)                   
Value PC 1 PC 2 PC 3 PC 4 PC 5 PC 6 PC 7 PC 8 PC 9 PC 10
Eigenvalue 7,18 6,64 1,32 0,80 0,69 0,52 0,30 0,22 0,08 0,08
% of Var. 39,90 36,88 7,34 4,46 3,84 2,90 1,67 1,23 0,46 0,42
Cum. % 39,90 76,78 84,12 88,57 92,42 95,32 96,99 98,22 98,68 99,11
 
Fig. 3.131 The metric data of the casewise scores for the principal components 1 and 2 (these 
describe the position of each sample in the plot of Fig. 3.129), the scree-plot (Eigenvalue plotted 
against PC1, PC2, etc.) and the calculated eigenvalues, explaining the variance. The first ten principal 
components cover more than 99 % of the variance (PC11 – PC18 are not shown). Though, PC3 has 
an eigenvalue > 1 (Kaiser-Criterion) it was not used for clarification. PC1 and PC2 have been sufficient 
for species classification. For further details see text. 
 
The statistical raw data, given in Figure 3.131, contains the calculated results of the 
casewise scores for every sample (position of every sample in Fig. 3.128 and 3.129), the 
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scree-plot (graphical depiction of the eigenvalues against PC1, PC2, PC3, etc; Kaiser 
criterion > 1) and the calculated eigenvalues (explained variances). Furthermore, in Tab. 
3.38 the descriptive statistics for all here analysed samples are given. Especially this table 
may be useful as an expectation value for classifying any resin being questioned as a resin 
of the genus Boswellia (Bpap, Bser and Bsac/Bcar). 
 
Tab. 3.38 The descriptive statistics for all 34 observations from Table 3.37. Basically, the arithmetic 
average of all quantitative HPLC measurements for every resin (Bpap, Bser and Bsac/Bcar) made in 
this work (except ß-Car-Ox and Verticillia). For further details see text. 
Descriptive Statistics         
Variable Mean Std Dev. Std Err N 
KBA (254nm) 1,829 1,674 0,287 34 
AKBA (254nm) 7,622 6,042 1,036 34 
ß-OH-TA 3,052 1,523 0,261 34 
a-OH-TA 3,482 2,450 0,420 34 
3-Oxo-TA 8,709 5,689 0,976 34 
a-Ac-TA 2,449 1,442 0,247 34 
a-BA (2D) 6,540 2,594 0,445 34 
b-BA(2D) 13,439 5,661 0,971 34 
LA 1,554 0,979 0,168 34 
Ac-LA 2,343 1,864 0,320 34 
a-ABA 6,768 3,048 0,523 34 
b-ABA 14,388 4,745 0,814 34 
Inc 7,750 9,135 1,567 34 
Inc-Ac 4,462 7,149 1,226 34 
Ser-OH 4,996 5,449 0,935 34 
Iso-Ser 0,940 1,046 0,179 34 
 
The here described classification by PCA may give a useful tool for quality control. Due to 
the expected confidence region, an incense resin being questioned may be found within a 
defined PCA area (see Fig. 3.128 and Fig. 3.129). Additionally, more results could be used 
for the PCA presented here, if quantitative GC-results, instead of TLC-results, are applied. 
Thus, there are still other possibilities for a different design by PCA.  
However, due to the fact that these resins are naturally occurring products from different 
harvesting sides, there occur generally great deviations concerning their biomarker 
compositions. These differences could be caused by environmental influences (soil, rain, 
sun, etc.) but also could be the product of genetically variations, where maybe one tree does 
not have a specific enzyme for the synthesis of a specific product. Thus, the general 
correctness of this model still has to be proved in the future by additional analytical evidence. 
 
Conclusion and Outlook 
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Conclusion and Outlook 
 
The aim of the study has been the unambiguous chemotaxonomic classification of resins 
from the frankincense species Boswellia papyrifera, Boswellia serrata and Boswellia sacra, 
respectively, Boswellia carterii by conventional chromatographic methods (TLC, HPLC and 
GC). All three methods enable the identification by means of typical biomarker compounds 
(e.g. TLC-analysis [11]). Additionally, the results were compared with reliable data from 
literature [13,15,74,79,184] and samples of certified origin [17].  
Besides, a HPLC method (external standard calibration with 2D-Offline option, if necessary) 
has been developed, capable of quantifying up to 17 and even possibly 19 compounds in the 
acid fraction matrix of all three species [59]. In total, 15 compounds (1-8 and 10-16) were 
quantified in this work. Particularly, the class of tirucallic acids has been firstly separated in 
the acid fraction matrix by reversed-phase liquid chromatography. Four compounds of the 
separated five were quantified (compounds 13-16, without 17). 
In case of the species Boswellia papyrifera and Boswellia serrata, where the ß-BA (3) peak 
co-eluted with two compounds (18 and 19), a second chromatography dimension was added 
[160] in order to quantify this compound (3) less error-prone and more accurate. This 
method, which is hitherto quite time-consuming and assumedly not very robust (additional 
manual preparation steps), gives evidently more correct results than a simple perpendicular 
drop [162] of the poorly resolved peaks (3, 18 and 19) does. 
Furthermore, it was revealed that the second chromatography dimension is not necessary for 
the species Boswellia sacra and Boswellia carterii, since the compounds 3α-O-acetyl-7,24-
dien-tirucallic acid (18) and 3ß-O-acetyl-8,24-dien-tirucallic acid (19) occur there in only 
minimal traces. Thus, the integration error, caused by co-elution of 18 and 19 with ß-BA (3), 
has been negligible (see chapter 3.7.5). 
Approximately, ca. 75 % of the total acids have been determined (see chapter 3.8). All of the 
three species approach this value independent from the quantities of the single components 
(e.g. high TA-contents, therefore a low BA/ABA and/or KBA/AKBA content and vice versa). 
When the quality of the resin being analysed is sufficient, this mean value is obtainable by 
comparable extraction procedures. However, samples of inferior quality were analysed 
revealing an extreme bias from the expectation value. This means principally that there 
exists a specific fingerprint-pattern for every species, but it must not be fulfilled mandatorily 
(see also chapter 3.8). These resins are more or less naturally grown products with their 
quality depending on environmental influences. Furthermore, it is important to measure a 
great overall population of the sample resin as even within one batch great quantitative 
variations can be found (e.g. to grind 10 g is safer than to grind 1 g, even though the 
consumption may be immense then). 
 
Unequivocal biomarkers for the species Boswellia papyrifera (Eritrea, Ethiopia and Sudan) 
are incensole (22), incensole acetate (23) and verticillia-4(20),7,11-triene (24). Boswellia 
papyrifera is identifiable by all three methods (TLC, HPLC and GC). Hitherto, this species 
has been often mistaken in the literature with the species Boswellia carterii (Somalia), though 
there have been already sufficient publications (e.g. Obermann in 1978 [79] and Hamm et al. 
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in 2005 [13]) giving similar conclusions as stated in the work presented here. Additionally, the 
species Boswellia papyrifera distinguishes itself through the highest ß-AKBA (6) content on 
average, and a rather high overall content of tirucallic acids (chapter 3.8). Another interesting 
fact is that in all relevant publications on this topic [13,74,79], as well as in all analysed 
samples during this work, the compound incensole acetate (23) had been merely detected in 
Boswellia papyrifera. The compounds incensole (22) and incensole acetate (23) have been 
firstly quantified by HPLC (external standard calibration) and are the main components in the 
neutral fraction of the species Boswellia papyrifera (contents from 30 to over 40 % were 
detected; see also chapter 3.8). The quantitative HPLC results had been verified by isolation 
experiments with incensole (22) and its acetate (23) (see chapter 3.11.1). Through 
enrichment of the incensole acetate (23) content by partial-synthesis in the neutral fraction of 
Boswellia papyrifera (acetylation of the neutral fraction) and the following chromatographic 
isolation, this compound has been isolated in great quantities (chapter 3.11.1). With the 
species Boswellia serrata and Boswellia sacra/Boswellia carterii this would not have been 
possible, as they show significantly lower contents of incensole (22), and the biosynthesis 
seems to be focused on serratol (21) instead, the precursor of incensole (22) (see chapter 
3.13.1.2 or [11]). The two compounds (22 and 23) could be conveniently transformed into 
one another by simple deacetylation and acetylation experiments. 
For the species Boswellia serrata (India) the compounds serratol (21), the here firstly 
described iso-serratol (20; see chapter 3.2.7) and a quite high overall content of tirucallic 
acids are typical (chapter 3.8). Apparently, the ubiquitous occurring compounds 
methylchavicol and methyleugenol, which were determined in the steam-distillate by means 
of their GC-retention-indices, seem to be also specific for Boswellia serrata [13,35,74]. The 
species is further characterised by an approximately equal ß-KBA/ß-AKBA-content and the 
highest BA-contents (α-BA, 1 and ß-BA, 3) on average. With regard to bio-availability, where 
ß-BA (3) revealed the throughout highest blood-plasma levels [125,126,144], this species 
seems to be the most promising, as long as it is standardised on ß-BA (3). 
For Boswellia sacra (Oman, Yemen) and Boswellia carterii (Somalia), which can be regarded 
as identical species so far [11-13,73], same biomarkers have been identified by the 
chromatographic methods implemented here (TLC, HPLC and GC). Specifically is therefore 
the occurrence of ß-caryophyllene (27) and its mono-oxidation product (28). Compound 27 
has been detectable by HPLC (chapter 3.7.3 and 3.7.4) and 28 significantly by TLC (see 
chapter 3.4). This result had been verified by the GC-tests and by reliable results from 
literature [13,74,184] (chapter 3.5). The compounds serratol (21) and iso-serratol (20) were 
also detected in these species. Both compounds, 20 and 21, have been firstly quantified in 
the neutral fraction of Bsac/Bcar, and additionally in Bser, by the HPLC method described 
here (see chapters 3.7 and 3.8). Their acid fractions reveal great quantities of BAs (1 and 3) 
and ABAs (2 and 4). Furthermore, they showed throughout significantly greater lupeolic acid 
contents (11 and 12), relatively compared with Boswellia papyrifera and Boswellia serrata 
(chapter 3.7.6 and 3.8). This is probably due to different characteristics of the specific 
biosynthesis pathways. The contents of ß-KBA (5) and ß-AKBA (6) varied considerably for 
the species Boswellia carterii and Boswellia sacra (chapter 3.8). Therefore, the ß-KBA/ß-
AKBA-ratio should be regarded with the uttermost caution if used for species identification. 
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Expectably, the ß-AKBA (6) peak is greater than the peak of ß-KBA (5). However, this must 
not always be the case since differing signal-ratios were detected. On average, these 
species revealed the smallest ß-KBA (5) content, compared with Boswellia papyrifera and 
Boswellia serrata. The great variation of biomarker concentrations found in samples of 
Boswellia carterii and Boswellia sacra may also be due to the many different distributor 
sources where these resin samples were purchased from. Basically, the same deductions 
have been already made by Bergmann [17]. Nevertheless, in all here analysed samples the 
overall tirucallic acid content has been significantly smaller than for Boswellia papyrifera and 
Boswellia serrata (chapter 3.8). This fact is again most probably due to the differences in the 
biosynthesis pathways with a focus on lupeolic (11 and 12) and boswellic acids (1-4) for 
Boswellia sacra, respectively, Boswellia carterii (see also chapter 3.13).  
 
Eleven compounds in total were isolated from the resins of Boswellia papyrifera (18, 19, 22, 
23 and 24) and Boswellia carterii (20, 21, 22, 25, 28, 29 and 30) and their structures were 
assigned by 1D and 2D NMR experiments. Iso-serratol (20), a derivate of the known 
compound serratol (21), has been firstly isolated from the resin of Boswellia carterii. 
Furthermore, the isolation of 3-ß-OH-tirucallol (29) and of 3-α-OH-11-keto-ursen (30) from 
the neutral fraction of Boswellia carterii has not been described in detail before. These two 
compounds, 29 and 30, are most likely biosynthetic precursors of the corresponding tirucallic 
and 11-keto-boswellic acids. 
The two acetylated tirucallic acid derivates 18 and 19, isolated from Boswellia papyrifera, 
have been comprehensively described for the first time in this work. Though Estrada et al. 
reported their isolation from a resin of the species Boswellia carterii, there is no explicit data 
(isolation details) published in literature by this working group [57,70]. Additionally, Boswellia 
carterii produces 18 and 19 in only minimal amounts (see especially chapter 3.7.5 on 2D-
HPLC). Hence, the species has been more likely Boswellia papyrifera instead, or a partial-
synthetic method was used, as it is described for the semi-synthesis of 18 starting from 17 by 
Banno et al. [68] and Akihisa et al. [67]. In the publications of Banno and Akihisa et al. the 
origin of 18 is also addressed to Boswellia carterii. However, the reported compounds, 
specifically the isolation of incensole acetate (23), lead also to the assumption that the resin 
has been Boswellia papyrifera instead. Particularly, the difficulty of the separation of these 
two compounds, 18 and 19, as well as the generally rather low content in frankincense 
resins, seems to substantiate this conjecture (see also chapter 3.1.1.3 and 3.7.5). Thus, this 
work describes the first chromatographic and spectroscopic “coordinates” for these two, 
pharmacologically interesting, compounds (18 and 19). In connection with the term 
“coordinates” it may be mentioned that they are synthesised in greater quantities by the 
species Boswellia papyrifera and Boswellia serrata and that additionally their HPLC retention 
times are denoted for the first time. The species Boswellia sacra, respectively, Boswellia 
carterii revealed continuously lower tirucallic acid contents. Hence, also the two compounds, 
18 and 19, were merely detected in traces (chapter 3.7.5). 
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The compounds for the quantitative HPLC tests (1-8, 10-16) have been also isolated and 
purified from the species Boswellia papyrifera as already stated in the dissertation of Seitz 
[56,59]. 
 
Another interesting fact has been that purified incensole (22) and its acetate (23) are quite 
unstable, if exposed to air over a longer period of time (chapter 3.11.3). Thus, their firstly 
presumed pharmacological activity has been repatriated to their decomposition products (see 
chapter 3.12.1). This assumption was confirmed by reaction kinetic experiments with 
incensole acetate (23) (chapter 3.11.2-3.11.4). It may be mentioned here that the working 
group of Moussaieff has published these compounds, especially incensole acetate (23), with 
promising pharmacological properties [87,145-147]. Though, in the work presented here, 
merely the decomposed fractions of incensole (22) and its acetate (23) did reveal 
pharmacological activity (chapter 3.12.1). The question may be thus, if the results by 
Moussaieff et al. have been based on the same decomposition phenomena as they were 
“accidentally” discovered here. 
 
Concerning synergy effects the fraction containing compounds 18 and 19 as well as another 
unidentified compound (presumably another isomer similar to 18 and 19) revealed an 
interesting pharmacological potential (see chapter 3.1.1.3 for isolation and 3.12.2 for 
pharmacology). Unfortunately, the unknown compound of this fraction could not be isolated 
hitherto. In the cell-free mPGES-1 assay the complex mixture (unknown compound, 18 and 
19) gave more efficient inhibitory concentrations than the subsequently purified single 
compounds. This could be evidence on a synergistic effect. Though it is not absolutely 
compelling as in other biological systems they could react in a completely different manner 
[150] which is a general problem for the evaluation of active agents [94]. However, these 
results may perhaps encourage other research groups to conduct further tests. But most 
likely, these findings conclude that the tirucallic acids, as essential parts of the acid fraction 
of frankincense resins, have not negligible pharmacological effects. 
 
Furthermore, the quantitative HPLC results are not completely validated thus far (chapter 
3.8). Up to here there is no real data on the inter-laboratory-reproducibility generated (e.g. 
another lab, other equipment, other staff, etc.; see also [156]), as the quantitation by this 
method has been firstly described in the thesis presented here. Nevertheless, accuracy has 
been confirmed by comparison of this method with a robust HPLC method from the literature 
[20,21], needing less preparation steps (selective quantitation of ß-KBA and ß-AKBA; see 
chapter 2.3.9 and 3.6.1). The results, dependent on the way of proceeding, are similar for 
both methods. Besides, comparison of the quantitation results from this work with results 
from other publications substantiates the general correctness thus far (see chapter 3.9). 
However, an absolute certainty will be only achieved, if the methodology is repeated several 
times – additionally in other laboratories – to lastly obtain a statistically sufficient and reliable 
overall population [159]. This concerns both, the number of measured samples 
representative for Boswellia papyrifera, Boswellia serrata and Boswellia sacra, respectively, 
Boswellia carterii, and the procedure characteristics which will be revealed by several 
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repetitions of the methodology [156]. From this point of view, the quantitative data generated 
in this work has to be regarded merely as a first estimation of reality. It still has to be proven 
by further investigations in the future. 
 
To summarise again, the data generated in this work may enable the determination of the 
origin of resins from the incense species Boswellia papyrifera, Boswellia serrata and 
Boswellia sacra, respectively, Boswellia carterii, by means of their specific chemotaxonomic 
markers, unambiguously. Even every single method (TLC, HPLC or GC) for itself may be 
able to achieve this. Whereby the TLC procedure, due to its convenient handling and 
significance, may be most convincing (chapter 3.4 and [11]).  
The GC method requires the steam-distillation of the resins, respectively, their neutral 
fractions, as a prior preparation step, and delivers ubiquitous mono- and incense specific 
diterpenes (e.g. compound 21, 22, 23 and 24; see also chapter 3.5).  
Certainly, the HPLC procedure requires the most effort, as for an unambiguous quantitative 
determination the acid fraction has to be separated from the neutral part of the resin (chapter 
2.2.4 and 2.3.4). However, this preparation step is necessary since the results would be 
falsified by other mono- and diterpenes co-eluting in the range of boswellic and tirucallic 
acids (e.g. 20, 21, 22 and 23). The method has been validated for the acid fraction of 
Boswellia papyrifera, which does not reveal any significant traces of serratol (21) and iso-
serratol (20). Thus, the quantitative results for α-TA (14) and ß-TA (15) are quite accurate. 
For the other species, which contain serratol (21) and iso-serratol (20) in greater quantities, 
the values for α-TA (14) and ß-TA (15) are afflicted with uncertainties. These two compounds 
co-elute with iso-serratol (20; with 15 = ß-TA) and serratol (21; with 14 = α-TA) in the 
unprepared raw extract (see especially the so-called “Triplet-Peak” in the Bser raw extract in 
chapter 3.7.2, but also chapter 3.7.3 and 3.7.4 for Boswellia sacra, respectively, Boswellia 
carterii). Even after separation of the acid fraction and neutral fraction by liquid-liquid-
extraction (chapter 2.2.4) there are still traces of serratol (21) and iso-serratol (20) in the acid 
fraction detectable (TLC analysis) co-eluting with the corresponding tirucallic acids. Thus, the 
contents of 14 and 15 appear bigger than they actually are. This experimental result has 
been already stated in the dissertation of Seitz, who also isolated serratol (21) from the acid 
fraction of Boswellia carterii [56]. For Boswellia papyrifera, which does not reveal any 
quantities of serratol (21) and iso-serratol (20), therefore incensole (22) and its acetate (23) 
in greater amounts, this problem does not exist. Incensole (22) is merely in traces detectable 
in the acid fraction extract of Boswellia papyrifera but does not co-elute with any of the target 
analytes (Rt = between ß-KBA and ß-AKBA). 
 
In addition, the quantitative HPLC results and even the qualitative HPLC fingerprints deliver 
some evidence on the preferred biosynthesis pathways of the single species (chapter 3.13). 
This evidence was substantiated by application of principal component analysis (PCA) 
(chapter 3.14). 
 
Boswellia papyrifera seems to synthesise ß-AKBA (6), incensole (22) and its acetate (23) in 
relatively great amounts. Furthermore, the content of tirucallic acids is rather high and the 
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lupeolic acid (11, 12) and boswellic acid content (1-4) is rather low instead. Incensole acetate 
(23) has been detected only in this species (see chapter 3.7.1 and 3.7.6). 
 
Boswellia serrata reveals quite low ß-AKBA (6) contents, but therefore rather great BA (1, 3) 
contents and also great tirucallic acid contents (13-19) instead. The ß-KBA (5) and ß-AKBA 
(6) peak-ratio is almost the factor 1, which is in good agreement with the results from 
literature [57,195]. The existence of serratol (21) and iso-serratol (20) and the absence of 
incensole acetate (23) are also characteristic for this species (see chapter 3.7.2 and 3.7.6). 
 
The species Boswellia sacra, respectively, Boswellia carterii, which both revealed the 
strongest content deviations, seem to accommodate a distinct pathway for the biosynthesis 
of ß-caryophyllene (27). Its oxide, ß-caryophyllene-oxide (28), is specifically detectable by 
TLC (chapter 3.4). Furthermore, they revealed significantly high BA (1, 3) contents and on 
average the greatest ABA (2, 4) contents. The lupeolic acid contents (11, 12) are additionally 
the greatest in these species, if compared with Boswellia papyrifera and Boswellia serrata. 
Interestingly, the tirucallic acid content (13-19) has been for all samples of Boswellia sacra 
and Boswellia carterii significantly lower (see chapter 3.7.3, 3.7.4 and 3.7.6). The two 
acetylated tirucallic acids, 18 and 19, are merely in traces detectable. Therefore, the second 
chromatography dimension is actually obsolete for these species (chapter 3.7.5). This result 
could be explained by the fact that the lupeolic acids (11 and 12) or lupeolic cations can be 
regarded as the biosynthetic precursors of the boswellic acids (chapter 3.13 or the book of 
Breitmaier on Terpenes [31]). Hence, the lupeolic acids (11 and 12) and boswellic acids, 
especially 1-4, are in greater quantities detectable in the resins of Boswellia sacra and 
Boswellia carterii. And as the synthesis of tirucallic acids (13-19) is probably proceeding via 
another biosynthetic step, they are only in minimal quantities produced (chapter 3.13). 
On the contrary, Boswellia papyrifera and Boswellia serrata reveal rather great amounts of 
tirucallic acids (13-19) and significantly lower values for the lupeolic acids (11 and 12). This 
leads to the conclusion that they differ in their biosynthesis pathways in detail (chapter 3.8 
and 3.13). Hitherto, these statements are merely speculations based on the quantitative 
HPLC results (chapter 3.8). There are definitely further biochemical experiments necessary 
to substantiate this proposal. To achieve this, access to trees or fresh Boswellia material 
must be ensured. Within this work it was unfortunately not possible to do this. 
 
Of further interest could be also still the systematic evaluation of the different incense resin 
ingredients with regard to their synergistic and/or antagonistic properties in pharmacological 
test systems [150]. Since the data presented here, but also the data previously generated by 
Bergmann [17] and Seitz [56], give essential information on the analytics, the identification, 
the isolation and even the quantitation of incense resin ingredients, it should be possible for 
other research groups to isolate the compounds necessary for further pharmacological 
investigations. 
Furthermore, the here developed HPLC method is still capable of improvement. It surely 
enables the certain quantitation of some tirucallic acids in the acid fraction matrix of 
Boswellia papyrifera, but is for the other species still with greater uncertainties combined 
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(keyword: Co-elution). Through hyphenation techniques like LC-MS/MS-coupling, it may be 
also finally achievable to determine blood-plasma concentration levels of the tirucallic acids. 
A mass selective detector could also overcome the co-elution problem of ß-BA (3, M = 
456.70 g/mol) with α-Ac-7,24-dien-TA (18, M = 498.73 g/mol), if no ion suppression 
phenomenon occurs. Some experiments on the in vitro and in vivo application of LC-MS, 
respectively, LC-MS/MS-couplings with incense resin ingredients have been already carried 
out [143,144,192,195]. In the long-term, the here described HPLC methodology should make 
it possible to even determine the biologically active class of tirucallic acids in complex 
matrices (e.g. blood plasma). 
The characteristic chemotaxonomy of the three species Boswellia papyrifera, Boswellia 
serrata und Boswellia sacra, respectively, Boswellia carterii, may be also finally clarified with 
publication of this work. Thus, it should not happen anymore that the species Boswellia 
carterii and Boswellia papyrifera are confused with each another as it occurred unfortunately 
several times before in the literature [35,67,68,85-88,146]. 
Questionable is also, if the species Boswellia papyrifera, which accommodates the 
significantly greatest quantities of incensole (22) and incensole acetate (23), will be one day 
extinct. According to the matrix-based model of Groenendijk et al. [26] this species is going 
to consist of only 10 % of the present population within the next 50 years, if there are no 
immediate precautions met. The yield of resin from this species could be already in the next 
15 years merely 50 % of the present supply. Thus, this material, whether useful for the 
Catholic Church or the Pharmacological Research, may be rather rare and hence expensive. 
 
In general, the results reported here are properly speaking merely valid for the in this work 
analysed sample population. However, the congruency with a few literature results 
substantiates the general correctness thus far. Further investigations in the future will have to 
finally prove the statements given here. 
 
 
 
 
 
 
 
 
 
 
 
Zusammenfassung und Ausblick 
_________________________________________________________________________________ 
 
Zusammenfassung und Ausblick 
 
Zielsetzung dieser Arbeit war eine eindeutige chemotaxonomische Klassifizierung der Harze 
der Weihrauchspezies Boswellia papyrifera, Boswellia serrata und Boswellia sacra, 
respektive, Boswellia carterii, mittels gängiger chromatographischer Methoden (DC, HPLC 
und GC). Alle drei Methoden erlauben eine eindeutige Identifizierung anhand typischer 
Biomarker (z. Bsp. DC-Analytik [11]). Zusätzlich wurden die Ergebnisse mit verlässlichen 
Literaturresultaten [13,15,74,79,184] verglichen und anhand von zertifizierten 
Referenzmustern abgesichert [17]. Außerdem wurde eine HPLC-Methode (Methode des 
externen Standards mit 2D-Offline-Option, falls notwendig) entwickelt, die bis zu 17 eventuell 
sogar 19 Verbindungen in der Rohsäurefraktion aller drei Spezies identifizieren bzw. 
quantifizieren kann [59]. Insgesamt sind 15 dieser Verbindungen (1-8 und 10-16) in dieser 
Arbeit quantifiziert worden. Erstmalig wurden einige Tirucallensäuren in der Rohsäurematrix 
chromatographisch aufgetrennt. Vier der fünf aufgelösten TA-Peaksignale sind schließlich 
quantifiziert worden (Verbindung 13-16, ohne 17). 
Da für die Spezies Boswellia papyrifera und Boswellia serrata der ß-BA-(3)-Peak mit 
koeluierenden Verbindungen (18 und 19) überlagerte, wurde eine zweite Chromatographie-
dimension hinzugefügt [160], um diese Verbindung relativ fehlerfrei quantifizieren zu können. 
Diese Methode ist zwar bis dato noch sehr aufwendig und vermutlich auch nicht sehr robust 
(manuelle Zwischenpräparationsschritte), liefert allerdings nachweislich richtigere Ergebnisse 
als eine einfache Lotfällung [162] der schlecht aufgelösten Peaks (3, 18 und 19). 
Weiterhin stellte sich heraus, dass die zweite Chromatographiedimension für die Spezies 
Boswellia sacra und Boswellia carterii nicht notwendig ist, da hier die Verbindungen 3α-O-
Acetyl-7,24-dien-tirucallensäure (18) und 3ß-O-Acetyl-8,24-dien-tirucallensäure (19) in so 
geringen Mengen vorkommen, dass der Integrationsfehler durch Koelution mit ß-BA (3) 
vernachlässigbar war (siehe Kapitel 3.7.5). 
Interessanterweise sind für alle drei Spezies durchschnittlich vergleichbare Gesamtgehalte 
im Rohsäureharz wiedergefunden worden, die sich zwar aus den verschiedenen 
unterschiedlichen Einzelkomponenten (BAs, ABAs, KBAs, TAs, LAs etc.) zusammensetzen, 
aber auf einen einheitlichen Kohlenstoff-Gesamtmetabolismus schließen lassen. 
Approximativ sind ca. 75 % der Gesamtrohsäuren determiniert worden (siehe Kapitel 3.8). 
Alle drei Spezies nähern sich diesem Wert an, unabhängig von den Quantitäten ihrer 
einzelnen Komponenten (z. Bsp. hoher TA-Gehalt, dafür niedrigerer BA/ABA und/oder 
KBA/AKBA-Gehalt und umgekehrt). Bei guter Harzqualität ist dieser Mittelwert mit 
vergleichbaren Extraktionsmethoden zu erreichen. Jedoch sind auch Proben analysiert 
worden, die definitiv von minderwertiger Qualität waren, was sich extrem auf den 
Erwartungswert auswirkte. Das bedeutet prinzipiell, dass es zwar ein typisches Fingerprint-
Muster für jede Spezies gibt, dieses allerdings nicht immer zwingend erfüllt sein muss (siehe 
ebenfalls Kapitel 3.8). Bei den Harzen handelt es sich mehr oder weniger um ein 
wildwachsendes Naturprodukt, dessen Qualität auch von Umwelteinflüssen abhängt. 
Weiterhin ist es wichtig eine große Gesamtpopulation des Probeharzes zu vermessen, da es 
bereits innerhalb einer Charge recht große Schwankungen geben kann (z. Bsp. 10 g zu 
vermahlen ist sicherer als 1 g, auch wenn der Verbrauch natürlich dann immens ist). 
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Eindeutige Biomarker für die Spezies Boswellia papyrifera (Eritrea, Äthiopien und Sudan) 
sind Incensol (22), Incensol-Acetat (23) und das Verticillia-4(20),7,11-trien (24). Boswellia 
papyrifera kann mit allen drei Methoden (DC, HPLC und GC) identifiziert werden. Die 
Spezies wurde in der Literatur bis dato oft mit der Spezies Boswellia carterii (Somalia) 
verwechselt, obwohl bereits genügend Arbeiten vorlagen (z. Bsp. Obermann [79], 1978, und 
Hamm et al. [13], 2005), die zu gleichen Schlussfolgerungen gelangten wie sie in dieser 
Dissertation publiziert sind. Weiterhin zeichnet sich diese Spezies durch den durchschnittlich 
höchsten ß-AKBA-Gehalt und einen recht hohen Gesamtgehalt an Tirucallensäuren aus 
(Kapitel 3.8). Interessant ist ebenso, dass in allen relevanten Publikationen zum Thema  
[13,74,79] sowie in allen in dieser Arbeit untersuchten Proben die Verbindung Incensol-
Acetat (23) nur in der Sorte Boswellia papyrifera nachgewiesen wurde. Die Verbindungen 
Incensol (22) und Incensol-Acetat (23) sind in dieser Arbeit ebenfalls erstmalig mittels HPLC 
quantifiziert worden (Methode des externen Standards) und stellen die Hauptkomponenten 
der Neutralbestandteile der Spezies Boswellia papyrifera dar (Gehalt von 30 bis über 40 % in 
den öligen Neutralbestandteilen; siehe auch Kapitel 3.8). Die HPLC-Ergebnisse wurden 
durch Isolierungsexperimente von Incensol (22) und seinem Acetat (23) bestätigt (siehe 
Kapitel 3.11.1). Durch Anreicherung des Incensol-Acetat-Gehaltes (23) in den 
Neutralbestandteilen von Boswellia papyrifera mittels Partial-Synthese (Acetylierung der 
Neutralbestandteile) sowie der anschließenden chromatographischen Isolierung, konnte 
diese Verbindung in sehr hohen Ausbeuten gewonnen werden (Kapitel 3.11.1). Mit den 
Spezies Boswellia serrata und Boswellia sacra/Boswellia carterii wäre dies nicht möglich 
gewesen, da diese signifikant geringere Incensol-(22)-Gehalte aufweisen und die 
Biosynthese auf der Stufe des Serratols (21) bereits zu stagnieren scheint (siehe Kapitel 
3.13.1.2 oder auch [11]). Mittels einfacher Deacetylierungs- und Acetylierungsexperimente 
konnten diese beiden Verbindungen (22 und 23) wieder ineinander umgewandelt werden. 
Für die Spezies Boswellia serrata (Indien) sind Serratol (21), die erstmalig beschriebene 
Verbindung Iso-Serratol (20; siehe Kapitel 3.2.7) und auch ein recht hoher Gesamtgehalt an 
Tirucallensäuren typisch (Kapitel 3.8). Scheinbar sind ebenfalls die ubiquitär vorkommenden 
Verbindungen Methyl-Chavicol und Methyl-Eugenol, die im Wasserdampfdestillat anhand 
ihrer GC-Retention-Indizes bestimmt wurden, für Boswellia serrata spezifisch [13,35,74]. 
Außerdem zeichnet sich diese Spezies durch einen relativ gleich großen ß-KBA/ß-AKBA-
Gehalt und den durchschnittlich höchsten BA-Gehalt (α-BA, 1 und ß-BA, 3) aus. Dieses 
Ergebnis stimmt mit den Ergebnissen von Büchele et al. überein [57]. In Hinblick auf die 
Bioverfügbarkeit, wo ß-BA (3) die höchsten Blutplasmakonzentrationen aufwies 
[125,126,144], scheint diese Spezies, sofern auf ß-BA (3) standardisiert, die 
vielversprechendste zu sein. 
Für die Spezies Boswellia sacra (Oman, Jemen) und Boswellia carterii (Somalia), die bis 
dato als identische Spezies zu betrachten sind [11-13,73], wurden auch in dieser Arbeit 
identische Biomarker mit allen drei chromatographischen Methoden gefunden (DC, HPLC 
und GC). Spezifisch sind hierfür speziell das Vorhandensein von ß-Caryophyllen (27) und 
seinem Monooxidationsprodukt (28), wobei 27 mittels HPLC (Kapitel 3.7.3 und 3.7.4) 
nachweisbar war, und 28 sehr signifikant mittels DC (siehe Kapitel 3.4). Diese Resultate 
wurden durch die GC-Experimente sowie auch durch Literaturresultate [13,74,184] bestätigt 
   217
Zusammenfassung und Ausblick 
_________________________________________________________________________________ 
 
(Kapitel 3.5). Weiterhin sind auch für diese beiden Spezies Serratol (21) und das Iso-Serratol 
(20) wiedergefunden worden. Beide Verbindungen, 20 und 21, wurden in den 
Neutralbestandteilen von Bsac/Bcar, aber auch Bser, mittels HPLC erstmalig quantifiziert 
(siehe Kapitel 3.7 und 3.8). Die Rohsäuren dieser Spezies zeichnen sich durch relativ große 
Gehalte an BAs (1 und 3) und ABAs (2 und 4) aus. Ebenfalls zeigten sie durchgehend 
signifikant größere Lupansäuregehalte (11 und 12), verglichen mit Boswellia papyrifera und 
Boswellia serrata (Kapitel 3.7.6 und 3.8). Dies lässt auf eine unterschiedliche Ausprägung 
der Biosynthesewege schließen. Der Gehalt von ß-KBA (5) und ß-AKBA (6) variierte stark in 
den Spezies Boswellia carterii und Boswellia sacra (Kapitel 3.8 und 3.14). Von daher ist das 
ß-KBA/ß-AKBA-Verhältnis zur Speziesidentifizierung mit äußerster Vorsicht zu betrachten. 
Erwartungsgemäß ist der ß-AKBA-Peak (6) größer als der ß-KBA-Peak (5); das ist jedoch 
nicht zwingend, da auch stark differierende Signalverhältnisse und Gehalte gemessen 
wurden. Im Durchschnitt offenbarten diese Spezies jedoch den geringsten ß-KBA-Gehalt (5) 
im Harz, verglichen mit Boswellia papyrifera und Boswellia serrata. Die Tirucallen-
säuregehalte waren in allen hier analysierten Proben für beide Spezies signifikant geringer 
als für Boswellia papyrifera und Boswellia serrata ermittelt (Kapitel 3.8 und 3.14). Diese 
Tatsache lässt erneut auf eine bevorzugte Biosynthese der Boswelliasäuren in Boswellia 
sacra und carterii schließen (siehe auch Kapitel 3.13). 
 
Insgesamt wurden elf Verbindungen aus den Harzen von Boswellia papyrifera (18, 19, 22, 
23, 24) und Boswellia carterii (20, 21, 22, 25, 28, 29, 30) isoliert und deren Struktur mittels 
1D- und 2D-NMR-Experimenten aufgeklärt. Erstmalig im Harz von Boswellia carterii wurde 
die Verbindung Iso-Serratol (20) gefunden, einem Derivat vom literaturbekannten Serratol 
(21). Weiterhin ist die Isolierung von 3-ß-OH-Tirucallol (29) und auch von 3-α-OH-11-Keto-
12-ursen (30) aus der Neutralfraktion von Boswellia carterii noch nicht detailliert beschrieben 
worden. Diese Verbindungen stellen mit hoher Wahrscheinlichkeit biosynthetische 
Zwischenstufen auf dem Weg zu den bekannten Tirucallen- und 11-Ketoboswelliasäuren 
dar. 
In der Rohsäurefraktion von Boswellia papyrifera wurden erstmalig die beiden acetylierten 
Tirucallensäure-Derivate 18 und 19 ausführlich beschrieben. Zwar wurde von Estrada et al. 
berichtet, dass diese beiden Verbindungen aus dem Harz der Spezies Boswellia carterii 
isoliert worden sind, jedoch sind keine expliziten Daten hierzu von dieser Arbeitsgruppe 
veröffentlicht [57,70]. Weiterhin scheint Boswellia carterii diese beiden Verbindungen, 18 und 
19, nur in minimalen Mengen zu synthetisieren (siehe speziell 2D-HPLC in Kapitel 3.7.5), so 
dass es sich eher um die Spezies Boswellia papyrifera oder eine partialsynthetische 
Methode gehandelt haben muss, wie es in den Veröffentlichungen von Banno et al. [68] und 
Akihisa et al. [67] für die Semisynthese von 18, ausgehend von 17, beschrieben wurde. Auch 
in den Publikationen von Banno und Akihisa et al. ist von der Spezies Boswellia carterii die 
Rede. Jedoch, die isolierten Verbindungen, insbesondere die Isolierung des Incensol-Acetats 
(23), legen auch hier die Vermutung nahe, dass es sich um das Harz der Sorte Boswellia 
papyrifera handelte. Speziell die Schwierigkeit der Trennung dieser beiden Verbindungen, 18 
und 19, sowie das relativ geringe Vorkommen dieser im Weihrauchharz, scheinen diese 
Annahme zu bekräftigen (siehe Kapitel 3.1.1.3 und 3.7.5). Folglich liefert diese Arbeit erste 
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chromatographische und spektroskopische „Koordinaten“ zu diesen beiden, ebenfalls 
pharmakologisch interessanten Verbindungen (18 und 19). Im Zusammenhang mit 
Koordinaten sei angemerkt, dass die Spezies Boswellia papyrifera und Boswellia serrata 
diese in größerer Menge synthetisieren, und auch erstmalig HPLC-Retentionsdaten für diese 
mit angegeben wurden. Die Spezies Boswellia sacra bzw. Boswellia carterii zeichneten sich 
durchgehend durch einen relativ geringen Tirucallensäure-Gehalt aus. Die beiden 
Verbindungen, 18 und 19, wurden dort nur in Spuren nachgewiesen (Kapitel 3.7.5). 
 
Die Verbindungen für die HPLC-Quantifizierung (1-8, 10-16) wurden ebenfalls alle aus dem 
Harz der Spezies Boswellia papyrifera isoliert, so wie bereits in der Dissertation von Stefanie 
Seitz beschrieben [56,59]. 
 
Eine weitere interessante Feststellung war die Tatsache, dass Incensol (22) und sein Acetat 
(23) relativ instabil sind, wenn sie über einen längeren Zeitraum in Reinform der Luft 
ausgesetzt werden (Kapitel 3.11.3). So wurden die ursprünglich gefundenen 
pharmakologischen Werte auf Zersetzungsprodukte dieser zurückgeführt (siehe Kapitel 
3.12.1). Durch reaktionskinetische Tests mit Incensol-Acetat (23) wurde diese Annahme 
bestätigt (Kapitel 3.11.2-3.11.4). Hier sei angemerkt, dass auch die Arbeitsgruppe um 
Moussaieff diese Verbindungen, speziell Incensol-Acetat (23), mit vielversprechenden 
pharmakologischen Eigenschaften publizierte [87,145-147]. In der hier publizierten Arbeit 
konnten jedoch sämtliche pharmakologische Wirkungen nur auf die Zersetzungsprodukte 
von Incensol (22) und seinem Acetat (23) zurückgeführt werden (Kapitel 3.11.3 und 3.12.1). 
Von daher stellt sich die prinzipielle Frage, ob diese Verbindungen in unzersetzter Reinform 
überhaupt wirklich bioaktiv sind. Weitere Arbeiten zu diesem Thema sollten aufklären helfen. 
 
In punkto Synergiewirkung wurde nur die Fraktion, die auch Verbindung 18 und 19 sowie 
eine nicht weiter identifizierte Verbindung (vermutlich auch eine isomere Verbindung von 18 
und 19) enthält, untersucht (siehe Kapitel 3.1.1.3 zur Isolierung und 3.12.2 zur 
Pharmakologie). Diese unbekannte Verbindung konnte leider noch nicht isoliert werden. 
Interessanterweise konnten hier für die komplexe Mischung, im zellfreien mPGES-1-Test, 
effektivere Hemmwerte als für die schrittweise gereinigten Verbindungen festgestellt werden. 
Dies könnte ein Hinweis auf Synergie sein, muss es jedoch nicht zwingend, da sich diese 
Verbindungen in anderen Systemen wieder komplett anders verhalten könnten [150]. Das ist 
ein generelles Problem der Wirkstoffevaluierung [94]. Doch sollten diese Ergebnisse 
vielleicht andere Forschergruppen zu weiteren Experimenten motivieren.  
Interessanterweise lässt sich dadurch aber auch schlussfolgern, dass die Tirucallensäuren, 
als wesentlicher Bestandteil der Rohsäurefraktion von Weihrauchharzen, bestimmt einen 
pharmakologischen Effekt haben. 
 
Weiterhin sind die quantitativen HPLC-Ergebnisse sicherlich noch mit Fehlern behaftet 
(Kapitel 3.8). Bisher liegen noch keine Daten auf Reproduzierbarkeit vor (z. Bsp. anderes 
Labor, andere Ausrüstung, andere Mitarbeiter etc.; siehe auch [156]), da die Quantifizierung 
mit dieser Methode in dieser Arbeit erstmalig beschrieben wurde. Gewisse Sicherheiten 
   219
Zusammenfassung und Ausblick 
_________________________________________________________________________________ 
 
konnten erlangt werden, indem die Methode mit einer robusten literaturbekannten HPLC-
Methode [20,21], die weniger Probenpräparationsschritte benötigt, verglichen wurde 
(selektive Quantifizierung von ß-KBA und ß-AKBA; siehe Kapitel 2.3.9 und 3.6.1). Die 
Ergebnisse, abhängig von der Vorgehensweise, sind ähnlich. Ein Vergleich der 
Quantifizierungsresultate dieser Arbeit mit weiteren Quantifizierungsergebnissen aus der 
Literatur untermauert jedoch die generelle Richtigkeit der Daten soweit (siehe Kapitel 3.9). 
Dennoch, absolute Sicherheit wird erst durch vermehrte Wiederholungen dieser Mess-
Methodik - auch in anderen Laboren - erreicht werden, um letztlich eine statistisch 
ausreichende und vertrauenswürdige Gesamtpopulation vorliegen zu haben [159]. Dies 
betrifft sowohl die Anzahl der gemessenen Proben, repräsentativ für Boswellia papyrifera, 
Boswellia serrata und Boswellia sacra bzw. Boswellia carterii, als auch die durch mehrfache 
Wiederholung der Messmethodik ermittelten Verfahrenskenndaten [156]. Von diesem 
Standpunkt her gesehen, sind die quantitativen Daten dieser Arbeit als eine erste Schätzung 
bzw. Stichprobe der Tatsächlichkeit zu betrachten. 
 
Abschließend sei noch einmal festgehalten, dass durch diese Arbeit die Spezies der 
Weihrauchharze von Boswellia papyrifera, Boswellia serrata und Boswellia sacra bzw. 
Boswellia carterii, anhand chemotaxonomischer Marker, eindeutig bestimmt werden kann. 
Selbst jede Methode (DC, HPLC, GC) für sich genommen, dürfte dies bereits eindeutig 
belegen können. Wobei die DC-Methode, wegen ihrer einfachen Handhabung, aber dafür 
recht signifikanten Aussagekraft, am meisten überzeugen sollte (Kapitel 3.4 und [11]). 
Die GC-Methode benötigt als Probenaufarbeitungsschritt die Wasserdampfdestillation der 
Harze bzw. der Neutralbestandteile dieser, und liefert ubiquitäre Mono- und auch 
weihrauchspezifische Diterpene (z. Bsp. Verbindungen 21, 22, 23 und 24; siehe auch Kapitel 
3.5). 
Die HPLC benötigt definitiv, durch Trennung der Rohsäuren von Neutralbestandteilen, den 
meisten Arbeitsaufwand (Kapitel 2.2.4 und 2.3.4). Jedoch scheint dies noch notwendig zu 
sein, da die Ergebnisse sonst zu sehr verfälscht würden, weil auch verschiedene Mono- und 
Diterpene im Bereich der Boswellia- und Tirucallensäuren eluieren (z. Bsp. 20, 21, 22 und 
23). Die Methode wurde anhand der Rohsäure von Boswellia papyrifera evaluiert, die keine 
signifikanten Spuren von Serratol (21) und Iso-Serratol (20) enthält. Folglich sind die 
quantitativen Angaben für α-TA (14) und ß-TA (15) relativ sicher. Für die anderen Spezies, 
die sich durch das Vorkommen von Serratol (21) und Iso-Serratol (20) auszeichnen, sind die 
Quantitäten für α-TA (14) und ß-TA (15) noch mit Ungenauigkeiten behaftet. Diese beiden 
Verbindungen koeluieren mit Iso-Serratol (20; mit 15 = ß-TA) und Serratol (21; mit 14 = α-
TA) im unbehandelten Rohextrakt (siehe speziell auch den sogenannten „Triplett-Peak“ für 
den Bser-Rohextrakt in Kapitel 3.7.2, aber auch die Kapitel 3.7.3 und 3.7.4 für Boswellia 
sacra, respektive, Boswellia carterii). Auch nach Trennung der Rohsäuren von den 
Neutralbestandteilen mittels Flüssig-flüssig-Extraktion (Kapitel 2.2.4) lassen sich noch 
Spuren von Serratol (21) und Iso-Serratol (20) in der Rohsäure finden (DC-Analytik), die mit 
den entsprechenden Tirucallensäuren koeluieren und somit die Gehalte dieser, 14 und 15, 
höher erscheinen lassen als sie es in Wirklichkeit sind. Dieser experimentelle Befund wurde 
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bereits in der Dissertation von Seitz bestätigt, die Serratol (21) ebenfalls aus der 
Rohsäurefraktion von Boswellia carterii isolierte [56].  
Für Boswellia papyrifera, die kaum bzw. nicht nachweisbar Serratol (21) und Iso-Serratol 
(20) enthält, dafür allerdings Incensol (22) und sein Acetat (23) in größeren Mengen, stellt 
sich dieses Problem nicht. Incensol (22) kann zwar in Spuren noch im Rohsäureextrakt von 
Boswellia papyrifera wiedergefunden werden, koeluiert aber mit keiner Zielkomponente (Rt = 
zwischen ß-KBA und ß-AKBA). 
 
Die quantitativen HPLC-Gehaltsangaben und auch die qualitativen HPLC-Fingerprints liefern 
Hinweise auf die bevorzugten Biosynthesewege der einzelnen Spezies (Kapitel 3.13). Dies 
wurde durch Anwendung der Hauptkomponentenanalyse (Principal Component Analysis, 
PCA) untermauert (Kapitel 3.14). 
Boswellia papyrifera scheint ß-AKBA (6), Incensol (22) und sein Acetat (23) in relativ großen 
Mengen zu synthetisieren. Weiterhin sind die Tirucallensäuregehalte (13-19) sehr hoch, und 
die Lupansäure-(11, 12) und Boswelliasäure-(1-4)-gehalte mit die geringsten. Incensol-
Acetat (23) wurde nur in dieser Spezies gefunden (siehe Kapitel 3.7.1 und 3.7.6). 
Boswellia serrata zeichnet sich durch geringere ß-AKBA-(6)-Gehalte, dafür aber durch sehr 
große BA-(1, 3)- sowie Tirucallensäuregehalte (13-19) aus. Das Verhältnis der ß-AKBA-(6)- 
und ß-KBA-(5)-Peaksignale ist annähernd dem Faktor 1, was der Literatur entspricht 
[57,195]. Das Auftreten von Serratol (21) und Iso-Serratol (20) bei gleichzeitiger Abwesenheit 
von Incensol-Acetat (23) ist ebenfalls typisch für diese Spezies (siehe Kapitel 3.7.2 und 
3.7.6). 
Die Spezies Boswellia sacra bzw. Boswellia carterii, die beide das am stärksten variierende 
Gehaltsmuster aufwiesen, scheinen sich durch eine recht ausgeprägte Biosynthese von ß-
Caryophyllen (27) auszuzeichnen, was sich als sein Oxid (28), speziell in der DC-Analytik 
(Kapitel 3.4), bemerkbar macht. Außerdem besitzen sie mitunter signifikant hohe BA-(1, 3)- 
und auch die durchschnittlich größten ABA-(2, 4)-Werte. Die Lupansäuregehalte (11, 12) 
sind in diesen Spezies ebenfalls durchgehend am größten, relativ verglichen mit Boswellia 
papyrifera und Boswellia serrata. Währenddessen die Tirucallensäuregehalte (13-19) in allen 
Proben von Boswellia sacra und Boswellia carterii signifikant niedriger waren (siehe Kapitel 
3.7.3, 3.7.4 und 3.7.6). Die beiden acetylierten Tirucallensäuren, 18 und 19, sind sogar nur 
noch in Spuren nachweisbar, wodurch die zweite Chromatographiedimension für diese 
Spezies eigentlich obsolet ist (Kapitel 3.7.5). Dieser Befund könnte dadurch erklärt werden, 
dass die Lupansäuren (11 und 12) als biosynthetische Vorstufen zu den Boswelliasäuren 
betrachtet werden können (siehe Kapitel 3.13 oder auch das Buch von Breitmaier über 
Terpene [31]). Folglich sind die Lupansäuren (11 und 12) und Boswelliasäuren, speziell 1-4, 
in den Spezies Boswellia sacra bzw. Boswellia carterii in größerer Quantität vorhanden. Da 
die Tirucallensäuren (13-19) wahrscheinlich über einen anderen Biosynthesezwischenschritt 
ablaufen (Kapitel 3.13) sind sie in nur geringen Mengen nachweisbar.  
Im Gegensatz dazu sind für Boswellia papyrifera und Boswellia serrata recht hohe Gehalte 
an Tirucallensäuren (13-19) sowie signifikant niedrigere Werte für die Lupansäuren (11 und 
12) wiedergefunden worden. Das lässt ebenfalls auf unterschiedlich exprimierte 
Biosynthesewege schließen (Kapitel 3.8 und 3.13). Bis dato sind diese Aussagen aber nur 
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reine Spekulation. Weitere Tests, speziell biochemischer und/oder molekularbiologischer 
Natur, sind notwendig. Hierfür müsste Zugang zu den Bäumen bzw. frischem Boswellia-
Material selbst gewährleistet sein, was aber im Rahmen dieser Arbeit nicht möglich bzw. 
auch nicht das Ziel war. 
 
Ebenfalls von weiterem Interesse könnte sein, wie die verschiedenen Weihrauchharz-
inhaltsstoffe in pharmakologischen Testsystemen zusammen- bzw. entgegenwirken. Dies in 
Hinblick auf synergistische bzw. antagonistische Effekte [150]. Da durch diese Arbeit, aber 
auch bereits durch die Dissertationen von Jochen Bergmann [17] und Stefanie Seitz [56], 
wesentliche Grundsteine zur Analytik, Identifizierung, Isolierung und Quantifizierung von 
Weihrauchharzen gelegt wurden, sollte es weiteren Forschergruppen gewährleistet sein, die 
für diese pharmakologischen Untersuchungen notwendigen Verbindungen zu gewinnen. 
Des Weiteren ist die hier entwickelte HPLC-Methode noch ausbaufähig. Sie ermöglicht zwar 
die relative sichere Quantifizierung einiger Tirucallensäuren in der Rohsäurematrix für die 
Spezies Boswellia papyrifera, ist aber für die anderen Spezies noch mit größeren 
Unsicherheiten behaftet (Stichwort: Koelution). Weiterhin könnten durch entsprechende LC-
MS/MS-Kopplungen dann vermutlich auch die Blutplasma-Konzentrationen der 
Tirucallensäuren bestimmt werden. Ein massenselektiver Detektor würde auch die 
Problematik der Koelution von ß-BA (3, M = 456,70 g/mol) mit α-Ac-7,24-dien-TA (18, M = 
498,73 g/mol) umgehen können, nicht stattfindende Ionen-Suppression vorausgesetzt. 
Einige Experimente zur in vitro und in vivo Anwendung der LC-MS bzw. MS/MS-Kopplung 
auf Weihrauchinhaltsstoffe wurden bereits publiziert [143,144,192,195]. Durch die hier 
beschriebene HPLC-Methodik sollte es auch langfristig gesehen möglich sein, die biologisch 
aktiven Tirucallensäuren in komplexen Matrizes (z. Bsp. Blutplasma) zu bestimmen. 
Die spezifische Chemotaxonomie der drei Spezies Boswellia papyrifera, Boswellia serrata 
und Boswellia sacra bzw. Boswellia carterii dürfte mit Veröffentlichung dieser Arbeit nun 
endgültig geklärt sein. Folglich sollten auch die Spezies Boswellia carterii und Boswellia 
papyrifera nicht mehr verwechselt werden können, was, wie in dieser Arbeit ausführlich 
geschildert, unglücklicherweise öfter geschehen ist [35,67,68,85-88,146]. 
Fraglich ist jedoch auch, ob die Spezies Boswellia papyrifera, die die größten Quantitäten an 
Incensol (22) und Incensol-Acetat (23) enthält, nicht eines Tages ausgestorben sein wird. 
Dem matrixbasierten Modell von Groenendijk et al. [26] nach, dürfte diese Sorte nämlich 
innerhalb der nächsten 50 Jahre – sofern keine sofortigen Gegenmaßnahmen eingeleitet 
werden - auf ca. 10 % ihres heutigen Bestandes zurückgegangen sein. Die Harzausbeute 
dieser Spezies könnte bereits innerhalb der nächsten 15 Jahre um ca. 50 % geringer 
ausfallen, was dieses Material, ob nun für die Kirchen oder die Pharmakologie, entsprechend 
rar und somit wertvoll bzw. teuer machte. 
 
Allgemein festzustellen ist, dass die Ergebnisse strenggenommen nur für dieses 
Datenmaterial gültig sind. Jedoch scheint die Kongruenz mit einigen Literaturdaten, die 
generelle Richtigkeit der hier getroffenen Aussagen bisher zu bestätigen. Zukünftige 
Untersuchungen werden das letztendlich beweisen. 
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